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1 Introduction 
The conservation and sustainable management of resources is one of the main goals in chemical 
syntheses, which is to be adopted by chemists to increase the awareness for the environment.1 In 
1998, Anastas and Warner defined the “12 Principles of Green Chemistry”, which guide the 
environmentally-benign processes of chemicals production.2 Besides waste-reduction, avoidance of 
auxiliaries and temporary derivatizations during a synthesis, minimization of energy consumption 
and use of innocuous substances, atom- and step-economy, and the catalytic use of reagents rather 
than the utilization of stoichiometric amounts are fundamental requirements in nowadays syntheses. 
C‒H activation is a tool in organic chemistry that leads contemporary chemical syntheses towards 
green and sustainable processes. 
 
1.1 C‒H Activation 
The traditional transition metal-catalyzed cross-coupling of organometallic reagents with organic 
(pseudo)halides has proven to be a powerful tool,3 which was recognized with the Nobel Prize for 
chemistry in 2010. However, in cross-coupling reactions substrates need to be metalated to form the 
organometallic reagents by usually time-consuming and economically inefficient multi-step 
transformations (Scheme 1). The handling and storage of those organometallic compounds can be 
difficult. Additionally, during the cross-coupling reaction stoichiometric amounts of metal salts are 
formed as undesired by-products. To confront these disadvantages, catalytic C‒H activation has been 
intensely studied in the last years.4,5 
 
H
R1
M
R1
X
R2
, -HX
direct arylation
cat. [TM]
cat. [TM]
-MX
X
R2
R2
R1
 
Scheme 1: Comparison between classical cross-coupling and direct arylation. 
 
These reactions can be divided into three categories depending on the nature of the coupling partner 
of the C‒H activated substrate (Scheme 2).5d The C‒H bond can react with an aryl (pseudo)halide as 
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an electrophile or with an organometallic reagent as a nucleophile. Furthermore, a cross-dehydro-
genative coupling reaction is possible. The latter two reaction types require stoichiometric oxidants. 
 
 
(a)
(b)
(c)
          activation
with electrophiles
C H
          activation
with nucleophiles
C H
cross-dehydrogenative
                activationC H
R1 H + X R2
cat. [TM]
cat. [TM]
 oxidant
R1 M + H R2
R1 H + H R2 cat. [TM] oxidant
R1 R2
 
Scheme 2: Comparison of C‒H activation strategies.5d 
 
 
The concept of C‒H activation implies the direct C‒H metalation by the active catalyst.6 Mechanistic 
studies mainly displayed five distinct pathways regarding the crucial C‒H metalation step 
(Scheme 3).7 For electron-rich, low-valent late transition metals, such as iridium, the oxidative 
addition (a) is often preferred. Since early transition metals with d0-configuration do usually not 
undergo an oxidative addition, they can activate the C‒H bond via a σ-bond metathesis (b). In a 
similar pathway the C‒H bond is cleaved via a 1,2-addition (c) to an unsaturated TM=X multiple bond. 
This mechanism is typical for group III to V transition metals. The electrophilic substitution (d), where 
the transition metal acts as a Lewis acid, commonly occurs with electron-deficient late transition 
metals, such as palladium(II), platinum(II) or platinum(IV). The base-assisted deprotonation (e) 
requires a bidentate base, such as a carboxylate or a secondary phosphine oxide (SPO), to form a six- 
or five-membered transition state, respectively. This mechanism can either be termed concerted 
metalation-deprotonation (CMD) or ambiphilic metal ligand activation (AMLA, Scheme 4).8 In the 
presence of alkoxy ligands transition metals are favored to undergo an internal electrophilic 
substitution (IES) based on a four-membered transition state. An additional mechanism is the base-
assisted intramolecular electrophilic substitution (BIES), which is prevalent for base assistance with 
electrophilic transition metals.9 
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MLn + H R1 LnM
H
R1 ‡ H
MLn
R1
(a) oxidative addition
+ H R2
LnM
H
R2 ‡
MLn
R2
(b) σ-bond metathesis MLn
R2 X
X
H
+ H R2(c) 1,2-additon MLn
X
LnM
H
R2 ‡
LnM
XHX
R2
+ H R2(d) electrophilic substitution MLn
LnM
H
R2 ‡
XX
MLn
R2
X
H
+ H R2(e) base-assisted deprotonation MLn
‡
O
LnM
O
R1
O
LnM
O O
H
R2
R1 R
1
R2
OH
 
Scheme 3: Pathways for the C–H activation step. 
 
‡
O
R
O
LnM H
C
CMD/AMLA IES BIES
‡
O
R
LnM H
C
‡
O
R
O
LnM H
Cδ δ
 
Scheme 4: Base-assisted metalation. 
 
One of the key obstacles for C‒H activation reactions is the regioselectivity, since organic molecules 
usually contain several C‒H bonds with almost equal dissociation energies and acidities. This issue 
can be circumvented by controlling the selectivity through electronic bias, steric hindrance or the 
incorporation of directing groups.10 The latter consist of Lewis basic functionalities, which 
precoordinate to the transition metal, and thus bring it in close proximity to the desired C‒H bond 
(Scheme 5). Today, many different directing groups have been established (Scheme 6).11 
 
H
DG
TM H
DG TM DG
TM
 
Scheme 5: Regioselective C–H activation using directing groups. DG: directing group. 
 
N
N N
N N
N
N
NN
NR
H
N
O
R
H/R/OR
O
R
N
OH
O
N
R
OMe
NH
N
OR
NH
NO
 
Scheme 6: Frequently used directing groups. 
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1.1.1 Palladium-Catalyzed C‒H Activation of Indoles 
Indole is one of the most ubiquitous nitrogen-heterocycle-containing substructures, appearing in 
natural compounds, pharmaceuticals as well as industrial products.12 A vast number of indole-
containing compounds is biologically active and therefore the syntheses of a variety of new indoles is 
of immense importance.13 Besides traditional synthetic routes, such as the Fischer indole synthesis, 
the Gassman indole synthesis or the Bischler indole synthesis,14 through which different indole 
structures can be achieved, C‒H arylation of the indole core structure emerged as a new and efficient 
way to further diversify indoles. 
Early examination of the palladium-catalyzed C‒H arylation of indoles by the group of Ohta in 1985 
showed a different regioselectivity for electronically different indoles (Scheme 7).15 While the NH-
free indole 1a was arylated with chloropyrazines 2, affording C2-functionalized indoles 3a, the tosyl-
protected indole 1b was arylated exclusively in the C3 position. Thus, the electron-withdrawing tosyl 
group changed the electronics and therefore the C2/C3 site-selectivity of the indole. 
N
H N
N
Cl
R+
AcOK (1.2 equiv)
DMA, 170 °C, 12 h
Pd(PPh3)4 (5 mol %)
N
H
N
N R(a)
1a 2 3a
H
H
H
 
N
Ts N
N
Cl
R+
as above
N
Ts
(b)
N
N R
1b 2 4a
H
H
H
 
Scheme 7: Divergent regioselectivity of the C–H arylation of indole.15 
In the past two decades new procedures for the palladium-catalyzed direct C‒H arylation of indoles 
were developed by the groups of Sanford,16 Sames,17 Larrosa18 and Daugulis,19 among others 
(Scheme 8). Generally, these reactions suffer from harsh reaction conditions, such as elevated 
reaction temperatures, the need for strong oxidants, bases or acids. Another issue is the already 
mentioned site-selectivity between the nitrogen as well as the C2 and C3 positions, which are prone 
to react prior to the C4–C7 positions. Inspecting the literature, the development of mild reaction 
conditions and the avoidance of rather toxic reagents becomes apparent. The applied ligands for the 
palladium-catalysis changed from phosphines,17,20 to carboxylate-assisted approaches,17d,21 
carboxylates,18,22 or other non-toxic ligands.16,23 The choice of the arylating agent varied from 
previously used iodoarenes,17,20,24 over bromoarenes23a,24 and chloroarenes19,25 to aryl boronic 
acids18a and other arenes, such as benzene,18b benzoic acids,21b aryl diazo borates,22a aryl sulfinates23b 
and diaryliodonium salts.16,22b The applied oxidants for the oxidative couplings also varied from toxic 
and expensive silver18b,21b or copper salts18b,23b to benign oxygen.18a,20b  
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N
R
+
ligand/oxidant/
base/acid
solvent, T, t
N
R
1c
X = halide, B(OH)2,
      N2BF4, ...
3b
H
H
H
cat. [Pd]
N
R
H
4b
or
X
R = H, PG, ...
Ar Ar
Ar
 
Scheme 8: General palladium-catalyzed arylation of indoles. 
 
These different reaction modes demonstrate the possibilities of tuning the regioselectivity. For 
example, the work of DeBoef shows an oxidant-controlled switch in the C2/C3 selectivity 
(Scheme 9).21a While the use of silver acetate in the palladium-catalyzed arylation of N-acetylindole 
1d with benzene delivered the C2-arylated indole 3c as the major product, the utilization of 
copper(II)acetate provided the C3 aryl indole 4c as the main product. Similar findings were previously 
shown by Fagnou22b and Itahara.26 
N
Ac
H
H
benzene
cat. Pd(OAc)2
dioxane, 120 °C
N
Ac
H
AgOAcCu(OAc)2
N
Ac
H
1d 3c4c
 
Scheme 9: Oxidant-controlled regioselectivity of the palladium-catalyzed arylation.21a 
Djakovitch showed a C2/C3-site-selective arylation depending on the base (Scheme 10).20a The 
formation of the C3-arylated product 4d was preferred when strong hard bases were used, while 
weak soft bases gave the C2-arylated indole 3d as the major product. 
Ph2P
Ph2P
dppm =
N
H
H
H
PhI
cat. Pd(OAc)2dppm
H2O
AcOKLiOH
N
H
H
N
H
H
1a4d 3d
 
Scheme 10: Base-controlled site-selectivity of the C–H arylation of indoles.20a 
 
Regarding the mechanism of the palladium-catalyzed C2-arylation of indoles with aryl halides, 
Djakovitch proposed a palladium(0)/palladium(II) catalytic pathway that is supported by 
experimental findings (Scheme 11).20a The highly electrophilic complex 7 could undergo a C3-
palladation to form the complex 9. From here, two pathways are reasonable: The first starts with a 
migration from C3 to C2, which is favored in the presence of a weak base. This leads to complex 10, 
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which delivers the C2-arylated isomer 3 through formation of the σ-complex 13 and subsequent 
reductive elimination. The second way is based on a rearomatization, which is facilitated by the 
presence of a strong base. The deprotonation leads to formation of complex 12 and finally to the C3 
regioisomer 4. 
N
H
OH- promoted with $015
7
N
PdArL
H
H
X-
favored with AcO-
C3/C2 migration
N
H
H
X-
PdArL
H
N
H
H O
OPd
Ar
7 rearomatization
fast with OH-Y = OH or Br
N
H
PdArL
N
H
PdArL
- HX
N
H
H O
OPd
Ar
N
H
Ar
N
H
Ar
C3-regioisomer C2-regioisomer
- Pd(0) - Pd(0)
CMD pathway
Pd
OAc
Ar
P
P
CMD pathway
Pd
OH2
Ar
P
P
X-
Pd(OAc)2 + ArI + dppm
Pd
I
Ar
P
P
5
6 7
Pd
Br
Ar
P
P
8
Pd(OAc)2 + ArBr + dppm
C3-palladation
electrophilic cationic
Pd species
neutral Pd complex
electrophilic palladation pathway
1a 9 10
11 12 13
14 4 3
 
Scheme 11: Proposed mechanistic pathway.20a 
An example for the selective C3–H modification of indoles was demonstrated by the palladium-
catalyzed HASPO-assisted arylation of indole 1a with bromoarenes (Scheme 12).27 The catalytic 
system consisted of Pd(OAc)2, a HASPO additive and K2CO3 in dioxane. Notably, air-stable HASPO 
preligands were applied. 
N
H
H
H
N
H
H
1a 4d
PhBr
Pd(OAc)2 (5 mol %)
HASPO preligand (10 mol %)
K2CO3, 1,4-dioxane
95 °C, 20 h
HASPO preligand
O
P
OO
O
Me
Me
oToloTol
oToloTol
O
H
 
Scheme 12: C3-selective arylation of indoles.27 
 
1.1.2 Arylations of (Hetero)Arenes with Diaryliodonium Salts 
Since diaryliodonium salts were first described by Hartmann and Meyer in 1894,28 these air- and 
moisture-stable hypervalent iodine(III) compounds have become readily available and widely used. 
Structurally, diaryliodonium compounds are usually T-shaped, which is typical for iodine(III) 
compounds (Scheme 13). The iodine, the apical aryl group and the “counterion” form a three-center 
four-electron (3c-4e) bond.29 In solution the degree of dissociation to Ar2I+ and X– depends on both 
the solvent and the counterion.30 The dissociated species is considered to maintain the roughly 90° 
angle of Ar‒I+̶ Ar as a solvent molecule coordinates instead.31 
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I
Ar
XAr Ar I
Ar
X Ar1 I
Ar2
X(a) (b) (c)
 
Scheme 13: Structure of Ar2IX: (a) T-shaped. (b) ionic T-shaped. (c) unsymmetric. 
 
The reactivity of the iodine(III) species is determined by the electrophilic nature of the iodine 
(Scheme 14). Typically, one aryl group is transferred to the nucleophile and consequently aryl iodide 
is formed as the stoichiometric leaving group. In nucleophilic aromatic substitutions or cross-coupling 
reactions neutral leaving groups are more beneficial as compared to anionic leaving groups.32 
As to the mechanism, it is generally believed that under transition metal-catalysis one aryl group is 
transferred to the metal to form an aryl metal complex in a high oxidation state. The product is 
formed through reductive elimination with the nucleophile that has coordinated to the metal either 
before or after the transfer of the aryl moiety.33 
I
Ar
XAr NuH M
Ar
X + Ar I Ar Nu +    HX+    M  
Scheme 14: General reaction of Ar2IX with nucleophiles. 
 
The use of diaryliodonium salts is considered a disadvantage due to the generation of equimolar 
amounts of aryl iodides, which becomes even more inexpedient when more complex aryls are to be 
introduced. To circumvent this issue, unsymmetrical diaryliodonium salts have been designed. The 
idea was to introduce an inexpensive “dummy” aryl moiety that can be wasted as aryl iodide. For this 
strategy, a high chemoselectivity with respect to the transferred aryl group is of immense 
importance. For metal-catalyzed reactions, the chemoselectivity is usually guided by the sterics of 
the aryl moieties. Sterically demanding aryl groups, such as the 2,4,6-trimethylphenyl (mesityl) or 
2,4,6-triisopropylphenyl (TRIP), can generally be used as dummy groups (Scheme 15).33d,34 
 
Me
Me
Me
Me
Me
Me
Me Me
Me
 
Scheme 15: Common dummy groups. 
 
Due to their high electrophilicity and their leaving group ability, diaryliodonium salts have been 
applied for various electrophilic arylations, for radical reactions, and for transition metal-catalyzed 
cross-coupling reactions.35,36 
In 2006, Sanford presented the C2-arylation of indole with [Ph2I]BF4 in the presence of catalytic 
amounts of Pd(OAc)2 or IMesPd(OAc)2 (Scheme 16).23c A catalytic cycle can be proposed according to 
a previously reported arylation of phenylpyridines under similar conditions (Scheme 17).33d A phenyl 
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group of the mixed diaryliodonium salt is transferred to the palladium dimer complex 17 to form the 
cationic palladium(II)/palladium(IV) complex 18. Thereafter, the initial palladium(II)/palladium(II) 
complex 17 is regenerated by reductive elimination of the product 3 and a subsequent addition of 
the substrate 1f. 
 
N
R2
R1 +    [Ar2I]BF4
IMesPd(OAc)2 (5 mol %)
HOAc, 25 °C, 15-24 h N
R2
R1H Ar
1e 15 3e  
Scheme 16: Palladium-catalyzed arylation with [Ar2I]BF4.
23c 
N
N
N
N
PdII
AcO
N
N
PdII
O
O
PdII
Ac
Ac
N
N
N
N
PdIV
O
O
PdII
Ac
Ac
N
NPh
BF4
N
PdII
O
O
PdII
Ac
Ac
N
NL
BF4
[Mes-I-Ph]BF4
Mes-IN
N
N
N
+  HBF4
16
17
1819
1f
3
NPh
Ph
15a
H
H
 
Scheme 17: Catalytic cycle for palladium-catalyzed arylation with [Ar2I]BF4.
23c 
 
A more recent publication by Huang in 2014 showed the palladium-catalyzed combined C2,C3-
diarylation of indole 1c with biphenyliodonium triflate 20 to obtain carbazoles 21 (Scheme 18).37 
Sanford’s report23c and further mechanistic observations37 indicate a palladium(II)/(IV)-catalytic 
system, in which the palladated C2 position of the indole first reacts with the biphenyliodonium 20 to 
give the palladium(IV) complex 24 (Scheme 19). After a reductive elimination to palladium(II) the 
intermediate 25 is formed. A second oxidative addition of the recycled palladium(II) species to the 
aryl iodide affords the complex 26, which is transformed to the complex 27 by C3-palladation to give 
the final product 21 after reductive elimination. This publication showed an economic way of the 
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utilization of diaryliodonium salts with a minimized waste-coproduction, which however is only 
useful when the diannulated carbazole is desired. 
 
N
R
I
OTf
+
Pd(OAc)2
Na2CO3
DCE, 100 °C
N
R1c 20 21
H
H
 
Scheme 18: Palladium-catalyzed C2,C3-diarylation of indoles.37 
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N
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R
HX
1c
23
I
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Pd(OTf)X
Pd(OTf)X
24
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21
HOTf
22
H
H
H
H
H
 
Scheme 19: Mechanism of the palladium-catalyzed C2,C3-diarylation of indoles.37 
 
A metal-free approach for the C–H arylation of indoles applying diaryliodonium salts was shown by 
the Ackermann group (Scheme 20).38 The reaction of indoles 1e with diaryliodonium salts 15 
proceeded smoothly in DMF at 100 °C. Diaryliodonium triflates, tosylates, tetrafluoroborates as well 
as trifluoroacetates and hexafluorophosphates were applicable for this reaction. Later this method 
was applied to peptide modification.39 
 
N
R2
R1 +    [Ar2I]X DMF, 100 °C, 22 h N
R2
R1
1e 15 4e
H Ar
Me Me
 
Scheme 20: Metal-free C–H arylation of indoles.38 
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1.2 Ruthenium-Catalyzed C‒H Arylations of (Hetero)Aryl Pyridines and Pyrimidines 
Since the first example of a direct ruthenium-catalyzed C‒H arylation of heteroarenes was published 
by Ackermann in 2011 (Scheme 21),40 the interest in these transformations has grown. Previous 
reports on ruthenium-catalyzed arylations focused on the C–H arylation of arenes without 
heteroatoms and thereby demonstrated the applicability of different directing groups in ruthenium 
catalysis.41,42 
The work of Ackermann from 2011 illustrated an efficient way for the C‒H arylation of N-pyridylated 
or N-pyrimidylated pyrroles and indoles 1g.40 Here, [RuCl2(p-cymene)]2 was used as the precatalyst in 
combination with catalytic amounts of user- and environment-friendly 1-adamantyl carboxylic acid as 
the preligand in a basic milieu of K2CO3 in m-xylene. Aryl bromides 28 as well as chlorides 2 were 
applied as the arylating agents. Finally, the traceless directing group arylation strategy was 
accomplished through removal of the directing group from the nitrogen of the indole and pyrrole by 
reacting the products 29 with sodium ethoxide in DMSO. The substrate scope demonstrated 
functional group tolerance towards fluoride, chloride, cyanide, ketone, ester, ether, dimethylaniline, 
as well as thiophene. 
 
N
2-pym
+    Ar-Br
[RuCl2(p-cymene)]2 (2.5 mol %)
1-AdCO2H (30 mol %)
K2CO3, m-xylene
120 °C, 22 h
H
N
2-pym
Ar
1g 2928
NaOEt, DMSO N
H
Ar
30  
N
2-pym
R
R = H (29a):
R = F (29b):
R = Cl (29c):
R = CN (29d):
R = CO2Et (29e):
R = NMe2 (29f):
84%
86%
84%
73%
84%
83%
N
2-pym
OMe
OMe
OMe
N
2-pym
S
29g: 42% 29h: 86%
N
H
R1 = H, R3 = OMe (30a): 77%
R1 = OMe, R3 = H (30b): 72%
R2
R1
 
Scheme 21: Ruthenium-catalyzed arylation of indoles with aryl bromides.40 
 
In 2014, the group of Pilarski expanded the ruthenium-catalyzed C‒H arylation of pyrimidyl indoles 
1g and pyrroles under oxidative conditions using aryl boronic acids 31 as the arylating agents 
(Scheme 22).43 The optimized reaction conditions revealed catalytic amounts of [RuCl2(p-cymene)]2 
and AgSbF6 combined with one equivalent of Cu(OAc)2∙H2O as the terminal oxidant to be best 
suitable for this transformation. The reaction proceeded in isopropanol at 120 °C within 18 h. 
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N
2-pym
+    Ar-B(OH)2
[RuCl2(p-cymene)]2 (2.5 mol %)
AgSbF6 (12 mol %)
Cu(OAc)2·H2O
iPrOH, 120 °C, 18 h
H
N
2-pym
Ar
1g 2931
N
2-pym
R
R = H (29a):
R = F (29b):
R = Cl (29c):
R = CF3 (29i):
R = NO2 (29j):
86%
75%
70%
64%
82%
N
2-pym
N
2-pym
29k: 93% 29l: 94%
O
 
Scheme 22: Ruthenium-catalyzed arylation of indoles with arylboronic acids.43 
 
A similar work with indole pyridines 1f was published by Kapur in 2015 (Scheme 23).44 In this case, 
various solvents and oxidants were tested. After optimization of the coupling of indole pyridine 1f 
with phenylboronic acids 31, catalytic amounts of [RuCl2(p-cymene)]2 with one equivalent of 
Cu(OTf)2 and Ag2O in dioxane appeared optimal at 100 °C. The pyridyl directing group could be 
successfully removed by treatment with MeOTf and subsequently with a base according to a 
literature procedure.45 
N
2-py
+    Ar-B(OH)2
[RuCl2(p-cymene)]2 (5 mol %)
Ag2O (1.0 equiv)
Cu(OTf)2 (1.0 equiv)
1,4-dioxane, 100 °C, 14 h
H
N
2-py
Ar
1f 3231
N
2-py
N
2-py
N
2-py
32b: 76% 32c: 67%
O
OBr Cl
Cl
32a: 67%
N
H
Ar
30
1) MeOTf/CH2Cl2
    0 °C-rt, 12 h
2) 2 M NaOH/MeOH
    60 °C, 10 h
 
Scheme 23: Ruthenium-catalyzed arylation of indioles with arylboronic acids.44 
 
A plausible catalytic cycle was proposed (Scheme 24). First, a ruthenium(II)-species 33 is coordinated 
by the pyridyl directing group and activates the C‒H bond in the C2 position. Thereafter, 
transmetalation with the arylboronic acid 31 followed by reductive elimination sets free the C2-
arylated indole 32. Finally, the released ruthenium(0)-species 36 is oxidized to ruthenium(II) 33 by 
copper(II). Possibly, the role of silver oxide is to facilitate the transmetalation and also to assist the 
reoxidation step. 
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N
N
[Ru(II)][Ru(0)]
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N
N
Ar
Ar B(OH)2 +  B
N
N1f
34
33
32
36
H+
B-B(OH)2
31N
N
[Ru]
Ar
35
H
 
Scheme 24: Mechanism of the ruthenium-catalyzed arylation of indoles.44 
 
 
1.3 Ruthenium-Catalyzed C‒H Hydroarylation of Unsaturated C‒C Bonds 
Hydroarylation of arenes is a powerful tool to gain access to alkylarenes.46 While traditional Friedel-
Crafts reactions47 and additions of organometallic substrates to α,β-unsaturated carbonyl 
compounds48 produce stoichiometric amounts of waste salts, hydroarylation features high step- and 
atom-economy and therefore synthetic efficiency.49 In recent years, significant progress has been 
achieved in the field of the addition of unactivated C‒H bonds of aryls to unsaturated compounds.50 
For transition metal-catalyzed hydroarylation reactions, different transition metals have been used, 
such as cobalt,51 iridium,52 manganese,53 rhenium,54 nickel55 as well as rhodium56 and ruthenium,56d,57 
among others.50 
In 2014, Zeng and coworkers published a ruthenium-catalyzed hydroarylation of alkynes 37 with 
indoles 1f (Scheme 25).57c The catalyst consisted of [RuCl2(p-cymene)]2 and one equivalent of acetic 
acid in DMF at 110 °C. A broad range of alkynes 37 and indole substrates 1f were coupled to give the 
desired olefinic products 38. The NH-free indoles 39 were released after the treatment with MeOTf 
and subsequent addition of base. 
 
N
2-py
[RuCl2(p-cymene)]2 (7 mol %)
HOAc (1.0 equiv)
DMF, Ar, 110 °C, 24 h
H
N
2-py
1f 3837
R3
R4
R1
R2
+
R4
R3
R2
R1
N
H
39
R4
R3
R2
R1
1) MeOTf/CH2Cl2
    0 °C-rt, 24 h
2) NaOH/MeOH
    60 °C, 12 h
 
Scheme 25: Ruthenium-catalyzed hydroarylation of alkynes with indoles.57c 
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Mechanistic studies, including H/D exchange experiments and kinetic isotope effect (KIE) studies, 
gave reason to suggest a catalytic cycle that starts with the coordination of the pyridine to the 
ruthenium complex 40 followed by an electrophilic activation to obtain complex 41 with a 
concomitant loss of a proton (Scheme 26). Next, an alkyne 37 inserts into the ruthenium-carbon 
bond to form complex 42, which liberates product 38 after protonation. 
 
[Ru(II)]
N
N
N
N
[Ru(II)]
R4R3
N
N
R4
[Ru(II)]
R3
N
N
R4
R3
H+
40
4142
1f
37
38
H+
 
Scheme 26: Catalytic cycle for the ruthenium-catalyzed hydroarylation.57c 
 
Activated alkenes, such as α,β-unsaturated carbonyls, vinyl heteroatom compounds, enol and 
enamine ethers, allenes, and also styrenes, are most likely to perform hydroarylation reactions. 
However, unactivated olefins are somewhat more challenging substrates. Concerning ruthenium-
catalyzed hydroarylations, the use of unactivated alkenes is rare. Regarding recent publications, in 
2009 Lee and coworkers showed the ruthenium hydride-catalyzed alkylation of acetophenones 43 
with 1-hexene (44a, Scheme 27).57g An isomerization of the obtained alkyl arenes 45 led to the 
formation of the byproducts 46. A similar work was later also demonstrated by the group of 
Williams.57f 
Me
O
C4H9+
{[(PCy3)(CO)RuH]4(µ4-O)(µ3-OH)(µ2-OH)}
HBF4·OEt2
C6H5Cl, 110 °CH
Me
O
C4H9
Me
Me
Me
+
43 44a 45 46
Me
O
C4H9R
R = H (45a):
R = Cl (45b):
R = OMe (45c):
R
O
C4H9
R = Et (45d):
R = iPr (45e):
R = Ph (45f):
Me
O
C4H9
R = H (45g):
R = Me (45h):
R = OMe (45i):
R
47%
61%
40%
38%
50%
59%
67%
65%
75%  
Scheme 27: Ruthenium-catalyzed hydroarylation of unactivated alkenes. Combined yields of both isomers are 
shown.57g 
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A remarkable report of the alkylation of phenylpyridines 47 with unactivated alkenes 44 was 
published by Ackermann in 2013 (Scheme 28),57e and further examined by Peris.57b In this work, a 
user-friendly, air-stable, carboxylate-assisted ruthenium-catalytic system was used at 100‒120 °C in 
toluene, dioxane or water. The optimized method was extended to indoles and thiophenes, which 
delivered the corresponding alkylated products 48f and 48g in good yields. 
 
N
+ R
[RuCl2(p-cymene)]2 (1.3-5.0 mol %)
cat. MesCO2K
toluene, 100-120 °C, 18-24 h
N
R
47 44 48
H
 
N
N
Me
SiMe3
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SiMe3
48g: 60%
N
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Me
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N
Cl
48e: 78%
9
 
Scheme 28: Ruthenium-catalyzed hydroarylation of unactivated alkenes.57e 
 
Based on H/D-exchange experiments, competition experiments and previous mechanistic studies, a 
plausible catalytic cycle was proposed (Scheme 29). After C‒H activation of the ortho-position, the 
alkene is hydrometalated to form complex 51. The reductive elimination, which is probably rate-
determining, provides the product 48 and regenerates the catalyst 49. 
 
NN
Alk
4748
[LRu]
N
O2CMes
50
Alk
44
51
[LRu(O2CMes)2]
49
H
HO2CMes
[LRu]N
Alk
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Scheme 29: Catalytic cycle of the ruthenium-catalyzed hydroarylation. 
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1.4 Chemical Late-Stage Peptide Modification 
Chemical peptide modification has emerged as a valuable tool for the development of a diversity of 
new peptides.58 The present demand for novel peptides is a consequence of the need for probing 
natural systems, designing therapeutic conjugates and creating new protein constructs. Proteins and 
peptides containing non-proteinogenic amino acids can have improved pharmacokinetic properties 
when compared to their natural counterparts.59 Moreover, peptides are efficient catalysts for 
selective asymmetric reactions.60 These peptide modifications are commonly referred to as 
posttranslational modifications (PTMs), as they are contrived after the actual peptide synthesis, 
which originally was the translation. However, nowadays, peptide synthesis is realized by automated 
methodologies, in particular by solid phase peptide synthesis (SPPS). While natural posttranslational 
modification is precise and diverse, which results in the vast biodiversity found in nature, our 
possibilities to specifically modify a peptide at a certain site are limited by the chemical 
transformations that are available. The true challenge is to chemically differentiate between a 
number of amides, carboxylic acids, amines, alcohols and thiols within a molecule. In order to study 
cellular processes, it is indispensable to mimic natural posttranslational changes of peptides, 
including acylation, methylation, phosphorylation, sulfation, ubiquitination and glycosylation, among 
others. To date, developed methods have primarily focused on the modification of particular 
peptides and therefore may not be applicable to any other peptide of interest. Consequently, the 
need for further methods for chemical modifications of peptides continues to persist. The pursued 
premises are site-selectivity, robustness, mildness and efficiency at temperatures below 40 °C, so as 
not to disrupt the architecture or function of the peptide or protein. It would be desirable to carry 
out these modification reactions under biologically ambient conditions, that are 37 °C at a pH of 6‒8 
in an aqueous media. Moreover, in order to modify peptides within living cells, the modification 
reactions must exhibit bioorthogonality and biocompatibility, high reaction rates at low substrate 
concentrations as well as the use of nontoxic reagents. 
An early example of a site-selective peptide modification was published in 1965 by Wilchek and 
coworkers (Scheme 30).61 They presented the conversion of serine 52 to cysteine 54 by nucleophilic 
substitution of activated hydroxyl groups, such as tosylates 52a and phosphoric esters 52b, with thio-
nucleophiles 53, such as thiolates and thioacylates. 
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Scheme 30: Conversion of serine to cysteine.61 
 
Since then, major development has been achieved and both natural and unnatural amino acid 
residues were modified. Amongst natural amino acids, functionalized residues have been commonly 
used, such as lysine, cysteine, tyrosine, threonine and serine (Scheme 31). Amines are likely to 
undergo reactions with electrophiles, for instance esterifications with activated carbonyls, additions 
to Michael acceptors, thiocyanates or ketenes, and condensations with carbonyls. Beyond that, even 
more nucleophilic cysteine is capable of reacting in nucleophilic substitutions of alkyl halides and 
disulfides, and cysteine can easily be converted to dehydroalanine, which is predestined for 
conjugate addition reactions. 
SH SH SH
peptide
X
O
Y HS
S
O
S
(a)
S S
peptide  
SuO
O
NH NH
NH
N
NH2 NH2 NH2(b)
O S
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S
•
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peptide  
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OH OH
N
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N
N
OH OH
N2
+ H2N
H H
O
peptide
peptide  
Scheme 31: Examples of peptide modification with (a) cysteine, (b) lysine, and (c) tyrosine. 
 
In addition to transition metal-free approaches, transition metal-catalyzed transformations have 
been examined.62 Typically, a “handle” or “tag”, which is supposed to possess a uniquely reactive 
functional group, is attached to an amino acid or an unnatural amino acid is implemented into the 
peptide (Scheme 32). This facilitates numerous established transition metal-catalytic reactions, 
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including click reactions,63,64 cross-metathesis,65 and cross-coupling reactions, among which Suzuki-
Miyaura66,67 and Sonogashira68 reactions have received the most attention (Scheme 33). Successively, 
some limitations, such as catalyst poisoning and the use of anhydrous solvents, were solved. Air- and 
moisture-stable as well as environmentally benign catalysts gave rise to mild, efficient and economic 
procedures. 
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N Me
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HN O
O
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Scheme 32: Examples of genetically encoded lysine-based amino acids for biocompatible reactions. 
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Scheme 33: Examples of (a) cross-metathesis, (b) cross-coupling and (c) click reactions on peptides. 
 
Early examples focused on the nucleophilic natural amino acids lysine and tyrosine. For example, in 
2005 the Francis group published an iridium-Cp*-catalyzed alkylation of lysine with an aldehyde with 
subsequent reduction of the formed imine by an in situ formed iridium hydride species 
(Scheme 34a).69 One year later, the same group reported on the palladium-catalyzed Tsuji-Trost 
reaction on tyrosine in peptides (Scheme 34b).70 An in situ formed π-allylpalladium complex, which 
was generated from allyl acetates or carbamates and Pd(OAc)2/triphenylphosphine tris-(sulfonate) 
(TPPTS), afforded the selective O-alkylation of tyrosine peptides. Rhodamine dyes and lipophilic 
moieties could thus be introduced into peptides. Further transition metals, such as nickel,71 iron,72 
copper,73 cerium,74 rhodium,75,76 and gold77 were also applied for peptide modifications. 
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Scheme 34: Examples of peptide modifications on (a) lysine and (b) tyrosine.69,70 
 
For late-stage modifications of peptides, carbon–carbon bond forming reactions, which can be 
realized by cross-coupling and cross-metathesis reactions, are amenable and attractive because they 
are selective and even applicable in living cells. 
In addition to the described transition metal-catalyzed protocols, approaches that require less 
prefunctionalization, namely transition metal-catalyzed C‒H modification reactions, were developed. 
Lastly, as on-resin reactions highlight completely new challenges and at the same time reveal 
completely new advantages, on-resin modification reactions of peptides have also been developed. 
Along these lines, C‒H activation reactions as well as on-resin reactions are described in the following 
chapters. 
 
1.4.1 C‒H-Activation of Peptides 
While nature provides a range of elegant modification approaches of peptides, chemical 
functionalization is still considerably more challenging because many established protocols do not 
suffice the bio-ambient requirements of peptide modification. Nevertheless, since the first C‒H 
functionalization of peptides was published, significant advances in this area have been made.78 In 
contrast to previous functionalization approaches, which relied on nucleophilic functions of the 
amino acids in a peptide, C‒H activation reactions can be performed at otherwise unreactive sites in 
the presence of more reactive functional groups. In this way, inter alia aliphatic amino acids became 
interesting for peptide modification reactions. 
Based on early findings on the iridium-catalyzed C‒H borylation of arenes and heteroarenes,79 the 
group of Smith and Maleczka showed the application of this regioselective C‒H borylation method to 
the indole moiety of a Boc-protected tryptophan 56a (Scheme 35a).80 The authors claim the 
importance of the Boc protection, as it serves as a directing group. Shortly after this report, James 
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and coworkers reported on a similar transformation of natural and unnatural amino acids 58 
(Scheme 35b).81 
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Scheme 35: Iridium-catalyzed C‒H borylation of (a) tryptophan80 and (b) unnatural amino acids.81 
 
 
Besides acetoxylation82 and halogenation83 reactions, arylation reactions received significant 
attention, due to the formation of stable carbon–carbon bonds by C‒H arylation reactions. Bedford 
and coworkers published the sequential rhodium-catalyzed twofold C‒H ortho-arylation of tyrosine 
(Scheme 36).84 Prior to the first arylation, a tert-butyl protecting group was installed. For the 
arylation reaction 7.5 mol % [RhCl(PPh3)3] was used, along with catalytic amounts of a phosphonite 
ligand, an aryl bromide and two equivalents of Cs2CO3 in toluene at 110 °C. After the first arylation 
and removal of the tert-butyl group, the arylation procedure was repeated. This procedure gave rise 
to novel disubstituted tyrosines 64. The second arylation resulted in low yields and formation of the 
side-products 65. The introduction of the tert-butyl group gave a racemic tyrosine, thus the obtained 
products 64 and 65 were racemic. 
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Scheme 36: Rhodium-catalyzed sequential C‒H diarylation of tyrosine.84 
 
Given the versatility of palladium catalysts, several further palladium-catalyzed C‒H arylation 
methods were developed, including C5 arylation of histidine85 and C2 arylation of tryptophan.86 
These palladium-catalyzed arylations are similar in two aspects: The use of a palladium(II) catalyst, 
mostly Pd(OAc)2, and some aryl electrophiles, such as aryl iodides or diaryliodonium salts, or 
nucleophiles, such as aryl boronic acids. For scavenging the iodide, silver salts were used. 
In 2010, the group of Lavilla reported the palladium-catalyzed C‒H arylation of tryptophan 56b using 
four equivalents of aryl iodides 66, 5 mol % Pd(OAc)2, 1.5 equivalents of 2-nitrobenzoic acid as the 
ligand and one equivalent of AgBF4 (Scheme 37).86b The reaction was carried out in DMF at 150 °C 
under microwave irradiation for 5 min. A slightly modified procedure was applied to tryptophan-
containing peptides 68. Here, the relative amount of aryl iodide 66 was increased to ten equivalents 
and the reaction took place at a pH 6 in phosphate buffer at 80 °C. 
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Scheme 37: Palladium-catalyzed C‒H arylation of (a) tryptophan and (b) tryptophan peptides.86b 
 
The authors considered either a palladium(0)/palladium(II) or a palladium(II)/palladium(IV) catalytic 
cycle.86a In the palladium(II)/palladium(IV) case, the indole undergoes a palladation via a concerted 
metalation deprotonation mechanism to generate complex 71 (Scheme 38). The following oxidative 
addition of aryl iodide 66 leads to the palladium(IV) complex 72 from which the silver cation removes 
the iodide, promoting the reductive elimination of the product 67 and regenerating the palladium(II) 
catalyst 70. 
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Scheme 38: Catalytic cycle of the palladium-catalyzed C‒H arylation.86a 
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Slightly modified reaction conditions were applied to the synthesis of brevianamide F (73), a cyclized 
dipeptide consisting of tryptophan and prolin (Scheme 39). A small library of arylated brevianamide F 
analogues 74 was assembled regarding different aryl moieties on the indole.86e Biological evaluation 
of the activity of the novel brevianamides 74 revealed para-trifluoromethylphenylated diketo-
piperazine 74a to possess higher activity against the tested human cancer cell lines as compared to 
the natural brevianamide F (73). Thus, this finding demonstrated that a change of the indole moiety 
had a large effect on the bioactivity of this small drug. 
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Scheme 39: Brevianamide F and its analogues.86e 
 
 
As the reaction conditions that are required for reaching full conversions are quite harsh and in some 
cases an epimerization of the stereocenter was observed,86e milder methods were desired. Thus, 
Fairlamb and coworkers published a similar arylation method with improved reaction conditions,86c 
which were peviously developed by Sanford.23c Tryptophan 56b was phenylated using a 
diphenyliodonium salt, which was in situ generated from PhB(OH)2 and PhI(OAc)2 (Scheme 40a). The 
reaction was performed in acetic acid at a relatively low temperature of 40 °C for 15 h. When these 
reaction conditions turned out to be limited to PhB(OH)2 while other arylboronic acids did not yield 
the desired products, a further optimization revealed that the use of Cu(OAc)2 and air as the oxidant 
instead of the iodonium compound is more beneficial for reactions on peptides 68 (Scheme 40b). 
During the reaction, the authors observed the formation of palladium nanoparticles (PdNPs), which 
they were able to encapsulate with a polymer stabilizer for analysis. Independently synthesized 
PdNPs were demonstrated to be catalytically active under the given reaction conditions. This finding 
supports the assumption that a Pd(0)/Pd(II) catalytic cycle prevails. 
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Scheme 40: Palladium-catalyzed C‒H arylation of (a) tryptophan and (b) tryptophan peptides.86c 
 
In addition to palladium-catalyzed arylation reactions, iridium87 and ruthenium40,43 complexes were 
found to perform C(sp2)‒H bond activation. Loach and coworkers demonstrated the C2,C7-
diboronation of the indole of a tryptophan 56d by applying 2.5 mol % [Ir(cod)OMe]2, 5 mol % of 
dtbpy as the ligand and five equivalents of pinacolborane as the boron source (Scheme 41). The 
reaction was performed in THF at 60 °C. Since the C2 position was faster boronated, the excess of 
pinacolborane was required in order to boronate the C7 position as well. A removal of the boron in 
the C2 position with TFA in CH2Cl2 delivered the C7-boronated indole 76. 
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Scheme 41: Iridium-catalyzed C7-boronation of tryptophan.87 
 
During their studies on the ruthenium-catalyzed arylation of pyrimidyl indoles by the Ackermann 
group,40 this method was applied exemplarily to tryptophan 56e to yield the desired product 67eb in 
41% (Scheme 42). Here, the catalytic system consisted of 5 mol % [RuCl2(p-cymene)]2 and 60 mol % 
1-adamantanecarboxylic acid, combined with three equivalents of K2CO3 in m-xylene at 120 °C. It is 
notable that this example was the first non-palladium transition metal-catalyzed direct C‒H 
functionalization of an amino acid. 
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Scheme 42: Ruthenium-catalyzed C‒H arylation of tryptophan.40 
 
A second example of a ruthenium-catalyzed C2 arylation was presented by Pilarski and coworkers 
(Scheme 43).43 In this case four equivalents of ferroceneboronic acid, 2.5 mol % [RuCl2(p-cymene)]2, 
12 mol % AgSbF6 and one equivalent of Cu(OAc)2∙H2O were used. The reaction was set up in 
isopropanol at 120 °C and the product 67fc was obtained in 76% yield. This example nicely 
demonstrated a dye labeling of tryptophan, since ferrocene absorbs light in the visible spectral 
range. 
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Scheme 43: Ruthenium-catalyzed C‒H arylation of tryptophan.43 
 
A metal-free approach to C2-arylated peptidomimetics was realized by the group of Ackermann 
(Scheme 44).39 The simple catalytic system contained only the two substrates, namely a peptide 77 
and a diaryliodonium salt 78, in DMF. The reaction mixture was heated to 100 °C, delivering peptides 
79 in good yields. During the optimization of this reaction, the influence of the diaryliodonium 
counterion on the product yields became clear. Tosylates 78 turned out to be better suited than 
tetrafluoroborates, trifluoroacetates or bromides. A range of di- and tripeptides 77 as well as a 
hexapeptide successfully underwent the transformation with differently-substituted diaryliodonium 
salts 78. 
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Scheme 44: Metal-free C‒H arylation of indole peptides.  
 
Under metal-free conditions the indolylacetamide moiety was exclusively arylated, even in the 
presence of the indole of a tryptophan (Scheme 44). In contrast, under palladium catalysis the 
tryptophan indole was C–H arylated. The palladium-catalyzed C–H arylation approach developed by 
the Ackermann group gave rise to arylated peptides 81 using diaryliodonium salts 78 (Table 1).88 The 
first optimization approach regarding the C‒H arylation of the tripeptide 80a with 1.5 equivalents of 
diphenyliodonium tosylate (78a) revealed that different copper species combined with various 
solvents were only able to perform the arylation with unsatisfactory yields of at most 41% (entry 1). 
The use of palladium as the catalyst gave much better results (entries 2‒12). A reaction using 
5.0 mol % Pd(OAc)2, [(MeCN)2PdCl2] or Pd(TFA)2 as catalysts and either DCE or acetic acid as the 
solvent, at ambient temperature turned out to be the most suitable conditions by giving the desired 
product 81aa in up to 99% yield (entries 4, 5, 10, 11). Lowering the palladium loading to 2.5 or 
0.5 mol % still delivered the arylated peptide 81aa in acceptable yields of 68 and 61%, respectively 
(entries 6 and 7). 
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Table 1: Optimization of the C‒H arylation of tripeptide 80a.a, 88 
N
H
H
H
N
Ac-Ala Gly-OEt
O
catalyst+    [Ph2I]OTs solvent
23 °C, 17 h
80a 78a
(1.5 equiv)
N
H
Ph
H
N
Ac-Ala Gly-OEt
O
81aa
 
entry catalyst (5.0 mol %) solvent yield 
1 Cu(I) or Cu(II) various 0‒41% 
2 Pd(OAc)2 DMF 59% 
3 Pd(OAc)2 toluene 66% 
4 Pd(OAc)2 DCE 85% 
5 Pd(OAc)2 HOAc 99% 
6 Pd(OAc)2 (2.5 mol %) HOAc 68% 
7 Pd(OAc)2 (0.5 mol %) HOAc 61% 
8 Pd(OAc)2 CF3CO2H 39% 
9 PdCl2 HOAc 52% 
10 (MeCN)2PdCl2 HOAc 99% 
11 Pd(TFA)2 HOAc 99% 
12 Pd(TFA)2 CF3CO2H 46% 
a: Reaction conditions: 80a (0.20 mmol), 78a (0.30 mmol), catalyst (5 mol %), solvent (3.0 mL), 23 °C, 17 h. 
 
Using the optimal conditions shown in entry 5, the scope was examined with symmetrical and 
unsymmetrical diaryliodonium salts, providing the corresponding peptides 81 in high yields (Table 2). 
Further exploration of this arylation method even allowed the use of water as the reaction medium. 
Consequently, the scope of the reaction of peptide 80a with symmetrical diaryliodonium tosylates 78 
was reexamined with water instead of the organic solvent, which afforded peptides 81. 
Table 2: Scope of the C‒H arylation of tripeptide 80a.88 
N
H
H
H
N
Ac-Ala Gly-OEt
O
Pd(OAc)2 (5 mol %)+    [Ar2I]OTs
HOAc or H2O
23 °C, 17 h
80a 78
(1.5 equiv)
N
H
Ar
H
N
Ac-Ala Gly-OEt
O
81
 
entry Ar compound yield in HOAc yield in H2O 
1 C6H5 (78a) 81aa 99% 70% 
2 4-MeOC6H4 (78b) 81ab 85% 80% 
3 2,4-Me2C6H3 (78c) 81ac 51% 71% 
4 4-FC6H4 (78d) 81ad 93% 95% 
5 4-ClC6H4 (78e) 81ae 94% 64% 
6 4-BrC6H4 (78f) 81af 79% 54% 
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In order to examine the applicability of this method to other peptides, several different tryptophan 
peptides 80 were submitted to the phenylation with diphenyliodonium tosylate (78a) (Scheme 45). 
Peptides 81 bearing aliphatic and aromatic amino acids as well as methyl ester protected glutamic 
and aspartic acid and benzoyl protected serine and tyrosine were isolated in good to excellent yields 
of 56‒98%. 
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Scheme 45: Scope with various tripeptides 80.88,89 
 
The results for this palladium-catalyzed C–H arylation method set the stage for further examination 
of this reaction in this thesis. 
 
While the cleavage of the relatively activated C(sp2)‒H bonds was realized straightforward, the 
activation of the more challenging C(sp3)‒H bonds was also achieved. In their studies on the 
application of peptides as ligands for palladium-catalyzed C‒H activation reactions, the Yu group 
reported on the arylation and acetoxylation of N-terminal alanine in di-, tri- and tetrapeptides 82 
(Scheme 46a).90 With the arylation of alanine, newly substituted phenylalanine peptides 83 were 
prepared. Pd(OAc)2 was used as the catalyst with no need for additional ligands, since the peptide is 
believed to take over this role. The proposed complexes 85 show the peptides pincer-like wrapping 
the palladium (Scheme 46b). 
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Scheme 46: Palladium-catalyzed C(sp3)‒H arylation of alanine. (a) Scope of the arylation reaction and (b) proposed 
palladium complexes of the C‒H activated peptides.  
 
Moreover, other C‒C bond forming reactions were demonstrated recently, such as C‒H 
carbonylation cyclization of valine,91 diastereoselective arylation of proline92 as well as arylations of 
glycine93 and alkynylation of tryptophan,94 such as the manganese-catalyzed C–H alkynylation of 
tryptophan peptides 86 with bromoacetylenes 87 developed by the Ackermann group in 2017 
(Scheme 47).93d 
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Scheme 47: Manganese-catalyzed C–H alkynylation of peptides. 
 
Another aim of C‒H modification reactions on peptides is the formation of carbon-heteroatom 
bonds. For example, the introduction of 18F can be used for radiolabeling of drug peptides for 
tracing.95 So far, selective methods have been developed using a manganese96 or a palladium97 
catalyst to afford β-fluorinated α-amino acids. 
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To summarize, while tag and modify strategies are frequently applied to proteins, C‒H modification 
reactions are scarcely used and the proof-of-concept reports that exist today are limited to small 
peptides. Despite the notable progress over the past decade, there is still much room for 
improvement. 
 
1.4.2 Chemical Peptide Cyclization including On-Resin Reactions 
The first bioactive cyclopeptide, gramicidin S (89, Scheme 48), was discovered in 1947.99 Since then, 
attention for cyclopeptides has been rising and chemical cyclization methods for cyclopeptides100 and 
structurally related cyclopeptide alkaloids101 have been developed. The term cyclopeptide is referred 
to as any form of cyclized peptide, in particular these are side chain to side chain cycles, backbone 
cycles, terminus to side chain cycles and backbone cycles containing an inhibitory-cysteine knot (ICK) 
domain. Naturally occurring peptides are associated with diverse biological activities, such as 
cytotoxic, antimicrobial and anti-HIV properties. The cyclization of a peptide increases its molecular 
stability and thus enhances its resistance towards degradation and therefore increases its half-life.108 
This is of particular interest for the development of orally available pharmaceuticals. 
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Scheme 48: Gramicidin S. 
Chemical cyclization of peptides has been realized via hydrocarbon stapling, like click reactions102 and 
ring-closing metathesis (RCM),103 hydrogen bond surrogate (HBS) stapling,104 intramolecular disulfide 
formation,105 peptide grafting106 and by use of lasso peptides107 (Scheme 49). 
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Scheme 49: Examples for peptide helix stabilization by cyclization. (a) Attachment of cysteines to a biaryl. (b) RCM to 
stabilize one coil. (c) RCM to stabilize two coils. 
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Backbone cyclizations can be achieved on-resin directly after SPPS utilizing resins with certain linkers 
to cleave the peptide from the resin through the cyclization procedure. Alternatively, certain 
cleavage procedures based on thioesters allow cyclization in solution.109,110 
Many cyclization reactions including metatheses, cross-coupling and click reactions, can also be 
carried out on the solid support.100e Additionally, C‒H activation methods have been applied for 
cyclizing peptides.111 Dong and coworkers used a palladium-catalyzed C‒H arylation procedure to 
connect para- or meta-iodophenylalanine and tryptophan within a peptide 90 (Scheme 50).111b This 
C‒H activation strategy gave rise to peptidomimetics 91, which contain alkane or alkylarene linkers 
and amino acids within the newly formed cycle. According to the Ruggli-Ziegler dilution principle, the 
reactions were performed at a low concentration of 0.03 M. 
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Scheme 50: Cyclization via palladium-catalyzed arylation of tryptophan.  
 
The groups of Lavilla and Albericio demonstrated a palladium-catalyzed cyclic dimer formation of 
tryptophan-peptides containing an ortho-, meta- or para-iodophenylalanine (Scheme 51).111a In order 
to prevent polymerization, the reactions were carried out at relatively low peptide concentrations of 
0.10‒0.25 M. Still, for i,i+1- and i,i+2-amino acid distance between tryptophan and para-
iodophenylalanine the formation of dimer 94 was predominant, while for larger peptides with a 
i,i+3- and i,i+4-located tryptophan and para-iodophenylalanine mainly the cyclic monopeptides 93 
were obtained. 
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Scheme 51: Cyclization via palladium-catalyzed arylation of tryptophan.111a 
 
Furthermore, the work of Albericio showed a palladium-catalyzed C(sp3)‒H arylation of the methyl 
group of alanine peptides with iodophenylalanine and its derivatives 95 (Scheme 52).111c Several 
cyclic peptides 96 were obtained by this procedure. In addition, this method was demonstrated 
exemplarily for the cyclization of peptides that were still anchored to the solid support. SPPS was 
carried out up to the phthalide protected alanine residue that was subjected to the C‒H arylation. 
The cyclization reaction was set up with a higher amount of the catalyst and thereafter, the peptide 
was prolonged by SPPS, after which a standard cleavage procedure afforded cyclic peptides 99. On-
resin peptide modifications have unbeatable advantages compared to reactions in solution. The 
purification, which is one major issue in peptide chemistry, is easily done just by washing out all 
reagents, without any loss of peptide. The reaction can be driven to completion by using a large 
excess of any reagent without hindering the purification procedure. Additionally, the poor solubility 
of polar peptides in organic solvents does not need to be of concern. Also no aggregation or 
jellification can occur. Especially for cyclization reactions, the resin-supported approach is powerful, 
because no dimers or polymers can be formed, whereas the reaction can be performed at high 
substrate and catalyst concentrations. This facilitates higher reaction rates as compared to diluted 
reaction mixtures. The necessary amount of solvent only depends on the swelling properties of the 
employed resin. After cleavage of the peptide from the resin, the yields depend mainly on the 
completeness of the cleavage and on the purification procedure. 
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Scheme 52: Cyclization via palladium-catalyzed arylation of alanine (a) in solution and (b) on-resin.111c 
 
The already mentioned manganese-catalyzed C–H alkynylation approach (Scheme 47) was also 
applied for the cyclization of a peptide (Scheme 53). The bromoalkyne was introduced into the 
peptide 86d via an ethyleneglycole moiety at the C-terminus. This allowed the formation of the 
cyclopeptide 88d. 
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Scheme 53: Cyclization via manganese-catalyzed C–H alkynylation. 
 
 
In summary, large advances in peptide and protein modification and functionalization methods have 
been achieved in recent years. Selective transformations enable specific applications and facilitate 
biological studies. So far, applications described in the literature range from 
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 labeling via introduction of radioactive or heavy isotopes or fluorophores, 
 change of solubility via PEGylation, 
 change of the peptide function via glycosylation, phosphorylation, biotinylation, lipidation, ubiqui-
tination or cyclization 
 stabilization of the three-dimensional structures to enhance reactivity via cyclization, 
 ligations to provide access to otherwise non-feasible syntheses of peptides, 
 change of properties for oral administration of peptide therapeutics112 as well as  
 change of peptide properties to diversify food properties.113 
Besides biological applications, chemical syntheses also make use of peptide modifications, for 
example by using peptides as ligands for stereoselective reactions or by mimicking biological systems 
to facilitate the construction of complex structures. 
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2 Objectives 
C‒H activation has emerged as a powerful tool for selective and more efficient chemical syntheses in 
comparison to previously used strategies. For modification of peptides, reactions relying on the 
direct C‒H cleavage are scarce as different kinds of drawbacks need to be overcome. Many C‒H 
activation procedures require the exclusion of air and water, the use of strong bases, which could 
racemize the stereocenters of amino acids and/or damage certain functionalities, or the use of 
strong acids, which could cleave the amide bonds or demolish other functional groups associated 
with peptides. Another obstacle can be a significantly decreased reaction rate, due to the fact that 
peptides posses several Lewis basic sites, which increase the possibilities to coordinate and chelate 
the transition metal at different positions (Scheme 54). This circumstance reduces the probability of 
coordination to the transition metal in the desired position and therefore results in a less efficient 
catalysis. 
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Scheme 54: Examples for coordination of the transition metal at different sites in a peptide. 
 
Regarding the potential of and need for new peptide designs, the goal of this thesis was to develop 
C‒H activation reactions that can be applied to peptides. Tryptophan was the amino acid of choice, 
because of its relatively low natural abundance and its distinct spectroscopic properties. 
 
 
2.1 Palladium-Catalyzed C‒H Arylation with Diaryliodonium Salts 
Lavilla86a,b and Fairlamb86c,d presented two approaches for the palladium-catalyzed C2‒H arylation of 
tryptophan peptides using aryl iodides or arylboronic acids as arylating agents. In contrast, in our 
group, a metal-free C2‒H arylation of indole-3-acetamides 77 was developed (Scheme 44).39 This 
method has two main advantages, namely transition metal-free reaction conditions and the use of 
diaryliodonium salts as mild electrophiles. However, this method is limited to peptides bearing an 
unnatural indole-3-acetamide fragment, as the procedure selectively facilitated the arylation of the 
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indole-3-acetamide moiety, while no reaction of a tryptophan indole moiety was observed. Based on 
these findings and the intention to use natural tryptophan peptides directly, a palladium-catalyzed 
procedure with diaryliodonium salts was developed by Dr. Yingjun Zhu and further examined by 
Michaela Bauer in our group. In order to extend the scope of this method, its applicability to peptides 
80, which bear amino acids with unprotected functionalities, should be examined (Scheme 55). 
Moreover, the robustness of this procedure was to be probed further by carrying out the reaction of 
the tripeptide 80a with diphenyliodonium tosylate (78a) in the presence of one equivalent of an 
amino acid 100, which bears further unprotected functional groups (Scheme 56). 
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Scheme 55: Palladium-catalyzed C‒H arylation of unprotected peptides. 
N
H
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H
N
Ac-Ala Gly-OEt
O
+    [Ph2I]OTs    +    Ac-AA-OH
80a 78a
(1.0 equiv)
N
H
Ph
H
N
Ac-Ala Gly-OEt
O
81aa
cat. Pd(OAc)2
100
(1.0 equiv)  
Scheme 56: Palladium-catalyzed arylation of peptide 80a in the presence of amino acids 100. 
 
 
2.2 Ruthenium-Catalyzed C‒H Arylation of Tryptophan-Containing Peptides 
Despite the advantages and versatility associated with palladium as a catalyst for C‒H activation 
reactions, which are described in chapters 1.1 and 1.4, some drawbacks remain. A reasonable 
alternative is ruthenium, because it is considerably cheaper than palladium114 and still capable to 
perform diverse C‒H transformations as described in chapters 1.2‒1.4. Based on the example of the 
ruthenium-catalyzed C‒H arylation of pyrimidyl tryptophan rac-56e with aryl bromide 28b 
(Scheme 42),40 a similar procedure for tryptophans 56 should be developed (Scheme 57). 
Additionally, the applicability to tryptophan peptides 101 should be explored. While the example 
shown by our group (Scheme 42)40 was performed with a racemic substrate rac-56e, for subsequent 
studies enantiomeric pure L-tryptophan 56e should be used to exclude a potential racemization of 
the tryptophan during the catalytic reaction. 
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Scheme 57: Ruthenium-catalyzed C‒H arylation of tryptophan peptides. 
 
To exploit the contrary reactivities of palladium and ruthenium, peptides 103 containing an NH-free 
tryptophan and one with a directing group were to be submitted to a subsequent selective twofold 
C‒H arylation (Scheme 58). 
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Scheme 58: Sequential twofold C‒H arylation of peptides 103. 
 
 
2.3 Ruthenium-Catalyzed C‒H Alkylation of Tryptophan-Containing Peptides 
Among the C‒H activation strategies applied for modifications of peptides, arylation reactions have 
been most extensively studied. The incorporation of an aryl group has certain effects on the 
substrate, such as a significant change of the fluorescent and absorption properties, as well as a 
potential change of the three-dimensional structure due to the formation of twisted biaryls in the 
case of tryptophan, tyrosine and histidine. Contrasting these effects, alkylation of peptides may be 
used for alternative intentions. For example, the introduction of long aliphatic chains could help to 
solubilize polar peptides in organic solvents. Furthermore, alkylation might help to prevent 
precipitation since long aliphatic chains hinder crystal packing. 
Since thus far only very few examples for C‒H alkylation reactions on peptides are known, our 
interest arose in developing C‒H alkylation methods that are suitable for peptides. Based on the 
ruthenium-catalyzed hydroarylation procedure published by our group (Scheme 28),57e a related 
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approach for peptides should be feasible (Scheme 59). Analogous to the conversion of 
phenylpyridines 47 with unactivated alkenes 44 in the presence of a ruthenium catalyst and a 
carboxylate salt, tryptophan peptides 101 should be able to hydroarylate alkenes 44 to provide 
alkylated peptides 107. 
 
44
cat. [Ru]
N
DG
N
H
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DG
+
ligand, base, solvent
R
R
peptide
101 107  
Scheme 59: Ruthenium-catalyzed C‒H alkylation of tryptophan peptides. 
 
 
2.4 Applications for the C‒H Functionalization Reactions 
Among the C‒H activation procedures presented in chapters 2.1–2.3, cyclization reactions of 
peptides had inter alia the highest level of our interest. The importance of chemical cyclization of 
peptides is described in chapter 1.4.2. Peptides could be cyclized by a C‒H arylation strategy using a 
dihaloarene (Scheme 60 a) to doublearylate a peptide 108, which contains two tryptophans. Another 
possibility (b) could be the incorporation of a halogenated phenylalanine into a tryptophan peptide 
110, which could then be cyclized through ruthenium catalysis, leading to cyclopeptides 111. 
Additionally, comparable methods based on the hydroarylation procedure presented in chapter 1.3 
appeared feasible. A twofold alkylation (c) of peptide 108 with a dialkene 44 would lead to 
cyclopeptides 112, while an intramolecular alkylation (d) of tryptophan peptides 113 that contain an 
amino acid with a terminal alkene, would provide cyclic peptides 114. 
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Scheme 60: Peptide cyclization by (a) twofold C‒H arylation, (b) intramolecular C‒H arylation, (c) twofold 
hydroarylation and (d) intramolecular hydroarylation. 
 
 
Another application of interest was the ligation of peptides. Peptide ligation does not only give rise to 
larger peptides, which otherwise might be difficult to prepare and infeasible to purify, it also allows 
the construction of new peptide motifs and unusual peptide branchings. Conceivable methods for 
peptide ligation could be the reaction of a tryptophan peptide 101 with (a) 0.5 equivalents of a 
dihaloarene 28 or with (b) 0.5 equivalents of a dialkene 44 to provide dimerlike peptides 117 and 
116, respectively (Scheme 61). If peptide 101 underwent a coupling with (c) one equivalent of a 
dihaloarene 28 or with (d) one equivalent of a dialkene 44, the corresponding products 102 and 108 
would be formed. These could undergo another similar arylation or alkylation reaction with a peptide 
101, which would form the ligation products 118 and 115. 
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Scheme 61: Peptide ligation by (a) twofold C‒H arylation with identical peptides, (b) twofold C‒H arylation with 
different peptides, (c) twofold hydroarylation with identical peptides and (d) twofold hydroarylation with different 
peptides. 
 
In addition to the already characteristic spectroscopic properties of tryptophan, another aim of this 
work was to label peptides, including labeling with fluorescent moieties (Scheme 62). This should be 
accomplished by (a) C‒H arylation of peptides 68 or 101 with highly fluorescent aryl halides 28, which 
feature extended conjugated π-systems. This method seems suitable because the arylation itself 
already extends the π-system of the indole. Moreover, the hydroarylation method (b) using an 
alkene 44 that is carrying a fluorophore should also be viable. 
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Scheme 62: Peptide labeling by (a) C‒H arylation and (b) hydroarylation. 
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3 Results and Discussion 
3.1 Palladium-Catalyzed C‒H Arylation of Tryptophan-Containing Peptides with 
Diaryliodonium Salts 
Lavilla86a,b and Fairlamb86c,d have presented palladium-catalyzed procedures for the direct C–H 
arylation of tryptophan peptides. Nonetheless, in order to obtain high conversions, those methods 
required a relatively high catalyst loading, an excess of the arylating agent, oxidants and elevated 
temperatures. In contemplation of the harshness of those reaction conditions, a mild protocol for the 
direct C–H arylation of tryptophan peptides was developed by our group (Scheme 45).88 
Since this palladium-catalyzed arylation method was only applied to protected peptides so far, the 
robustness of this procedure had to be proven by an intermolecular competition screening.115 
For this purpose peptide 80a was reacted with one equivalent of diphenyliodonium tosylate (78a) in 
the presence of one equivalent of an acetylated amino acid 100 in water as the reaction medium 
(Table 3). After 17 h at ambient temperature the product 81aa was isolated. When no additional 
amino acid 100 was added, the product 81aa was isolated with a yield of 68% (entry 1). In the case of 
free hydroxygroup-containing amino acids as additives, the resulted yield of peptide 81aa was found 
to be inconsistent (entries 2–4). While tyrosine 100c and serine 100b affected only a slight decrease 
of the yield, the addition of threonine 100a shut down the reaction. The reason might be a 
coordination and binding of the amino acids 100 to palladium, forming catalytically inactive 
complexes 119 (Scheme 63). The same applies to histidine (entry 8). The addition of free amides 
100d and 100e caused a slight decrease of the yield. In contrast, the presence of glutamic acid 100f 
increased the reaction rate, yielding 80% of product 81aa. As glutamic acid is diprotic, it can be 
speculated that protons are involved in the catalytic process and a higher acid concentration has a 
positive effect on the reaction rate. This finding is in accordance with the previously achieved full 
conversion of substrate 80a when using acetic acid as the reaction medium. The reaction with 
glutamic acid was performed by Dr. Yingjun Zhu (entry 7). 
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Table 3: Robustness screening for the palladium-catalyzed C–H arylation.a 
N
H
H
H
N
Ac-Ala Gly-OEt
O
+    [Ph2I]OTs    +    Ac-AA-OH
80a 78a
(1.0 equiv)
N
H
Ph
H
N
Ac-Ala Gly-OEt
O
81aa
Pd(OAc)2 (5 mol %)
H2O
23 °C, 17 h
100
(1.0 equiv)  
entry AA yield entry AA yield 
1 - 68% 5 Asn (100d) 17% 
2 Thr (100a) 10% 6 Gln (100e) 52% 
3 Ser (100b) 46% 7 Glu (100f) 80%b 
4 Tyr (100c) 60%b 8 His (100g) 6% 
a: Reaction conditions: 80a (0.20 mmol), 78a (0.20 mmol), 100 (0.20 mmol), Pd(OAc)2 (5 mol %), H2O (3.0 mL), 23 °C, 
17 h. b: The reaction was performed by Dr. Yingjun Zhu. 
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Scheme 63: Possible binding of amino acids to palladium. 
 
The desire to use a solvent milder than acetic acid and to achieve full conversions at the same time 
led to further attempts to optimize the reaction of peptide 80a with diphenyliodonium tosylate 
(78a). An analysis of the pH course of the reaction in water using a digtal pH meter with a glas 
electrode placed in the reaction tube showed a pH of 3.2 at the beginning of the reaction (Figure 1). 
During the first five hours the pH smoothly declined to 1.8, due to the formation of tosylic acid during 
the reaction. The reaction thus is proposed autocatalyic, because acid accelerates the reaction rate. 
With these findings in hand, initial additions of acids to the reaction mixture were probed. 
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Figure 1: pH curve of the palladium-catalyzed coupling of peptide 80a with diphenyliodonium tosylate (78a). 
 
The addition of two equivalents of acetic acid provided an unsatisfactory result (Table 4, entry 2). As 
during the reaction of the tosylate salt 78a tosylic acid is formed, an addition of one equivalent of 
tosylic acid was probed (entry 3). The resulting yield of 50% was even lower than without the 
addition of acid (entry 1). For the pH curve has the biggest slope at pH 2.5, it can be assumed, that 
the reaction rate was highest at this point. Therefore, a phosphate buffer of pH 2.5 as the reaction 
medium was probed, which gave a disappointing result of 44% yield (entry 4). Because the substrate 
78a is barely dissolvable in water at ambient temperature, the phase transfer catalyst 
tetrabutylammonium bromide (TBAB) was added (entry 5). This shut down the reaction. A slight 
excess of 1.5 equivalents of tosylate 78a increased the yield to 80% (entry 6), but the conversion 
remained incomplete. Since the optimization attempts did not succeed, for further reactions 1.5 
equivalents of the arylating agent 78 and acetic acid or water as the solvent were used. 
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Table 4: Attempts for further optimization of palladium-catalyzed C–H arylation.a 
N
H
H
H
N
Ac-Ala Gly-OEt
O
+      [Ph2I]OTs
80a 78a
(1.0 equiv)
N
H
Ph
H
N
Ac-Ala Gly-OEt
O
81aa
Pd(OAc)2 (5 mol %)
solvent
23 °C, 17 h
 
entry solvent additive yield 
1 H2O - 68% 
2 H2O HOAc (2 equiv) 77% 
3 H2O HOTs (1 equiv) 50% 
4 phosphate buffer pH 2.5 - 44% 
5 H2O TBAB (10 mol %) 0% 
6 H2O - 80%b 
a: Reaction conditions: 80a (0.20 mmol), 78a (0.20 mmol), Pd(OAc)2 (5 mol %), solvent (3.0 mL), 23 °C, 17 h. b: 
1.5 equiv 78a were used. 
 
In order to expand the substrate scope shown in scheme 45, peptides 80 were reacted with 
diphenyliodonium tosylate (78a) to yield arylated peptides 81 (Table 5). As expected, fully protected 
peptides 80k and 80l and a free amide bearing peptide 80m were converted to afford high yields of 
52, 96 and 85% when using acetic acid, and slightly reduced yields when using water as the solvent 
(entries 1–3). Due to the relatively unpolar nature of phenylalanine and its resulting low solubility in 
water, peptide 80k was isolated with a low yield of 25% after the reaction in water. Tripeptide 80n 
with an unprotected C-terminus was obtained with a high yield when reacted in acetic acid, and a 
lower yield when water was used (entry 4). The free amide and carboxyic acid containing substrate 
80o was transformed to the product 81oa in acetic acid in 72% yield (entry 5). The structurally similar 
peptide 80p was reacted in water, but afforded only little formation of 20% of product 81pa, which 
was determined by 1H NMR measurement (entry 6). Neither free amine hydrochloride salt 80q nor 
free amine peptide 80r were tolerated by this palladium-catalyzed C–H arylation (entries 7 and 8). 
The products 81qa and 81ra were not detected and the corresponding starting materials were 
reisolated. Tetrapeptides 81s and 81t bearing tert-butyl and trityl protected threonine and histidine, 
respectively, were submitted to the catalytic reaction in acetic acid in order to cleave the acid labile 
protecting groups and thus set free the hydroxyl group and the imidazole during the reaction (entries 
9 and 10). In both cases, a complex mixture of several arylated compounds was found, which could 
not be separated. Methionine-containing substrate 80u was not converted, likely because thioethers 
are strong Lewis bases and hence potential poisons to the catalyst (entry 11). For the reason that the 
synthesis of small peptides, such as the presented tri- and tetrapeptides, is conventionally carried out 
in solution, which is much cheaper than SPPS, the peptides were assembled stepwise from Boc-
protected amino acids. For the synthesis of peptides 80 the N-terminal acetylation is the last and 
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unfortunately relatively low-yielding step. To confront this disadvantageous synthetic step, it is 
desirable to use Boc-protected peptides directly. Hence, Boc-peptide 80v was probed in the 
palladium-catalyzed arylation in acetic acid (entry 12). As expected, the peptide 81va was partially 
deprotected and the free amine shut down the reaction, so that no arylated product could be 
isolated. On the other hand, no deprotection occurred in water. However, due to the low solubility of 
the unpolar Boc-phenylalanine peptide 80v and the resulting reduced reaction rate, only 23% yield of 
product 81va was obtained. 
Table 5: Further scope of the palladium-catalyzed arylation of peptides 80. 
N
H
H
Pd(OAc)2 (5 mol %)+    [Ph2I]OTs
HOAc or H2O
23 °C, 17 h
80 78a
(1.5 equiv)
peptide
81
N
H
Ph
peptide
 
entry product yield  entry product yield 
1 
N
H
Ph
H
N
Ac-Phe-Gly OMe
O
81ka  
25% (H2O) 
52% (HOAc)  7 
N
H
Ph
H
N
Gly-OEt
O
H-Ala
·HCl
81qa  
0% (H2O)c 
2 
N
H
Ph
H
N
Ac-Ala Gly-OMe
O
81la  
67% (H2O) 
96% (HOAc)  8 
N
H
Ph
H
N
OMe
O
H-Gly
81ra  
0% (H2O)c 
3 
N
H
Ph
H
N
OMe
O
Ac-Asn-Gly
81ma  
63% (H2O) 
85% (HOAc)  9 
N
H
Ph
H
N
Ac-Thr-Gly Gly-OMe
O
81sa  
0% (HOAc)d 
4 
N
H
Ph
H
N
Ac-Ala Gly-OH
O
81na  
49% (H2O) 
80% (HOAc)  10 
N
H
Ph
H
N
Ac-His-Gly Gly-OMe
O
81ta  
0% (HOAc)e 
5 
N
H
Ph
H
N
Gly-OH
O
Ac-Gln-Gly
81oa  
72% (HOAc)  11 
N
H
Ph
H
N
Ac-Met-Gly OMe
O
81ua  
0% (HOAc) 
6 
N
H
Ph
H
N
OH
O
Ac-Asn-Gly
81pa  
20%b (H2O)  12 
N
H
Ph
H
N
Boc-Phe-Gly OMe
O
81va  
23% (H2O) 
0% (HOAc) 
a: Reaction conditions: 80 (0.20 mmol), 78a (0.30 mmol), Pd(OAc)2 (5 mol %), HOAc (3.0 mL) or H2O (3.0 mL), 23 °C, 
17 h. b: The conversion was determined by 1H NMR (IntStd trimethoxybenzene). c: The reaction was carried out at 
40 °C. d: tBu-protected peptide 80s was used. e: Trityl-protected peptide 80t was used. 
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The methionine peptide 80u possessing a thioether group was anticipated to be challenging, because 
the thioether is capable to coordinate to palladium irreversibly, and thus stop the catalysis. Further 
attempts to arylate peptide 80u were thus done (Table 6) by applying three equivalents of Pd(OAc)2 
in order to provide free palladium, while one equivalent is bound to methionine (entry 1). After the 
reaction no peptide — neither starting material nor product — could be detected in solution. An 
excess of ethane-1,2-dithiole was added to set free the peptide, but still no peptide could be 
observed in solution. However, a solid was formed which could not be analyzed by NMR, because it 
was insoluble in CDCl3 or DMSO-d6. According to studies regarding the affinity of sulfur to metals, 
zinc appears to bind sulfur strongest among the probed metals.116 An addition of zinc might therefore 
saturate the sulfur and ensure that the palladium stays free to proceed the C–H activation reaction. 
Nonetheless, neither the addition of three equivalents of elemental zinc nor zinc bromide furnished 
arylated product 81ua (entries 2 and 3). 
 
Table 6: Further attempts to palladium-catalyzed C–H arylate peptide 80u.a 
+      [Ph2I]OTs
80u 78a
(1.5 equiv)
23 °C, 17 hN
H
H
H
N
Ac-Met-Gly OMe
O
81ua
N
H
Ph
H
N
Ac-Met-Gly OMe
O
2) xs HS
SH
1) Pd(OAc)2 (3.0 equiv)
additive, HOAc
 
entry additive yield 
1 - 0% 
2 Zn (3.0 equiv) 0% 
3 ZnBr2 (3.0 equiv) 0% 
a: Reaction conditions: 80u (0.20 mmol), 78a (0.30 mmol), Pd(OAc)2 (0.60 mmol), additive (0.60 mmol), HOAc 
(3.0 mL), 23 °C, 17 h. 
 
 
Overall, these results demonstrated a good compatibility with carboxylic acids and free amides, 
which are both common functional groups in biological environments. Unfortunately, more 
sophisticated functional groups, such as hydroxyl groups and amines, imidazoles and thioethers, 
were not tolerated by the palladium-catalyzed C–H arylation. 
 
 
 
 
 
 
Results and Discussion 
47 
 
3.2 Ruthenium-Catalyzed C‒H Arylation of Tryptophan-Containing Peptides 
Based on the ruthenium-catalyzed C–H arylation of indoles with aryl bromides and chlorides 
developed in our group (Scheme 21),40 a C–H arylation method should be developed for structurally 
complex peptides. The tryptophan example that was previously demonstrated was a preliminary 
result with a racemic amino acid. It afforded the desired tryptophan rac-56e in an unsatisfactory 
yield of 41% including impurities (Scheme 42). Although this example proved that this C–H arylation 
method is in principle applicable to protected tryptophan, further optimization was needed. 
 
 
3.2.1 Optimization of the Ruthenium-Catalyzed C–H Arylation 
First, the result mentioned above was reproduced, which afforded 33% of the isolated pure 
tryptophan 67eb (Table 7, entry 1). Additionally, a diarylated byproduct 67ebb was isolated in 12% 
yield. Exchanging substrate 56e with acetylated tryptophan 56g caused no significant change in the 
reactivity (entry 2). Therefore, further optimization was done using the cheaper and easier to 
synthesize tryptophan 56g. When the reaction was carried out under air instead of a nitrogen 
atmosphere, no product formation could be observed (entry 3). The use of an aryl iodide 66b 
resulted in almost the same yield as with the corresponding bromide 28b (entry 4). Changing the 
solvent to tert-amyl alcohol, DMSO, DMA, DMF or NMP yielded no product (entries 5–10). In tert-
amyl alcohol and DMSO a cleavage of the methyl ester of substrate 56g was observed. Changing the 
base to CsOPiv or KOAc in meta-xylene or NMP did not improve the yield (entries 11–14). An 
elevated temperature of 140 °C raised the yield of the monoarylated substrate 67gb to 46% 
(entry 15), while 14% of the diarylated species 67gbb was formed. A further increase of the reaction 
temperature or a prolongation of the reaction time beyond 22 h at 120 °C were discarded as too 
harsh conditions. One hour at 140 °C under microwave irradiation yielded 21% of the mono- and 11% 
of the diarylated product (entry 16). Thus, the ratio of the mono- to diarylation considerably 
worsened. Different carboxylic acids or triphenylphosphine did not greatly improve the yield of the 
desired product 67gb (entries 17–21), so that other strategies had to be considered. 
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Table 7: Optimization of the ruthenium-catalyzed C–H arylation of tryptophan. 
Br
OMe
+
[RuCl2(p-cymene)]2 (5 mol %)
additive (30 mol %)
28b
(1.2 equiv)
N
AcHN
CO2Me
2-pym
H
56g
N
AcHN
CO2Me
2-pym
67gb
OMe
base (3.0 equiv), solvent
120 °C, 22 h, N2
N
AcHN
CO2Me
2-pym
67gbb
OMe
OMe
+
 
entry base additive solvent note yield 67gb + 67gbb/% 
1 K2CO3 1-AdCO2H m-xylene 
56e (Boc)/67eb (Boc) instead 
of 56g (Ac)/67gb (Ac) 33 + 12 
2 K2CO3 1-AdCO2H m-xylene - 33 + 7 
3 K2CO3 1-AdCO2H m-xylene under air 0 
4 K2CO3 1-AdCO2H m-xylene aryl iodide 66b was used 31 + 9 
5 K2CO3 1-AdCO2H t-amyl alcohol - 0 
6 K2CO3 1-AdCO2H DMSO - 0 
7 K2CO3 1-AdCO2H DMA - 0 
8 K2CO3 1-AdCO2H DMF - 0 
9 K2CO3 1-AdCO2H NMP - 0 
10 K2CO3 PPh3 NMP - 0 
11 CsOPiv 1-AdCO2H m-xylene - 14 + 0 
12 KOAc 1-AdCO2H m-xylene - traces 
13 CsOPiv 1-AdCO2H NMP - traces 
14 KOAc 1-AdCO2H NMP - 10 + 0 
15 K2CO3 1-AdCO2H m-xylene at 140 °C 46 + 14 
16 K2CO3 1-AdCO2H m-xylene 
1 h at 140 °C under 
microwave irradiation 21 + 11 
17 K2CO3 PhCO2H m-xylene - 11 + 3 
18 K2CO3 PPh3 m-xylene - 40 + 0 
19 K2CO3 MesCO2H m-xylene - 5 + 2 
20 K2CO3 (TRIP)CO2H m-xylene - 12 + 3 
21 K2CO3 Boc-Ile-OH m-xylene - 13 + 4 
a: Reaction conditions: 56g (0.30 mmol), 28b (0.36 mmol), [RuCl2(p-cymene)]2 (5 mol %), additive (30 mol %), base 
(0.90 mmol), solvent (3.0 mL), 120 °C, 22 h, N2. 
 
In order to test if the low conversion was caused by the electron-donating nature of the methoxy 
group of the aryl halogenides 28b/66b, the electron-deficient aryl halogenides 28d/66d were probed, 
which posses an electron-withdrawing ester group. The obtained results were comparable to those 
obtained with aryl halogenides 28b/28b (Scheme 64). 
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CO2Me
+
[RuCl2(p-cymene)]2 (5 mol %)
1-AdCO2H (30 mol %)
(1.2 equiv)
N
AcHN
CO2Me
2-pym
H
56g
N
AcHN
CO2Me
2-pym
67gd:
CO2Me
K2CO3 (3.0 equiv), m-xylene
120 °C, 22 h, N2
28d (Br)
66d (I)
Hal
N
AcHN
CO2Me
2-pym
67gdd:
CO2Me
CO2Me32% (Br)
33% (I)
13% (Br)
traces (I)
 
Scheme 64: Examination of aryl halogenides 28 and 66. 
 
Furthermore, the tryptophans 56g, 56h, 56i and 56b were compared, which were decorated with the 
directing groups 2-pyrimidyl, 2-pyridyl, a carbamoyl group or no directing group (Table 8). While the 
carbamoyl group and no directing group showed no conversion (entries 3 and 4), an outstanding 
result was achieved using 2-pyridine as the directing group, which afforded the arylated product 
67hb in 74% yield along with only 11% of the diarylated byproduct (entry 2). Further optimization 
was carried out using substrate 56h. 
 
Table 8: Examination of directing groups.a 
Br
OMe
+
[RuCl2(p-cymene)]2 (5 mol %)
1-AdCO2H (30 mol %)
28b
(1.2 equiv)
N
AcHN
CO2Me
DG
H
N
AcHN
CO2Me
DG
OMe
K2CO3 (3.0 equiv), m-xylene
120 °C, 22 h, N2
56 67 (mono)
N
AcHN
CO2Me
DG
OMe
67 (di)
+
OMe
 
entry DG starting material product yield mono + di/% 
1 2-pym 56g 67gb + 67gbb 33 + 7 
2 2-py 56h 67hb + 67hbb 74 + 11 
3 (CO)NH2 56i 67ib 0 
4 H 56b 67bb 0 
a: Reaction conditions: 56 (0.30 mmol), 28b (0.36 mmol), [RuCl2(p-cymene)]2 (5 mol %), 1-AdCO2H (30 mol %), K2CO3 
(0.90 mmol), m-xylene (3.0 mL), 120 °C, 22 h, N2. 
 
 
When the reaction was performed at 120 °C, the conversion was complete, affording 74% yield of 
the arylated tryptophan 67hb (Table 9, entry 1). In order to probe if lower reaction temperatures 
sufficed, the reaction was carried out at 100 and 80 °C, which afforded only incomplete conversions 
and lower yields (entries 2 and 3), while at 60 °C no conversion was detected (entry 4). The 
reactivities of different aryl halides were probed by performing the corresponding reactions at 80 °C, 
so that the conversions were incomplete and a comparison was meaningful. In contrast to the aryl 
chloride 2b, which was not reactive, the aryl iodide 66b delivered a comparable result as the aryl 
Results and Discussion 
50 
 
bromide 28b (entries 5 and 6). Since previous studies revealed phosphines to be suitable additives 
for different transition metal-catalyzed transformations, triphenylphosphine and tricyclohexylphos-
phine were tested, yielding product 67hb in 66 and 90%, respectively (entries 7 and 8). Notably, no 
formation of diarylated species could be observed when phosphines were applied. 
 
Table 9: Optimization with tryptophan 56h and aryl halides.a 
OMe
+
[RuCl2(p-cymene)]2 (5 mol %)
additive (30 mol %)
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
OMe
base (3.0 equiv), solvent
T, 22 h, N2
56h 67hb
(1.2 equiv)
66b (I)
28b (Br)
2b (Cl)
Hal
 
entry Hal additive base solvent T/°C yield 
1 Br 1-AdCO2H K2CO3 m-xylene 120 74% 
2 Br 1-AdCO2H K2CO3 m-xylene 100 53% 
3 Br 1-AdCO2H K2CO3 m-xylene 80 26% 
4 Br 1-AdCO2H K2CO3 m-xylene 60 0% 
5 I 1-AdCO2H K2CO3 m-xylene 80 30% 
6 Cl 1-AdCO2H K2CO3 m-xylene 80 0% 
7 Br PPh3 K2CO3 m-xylene 120 66% 
8 Br PCy3 K2CO3 m-xylene 120 90% 
a: Reaction conditions: 56h (0.30 mmol), aryl halide (0.36 mmol), [RuCl2(p-cymene)]2 (5 mol %), additive (30 mol %), 
base (0.90 mmol), solvent (3.0 mL), 22 h, N2. 
 
 
For the reasons that phosphines are relatively toxic and harmful to the environment, and at the same 
time user-unfriendly as they tend to be oxidized by air oxygen so that a storage under exclusion of air 
is necessary, the aim was to identify a more environmentally benign and user-friendly additive. 
Further optimization was undertaken with the aryl halides 28d and 66d, because it was impossible to 
separate the tryptophan 67hb from the starting material and the diarylated byproduct by column 
chromatography on silica, while the GPC purification was rather time-consuming and costly. The 
product 67hd, on the other hand, could be purified by column chromatography on silica. 
Different combinations of additives, bases and solvents were examined (Table 10).117 A part of the 
optimization was performed by Prof. Dr. Hongjun Ren. Among the commonly used benzoic acids and 
inorganic bases, pentafluorobenzoic acid combined with potassium phosphate revealed to perform 
the arylation reaction with full conversion, delivering 83% yield of the desired product 67hd (entry 9). 
Suitable solvents for this transformation seemed to be the aromatic toluene (entry 19) and meta-
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xylene (entries 4, 6, 7, 9, 10). Other solvents, such as GVL (entry 5, 13, 14), NMP, DMF, DME and DMA 
turned out to harm the process (entries 15–18). RuCl3∙(H2O)n and [RuCl2(benzene)]2 did not perform 
as well as did [RuCl2(p-cymene)]2 (entries 20 and 21). With the optimized reaction conditions in 
hand, the scope of the reaction was explored. Either the combination of 1-adamantanecarboxylic 
acid and potassium carbonate or pentafluorobenzoic acid and potassium phosphate in meta-xylene 
was used for the following reactions. 
Table 10: Optimization with tryptophan 56h and aryl halide 28d.a 
Br
CO2Me
+
[Ru] (5 mol %)
additive (30 mol %)
28d
(1.1 equiv)
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
CO2Me
base (3.0 equiv), solvent
120 °C, 22 h, N2
56h 67hd
 
entry [Ru] additive base solvent yield 
1 [RuCl2(p-cymene)]2 1-AdCO2H KOAc m-xylene 22%b 
2 [RuCl2(p-cymene)]2 MesCO2H KOAc m-xylene 0%b 
3 [RuCl2(p-cymene)]2 - KOAc m-xylene 0%b 
4 [RuCl2(p-cymene)]2 
1-AdCO2H K2CO3 m-xylene 70% 
5 [RuCl2(p-cymene)]2 1-AdCO2H K2CO3 GVL 15%b 
6 [RuCl2(p-cymene)]2 F5C6CO2H K2CO3 m-xylene 69%b 
7 [RuCl2(p-cymene)]2 1-AdCO2H K3PO4 m-xylene 64%b 
8 [RuCl2(p-cymene)]2 (3-F3CC6H4)CO2H K3PO4 m-xylene 11% 
9 [RuCl2(p-cymene)]2 
F5C6CO2H K3PO4 m-xylene 83% 
10 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 m-xylene 78%c 
11 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 m-xylene 11%d 
12 [RuCl2(p-cymene)]2 (TRIP)CO2H K3PO4 m-xylene 35%b 
13 [RuCl2(p-cymene)]2 1-AdCO2H K3PO4 m-xylene/GVL (1:1) 20%b 
14 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 m-xylene/GVL (1:1) 18%b 
15 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 NMP 28% 
16 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 DMF traces 
17 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 DME 34% 
18 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 DMA 16% 
19 [RuCl2(p-cymene)]2 F5C6CO2H K3PO4 toluene 59% 
20 RuCl3∙(H2O)n F5C6CO2H K3PO4 m-xylene 0% 
21 [RuCl2(benzene)]2 F5C6CO2H K3PO4 m-xylene 64% 
a: Reaction conditions: 56h (0.30 mmol), 28d (0.33 mmol), [Ru] (5 mol %), additive (30 mol %), base (0.90 mmol), 
solvent (3.0 mL), 120 °C, 22 h, N2. b: The reaction was performed by Prof. Dr. Hongjun Ren. c: 2.5 mol % [Ru]2 was 
used. d: 1.0 mol % [Ru]2 was used. 
 
Results and Discussion 
52 
 
The reactions presented so far were carried out at a tryptophan concentration of 1∙10-1 M (Table 11, 
entry 3). Higher concentrations of 2∙10-1 and 5∙10-1 M afforded almost quantitative yields of 97 and 
94%, respectively (entries 1 and 2), whereas the reaction proceeded slower at lower concentrations 
and thus the yield dropped to 54% at 2∙10-2 M and 9% at 1∙10-2 M (entries 4 and 5). 
 
Table 11: Examination of the tryptophan concentration dependence.a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
56h 67hd28d
(1.1 equiv)
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
CO2Me
Br
CO2Me
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
 
entry 56h concentration yield entry 56h concentration yield 
1 5∙10-1 M 94% 4 2∙10-2 M 54% 
2 2∙10-1 M 97% 5 1∙10-2 M 9% 
3 1∙10-1 M 83%    
a: Reaction conditions: 56h (0.30 mmol), 28d (0.33 mmol), [RuCl2(p-cymene)]2 (5 mol %), F5C6CO2H (30 mol %), 
K3PO4 (0.90 mmol), m-xylene (0.6–30.0 mL), 120 °C, 22 h, N2. 
 
 
 
3.2.2 Scope and Limitations of the Ruthenium-Catalyzed Peptide C‒H Arylation 
Tryptophan 56h was tested with different aryl bromides 28 and iodides 66 bearing a variety of 
functional groups (Table 12). A part of this scope was performed by Prof. Dr. Hongjun Ren. The 
reactions were set up with 5 mol % [RuCl2(p-cymene)]2 in meta-xylene at 120 °C and either 30 mol % 
1-adamantylcarboxylic acid and 3.0 equivalents of potassium carbonate (conditions a), or 30 mol % 
pentafluorobenzoic acid and 3.0 equivalents of potassium phosphate (conditions b) were used. 
Fortunately, different functional groups were well tolerated by the ruthenium-catalyzed C–H 
arylation. Products 67 bearing methoxy groups (entries 1 and 3), esters (entries 2 and 4), aniline 
(entry 5), cyanide (entry 6), fluoride (entry 9), enolizable ketone (entry 10), as well as pyridine 
(entry 11), ferrocene (entry 12), various polyarenes (entries 13–16) and styrene (entry 21) were thus 
synthesized in high to excellent yields. It is noteworthy, that in most cases conditions b resulted in 
higher yields than conditions a. One exception was the pyridyl bromide 28m, which afforded product 
67hm in 95% yield under conditions a, while only 48% of product 67hm were isolated using 
conditions b. The obtained compounds highlighted vast potential for peptide applications. For 
example, the introduced fluorine in compound 67hk could serve as a radioactive tracer. 
Furthermore, the incorporation of chromophores and fluorophores was demonstrated with 
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compounds 67hb and 67hn–67hq. Additionally, compounds 67hg, 67hh, 67hl and 67hv can easily 
undergo further chemical modifications. 
Aryl halides bearing a nitro group (entry 7), an azide (entry 8) or alkyne (entry 17), an aldehyde 
(entry 18) or an allyloxy group (entries 19 and 20) were not tolerated, which resulted in very little 
conversions and either no or low yields of the corresponding tryptophans 67. The formation of 
products 67ht and 67hu were observed by LC-MS, but due to the formation of several byproducts, 
the purifications was challenging. Unfortunately, the introduction of a BODIPY dye attached to 
iodobenzene did not work (entry 22). 
 
 
Table 12: Scope of the ruthenium-catalyzed C–H arylation of tryptophan 56h.a 
+
a) [RuCl2(p-cymene)]2 (5 mol %)
1-AdCO2H (30 mol %)
K2CO3 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
28 (Br)
66 (I)
(1.1 equiv)
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
56h 67
or
b) [RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
Hal-Ar Ar
 
entry product yield entry product yield 
1 
N
AcHN
CO2Me
2-py
OMe
67hb  
a) 74% (Br) 
b) 70% (Br) 6 N
AcHN
CO2Me
2-py
67hh
CN
 
b) 75%b (Br) 
2 
N
AcHN
CO2Me
2-py
67hd
CO2Me
 
a) 70% (Br) 
b) 83% (Br) 7 N
AcHN
CO2Me
2-py
67hi
NO2
 
a) 10% (Br) 
b) 18% (Br) 
3 
N
AcHN
CO2Me
2-py
67he
OMe
 
b) 53% (Br) 
+ 10% di 8 N
AcHN
CO2Me
2-py
67hj
N3
 
b) 0% (Br) 
4 
N
AcHN
CO2Me
2-py
67hf
CO2Et
 
b) 66% (Br) 9 
N
AcHN
CO2Me
2-py
67hk
F
 
a) 82% (Br) 
b) 95%b (Br) 
5 
N
AcHN
CO2Me
2-py
67hg
NH2
 
a) 77% (Br) 
b) 76% (Br) 10 N
AcHN
CO2Me
2-py
67hl
O
Me
 
b) 76%b (Br) 
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entry product yield entry product yield 
11 
N
AcHN
CO2Me
2-py
67hm
N
 
a) 95% (Br) 
b) 48% (Br) 17 N
AcHN
CO2Me
2-py
67hr  
b) 0%b (Br) 
12 
N
AcHN
CO2Me
2-py
67hc
Fe
 
b) 17% (I), 
52%c (I) 18 N
AcHN
CO2Me
2-py
67hs
O
H
 
b) 0%b (I) 
13 
N
AcHN
CO2Me
2-py
67hn  
b) 72%b (Br) 19 
N
AcHN
CO2Me
2-py
67ht
O
 
b) 0% (Br) 
14 
N
AcHN
CO2Me
2-py
67ho  
a) 56% (Br) 
b) 87% (Br) 
+ 11% di 
20 
N
AcHN
CO2Me
2-py
67hu
O
 
b) 25% (Br), 
36%d (Br) 
15 
N
AcHN
CO2Me
2-py
67hp  
a) 32% (Br) 
b) 13% (Br) 21 N
AcHN
CO2Me
2-py
67hv  
b) 74% (Br) 
16 
N
AcHN
CO2Me
2-py
67hq  
a) 51% (I) 
b) 74% (Br) 22 N
AcHN
CO2Me
2-py
67hw
N
B
N F
F
MeMe
Me Me
 
b) 0% (I) 
a: Reaction conditions: 56h (0.30 mmol), 28 or 66 (0.33 mmol), [RuCl2(p-cymene)]2 (5 mol %), additive (30 mol %), 
base (0.90 mmol), m-xylene (3.0 mL), 120 °C, 22 h, N2. b: The reaction was performed by Prof. Dr. Hongjun Ren. c: 
20 mol % [Ru]2 and 120 mol % F5C6CO2H were used. d: 10 mol % [Ru]2 and 60 mol % F5C6CO2H were used. 
 
 
Having established the scope of tryptophan 56h, β3-homo-tryptophans 120 were investigated for the 
ruthenium-catalyzed C–H arylation method (Table 13). Several aryl groups were coupled to β3-homo-
tryptophan 120, affording arylated products 121 in moderate to excellent yields. Surprisingly, only 
little amounts of product 121ay were observed by LC-MS. 
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Table 13: Scope with β3-homo-tryptophans 120.a 
+
28
(1.1 equiv)
N
BocHN
2-py
H
N
BocHN
2-py
Ar
120 121
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
CO2R
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
CO2R
Br-Ar
 
entry product yield entry product yield 
1 
N
BocHN
2-py
121ad
CO2Me
CO2Me
 
54% 5 
N
BocHN
2-py
121ag
CO2Me
NH2
 
96% 
2 
N
BocHN
2-py
121bd
CO2Bn
CO2Me
 
61% 6 
N
BocHN
2-py
121ay
CO2Me
F
F
 
traces 
3 
N
BocHN
2-py
121ax
CO2Me
OMe
OMe
OMe
 
42% 7 
N
BocHN
2-py
121aq
CO2Me
 
28% 
4 
N
BocHN
2-py
121ak
CO2Me
F
 
89%    
a: Reaction conditions: 120 (0.30 mmol), 28 (0.33 mmol), [RuCl2(p-cymene)]2 (5 mol %), F5C6CO2H (30 mol %), K3PO4 
(0.90 mmol), m-xylene (3.0 mL), 120 °C, 22 h, N2. 
 
In addition to the examined single tryptophans 56 and 120, the ruthenium-catalyzed C–H arylation 
was applied for the diversification of tryptophan peptides 101 (Table 14). Some of these reactions 
were performed by Prof. Dr. Hongjun Ren. As the peptides showed a lower reactivity than single 
tryptophans, the catalyst loading was increased to 10 mol %. A range of differently substituted 
arylated peptides 102 could be synthesized in good yields (entries 1–8). Remarkably, free indole-
containing peptides were arylated exclusively on the pyridylated indole moiety (entries 2, 4, 5, 8–10). 
Also, 6-bromoindole (28z) as the coupling partner was well tolerated, providing novel 2,6-biindole 
structures 102cz and 102fz (entries 6 and 7). Due to incomplete conversions and a thereof resulting 
difficult purification, peptide 102bq was isolated in a low yield (entries 9). For peptides 102gd, 102bp 
and 102hd the purification was not successful, although they were the major compounds in the 
reaction mixtures as determined by LC-MS analysis, so that not even an analytical amount could be 
isolated (entries 10–12). 
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Table 14: : Scope of the ruthenium-catalyzed C–H arylation of tryptophan peptides 101.a 
+
28
(1.1 equiv)
101
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
F5C6CO2H (60 mol %)Br-Ar
N
H
peptide
2-py
102
N
Ar
peptide
2-py
1-pyrenyl =
 
entry product yield entry product yield 
1 
N
H
N
Boc-Gly OMe
O
102an
2-py
 
61%b 7 
N
H
N
Boc-Gly Gly-OMe
O
102fz
2-py NH
 
62% 
2 
N
H
N
Boc Gly-Trp-OMe
O
102bd
CO2Me
2-py
 
64% 8 
N
H
N
Boc Leu-Trp-OEt
102dq
1-pyrenyl
2-py
O
 
58% 
3 
N
H
N
Boc-Leu-Ala CO2Bn
102cd
CO2Me
2-py
 
65% 9 
N
H
N
Boc Gly-Trp-OMe
O
102bq
1-pyrenyl
2-py
 
10% 
4 
N
H
N
Boc Leu-Trp-OEt
102dk
F
2-py
O
 
51% 10 
N
H
N
OMe
O
102gd
2-py
O
BocHN
OH
CO2Me
 
0% 
5 
N
H
N
Boc Trp-Gly-OEt
102ed
CO2Me
2-py
O
 
70% 11 
N
1-pyrenyl
H
N
Boc Gly-Trp-OMe
O
102bp
2-py
 
0% 
6 
N
H
N
Boc-Leu-Ala CO2Bn
102cz
2-py NH
 
70% 12 
N
H
N
Boc N
H
O
102hd
CO2Me
2-py
Trp-OEt
O
NH2
O
 
0% 
a: Reaction conditions: 101 (50–100 mg), 28 (1.1 equiv), [RuCl2(p-cymene)]2 (10 mol %), F5C6CO2H (60 mol %), K3PO4 
(3.0 equiv), m-xylene (3.0 mL), 120 °C, 22 h, N2. b: The reaction was performed by Prof. Dr. Hongjun Ren. 
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3.2.3 Bioorthogonal Screening of the Ruthenium-Catalyzed C–H Arylation 
In order to determine, which of the naturally occurring amino acids are tolerated, and thereby 
demonstrate the chemoselectivity of the developed C–H arylation method, the catalytic reactions 
were carried out in the presence of one equivalent of an amino acid 122 (Table 15). Some of these 
test reactions were performed by Nikolaos Kaplaneris. Most of the tested amino acids 122 were well 
tolerated (entries 1–16) affording tryptophan 67hd in good yields. In cases of low yields, it is 
conceivable that the added amino acid irreversibly chelated the ruthenium and thus deactivated the 
catalyst (entries 17–21). The bioorthogonal screening showed a tolerability of heteroaromatics, such 
as indoles (entries 1 and 7) and imidazoles (entry 13), aromatics (entries 8 and 9), free amides 
(entries 2 and 5), free hydroxyl groups (entries 8, 10, 11), aliphatics (entries 3, 4, 6), guanidine 
(entry 14) as well as free carboxylic acids (entries 1–16). Thiols and thioethers, on the other hand, did 
shut down the reaction (entries 19 and 20). Free amines were partially tolerated (entries 7, 10, 12, 
14, 15), while in some cases free amines or free amines combined with carboxylic acids hindered the 
reaction (entries 17, 18, 21). 
Table 15: Robustness screening for the ruthenium-catalyzed C–H arylation.a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
56h 67hd28d
(1.1 equiv)
K3PO4 (4.0 equiv)
m-xylene, 120 °C, 22 h, N2
CO2Me
Br
CO2Me
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)+ AA
122
(1.0 equiv)  
entry AA yield entry AA yield entry AA yield 
1 
BocHN CO2H
122a
N
H  
81%b 7 
ClH3N CO2H
122g
N
H  
43%b 13 
AcHN CO2H
122m HN
N
 
83% 
2 
122b
AcHN CO2H
NH2O  
59% 8 
BocHN CO2H
122h OH  
76%b 14 
122n
H2N CO2H
NH
NH2ClH2N  
50% 
3 
BocHN CO2H
Me
122c  
79%b 9 
BocHN CO2H
122i  
90% 15 
122o
H2N CO2H
CO2H  
40% 
4 
122d
BocHN CO2H
Me Me
 
89% 10 
H2N CO2H
122j
OH
 
43% 16 
H
N CO2HO
122q  
77%b 
5 
AcHN CO2H
122e O
NH2
 
95% 11 
122k
AcHN CO2H
OHMe
 
64% 17 
H2N CO2H
122p
Me
Me
 
23% 
6 
BocHN CO2H
122f Me
Me
 
75% 12 
H2N CO2H
122l
CO2H
 
57% 18 
H
N CO2H
122r  
4% 
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entry AA yield entry AA yield entry AA yield 
19 H2N CO2H
122s
SH
 
0% 20 
AcHN CO2H
122t SMe  
11% 21 
122u
ClH3N CO2H
NH2  
33%b 
a: Reaction conditions: 56h (0.30 mmol), 28d (0.33 mmol), 122 (0.30 mmol), [RuCl2(p-cymene)]2 (5 mol %), F5C6CO2H 
(30 mol %), K3PO4 (0.90 mmol), m-xylene (3.0 mL), 120 °C, 22 h, N2. b: The reaction was performed by Nikolaos 
Kaplaneris. 
 
 
3.2.4 Studies on a Potential Racemization of Tryptophan 
The tryptophan 56h was racemized using NaH in DMF, affording the racemic substrate rac-56h 
(Scheme 65). The ruthenium-catalyzed C–H arylation of rac-56h delivered the racemic products rac-
67hd and rac-67hg. An HPLC analysis showed that no racemization of the stereocenter occured 
during the reaction (Figure 2). 
 
N
AcHN
CO2Me
2-py
56h
NaH (1.1 equiv)
DMF, 0 °C, 2 h N
AcHN
CO2Me
2-py
rac-56h: 20%  
Scheme 65: Probing racemization with tryptophan 56h. 
 
 
 
Figure 2: HPLC-chromatograms of the racemic mixture of compound rac-56h and of isolated product L-56h. 
 
N
AcHN
CO2Me
2-py
rac-67hd
CO2Me
N
AcHN
CO2Me
2-py
L-67hd
CO2Me
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Due to the basic free amine of the 4-bromoaniline (28g), the product 67hg partially racemized during 
the arylation reaction. Compound 67hg was then isolated with 92%ee (Figure 3). A control reaction 
of tryptophan 56h with methyl 4-bromobenzoate (28d) in the presence of 1.1 equivalents of aniline 
showed that the product 67hd was almost fully racemic, since it was obtained with only 10%ee 
(Figure 4). 
 
 
Figure 3: HPLC-chromatograms of racemic mixture of the compound rac-67hg and of isolated product 67hg, 92%ee. 
 
 
Figure 4: HPLC-chromatogram of the compound 67hd, 10%ee, isolated after the reaction of 56h with 28d in the 
presence of 1.1 equiv aniline. 
 
 
3.2.5 Ruthenium-Catalyzed C‒H Arylation of Tryptophan-Containing Peptides in Water 
Having established the ruthenium-catalyzed C–H arylation procedure in an organic solvent under 
inert atmosphere, we became intrigued by more biocompatible reaction conditions. The necessity 
for the oxygen-free atmosphere could not be circumvented. Contrary to this, the anhydrous organic 
solvent could be replaced by water. Initial results of adding water to meta-xylene showed the 
formation of the desired product 67hd in 39 and 33% yield (Table 16, entries 1 and 2). This drop of 
N
AcHN
CO2Me
2-py
L-67hg
NH2
N
AcHN
CO2Me
2-py
rac-67hg
NH2
N
AcHN
CO2Me
2-py
67hd
CO2Me
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yield was due to the partial saponification of the esters, resulting in a mixture of byproducts, which 
were detected by LC-MS. In a 1:1 ratio of meta-xylene and water as well as in pure water no product 
67hd was formed and only the shown byproducts were observed (entries 3 and 4). Also, mixtures of 
acetonitrile and water in combination with potassium phosphate or the weaker base potassium 
carbonate gave the same results (entries 5–7). The change to the organic base triethylamine made 
the difference, affording 40% of isolated product 67hd (entry 8). Still, the major part of the 
compounds hydrolysed. The use of a triethylamine/TFA buffer-like system to avoid hydrolysis did not 
improve the result (entry 9). 
 
Table 16: Exchange of the organic solvent with water.a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
56h 67hd28d
(1.1 equiv)
base (3.0 equiv)
solvent, 120 °C, 22 h, N2
CO2Me
Br
CO2Me
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
 
N
AcHN
CO2H
2-py
CO2Me
N
AcHN
CO2Me
2-py
CO2H
N
AcHN
CO2H
2-py
N
AcHN
CO2H
2-py
CO2H
Br
CO2H
byproducts
67jd67hα67jα56j 28α
 
entry base solvent yield 
1 K3PO4 m-xylene/H2O 100:1 39% 
2 K3PO4 m-xylene/H2O 10:1 33% 
3 K3PO4 m-xylene/H2O 1:1 0% 
4 K3PO4 H2O 0% 
5 K3PO4 H2O/MeCN 1:1 0% 
6 K2CO3 H2O/MeCN 1:1 0% 
7 K2CO3 H2O/MeCN 1:10 0% 
8 Et3N H2O/MeCN 10:1 40% 
9 Et3N/TFA 2:1 H2O/MeCN 10:1 37% 
a: Reaction conditions: 56h (0.30 mmol), 28d (0.33 mmol), [RuCl2(p-cymene)]2 (5 mol %), F5C6CO2H (30 mol %), base 
(3.0 equiv), solvent (3.0 mL), 120 °C, 22 h, N2. 
 
 
The reduction of the amount of potassium phosphate to 0.6 equivalents decreased the extent of 
saponification, so that products 67 were isolated in reasonable yields after reaction in a 1:1 mixture 
of water and meta-xylene (Scheme 66). The reactions shown in scheme 66 were all performed by 
Nikolaos Kaplaneris. 
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+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
Ar
56h 6728
(1.1 equiv)
K3PO4 (0.6 equiv)
m-xylene/H2O (1:1)
120 °C, 20 h, N2
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)Ar-Br
 
N
AcHN
CO2Me
2-py
67hd: 56%a
CO2Me
N
AcHN
CO2Me
2-py
67he: 57%a,b
OMe
N
AcHN
CO2Me
2-py
67hb: 59%a,b
OMe
N
AcHN
CO2Me
2-py
67hn: 87%a
Ph
 
Scheme 66: Ruthenium-catalyzed C–H arylation in a water-meta-xylene mixture. a: The reaction was performed by 
Nikolaos Kaplaneris. b: 10 mol % catalyst were used. 
 
Next, to circumvent saponifications, free carboxylic acid substrate 56j was reacted with arene 28l in 
water or in a 1:1 mixture of water and acetonitrile (Scheme 67). Due to the poor solubility of the 
starting materials in water, the conversion was low and no product 67jl was isolated. The addition of 
acetonitrile solved this problem and the desired arylated tryptophan 67jl could be isolated in 63% 
yield. 
+
N
AcHN
CO2H
2-py
H
N
AcHN
CO2H
2-py
56j 67jl:28l
(1.1 equiv)
K3PO4 (3.0 equiv)
solvent, 120 °C, 22 h, N2
Br
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
MeO
O
Me
0%
63%
(in H2O)
(in H2O/MeCN 1:1)  
Scheme 67: Ruthenium-catalyzed C–H arylation in water. 
 
To assure full solubility of all substrates used, substrate 56j was reacted with arene 66α, which are 
both soluble in water (Table 17). As all attempts to isolate pure tryptophan 67jα failed, and thus no 
calibration of the liquid chromatograms could be recorded, the measured ratios of starting material 
56j to product 67jα are given. Although these ratios do not correspond to yields of formed product, 
they indicate an approximate outcome of the reaction and were therefore successfully applied to 
further reactions. 
Using potassium phosphate and pentafluorobenzoic acid in water, the substrate 56j could not be 
observed in the LC-MS and only arylated product 67jα was found (entry 1). The same result was 
achieved when no additive was added (entry 2). The use of potassium carbonate, potassium acetate 
or sodium hydroxide without additives indicated incomplete or no conversion (entries 3–5). Similar 
results were obtained when basic buffers of pH 8–12 were used (entries 6–9). 
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Table 17: Ruthenium-catalyzed C–H arylation in water.a 
+
N
AcHN
CO2H
2-py
H
N
AcHN
CO2H
2-py
56j 67jα66α
(1.1 equiv)
base
solvent, 120 °C, 22 h, N2
CO2H
I
CO2H
[RuCl2(p-cymene)]2 (10 mol %)
additive
 
entry base (equiv) additive (equiv) solvent LC-MS 56j/67jαb 
1 K3PO4 (3.0) F5C6CO2H (0.6) H2O 0:100 
2 K3PO4 (3.0) - H2O 0:100 
3 K2CO3 (3.0) - H2O 26:74 
4 KOAc (3.0) - H2O 100:0 
5 NaOH (2.1) - H2O 29:71 
6 - - buffer pH 8 100:0 
7 - - buffer pH 9 100:0 
8 - - buffer pH 11 57:43 
9 - - buffer pH 12 27:73 
a: Reaction conditions: 56j (0.30 mmol), 66α (0.33 mmol), [RuCl2(p-cymene)]2 (5 mol %), additive, base, solvent 
(3.0 mL), 120 °C, 22 h, N2. b: Product 67jα could not be isolated. 
 
 
Due to the unsuccessful purification of product 67jα, aryl halide 28β was submitted to the C–H 
arylation of tryptophan 56j under the best suitable conditions for the reaction in water (Table 17, 
entry 2). Water-soluble aryl halide 28β bearing a carboxylic acid was coupled to tryptophan 56j in 
order to give the corresponding arylated product 67jβ in 61% yield (Scheme 68). The isolated and 
structurally confirmed compound 67jβ exemplarily proved the general possibility of the applicability 
of water as the reaction medium. 
 
 
+
N
AcHN
CO2H
2-py
H
N
AcHN
CO2H
2-py
56j 67jβ: 61%28β
(1.1 equiv)
K3PO4 (3.0 equiv)
H2O, 120 °C, 22 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
Br
CO2H
Me
CO2H
Me
 
Scheme 68: Ruthenium-catalyzed C–H arylation in water. 
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3.2.6 Ruthenium-Catalyzed Ligation of Tryptophan-Containing Peptides 
Several different strategies were carried out for the ruthenium-catalyzed ligation of tryptophans 56, 
67 ans 101. Styrene-containing substrate 67hv was successfully submitted to a cross-metathesis 
reaction using the Grubbs II catalyst, delivering the ligation product 123 in 90% yield (Scheme 69). As 
expected, the E-configured product was formed exclusively. 
N
AcHN
CO2Me
2-py
67hv
Grubbs II (5 mol %)
CH2Cl2 (0.5 M)
40 °C, 6 h, N2
N
AcHN
CO2Me
2-py
123: 90%
N
2-py
AcHN
CO2Me
N N MesMes
Ru
Ph
PCy3
Cl
Cl
Grubbs II
 
Scheme 69: Ligation of tryptophan 67hv. 
Another double functionalization ligation strategy provided products 117 by the reaction of 
tryptophans 101 with half an equivalent of 1,4- or 1,3-dibromobenzene 28 (Table 18). Single 
tryptophans furnished dipeptides 117a and 117b in excellent yields (entries 1 and 2). The product 
117b was synthesized by Prof. Dr. Hongjun Ren. Also, tetrapeptide 117c was synthesized in a very 
high yield of 79% (entry 3). Due to complications during the purification process, hexapeptide 117d 
was obtained in a comparably low yield of 35% (entry 4). 
Table 18: Peptide ligation by twofold ruthenium-catalyzed C–H arylation.a 
+
28
(0.5 equiv)
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
Br
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
Br
101
N
H
peptide1
2-py
117
N
peptide1
2-py
N
2-py
peptide1
 
entry product yield entry product yield 
1 
N
AcHN
CO2Me
2-py
117a
N
CO2Me
AcHN
2-py
 
91% 3 
117c
H
N
O
Ala-OBn
N N
2-py
2-py
N
H O
Ala-OBn
Boc
Boc
 
79% 
2 
N
2-py
CO2Me
AcHN
NHAc
CO2Me
2-py
117b  
82%b 4 
117d
H
N
O
Gly-OMeBoc-Gly
N N
2-py
2-py
N
H O
Gly-OMeBoc-Gly
 
35% 
a: Reaction conditions: 101 (50–100 mg), 28 (0.5 equiv), [RuCl2(p-cymene)]2 (5–10 mol %), F5C6CO2H (30–60 mol %), 
K3PO4 (3.0 equiv), m-xylene (3.0 mL), 120 °C, 22 h, N2. b: The reaction was performed by Prof. Dr. Hongjun Ren. 
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A further ligation approach by twofold C–H arylation was the introduction of a para-bromophenyl 
substituent for a subsequent coupling with a second peptide 56 or 101 in order to provide ligation 
products 118 (Scheme 70). Although 1.1 equivalents of 1,4-dibromobenzene (28γ) were used, the 
formation of ligation products 117 was also observed, accompanied by a low-yielding generation of 
the desired bromine-containing peptides 67 and 102 (Table 19). This observation indicated an 
accelerated reactivity of aryl bromides 67 and 102 as compared to dibromide 28γ. For the reason of 
such low yields for the first desired step, this ligation approach was discarded. Moreover, the 
obtained small amounts of the substrates 67hγ and 102cγ were not reacted further with a second 
peptide 56 or 101. 
+
28γ
(1.1 equiv)
Br
56 or 101
N
H
peptide1
2-py
67 or 102
N
peptide1
2-pyBr
Br
118
N
peptide1
2-py
N
2-py
peptide2
RuRu
56
 or 101
N
H
peptide2
2-py
 
Scheme 70: Ligation of two different peptides 56 or 101 by twofold ruthenium-catalyzed C–H arylation. 
 
Table 19: Syntheses of para-bromophenyl peptides 67 and 102.a 
+
28γ
(1.1 equiv)
Br
56 or 101
N
H
peptide1
2-py
67 or 102
N
peptide1
2-pyBr
Br
117
N
peptide1
2-py
N
2-py
peptide1
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %) +
 
entry product yield entry product yield 
1 
N
AcHN
CO2Me
2-py
67hγ
Br
 
17% 2 
H
N
CO2Bn
N
2-py Br
Boc-Leu-Ala
102cγ  
31% 
a: Reaction conditions: 56 or 101 (50–100 mg), 28γ (1.1 equiv), [RuCl2(p-cymene)]2 (5 mol %), F5C6CO2H (30 mol %), 
K3PO4 (3.0 equiv), m-xylene (3.0 mL), 120 °C, 22 h, N2. 
 
Along with the intention of producing aryl bromide-containing peptides, peptides 124 equipped with 
an aryl bromide-containing linker were ligated with peptides 56 and 101 in order to provide products 
125 (Table 20). The ligation reactions delivering products 125 were all performed by Prof. Dr. 
Hongjun Ren in our group. Compared to the wasteful and costly preparation of peptides 67hγ and 
102cγ, meta- and para-bromophenacylated peptides 124 were easily accessible by application of 
Results and Discussion 
65 
 
standard protection chemistry. Ligation products 125a–d were formed and isolated in very good 
yields of 58–68%. NH-free indole-containing products 125c and 125d once more proved the excellent 
selectivity of this ruthenium-catalyzed C–H arylation method. 
Table 20: Ruthenium-catalyzed C–H ligation of petides 56 or 101 and 124.a 
+
124
(1.1 equiv)
56 or 101
N
H
peptide1
2-py
125
N
peptide1
2-py
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 22 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
F5C6CO2H (60 mol %)
Br
O
peptide2
O
peptide2
 
entry product yield entry product yield 
1 
125a
N
2-py
AcHN
CO2Me
O
Ala-OBn
 
68%b 3 
125c
N
2-py
H
N
Leu-Trp-OEt
O
Ala-OBn
O
Boc
 
58%b 
2 
125b
N
2-py
AcHN
CO2Me
Ala-OBn
O
 
58%b 4 
125d
N
2-py
H
N
Leu-Trp-OEt
O
O
Ala-OBn
Boc
 
68%b 
a: Reaction conditions: 56 or 101 (50–100 mg), 124 (1.1 equiv), [RuCl2(p-cymene)]2 (10 mol %), F5C6CO2H (60 mol %), 
K3PO4 (3.0 equiv), m-xylene (3.0 mL), 120 °C, 22 h, N2. b: The reaction was performed by Prof. Dr. Hongjun Ren. 
 
An additional ligation attempt was realized by a sequential multicatalytic C–H arylation combination 
(Scheme 71). First, palladium-catalysis furnished aryl bromide-containing peptides 81,89 (Table 21). 
The aryl bromide peptides 81af and 81wf were obtained with 67 and 57% yield, respectively. Next, 
these peptides were coupled with peptides 56 or 101 yielding ligation products 126 (Table 22). Thus, 
tetrapeptide 126a and β3-homo-tryptophan hexapeptide 126b were prepared in good yields of 53 
and 56% (entries 1 and 2). Unfortunately, ligation products derived from peptide 81wf could not be 
isolated, although the product masses were observed by LC-MS analyses (entries 3 and 4). 
 
78f
Pd
Br
IOTs
2
80
N
H
H
peptide1
81
N
H
peptide1
Br
101
Ru
126
N
H
peptide1
N
H
peptide2
2-py
N
2-py
peptide2
 
Scheme 71: Ligation by multicatalytic C–H arylation. 
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Table 21: First step of the multicatalytic C–H arylation approach.a 
Br
IOTs
2
80
N
H
H
peptide1
81
N
H
peptide1
Br
78f
(1.5 equiv)
Pd(OAc)2 (5 mol %)
HOAc, 25 °C, 24 h
+
 
entry product yield entry product yield 
1 
81af
H
N
O
Gly-OEtAc-Ala
N
H Br
 
67% 2 
81wf
H
N
O
Gly-OEtAc-Gly
N
H Br
 
57% 
a: Reaction conditions: 80 (0.20 mmol), 78f (0.30 mmol), Pd(OAc)2 (5 mol %), HOAc (3.0 mL), 25 °C, 24 h. 
 
 
 
Table 22: Second step of the multicatalytic C–H arylation approach.a 
56 or 101
(1.0 equiv)
126
N
H
peptide1
N
H
peptide2
2-py
N
2-py
peptide2
81
N
H
peptide1
Br
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 20 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
F5C6CO2H (60 mol %)
+
 
entry peptide1 peptide2 product yield 
1 81af Ac-Trppy-OMe (56h) 
126a
H
N
O
Gly-OEtAc-Ala
N
H N
2-py
CO2MeAcHN  
53% 
2 81af Boc-Leu-Ala-β3hTrppy-OBn (101c) 
126b
H
N
O
Gly-OEtAc-Ala
N
H N
2-py
N
H
CO2BnBoc-Leu-Ala
 
56% 
3 81wf Boc-Gly-Trppy-Gly-OMe (101f) 
126c
H
N
O
Gly-OEtAc-Gly
N
H N
2-py
N
H
Boc-Gly
O
Gly-OMe
 
0%b 
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entry peptide1 peptide2 product yield 
4 81wf Boc-Trppy-Trp-Gly-OEt (101e) 
126d
H
N
O
Gly-OEtAc-Gly
N
H N
2-py
N
H O
Trp-Gly-OEtBoc
 
0%b 
a: Reaction conditions: 81 (20–40 mg), 101 (1.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), F5C6CO2H (60 mol %), K3PO4 
(3.0 equiv), m-xylene (1.0 mL), 120 °C, 22 h, N2. b: LC-MS indicated product formation. 
 
 
The last two presented ligation approaches, applying bromophenacylated peptides 124 or using the 
sequential palladium-ruthenium-catalysis, nicely demonstrated the simple accessibility of chemically 
ligated peptides with a unique branching at the tryptophan moiety. 
 
 
3.2.7 Attempted Ruthenium-Catalyzed Cyclization of Tryptophan-Containing Peptides 
The application of the ruthenium-catalyzed C–H arylation method developed in this work should be 
suitable for the cyclization of peptides 108, which contain two pyridylated tryptophans. A twofold C–
H arylation with an aryl dibromide 28 should afford cyclopeptides 109 (Scheme 72 a). A preliminary 
attempt was performed by reacting pentapeptide 108a, bearing tryptophans in an i,i+3-distance with 
1,4-dibromobenzene (28γ), under the best suitable conditions using 10 mol % of the ruthenium-
catalyst, pentafluorobenzoic acid and potassium phosphate in meta-xylene at 120 °C. Unfortunately, 
an LC-MS analysis of the crude reaction mixture indicated no product formation. 
 
Ru
109
N
108
N
peptide
H
N
2-py
H
2-py
Br
28
2-py
(a)
Br
N
2-py
peptide
 
Br
Br
O
HN
Me O
HN
O
NH
HN
O
N
2-py
BocHN
N
2-py
108a
N
H
N
2-py
H
2-py
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 20 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
F5C6CO2H (60 mol %)
28γ
(1.0 equiv)
H
N
Ala-Gly
O H
N
Gly-OMe
O
109a
no product (LC-MS)
+
(b)
CO2EtBoc
20
 
Scheme 72: Ruthenium-catalyzed cyclization of peptides 108. (a) General approach. (b) Unsuccessful attempt. 
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Another intended cyclization approach was the palladium-catalyzed C–H arylation of peptides 103 
according to the method discribed in chapter 3.189 followed by an intramolecular C–H arylation of a 
pyridylated tryptophan in order to form cyclic peptides 127 (Scheme 73). 
 
N
2-py
H
78f
Pd
Br
IOTs
2
103
N
H
H
peptide
N
2-py
H
105
N
H
peptide
Br Ru
127
N
H
peptide
N
2-py
 
Scheme 73: Cyclization by multicatalytic C–H aylation. 
 
Initially, the first step was examined with the peptide 103a as the model peptide (Table 23). The 
concern that the pyridyl group might harm the palladium-catalyzed reaction was confirmed. 
Although the reaction was carried out in the most suitable solvents sought out for this 
transformation, namely DCE, DMF, toluene, water and acetic acid, no formation of product 105af 
could be detected. Also, no arylation of the pyridylated tryptophan was observed. 
Table 23: Palladium-catalyzed C–H arylation of peptide 103a.a 
78f
(1.5 equiv)
Br
IOTs
2
103a
H
N
O
Gly-OEt
N
H
H
Pd(OAc)2 (5 mol %)
solvent, 25 °C, 24 h
Boc-Trppy
105af
H
N
O
Gly-OEt
N
H
Boc-Trppy
Br
+
 
entry solvent yield entry solvent yield 
1 DCE 0% 4 H2O 0% 
2 DMF 0% 5 H2O/HOAc 1:1 0% 
3 toluene 0% 6 HOAc 0% 
a: Reaction conditions: 103a (0.10 mmol), 78f (0.15 mmol), Pd(OAc)2 (5 mol %), solvent (1.0 mL), 25 °C, 24 h. 
 
 
In order to examine harsher reaction conditions, acetylated peptide 103b was used (Table 24). No 
product 105bf were formed when DCE, DMF, toluene or acetic acid were used as the solvents 
(entries 1–4). In TFA as the reaction medium, LC-MS analysis gave reason to assume product 
formation. However, the conversion was low and no product 105bf was isolated (entry 5). An 
increase of the reaction temperature to 60 °C resulted in an increased conversion and thus arylated 
peptide 105bf was isolated in 35% yield (entry 6). To accomplish full conversion, the reaction was 
carried out in TFA at 100 °C. After the reaction, neither starting material 103b nor product 105bf was 
detected. 
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Table 24: Palladium-catalyzed C–H arylation of peptide 103b.a 
78f
(1.5 equiv)
Br
IOTs
2
103b
H
N
O
Gly-OEt
N
H
H
Pd(OAc)2 (5 mol %)
solvent, T, 24 h
Ac-Trppy
105bf
H
N
O
Gly-OEt
N
H
Ac-Trppy
Br
+
 
entry solvent T/°C yield entry solvent T/°C yield 
1 DCE 25 0% 5 TFA 25 0%b 
2 DMF 25 0% 6 TFA 60 35% 
3 toluene 25 0% 7 TFA 100 0% 
4 HOAc 25 0%     
a: Reaction conditions: 103b (0.05 mmol, 30 mg), 78f (0.08 mmol), Pd(OAc)2 (5 mol %), solvent (1.0 mL), 25 °C, 24 h. 
b: LC-MS indicated product formation. 
 
 
For the synthesis of cyclopeptides 127, peptides 103 would need to have a certain minimum 
backbone length in order to assure sufficient space and flexibility for the formation of the triarylated 
system of the final products 105. However, it was deemed as unreasonable to attempt further 
experiments with longer peptides 103, because in our experience larger peptides tend to react 
slower, while peptide 103b, which is far too small for the intended cyclization, was already isolated in 
only 35% yield. 
 
 
3.2.8 Fluorescence Studies of the Arylated Tryptophans 
The fluorescence properties of selected C–H arylated tryptophans 67 were examined and compared 
to the parent unarylated tryptophan 56h. Initially, 2D-scans of the examined compounds were 
recorded in order to figure out at which excitation wavelength the maximum emission occurs. The 2D 
spectra of compound 67hq is shown exemplarily (Figure 5 a). This highly fluorescent tryptophan 
showed two emission maxima at excitations with 280 and 350 nm, respectively. 
The arylated compounds 67hd, 67hq, 67ho and 67hn all showed enhanced fluorescence as 
compared to the native non-arylated compound 56h (Figure 5 b). The Stokes shift varies from 
103 nm for compound 67hn to 196 nm for compound 67hq (Table 25). 
A fluorine in the para-position of the phenyl group in compound 67hk drastically diminished the 
fluorescence intensity (Figure 5 c). Futhermore, the ferrocene of compound 67hc completely 
quenched the fluorescence. 
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Figure 5: Fluorescent measurements. (a) Excitation-Emission-scan of compound 67hq. (b) and (c) Emission of 
selected compounds. All spectra were recorded at a concentration of 1 mg/L. The excitation wavelengths correspond 
to the λmax values shown in table 25. 
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Table 25: Fluorescence data. 
entry compound absorption λmax/nm emission λmax/nm Stokes shift/nm 
1 56h 280 412 132 
2 67hd 320 450 130 
3 67hq 270 466 196 
4 67ho 280 419 139 
5 67hn 311 414 103 
6 67hk 255 432 177 
7 67hc 270 n. d. - 
 
 
 
3.3 Ruthenium-Catalyzed C‒H Alkylation of Tryptophan-Containing Peptides 
Having established C–H arylation methods for the modification of tryptophan-containing peptides 80 
and 101, our interest for alkylation methods for peptides arose. Despite of a widespread research on 
peptide modification reactions and a few examples of C–H functionalization procedures, C–H 
alkylation methods for peptides are scarce in literature. 
Analogous to the transference of the ruthenium-catalyzed C–H arylation of phenylpyridines to 
pyrimidylated or pyridylated tryptophans, alkylation methods developed for simple structures such 
as phenylpyridines should be transferred to tryptophan peptides. Two alkylation strategies were 
considered: reactions with alkyl halides and hydroarylations of unsaturated compounds. Ruthenium-
catalyzed C–H alkylations developed by our group have been successfully applied to 
phenylpyridines.118 Similar reaction conditions were tested on the tryptophans 56g and 56h 
(Table 26). A primary, a secondary and a benzylic alkyl bromide were chosen as test substrates for 
the ruthenium-catalyzed C–H alkylation using [RuCl2(p-cymene)]2 as the catalyst and 1-adamantyl 
carboxylic acid or mesityl carboxylic acid in combination with a base. Unfortunately, these alkylation 
reactions did not deliver the desired products. Instead, the starting material 56 was reisolated. 
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Table 26: Ruthenium-catalyzed alkylation of tryptophan with alkyl bromides.a 
+
N
AcHN
CO2Me
2-py(m)
H
N
AcHN
CO2Me
2-py(m)
Alk
(2-pym) 
(2-py) 128
additive, base
solvent, T, 24 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
Alk-Br
56g
56h 107  
entry Trp alkyl bromide additive base solvent T/° C result 
1 56g nHexBr (128a, 1.2 equiv) 
1-AdCO2H 
(30 mol %) K2CO3 m-xylene 140 n. d. 
2 56g CyBr (128b, 1.2 equiv) 
1-AdCO2H 
(30 mol %) K2CO3 m-xylene 140 n. d. 
3 56g BnBr (128c, 1.2 equiv) 
1-AdCO2H 
(30 mol %) K2CO3 m-xylene 140 traces 
4 56h nHexBr (128a, 3.0 equiv) 
MesCO2H 
(60 mol %) K3PO4 m-xylene 120 n. d. 
5 56h CyBr (128b, 3.0 equiv) 
MesCO2H 
(60 mol %) K3PO4 m-xylene 120 n. d. 
6 56h CyBr (128b, 3.0 equiv) 
MesCO2H 
(60 mol %) K2CO3 1,4-dioxane 120 traces 
a: Reaction conditions: 56 (0.30 mmol), 128, [RuCl2(p-cymene)]2 (10 mol %), additive, base (3.0 equiv), solvent, 24 h, 
N2. n. d.: Product was not detected. 
 
 
 
Inspired by the ruthenium-catalyzed alkylation of phenylpyridines using unactivated alkenes, which 
was developed by our group in 2013 (Scheme 28),57e similar reaction conditions were applied to 
tryptophan 56g, delivering the alkylated product 107gb in 38 and 60% when the reaction was carried 
out at 120 and 140 °C, respectively (Table 27, entries 1 and 2). When Boc- or phthalide-protected 
tryptophan 56e or 56f was used, the yield dropped to 31 and 13%, respectively (entries 3 and 4). 
Acetylated tryptophan 56g was most suitable for this transformation, so it was used for the following 
reactions. Changing the solvent to other aromatic, aliphatic, etheric or alcoholic solvents did not 
improve the yield (entries 5–13). Moreover, the alcohols 1-butanol and ethylene glycol led to a 
transesterification of the starting material 56g. The increase of the amount of additive mesityl 
carboxylic acid yielded 21% of the alkylated product 107gb (entry 14). The use of microwave 
irradiation also did not improve the outcome of the reaction (entries 15 and 16). 
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Table 27: Optimization of the ruthenium-catalyzed C–H alkylation of tryptophan with unactivated alkenes.a 
+
N
R2N
CO2Me
2-pym
H
N
R2N
CO2Me
2-pym
(R2 = H, Ac)
(R2 = H, Boc) 
(R2 = Phth)
44b
(3.0 equiv)
MesCO2K (30 mol %)
solvent, 140 °C, 24 h, N2
[RuCl2(p-cymene)]2 (10 mol %)nOct
nOct
56g
56e
56f
107gb
107eb
107fb  
entry Trp solvent note yield 
1 56g toluene at 120 °C 38% 
2 56g toluene - 60% 
3 56e toluene - 31% 
4 56f toluene - 13% 
5 56g m-xylene - 29% 
6 56g NMP - n. d. 
7 56g hexanes - 24% 
8 56g 1,4-dioxane - 8% 
9 56g DME - 10% 
10 56g HOAc - 25% 
11 56g 1-butanol - n. d.b 
12 56g n-octane - n. d. 
13 56g ethylene glycol - n. d.b 
14 56g toluene MesCO2K (2.0 equiv) 21% 
15 56g toluene 140 °C, 1 h, MW traces 
16 56g toluene 140 °C, 4 h, MW traces 
a: Reaction conditions: 56 (0.30 mmol), 44b (0.90 mmol), [RuCl2(p-cymene)]2 (10 mol %), MesCO2K (30 mol %), 
solvent (3.0 mL), 140 °C, 24 h, N2. b: Transesterification of the tryptophan substrate was observed. 
 
 
A similar approach was the alkylation of tryptophan 56j with alkene 44c, which are both soluble in 
basic water (Table 28). Different additives were tested for this reaction. When mesityl carboxylic acid 
or 1-adamantyl carboxylic acid were used (entries 1 and 3), the product mass was detected by the LC-
MS analysis. However, due to purification difficulties, alkylated product 107jc was not isolated. When 
other additives were used, only traces of the product were observed. 
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Table 28: Optimization of the ruthenium-catalyzed C–H alkylation in water.a 
+
N
AcHN
CO2H
2-py
H
N
AcHN
CO2H
2-py
44c
(3.0 equiv)
K3PO4 (6.0 equiv)
H2O, 120 °C, 24 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
additive (1.0 equiv)
56j 107jc
CO2H
CO2H
 
entry additive yield entry additive yield 
1 MesCO2K 0%b,c 5 (TRIP)CO2H 0% 
2 F5C6CO2H 0% 6 PPh3 0% 
3 1-AdCO2H 0%c 7 HOPiv 0% 
4 (3-F3CC6H4)CO2H 0% 8 - 0%d 
a: Reaction conditions: 56j (0.30 mmol), 44c (0.90 mmol), [RuCl2(p-cymene)]2 (10 mol %), additive (0.30 mmol), 
K3PO4 (1.80 mmol), H2O (3.0 mL), 120 °C, 24 h, N2. b: No K3PO4 was added. c: LC-MS indicated product formation. d: 
The reaction was set up in acetic acid. 
 
 
Furthermore, different types of olefins were examined in order to identify suitable alkylating agents 
for tryptophan peptides (Table 29). Activated olefins were reacted with tryptophan 56g, applying 
10 mol % [RuCl2(p-cymene)]2 and 30 mol % mesityl carboxylate in toluene at 140 °C (entries 1–11). 
For these reactions, only in the case of norbornene 136a the alkylation product 137ga was isolated 
with a reasonable yield of 36%. NMR analysis of the product 137ga showed a 1:1:1:1 mixture of 
isomers. The reaction with styrene delivered 4% of the corresponding alkylated tryptophan 133ga. 
Since under basic conditions the alkylation reactions did not proceed, the substrates 129–134 were 
reacted with tryptophan 56g in acetic acid (entries 12–16). Interestingly, the desired alkylation 
products could be isolated in a very high yield of 91% when using methyl vinyl ketone (130a) (entry 
13). This result set the stage for further optimization reactions with α,β-unsaturated substrates 129–
131. 
Table 29: Screening of olefins for the ruthenium-catalyzed C–H alkylation.a 
+
N
AcHN
CO2Me
2-pym
H
N
AcHN
CO2Me
2-pym
additive, solvent
140 °C, 24 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
56g
R2
R1 R1
R2
 
entry alkene additive solvent result 
1 
129a
OEt
O
 
MesCO2K (30 mol %) toluene n. d. 
2 
129b
OBn
O
 
MesCO2K (30 mol %) toluene n. d. 
3 
130a
Me
O
 
MesCO2K (30 mol %) toluene n. d. 
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entry alkene additive solvent result 
4 
131a
NHiPr
O
 
MesCO2K (30 mol %) toluene n. d. 
5 
Ph
132a  
MesCO2K (30 mol %) toluene 
N
AcHN
CO2Me
2-pym
Ph
133ga: 4%  
6 NH
134a
Me
O
 
MesCO2K (30 mol %) toluene n. d. 
7 
135a  
MesCO2K (30 mol %) toluene n. d. 
8 
136a  
MesCO2K (30 mol %) toluene 
N
AcHN
CO2Me
2-pym
137ga: 36%b  
9 
SiMe3
138a  
MesCO2K (30 mol %) toluene n. d. 
10 
Si(OMe)3
139a  
MesCO2K (30 mol %) toluene n. d. 
11 
OnBu
140a  
MesCO2K (30 mol %) toluene n. d. 
12 
129a
OEt
O
 
- HOAc traces 
13 
130a
Me
O
 
- HOAc 
N
AcHN
CO2Me
2-pym
Me
O
141ga: 91%  
14 
131a
NHiPr
O
 
- HOAc n. d. 
15 
Ph
132a  
- HOAc traces 
16 NH
134a
Me
O
 
- HOAc n. d. 
a: Reaction conditions: 56g (0.30 mmol), alkene (0.90 mmol), [RuCl2(p-cymene)]2 (10 mol %), additive (30 mol %), 
solvent (3.0 mL), 140 °C, 24 h, N2. b: A mixture of diastereomers was isolated. n. d.: No alkyl product was detected. 
 
 
3.3.1 Ruthenium-Catalyzed C–H Alkylation with Acrylates 
3.3.1.1 Optimization of the C–H Alkylation 
Based on the successful alkylation of tryptophan 56g with methyl vinyl ketone (130a) and the 
previous finding that pyridylated tryptophans are more reactive than pyrimidylated derivatives, the 
alkylation of tryptophan 56h with ethyl acrylate (129a) was subsequently optimized (Table 30). A part 
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of the optimization was performed by Nikolaos Kaplaneris (entry 18). The first attempt was related to 
the results with vinyl ketone 130a reacting tryptophan 56h with 3 equivalents of ethyl acrylate (129a) 
and 10 mol % [RuCl2(p-cymene)]2 in acetic acid at 120 °C under an atmosphere of nitrogen, resulting 
in a remarkable yield of 81% (entry 1). At this high temperature, partial transesterification of the 
methyl and ethyl esters was observed. In order to derive mild reaction conditions, less acidic solvents 
were tested. However, acetic acid buffers (entries 2 and 3), mixtures of acetic acid and organic 
solvents or water (entries 4–10) as well as weaker acids (entries 11–16), such as propionic acid, 
pivalic acid and ammonium chloride, did not improve the yield. A decrease of the reaction 
temperature to 100 °C increased the yield to 88% (entry 17). A reason could be the reduction of 
possible side reactions, such as transesterification, Michael addition or polymerization. A further 
decrease of the reaction temperature to 80 °C combined with an increased concentration of the 
starting material 56h of 1.0 M afforded the best achieved yield of 90% (entry 19). Here, no 
transesterification was observed and the reaction could be easily set up under air. At lower reaction 
temperatures of 60 and even 38 °C hydroarylation product 142ha was formed in 80 and 54% yield, 
respectively (entries 20 and 21). A decrease of the ruthenium catalyst loading to 5.0 mol % still 
delivered a high yield of 83% at 80 °C, however, the conversion was incomplete (entry 22). Further 
reduction of the catalyst loading to 2.5 or 1.0 mol % gave unsatisfying results (entries 23 and 24). The 
tolerance towards water was demonstrated by using a 3:1 or 1:1 mixture of acetic acid and water, 
affording product 142ha in good yields of 75 and 60% (entries 25 and 26). To emphasize, the herein 
developed ruthenium-catalyzed C–H alkylation reaction was successfully performed at a biocompa-
tible temperature of 38 °C in an aqueous acidic medium under air. This is an important prerequisite 
for possible bioorthogonal applications. 
 
Table 30: Optimization of the ruthenium-catalyzed C–H alkylation with ethyl acrylate (129a).a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
129a
(3.0 equiv)
solvent
T, 24 h, N2
[RuCl2(p-cymene)]2 (10 mol %)
56h
CO2Et
CO2Et
142ha
 
entry [Ru]2/mol % solvent Trp conc./M T/°C yield 
1 10 HOAc 0.3 120 81% 
2 10 HOAc/KOAc buffer pH 4.0 0.3 120 traces 
3 10 HOAc/KOAc buffer pH 3.7 0.3 120 traces 
4 10 GVL/HOAc 1:1 0.3 120 58% 
5 10 HOAc/t-amyl alcohol 1:9 0.3 120 traces 
6 10 HOAc/H2O 1:9 0.3 120 traces 
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entry [Ru]2/mol % solvent Trp conc./M T/°C yield 
7 10 HOAc/toluene 1:9 0.3 120 traces 
8 10 HOAc/m-xylene1:9 0.3 120 traces 
9 10 HOAc/n-octane 1:9 0.3 120 47% 
10 10 HOAc/DME 1:9 0.3 120 traces 
11 10 HO2CEt 0.3 120 35% 
12 10 HOPiv 0.3 120 23% 
13 10 citric acid/NaOH in H2O pH 3.5 0.3 120 n. d. 
14 10 KHSO4 in H2O pH 1.6 0.3 120 n. d. 
15 10 GVL/NH4Cl (5 M in H2O) 1:1 0.3 120 13% 
16 10 NH4Cl (5 M in H2O) 0.3 120 traces 
17 10 HOAc 0.3 100 88% 
18 10 HOAc 0.3 80 73%b,c 
19 10 HOAc 1.0 80 90%c 
20 10 HOAc 1.0 60 80%c 
21 10 HOAc 1.0 38 54%c 
22 5.0 HOAc 1.0 80 83%c 
23 2.5 HOAc 1.0 80 28%c 
24 1.0 HOAc 1.0 80 tracesc 
25 10 HOAc/H2O 3:1 1.0 80 75%c 
26 10 HOAc/H2O 1:1 1.0 80 60%c 
a: Reaction conditions: 56h (0.15 mmol), 129a (0.45 mmol), [RuCl2(p-cymene)]2 (1.0–10 mol %), solvent (0.15–
0.45 mL), 24 h, N2 or air. b: The reaction was performed by Nikolaos Kaplaneris. c: The reaction was set up under air. 
n. d.: Product was not detected. 
 
 
Later experiments showed that under the optimal reaction conditions (entry 19), the conversion was 
complete after 15 h. All following reactions were therefore stopped after 15 h. 
When [RuCl2(p-cymene)]2 is dissolved in acetic acid, it is prone to exchange its two chloride ligands 
for two acetates (Scheme 74). This gave reason to assume that the formed [Ru(OAc)2(p-cymene)] 
could be the active complex, because the reaction did not proceed without acid. In order to prove 
this, the reaction was carried out using 10 mol % [Ru(OAc)2(p-cymene)] instead of [RuCl2(p-
cymene)]2 (Table 31). Unexpectedly, no desired product was formed (entry 1). The addition of 
40 mol % HCl afforded 92% of product 142ha, just as for the optimal reaction conditions (entry 2). In 
order to prove if the addition of protons is necessary or if the addition of chloride suffices to 
accomplish the reaction, sodium and potassium chloride were added, respectively (entries 3 and 4). 
Surprisingly, in these cases the unsaturated product 143ha was formed in addition to the expected 
product 142ha. The conversion was rather low and thus the products were isolated with 
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unsatisfactory low yields. It is a notable discovery that the electroneutral coupling was switched to an 
oxidative one only through the addition of sodium or potassium chloride. The following reactions 
were set up with 40 mol % of the ruthenium catalyst in order to guarantee full conversion. The aim 
was to push the selectivity completely to the unsaturated product 143ha. The increase of the 
amount of sodium chloride to 6.0 equivalents still gave a mixture of products 142ha and 143ha 
(entry 5). Although no starting material 56h was present anymore, isolation of the products by 
chromatography afforded only 14 and 8% of the products. When 20 equivalents of sodium chloride 
were applied, no hydroarylation product 142ha was detected and only the olefin 143ha seemed to 
have been formed (entry 6). Comparable to the previous case, only a small amount of 15% of 
tryptophan 143ha was isolated. The elevated amounts of ruthenium or sodium chloride might have 
caused a precipitation of the tryptophans by being chelated. Attempts to release the tryptophan 
143ha after the reaction and before the chromatography by the addition of propane-1,3-dithiol 
failed. 
 
[RuCl2(p-cymene)]2
4 HOAc 2    [Ru(OAc)2(p-cymene)]
4 HCl  
Scheme 74: [RuCl2(p-cymene)]2 in acetic acid. 
 
Table 31: Ruthenium-catalyzed C–H alkylation with [Ru(OAc)2(p-cymene)].
a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
129a
(3.0 equiv)
additive, HOAc
80 °C, 15 h, air
[Ru(OAc)2(p-cymene)] (20 mol %)
56h
CO2Et
CO2Et
142ha
N
AcHN
CO2Me
2-py
CO2Et
143ha
+
 
entry additive yield 142ha 
yield 
143ha entry additive 
yield 
142ha 
yield 
143ha 
1 - n. d. n. d. 4 KCl (3.0 equiv) 24% 10% 
2 aq. HCl (40 mol %) 92% n. d. 5 NaCl (6.0 equiv) 14% 8%b 
3 NaCl (3.0 equiv) 22% 9% 6 NaCl (20 equiv) n. d. 15%b 
a: Reaction conditions: 56h (0.15 mmol), 129a (0.45 mmol), [Ru(OAc)2(p-cymene)] (20 mol %), additive, HOAc 
(0.15 mL), 80 °C, 15 h, air. b: 40 mol % [Ru] were used. n. d.: Product was not detected. 
 
 
3.3.1.2 Scope with Tryptophan and Acrylates 
Next, the versatility of the C–H alkylation method was examined (Table 32). Several reactions of this 
scope were performed by Nikolaos Kaplaneris. Aliphatic, aromatic as well as benzylic acrylates were 
coupled efficiently to tryptophan 56h, affording the alkylated products 142 in excellent yields. 
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Functional groups, such as methoxy, enolizable ketone, cyanide, nitro, chloride, bromide, fluoride as 
well as styrene, terminal alkene, and hydroxyl were well tolerated. Also, the thioester 142hq was 
successfully synthesized, showing tolerance towards thioacrylates. The synthetic approaches for 
further modifications of the demonstrated spectrum of compounds that are available by this method 
are widespread. Halogenated compounds could be used for cross-coupling reactions, enolizable 
ketones for aldol and Grignard additions, olefins for metathesis reactions, cyanides and nitro 
compounds could be reduced to amines, fluorides could be employed for 18F-labeling and 
polyaromatics for fluorescence labeling. Another noteworthy functionality is the PEG moiety of 
substrate 142ht, which is of high interest because PEGylated peptides promise great potential. 
PEGylation creates a possibility to tune the solubility of small drugs or peptides.119 Moreover, 
PEGylation can assist the self-organization of supramolecular nanostructures and can cause changes 
of the photoluminescent properties.120 Furthermore, PEGylation is used for protein conjugation in 
order to enhance pharmacological and pharmaceutical properties.121 It is also used for drug 
delivery122 and other applications. Last, the natural products menthol and cholesterol were ligated 
with tryptophan 56h, providing the products 142hu and 142hv in high yields of 62 and 86%. 
The substrates 142hw and 142hx were obtained with rather low yields of 27 and 40%, respectively. 
The ruthenium-catalyst might insert into the C–I bond causing side reactions. The tert-butyl group is 
sensitive to acid and was therefore cleaved under the reaction conditions. 
The obtained products illustrate the possibility of the introduction of a variety of diversely decorated 
molecules with the prospect for subsequent modifications. It is particularly noteworthy, that basically 
any substrate, that contains a hydroxyl or thiol group, which can be easily converted to the 
corresponding acrylate, could be applied. 
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Table 32: Scope of the ruthenium-catalyzed C–H alkylation.a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
129
(1.5-3.0 equiv)
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
56h
CO2R
CO2R
142
 
entry product yield entry product yield 
1 
N
2-py
CO2Me
AcHN
142hb
OBn
O
 
89% 9 
N
2-py
CO2Me
AcHN
142hj
O
O
Cl
 
64% 
2 
N
2-py
CO2Me
AcHN
142hc
OnBu
O
 
90% 10 
N
2-py
CO2Me
AcHN
142hk
O
O
Br
 
72%b 
3 
N
2-py
CO2Me
AcHN
142hd
O
O
Me Me
 
74% 11 
N
2-py
CO2Me
AcHN
142hl
O
O
OMe
 
72%b 
4 
N
2-py
CO2Me
AcHN
142he
O
O
CF3
 
71% 12 
N
2-py
CO2Me
AcHN
142hm
O
O
Ph
 
79%b 
5 
N
2-py
CO2Me
AcHN
142hf
O
O
OMe
 
73% 13 
N
2-py
CO2Me
AcHN
142hn
O
O
F3C
 
75%b 
6 
N
2-py
CO2Me
AcHN
142hg
O
O
O
Me
 
70% 14 
N
2-py
CO2Me
AcHN
142ho
O
O
 
55% 
7 
N
2-py
CO2Me
AcHN
142hh
O
O
CN
 
61%b 15 
N
2-py
CO2Me
AcHN
142hp
O
O
 
75% 
8 
N
2-py
CO2Me
AcHN
142hi
O
O
NO2
 
53%b 16 
N
2-py
CO2Me
AcHN
142hq
O
SCy
 
75% 
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N
2-py
CO2Me
AcHN
142hv (from  cholesterol)l l)
O
O
MeMe
MeMe
H
Me
H
entry product yield entry product yield 
17 
N
2-py
CO2Me
AcHN
142hr
O
O
F
 
66% 21 
 
86%c 
18 
N
2-py
CO2Me
AcHN
142hs
O
O
OH
 
51% 22 
N
2-py
CO2Me
AcHN
142hw
O
O
I
 
27%b 
19 
N
2-py
CO2Me
AcHN
142ht
O
O
OMe
3
 
74% 23 
N
2-py
CO2Me
AcHN
142hx
OtBu
O
 
40% 
20 
N
2-py
CO2Me
AcHN
142hu (from menthol)
O
O
Me
Me
Me
 
62%    
a: Reaction conditions: 56h (0.15 mmol), 129 (1.5–3.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), HOAc (0.15 mL), 80 °C, 
15 h, air. b: The reaction was performed by Nikolaos Kaplaneris. c: Toluene/HOAc (1:1) was used and the reaction 
was carried out at 100 °C. 
 
 
Fluoresceinyl acrylate 129y was not suitable for this ruthenium-catalyzed C–H alkylation approach 
(Scheme 75 a). Although the actual C–H alkylation occurred, the acrylic ester was cleaved during the 
reaction and tryptophan 142h was observed in the LC-MS spectra, while neither starting meterial 56h 
nor desired product 142hy was detected. Alkyne 129z and tertiary amine 129α were not tolerated by 
the ruthenium catalysis, resulting in no product formation (Scheme 75 b). Also, the α-substituted 
acrylates 129β and γ as well as the dehydroalanine 129δ did not deliver the desired products 142. For 
the reaction with acrylate 129β, the mass of the product 143ha was observed in the LC-MS 
(Scheme 76). A possible explanation is the elimination of hydrogen chloride followed by the 
hydroarylation of the propiolate 144. Possibly, propiolates 144 would be suitable substrates for this 
reaction. Another possibility is the direct coupling of the halogenated alkene 129β affording 
regioisomer 145ha, whose molecular weight is the same as that of product 143ha. 
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+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
56h
CO2H
142h
O
CO2H
OO
O
129y
+     fluorescein
(a)
 
O
O
O
O
NMe2
OEt
O
Cl
O
O
CF3
Me
129z 129α 129β 129γ
OMe
O
NHAc
129δ
(b)
 
Scheme 75: (a) Coupling with acrylate 129y. (b) Unsuitable substrates for the ruthenium-catalyzed C–H alkylation. 
 
OEt
O
Cl
129β
OEt
O
144
-HCl
56h
Ru
N
AcHN
CO2Me
2-py
CO2Et
143ha
N
AcHN
CO2Me
2-py
145ha
56h
Ru
CO2Et
 
Scheme 76: Possible ruthenium-catalyzed reactions of acrylate 129β with tryptophan 56h. 
 
The tolerance of disulfides was examined by a bioorthogonal test with the disulfide 146 (Scheme 77). 
The standard reaction of tryptophan 56h with acrylate 129a was carried out in the presence of one 
equivalent of disulfide 146. No product 142ha was detected thus showing an intolerance towards 
disulfides. 
 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
129a
(3.0 equiv)
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
56h
CO2Et
CO2Et
142ha, not detected
+
CO2MeAcHN
S
S
CO2MeAcHN
146
(1.0 equiv)  
Scheme 77: Bioorthogonal test with a disulfide. 
 
 
3.3.1.3 Studies on a Potential Racemization of Tryptophan 
Tryptophan 56h was partially racemized using a modified literature procedure.44 
The ruthenium-catalyzed C–H alkylation of rac-56h yielded partially racemic products rac-142ha, rac-
142hd and rac-142hu. HPLC analysis showed that no racemization occurred during the ruthenium-
catalyzed C–H alkylation (Figure 7–9). 
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Figure 6: HPLC-Chromatograms of the partially racemic mixture of the compound rac-56h and of starting material 
L-56h. 
 
 
 
Figure 7: HPLC-Chromatograms of the partially racemic mixture of the compound rac-142ha and of isolated product 
L-142ha. 
 
N
AcHN
CO2Me
2-py
L-56h
N
AcHN
CO2Me
2-py
rac-56h
N
AcHN
CO2Me
2-py
rac-142ha
CO2Et
N
AcHN
CO2Me
2-py
L-142ha
CO2Et
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Figure 8: HPLC-Chromatograms of the partially racemic mixture of the compound rac-142hd and of isolated product 
L-142hd.  
 
 
 
Figure 9: HPLC-Chromatograms of the partially racemic mixture of the compound rac-142hu and of isolated product 
L-142hu. 
 
3.3.1.4 Scope of the C–H Alkylation of Peptides with Acrylates 
Having explored the scope and limitations of the ruthenium-catalyzed C–H alkylation of single 
tryptophan, the focus was next shifted to peptides 101 (Table 33). Some reactions were performed 
by Nikolaos Kaplaneris. Di- and tripeptides 101 were alkylated providing alkylated peptides 147 
(entries 1–6). Both aromatic and aliphatic acrylates were applicable and the yields of the isolated 
compounds 147 vary from 53 to 76%. Due to difficulties regarding the purification, the alkylated 
N
AcHN
CO2Me
2-py
rac-142hd
O
O
MeMe
N
AcHN
CO2Me
2-py
L-142hd
O
O
MeMe
N
AcHN
CO2Me
2-py
rac-142hu
O
O Me
Me
Me
N
AcHN
CO2Me
2-py
L-142hu
O
O Me
Me
Me
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peptide 147ja was not isolated, although the product mass was detected in the LC-MS analysis, while 
no starting material 101j was detectable, which indicated a full conversion. The product 147jo was 
also not obtained and in this case, the LC-MS analysis revealed a complex mixture of products. 
Methionine-containing peptide 147ma was not formed. 
 
Table 33: Scope of the ruthenium-catalyzed C–H alkylation of peptides 101.a 
129
(3.0 equiv)
147
N
peptide
101
N
H
peptide
+
2-py 2-py
CO2R
CO2R
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
 
entry product yield entry product yield 
1 
147im
H
N
Ile-OMe
O
N
2-py
O
O
Ph
Ac
 
76%b 6 
147ll
H
N
Ala-Phe-OMe
O
N
2-py
O
O
OMe
Ac
 
53%b 
2 
147jd
H
N
Trp-Gly-OEt
O
N
2-py
O
O
Me
Me
Ac
 
60% 7 
147ja
H
N
Trp-Gly-OEt
O
N
2-py
O
OEt
Ac
 
0%c 
3 
147kc
H
N
Leu-Trp-OEt
O
N
2-py
O
O
CF3
Ac
 
57% 8 
147jo
H
N
Trp-Gly-OEt
O
N
2-py
O
O
Ac
 
0%d 
4 
147jk
H
N
Trp-Gly-OEt
O
N
2-py
O
O
Br
Ac
 
58% 9 
147ma
H
N
OMe
O
N
2-py
O
Ac-Met
OEt
 
0% 
5 
147lm
H
N
Ala-Phe-OMe
O
N
2-py
O
O
Ph
Ac
 
59%b    
a: Reaction conditions: 101 (50–100 mg), 129 (1.1–5.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), HOAc (0.1–0.3 mL), 
80 °C, 15 h, air. b: The reaction was performed by Nikolaos Kaplaneris. c: LC-MS analysis indicated product formation. 
d: LC-MS analysis indicated a complex mixture of products. 
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3.3.1.5 C–H Activation Ligation of Peptides 
The ruthenium-catalyzed C–H alkylation approach was successfully applied for peptide ligation 
(Table 34). Ligation products 149 were obtained through the reaction of tryptophan peptides 101 
with acryloyl peptides 148. Some ligation reactions were performed by Nikolaos Kaplaneris. Acrylates 
of the natural amino acids tyrosine and serine delivered di- to hexapeptides 149a–e in good yields of 
42 to 64%. Furthermore, for peptides that do not contain a hydroxyl group, linkers were used to 
introduce the acrylate. For the N-terminus, 2-hydroxy acetic acid was used, which is incorporated in 
products 149f–h, while for the C-terminus, 2-aminoethanol was applied, presented in product 149i. 
With these two simple linkers any peptides could be used for this ligation method. The last example 
showed the ligation of two tryptophans 56h, which were reacted with 0.5 equivalents of a diacrylate, 
affording product 149j. 
 
Table 34: Ligation by ruthenium-catalyzed C–H alkylation.a 
148
(1.1 equiv)
149
N
peptide1
101
N
H
peptide1
+
2-py 2-py
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)O
O
peptide2 O
O
peptide2
 
entry product yield entry product yield 
1 
Ac Trppy OMe
Ac Tyr OEt
149a
O
 
59%b 6 
Ac Trppy OMe
OO
Phe OMe
O
149f  
67%c 
2 
Ac Trppy OMe
Phe Ser OMeAc
149b
O
 
64%c 7 
Ac Trppy OMe
OO
Phe Leu OMe
O
149g  
61%c 
3 
Ac Trppy Ile
Phe Ser OMeAc
OMe
149c
O
 
56%c 8 
Ac Trppy Ala Phe OMe
OO
Phe Leu OMe
O
149h  
52%c 
4 
Ac Trppy Trp
Ac Tyr Gly
Gly OEt
OEt
149d
O
 
57%b 9 
Ac Trppy Ala Phe OMe
OO
Ac Phe NH
149i  
52%c 
5 
Ala β3hTrppy OBn
Phe Ser OMeAc
LeuSerAc
149e
O
 
42% 10 
Ac Trppy OMe
O
Ac Trppy OMe
O
149j
O
O  
54% 
a: Reaction conditions: 101 (50–100 mg), 148 (1.1 equiv), [RuCl2(p-cymene)]2 (10 mol %), HOAc (0.1–0.3 mL), 80 °C, 
15 h, air. b: The reaction was stopped after 8 h to prevent phenolic ester cleavage. c: The reaction was performed by 
Nikolaos Kaplaneris. 
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Next, a combinatorial twofold ruthenium-catalyzed C–H ligation method was sought. The idea was to 
first alkylate peptides 56 or 101 with the acrylate 129k followed by the arylation of a second peptide 
101 (Scheme 78). The ligation products 150 would consist of two peptides, bridged by a phenol 
propionate. The first step of this procedure is presented in chapters 3.3.1.2 and 3.3.1.4, providing 
substrates 142hk and 147jk, which should be applied for this approach. 
 
Ru
56 or 101
N
H
peptide1
142 or 147
N
peptide1
101
Ru
150
N
peptide1
N
H
peptide2
2-py
N
2-py
peptide2
O
O O
O
Br
2-py 2-py
O
O
Br
129k
2-py
 
Scheme 78: Ligation through a sequential twofold C–H modification approach. 
 
 
The structurally simpler substrate 142hk was submitted to the ruthenium-catalyzed C–H arylation 
reaction to be ligated with two different peptides 101c and 101d (Scheme 79). Traces of the ligation 
products 150a and 150b were detected in the LC-MS, however, these peptides could not be isolated. 
Due to a cleavage of the phenolic ester, tryptophan 142h and peptides 102cδ and 102dδ were found 
in the LC-MS analysis. In the case of the reaction with peptide 101c the cleavage product 102cδ was 
isolated in 61% yield. On the one hand, these results demonstrate that in principle this ruthenium-
catalyzed C–H arylation method works. On the other hand, the choice of the linker was not suitable 
due to the instability of the phenolic ester under basic reaction conditions. A conceivably more 
suitable linker might be the acrylate 129ε consisting of a bromoaniline connected to the acryloyl 
moiety by 2-hydroxy acetic acid. The more complex substrate 147jk was not used due to the results, 
that were obtained with the substrate 142hk. 
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K3PO4 (3.0 equiv)
m-xylene, 120 °C, 20 h, N2
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
Ac Trppy OMe
OO
142hk
Br
Boc Leu Ala β3hTrppy OBn
101c
Ac Trppy OMe
OO
Boc Leu Ala β3hTrppy OBn
OH
Boc Leu Ala β3hTrppy OBn
Ac Trppy OMe
OHO
150a 102cδ: 61%
142h
Boc Trppy Leu Trp OEt
[RuCl2(p-cymene)]2 (5 mol %)
F5C6CO2H (30 mol %)
K3PO4 (3.0 equiv)
m-xylene, 120 °C, 20 h, N2
101d
Boc Trppy Leu Trp OEt
Ac Trppy OMe
OO
150b
OH
Ac Trppy OMe
OHO
102dδ
142h
Boc Trppy Leu Trp OEt
(a)
(b)
BrHN
O O
O
129ε  
Scheme 79: (a) Ligation through ruthenium-catalyzed arylation with bromide 142hk. (b) Ligation linker 129ε. 
 
 
3.3.1.5 Attempted Cyclization of Acryloyl Peptides 
The ruthenium-catalyzed C–H alkylation was attempted in an intramolecular fashion in order to 
obtain cyclopeptides 152 (Scheme 80). The cyclization reactions were carried out at a concentration 
of 0.1 M. Unfortunately, neither cyclic peptide 152a nor 152b were obtained. In the case of the 
tyrosine acrylate 151a, acrylic ester hydrolysis led to peptide 101n, whose molecular mass was 
observed in the LC-MS analysis. After the reaction of peptide 151b, the serine acrylate signals were 
still present in the NMR spectra and the LC-MS analysis did not indicate the formation of the cyclic 
peptide 152b. 
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152
N
2-py
O
O
peptide
151
N
H
2-py
O
peptide
O
(a)
Ru
 
NHAc
HN
O
CO2Me
N
2-py
O
O
16HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
0.1 M
151a 152a
Ac Tyr Trppy OMe
O
(b)
Ac Tyr Trppy OMe
101n
 
NH
O
N
Py
O
O
CO2BnN
H
MeO
NH
O
AcHN
Me
Me
18
152b
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
0.1 M
151b
Ac Ser Leu Ala β3hTrppy OBn
O
 
Scheme 80: Ruthenium-catalyzed intramolecular cyclization. (a) General approach. (b) Unsuccessful attempts. 
 
Another attempt to achieve a cyclic peptide was the C–H alkylation of peptides 108 with an acrylate 
129, which contained a terminal alkene. A subsequent RCM reaction would lead to cyclic peptides 
154 (Scheme 81). Regrettably, neither dialkene 153bp nor 153cp could be isolated due to purification 
difficulties, such as the non-feasible separation by chromatography. 
Last but not least, peptides 108 were submitted to undergo a cyclization by a twofold C–H alkylation 
with a diacrylate 129 (Scheme 82). Traces of an addition product — cyclic or monoalkylated — were 
observed in the LC-MS analysis. However, after a prolonged reaction time or at an elevated reaction 
temperature, no peptide substrates — neither starting materials 108b and 108c nor alkylated 
peptides 153 — could be detected. Possibly, the substrates polymerized after a monoalkylation. 
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153
N
2-py
N
2-py
peptide
O O
154
N
2-py
N
2-py
peptide
O O
RCM
108
N
H
2-py
N
H
2-py
peptide O
O
n
129
Ru
(a)
O O OO
n n n n
 
 
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
129p
(10.0 equiv)
O
O
O OO O
Ac Trppy Ala Gly Trppy Gly OMe + Ac Trppy Ala Gly Trppy Gly OMe
108b 153bp: 0%
(b)
 
Ac Trppy NH
108c
Ac Trppy NH
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
129p
(10.0 equiv)
O
O
O
O
+
153cp: 0%
Ac
Trppy NH
Ac
Trppy NHO
O
 
Scheme 81: Ruthenium-catalyzed cyclization by RCM. (a) General approach. (b) Unsuccessful attempts. 
 
 
155
N
2-py
N
2-py
peptide
O
O O
O
n
108
O
O
O
n
129
Ru
N
H
2-py
N
H
2-py
peptide
(a)
O
 
 
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
129ζ
(1.0 equiv)
OO O
Ac Trppy Ala Gly Trppy Gly OMe + Ac Trppy Ala Gly Trppy Gly OMe
108b
(0.05 M)
155bζ
O
2
(b)
O
O
O
4
O
 
O
O
O
4 HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
129ζ
(1.0 equiv)
Ac Trppy NH
+
108c
(0.1 M)
Ac Trppy NH O
Trppy NH
155cζ
Trppy NH
Ac
Ac
O
O
O
O
2
 
Scheme 82: Ruthenium-catalyzed cyclization with a diacrylate. (a) General approach. (b) Unsuccessful attempts. 
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3.3.2 Ruthenium-Catalyzed C–H Alkylation with Vinyl Ketones 
3.3.2.1 Optimization of the Reaction 
Starting from the successful reaction of trytophan 56g with vinyl ketone 130a (Table 29, entry 13), 
the ruthenium-catalyzed C–H alkylation reaction with vinyl ketones was optimized in order to make 
the reaction conditions as mild as possible (Table 35). Similar to the C–H alkylation method with 
acrylates 129 the coupling of vinyl ketone 130a with the pyridylated tryptophan 56h proceeded 
better than with the pyrimidylated tryptophan 56g (entries 1–6). The use of either one percent of 
acetic acid in water or 10 percent in GVL at a reaction temperature of 80 °C was sufficient to deliver 
the desired product in excellent yields (entries 7–15). Also, mixtures of weaker acids, such as 
propionic acid and even ammonium chloride, could be used with GVL, affording the alkylated 
product 141ha in excellent yields (entries 16–21). At temperatures lower than 80 °C the yield 
dropped (entries 22 and 23). 
Table 35: Optimization of the ruthenium-catalyzed C–H alkylation with vinyl ketones.a 
+
N
AcHN
CO2Me
2-py(m)
H
N
AcHN
CO2Me
2-py(m)
130a
(3.0 equiv)
solvent, T, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
141ga
141ha
O
Me
56g (2-pym)
56h (2-py)
O
Me
 
entry Trp (0.3 M) solvent T/°C yield 
1 56g HOAc 140 91% 
2 56g HOAc 120 90% 
3 56g HOAc 100 81% 
4 56g HOAc 80 41% 
5 56g HOAc 60 18% 
6 56h HOAc 80 98% 
7 56h HOAc/H2O 1:1 80 98% 
8 56h HOAc/H2O 1:9 80 99% 
9 56h HOAc/H2O 1:99 80 98% 
10 56h HOAc/GVL 1:1 80 99% 
11 56h HOAc/GVL 1:99 80 30% 
12 56h HOAc/GVL 5:95 80 73% 
13 56h HOAc/GVL 1:9 80 98% 
14 56h HOAc/GVL 1:9 70 92% 
15 56h HOAc/GVL 1:9 60 23% 
16 56h HO2CEt/GVL 1:9 80 95% 
17 56h buffer pH 5 80 traces 
18 56h buffer pH 5/GVL 80 traces 
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entry Trp (0.3 M) solvent T/°C yield 
19 56h NH4Cl (5 M in H2O) 80 91% 
20 56h NH4Cl (5 M in H2O)/GVL 9:1 80 98% 
21 56h NH4Cl (1 M in H2O)/GVL 9:1 80 96% 
22 56h NH4Cl (5 M in H2O)/GVL 9:1 60 35% 
23 56h NH4Cl (5 M in H2O)/GVL 9:1 38 17% 
a: Reaction conditions: 56 (0.15 mmol), 130a (0.45 mmol), [RuCl2(p-cymene)]2 (10 mol %), solvent (0.15 mL), 80 °C, 
15 h, air. 
 
3.3.2.2 Scope with Tryptophan and Vinyl Ketones 
The scope of the ruthenium-catalyzed C–H alkylation reaction with vinyl ketones 130 showed the 
applicability of aliphatic and aromatic vinyl ketones 130, providing alkyl tryptophans 141 in high 
yields (Table 36, entries 1–4). Notably, the Boc-containing substrates 141ka and 141hd were 
obtained from the reaction in a 9:1 mixture of water and acetic acid and no deprotection of the Boc-
moiety was detected. The bromide-containing tryptophan 141he, which was intended to be used for 
peptide ligation similar to substrates 142hk and 147jk, was not formed by this C–H alkylation method 
(entry 5). Instead, the unreacted tryptophan 56h was reisolated with 78% yield. 
Table 36: Scope of the ruthenium-catalyzed C–H alkylation with vinyl ketones.a 
+
N
RHN
CO2Me
2-py
H
N
RHN
CO2Me
2-py
130
(1.1-3.0 equiv)
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
(R = Boc)
(R = Ac) 141
O
R
56k
56h
O
R
 
entry product yield entry product yield 
1 
N
AcHN
CO2Me
2-py
141hb
O
nPent
 
97% 4 
N
AcHN
CO2Me
2-py
141hd
O
NHBoc
 
88%b 
2 
N
AcHN
CO2Me
2-py
141hc
O
Ph
 
68% 5 
N
AcHN
CO2Me
2-py
141he
O
Br
 
0% 
3 
N
BocHN
CO2Me
2-py
141ka
O
Me
 
89%b    
a: Reaction conditions: 56 (0.15 mmol), 130 (1.1–3.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), HOAc (0.15 mL), 80 °C, 
15 h, air. b: The reaction was carried out in H2O/HOAc 9:1. 
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3.3.2.3 Scope with Peptides and Vinyl Ketones 
Peptides 101 were successfully alkylated with vinyl ketones 130, delivering alkylated peptides 156 
(Table 37). The examples 156ja, 156kb and 156ea showed an excellent regioselectivity as the 
pyridylated tryptophan was alkylated exclusively, not affecting the NH-free tryptophans. The use of a 
9:1 mixture of water and acetic acid allowed the alkylation of the Boc-protected peptides, providing 
Boc-peptide 156ea. Alkylated peptides 156jb, 156jf, 156oa and 156ma were not isolated due to 
difficulties separating them from the unreacted peptides 101. In these cases, the target masses were 
found in the LC-MS chromatograms, indicating product formation. Even the methionine peptides 
156oa and 156ma were indicated to have been formed. 
 
Table 37: Scope of the ruthenium-catalyzed C–H alkylation with peptides and vinyl ketones.a 
130
(1.1-5.0 equiv)
156
N
peptide
101
N
H
peptide
+
2-py 2-py
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
O
R
O
R
 
entry product yield entry product yield 
1 
156ja
H
N
Trp-Gly-OEt
O
N
2-py
O
Me
Ac
 
83% 5 
156jf
H
N
Trp-Gly-OEt
O
N
2-py
O
O
Me
Me
Br
Ac
 
0%c 
2 
156kb
H
N
Leu-Trp-OEt
O
N
2-py
O
nPent
Ac
 
51% 6 
H
N
Phe-Gly-OEt
O
N
2-py
O
Me
156oa
Boc-Met
 
0%b,c 
3 
156ea
H
N
Trp-Gly-OEt
O
N
2-py
O
Me
Boc
 
56%b 7 
H
N
OMe
O
N
2-py
O
Me
156ma
Ac-Met
 
0%c 
4 
156jb
H
N
Trp-Gly-OEt
O
N
2-py
O
nPent
Ac
 
0%c    
a: Reaction conditions: 101 (50–100 mg), 130 (1.1–5.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), solvent (0.1–0.3 mL), 
80 °C, 15 h, air. b: The reaction was carried out in H2O/HOAc 9:1. c: LC-MS indicated product formation.  
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3.3.3 Ruthenium-Catalyzed C–H Alkylation with Acrylamides 
Due to the successful alkylation of tryptophan peptides with acrylates and vinyl ketones, acrylamides 
131 gained our interest. Several advantages are associated with acrylamides, as they are easily 
accessible from primary or secondary amines. Regarding peptides, amines are present in every amino 
acid and thus every peptide could be acrylated to be used for novel ligation or cyclization motifs. 
 
3.3.3.1 Optimization of the Reaction 
For the optimization of the hydroarylation of acrylamide 131a with tryptophan 56h, similar to the 
reactions with acrylates and vinyl ketones, 10 mol % [RuCl2(p-cymene)]2 was used as the catalyst and 
various acidic solvent mixtures were screened (Table 38). The measured peak area ratios of the 
substrates 56h and 157ha are given as an indicator for the approximate reaction result. In all cases, 
only small amounts of an alkylated product were formed. For the reactions in acetic acid, 
hexanes/acetic acid and ethanol/acetic acid (entries 1, 10, 14), the N-alkylated product 158ha was 
isolated as the sole product in 19, 21 and 47% yield, respectively. As the retention time of all 
detected alkyl products was identical, the probability for the formation of the C2 product is rather 
low. For this reason, no further experiments were attempted towards the C2 alkylation of tryptophan 
with acrylamides 131. 
Table 38: Optimization of the ruthenium-catalyzed alkylation with acrylamide 131a.a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
131a
(2.0 equiv)
solvent, 120 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
56h 157ha
NHiPr
O
NHiPr
O
N
N
Ac
CO2Me
2-py
H
158ha
O
NHiPr
 
entry solvent 56h/158ha (LC-MS) entry solvent 
56h/158ha 
(LC-MS) 
1 HOAc 77:23 10 hexanes/HOAc 9:1 75:25 
2 TFA 100:traces 11 1,4-dioxane/HOAc 9:1 100:traces 
3 HO2CH 100:0 12 DME/HOAc 9:1 96:4 
4 GVL/HOTf 9:1 100:traces 13 DMF/HOAc 9:1 100:traces 
5 GVL/HCl 9:1 88:12 14 EtOH/HOAc 9:1 45:55 
6 GVL/HOAc 9:1 88:12 15 DMSO/HOAc 9:1 100:0 
7 GVL/NH4Cl (5 M in H2O) 9:1 92:8 16 MeCN/HOAc 9:1 80:20 
8 m-xylene/HOAc 9:1 95:5 17 acetone/HOAc 9:1 80:20 
9 NMP/HOAc 9:1 90:10 18 mesitylene/HOAc 9:1 100:0 
a: Reaction conditions: 56h (0.15 mmol), 131a (0.30 mmol), [RuCl2(p-cymene)]2 (10 mol %), solvent (0.15 mL), 120 °C, 
15 h, air. 
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3.4 On-Resin C–H Alkylation of Peptides 
A number of methods for postsynthetic peptide modification has been developed. Although, 
different kinds of issues have been overcome, a few challenges remain. Some of these are  
 purification of the peptidic products, 
 removal of metal catalyst traces, 
 solubility of peptides in common organic solvents, and 
 aggregation and jellification during the reaction. 
To circumvent these problems, the modification reactions can be carried out on peptides bound to a 
resin. On-resin reactions of peptides have already been used since the first SPPS was developed by 
Merrifield in 1963.123 The idea was that a peptide which is chemically bound to a resin, is reacted 
with a substrate, which afterwards is washed out through a filter without any peptide loss. After the 
washing, further reactions could be carried out. Finally, when all necessary modifications are 
finished, the peptide is cleaved from the resin. This solid-phase-supported approach enjoys great 
reputation due to a wide range of successful applications. 
 
3.4.1 On-Resin C–H Alkylation with Acrylates and Vinyl Ketones 
The ruthenium-catalyzed alkylation method described in chapters 3.3.1 and 3.3.2 should be applied 
to peptides on the solid phase (Scheme 83). Pyridylated tryptophan-containing peptides 159 should 
be synthesized according to standard procedures of SPPS and afterwards alkylated by the ruthenium-
catalyzed alkylation approach in order to deliver alkylated peptides on resin 160. The cleavage of the 
peptide from the resin would set free a C–H alkylated peptide 161. 
SPPS
peptide Ru
O
R/OR
peptide
cleavage
peptide
159 160 161
R/ORO R/ORO
129 or 130
 
Scheme 83: On-resin ruthenium-catalyzed C–H alkylation of peptides. 
For the synthesis of peptides 159, which contain a pyridylated tryptophan, an Fmoc-protected 
pyridylated tryptophan was synthesized (Scheme 84). Starting from tryptophan 162, the amine and 
the carboxylic acid were protected with base-orthogonal protecting groups. The 2-pyridyl group was 
introduced via an Ullmann coupling in order to obtain tryptophan 164. Hydrogenative deprotection 
of the benzyl ester followed by an acidic cleavage of the Boc-moiety furnished the hydrochloride 165. 
The Fmoc-protection was accomplished using FmocOSu in a basic medium. The ready-to-use Fmoc-
protected tryptophan 166a was thus synthesized in 37% overall yield. 
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N
H
H2N
CO2H
N
H
BocHN
CO2Bn
N
BocHN
CO2Bn
2-py
N
ClH3N
CO2H
2-py
N
FmocHN
CO2H
2-py
1) Boc2O (1.2 equiv)
    K2CO3
    THF/H2O
    25 °C, 1 d
2) BnBr (3.0 equiv)
    K2CO3 (2.0 equiv)
    MeCN/H2O 10:1
    50 °C, 3 d162 163: 85%
2-Br-py (28m, 1.3 equiv)
CuI (20 mol %)
DMEDA (40 mol %)
K3PO4·(H2O)x (2.5 equiv)
toluene, 110 °C, 1 d
164: 60%
1) H2 (1 atm)
    Pd/C (10 mol %)
    MeOH, 25 °C, 1 d
2) aq. HCl (12 M, 3 equiv)
    EtOAc, 25 °C, 4 h
165: quantitative
FmocOSu (1.0 equiv)
DIEA (20 equiv)
166a: 72%
37% over 6 steps
1,4-dioxane/DMF (1:1)
25 °C, 1 d
NO O
O
Fmoc
FmocOSu
 
Scheme 84: Synthesis of tryptophan 166a for the SPPS.  
 
Prior to the ruthenium-catalyzed procedure, the acid stability of the commonly used Rink amide AM 
and Wang resins was examined (Scheme 85 a). Both Rink amide and Wang resins are commonly 
applied for the Fmoc SPPS strategy and thus the cleavage is accomplished with acids. An Fmoc-Val 
Wang resin and an Fmoc-Val Rink amide resin were treated with trifluoroacetic acid at ambient 
temperature and with acetic acid at 80 °C, respectively. The cleaved Fmoc-amino acids 166b and c 
were detected by an LC-MS analysis. As expected, the Fmoc-amino acids were cleaved with 
trifluoroacetic acid. Fortunately, no Fmoc-amino acids were detected in the solution after heating 
the resins in acetic acid. With this finding, the established conditions for the ruthenium-catalyzed C–
H alkylation reactions could be applied. Another advantage of acetic acid as the reaction medium is a 
swelling of 2.8 mL/g (Wang resin), which is a moderate value as compared to other organic 
solvents.124 
N
H
O
O
FmocHN
MeO
OMe
Fmoc-Rink amide AM resin
0.55 mmol/g, Iris Biotech
Rink amide AM resin
0.50 mmol/g, Biotage
HO
Wang resin
0.63 mmol/g, Novabiochem
N
H
O
O
H2N
OMe
MeOPS
PSPS
(a)
 
O
Fmoc-Val
H
N
Fmoc-Val
Wang resin Rink amide AM resin
or Fmoc-Val-OH or Fmoc-Val-NH
a) TFA, 25 °C
          or
b) HOAc, 80 °C
    20 h, air
(b)
166b 166c  
 a)   
 b) n. d. n. d. 
Scheme 85: (a) Resins used. PS: polystyrene. (b) Acid stability test of resins. : Fmoc amino acid was cleaved from 
resin. n. d.: The Fmoc-amino acid was not detected in solution. 
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Pyridylated tryptophan-containing peptides 159 with a sequence of up to 10 amino acids were 
synthesized using automated SPPS (Scheme 86). Peptides 159a and 159b contain only aliphatic and 
aromatic amino acids with no further functionalities, whereas peptides 159c, 159d and 159e were 
equipped with a free amide of glutamine, a Pbf-protected arginine and a trityl-protected histidine, 
respectively. 
Ac OGly Ala Ala Trppy Gly Phe Val
159a, 0.63 mmol/g  
Ac Ala Gly Gly Val Ala Gly Trppy Gly Gly NH
159b, 0.35 mmol/g  
Ac Ile Ala Gln Gly Leu Gly Ala Trppy Gly Ala NH
159c, 0.37 mmol/g  
Ac Ala Arg Gly Ala Ala Leu Trppy Val Val NH
(Pbf)
159d, 0.37 mmol/g  
Ac Gly His Phe Phe Ala Trppy Gly Ala Gly NH
(Trt)
159e, 0.37 mmol/g  
Scheme 86: Peptides 159. 
 
The acid stability of the Pbf and the trityl protecting groups was tested via heating Fmoc-Arg(Pbf)-OH 
(166d) and Fmoc-His(Trt)-OH (166f) in acetic acid (Scheme 87). An LC-MS analysis showed no 
deprotection of arginine 166d, whereas histidine 166f was completely trityl-deprotected. 
 
Fmoc Arg OH
(Pbf)
HOAc
80 °C, 20 h, air
Fmoc Arg OH
Fmoc His OH
(Trt)
HOAc
80 °C, 20 h, air
Fmoc His OH
166d 166e
166f 166g  
Scheme 87: Acid stability test of protecting groups. 
 
Next, the scope of the ruthenium-catalyzed C–H alkylation was examined. The reactions were set up 
in 10 mL conical-bottom test tubes without stir bar. 30 µmol of resin 159 was placed in the test tube 
and 100 µL of a catalyst stock solution were added ([RuCl2(p-cymene)]2 in HOAc, 18.4 mg/mL, 
10 mol %). After the addition of an alkene, the mixture was slightly shaken and then left calm to swell 
the resin. After 30 min of swelling, a few drops of acetic acid were added if necessary, until the resin 
was completely covered with solvent. The test tube was fitted with a septum and placed in a glove 
finger with a stir bar, which allowed for a slight shaking of the reaction mixture in the heating bath. 
The glove was fixated above the heating bath and the reaction mixture was heated to 80 °C for 15 h. 
Thereafter, the resin was alternately washed with acetic acid and methanol several times and dried 
overnight at 40 °C. For the cleavage, the resins were treated with TFA or a mixture of 
TFA/TIS/CH2Cl2/H2O (95:2.5:1.25:1.25). The cleaved peptides were precipitated from –20 °C cold 
diethylether and centrifuged three times and finally dried in vacuum. 
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Acrylates and vinyl ketones were applied, delivering alkylated peptides 161 (Table 39). The yields 
shown refer to the SPPS-alkylation-cleavage-purification sequence and do not only represent the 
ruthenium-catalyzed step. Peptides 161a, 161d, and 161f–h were isolated in good yields of 43–78%. 
Peptides 161b, 161c and 161e were observed in the LC-MS, but they could not be purified by 
crystallization and washings or preparative HPLC. While the protected arginine peptide 159d was not 
deprotected during the ruthenium-catalyzed procedure and thus the nucleophilic guanidine was not 
affected, alkylated peptides 161g and 161h were obtained with a selective alkylation of the 
tryptophan moiety. In contrast, histidine peptide 159e was deprotected during the alkylation 
reaction, resulting in the formation of byproducts and a 1:1 mixture of di- and trialkylated peptides 
was isolated. Probably, one of the imidazole N-atoms underwent an aza-Michael addition to form 
peptides 161j and 161k (Scheme 88). A subsequent electrophilic aromatic substitution afforded 
peptides 161l and 161m. 
Table 39: Scope of the ruthenium-catalyzed on-resin C–H alkylation.a 
peptide
O
R/OR peptide
159 161
1) [RuCl2(p-cymene)]2 
    (10 mol %)
    HOAc, 80 °C, 15 h, air
2) TFA
    or TFA/TIS/CH2Cl2/H2O
    (95:2.5:1.25:1.25)
+
130 (R) or 129 (OR)
(5.0 equiv)
R/ORO
 
entry peptide alkene product yield 
1 159a 
nPent
O
130b  
Ac OHGly Ala Ala Trppy Gly Phe Val
161a
OMe
 
78% 
2 159a 
Me
O
130a  
Ac OHGly Ala Ala Trppy Gly Phe Val
161b
OMe
 
n. i. 
3 159a O
O
129d
Me
Me
 
Ac OHGly Ala Ala Trppy Gly Phe Val
161c
OOMe
Me
 
n. i. 
4 159b 
OBn
O
129b  
Ac Ala Gly Gly Val Ala Gly Trppy Gly Gly NH2
161d
OOPh
 
69% 
5 159b 
O
O
129t
OMe
3
 
Ac Ala Gly Gly Val Ala Gly Trppy Gly Gly NH2
161e
OO
O
O
MeO
 
n. i. 
6 159c 
O
O
129t
OMe
3
 
Ac Ile Ala Gln Gly Leu Gly Ala Trppy Gly Ala NH2
161f
OO
O
O
MeO
 
43% 
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entry peptide alkene product yield 
7 159d 
Me
O
130a  
Ac Ala Arg Gly Ala Ala Leu Trppy Val Val NH2
161g
OMe
 
71% 
8 159d 
O
O
129t
OMe
3
 
Ac Ala Arg Gly Ala Ala Leu Trppy Val Val NH2
161h
OO
O
O
MeO
 
45% 
9 159e 
Me
O
130a  
Ac Gly His Phe Phe Ala Trppy Gly Ala Gly NH2
161i
OMe
 
n. d. 
a: Reaction conditions: 1) 159 (30 µmol), 129 or 130 (3.0–10.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), HOAc (30–
150 µL), 80 °C, 15 h, air; 2) TFA (3 mL) or TFA/TIS/CH2Cl2/H2O (3 mL, 95:2.5:1.25:1.25), 25 °C, 4 h. n. i.: The product 
could not be isolated. n. d.: The product was not detected. 
 
 
Phe Phe Ala Trppy Gly Ala Gly NH2
161j
OMe
N
H O
GlyAc
N
N
Me
O
     
Phe Phe Ala Trppy Gly Ala Gly NH2
161k
OMe
N
H O
GlyAc
N
N MeO
 
Phe Phe Ala Trppy Gly Ala Gly NH2
161l
OMe
N
H O
GlyAc
N
N
Me
O
O
Me
     
Phe Phe Ala Trppy Gly Ala Gly NH2
161m
OMe
N
H O
GlyAc
N
N MeO
Me
O
 
Scheme 88: Possible products for the ruthenium-catalyzed alkylation of peptide 159e. 
 
To summarize, the ruthenium-catalyzed on-resin C–H alkylation of peptides was highly successful. 
The developed on-resin modification allowed the efficient and selective introduction of 
functionalized alkanes as shown in chapter 3.3.1.2. Furthermore, the on-resin procedure allowed the 
incorporation of side chain-protected amino acids, such as arginine, that would otherwise lead to 
side reactions. For this on-resin reaction it is possible to use large excess of reagents to drive the 
reaction to completion without affecting the purification, or to set up the reaction several times 
without intermediate purification. Remaining reagents can be easily washed out without a loss of 
product. The reaction can be followed by an LC-MS analysis after cleavage of analytical amounts of 
the resin. The reaction set up is very simple and bench solvents can be used. The necessary amount 
of solvent is reduced to the volume needed for swelling the resin, which depends on the properties 
of the resin used and on the peptide attached to it. With the peptides attached to the solid phase, 
poor solubility of peptides is not an issue. Moreover, no peptide aggregation or jellification can occur 
during the reaction. 
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3.4.2 Attempted Cyclization via On-Resin C–H Alkylation 
Having achieved a successful procedure for the ruthenium-catalyzed C–H alkylation of peptides on 
the solid phase, on-resin cyclization of peptides was investigated. Peptides 167, containing 
pyridylated tryptophan and an acrylate moiety, should be cyclized on-resin in order to form peptides 
168, which would set free cyclopeptides 169 after cleavage from the resin (Scheme 89). The acrylic 
moiety should be introduced via the natural amino acids serine, threonine, tyrosine or cysteine. In 
addition to the advantages of reactions on the solid phase as described above, cyclization reactions 
in particular may profit significantly from the on-resin approach, because dimerization and 
polimerization are efficiently avoided. Therefore, the reaction does not need to be carried out in a 
highly diluted mixture, which would decrease the reaction rate significantly. 
 
167
N
2-py
O
O H
peptide
Ru
N
2-py
O
O
peptide
168
cleavage
N
2-py
O
O
peptide
169  
Scheme 89: Ruthenium-catalyzed on-resin cyclization of peptides. 
 
For the synthesis of the acryloyl peptides 167, peptides 170 from the SPPS needed to be deprotected 
without cleaving the peptide from the resin (Table 40). The tert-butyl protected serine-containing 
peptides 170a and 170b were chosen for the optimization of the deprotection step. After each 
deprotection procedure, an analytical amount of the resin was acetylated twice, using a 1 M solution 
of a 1:2 mixture of acetic anhydride and diisopropylethylamine in CH2Cl2. After the cleavage of the 
analytical acetylated sample with TFA at ambient temperature, the ratio of acetylated to free peptide 
was determined by LC-MS analysis. 
The simplest method for the cleavage of the tert-butyl ether would be heating peptides 170a and 
170b in acetic acid, but, unfortunately, only traces of peptide 170 were deprotected in this way 
(entries 1a and 2a). Therefore, further literature-known methods using Lewis acids were tested. 
However, the results were unsatisfactory (entries 1b–e and 2b–f). The CeCl3/NaI procedure was 
found to be most promising.125 Indeed, after several repetitions of this procedure, no more hydroxyl-
free peptide 174b was detected. Only acetylated peptide 173b was present. Hence, the deprotection 
was complete and hydroxyl-free peptide 174b was acryloylated using a solution of a 10-fold excess of 
acryloyl chloride and 20-fold excess of diisopropylethylamine in CH2Cl2 affording acryloyl peptide 
167b. 
Due to the difficult deprotection of tert-butyl ethers, the trityl protected cysteine peptide 170c was 
explored instead. Neither 2 N HCl nor HBr in acetic acid at ambient temperature afforded the desired 
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deprotected products (entries 3a and b). Also, LiCl in refluxing methanol, acetic acid at 80 °C and 2 N 
HBr in acetic acid at 80 °C did not deliver free thiopeptide 171c (entries 3c–e). 
 
Table 40: Deprotection of peptide side chains on the solid support. 
X-PG
deprotection
X-H
acetylation
of an analytical
amount
X-Ac
cleavage
of the analytical
amount
peptide
peptide peptide
X-PG
peptide
X-PG
peptide
X-Ac
peptide
X-H
peptide
170
171
170
172
170 174
173
 
entry peptide deprotection procedure 173/174 (LC-MS) 
1 AcHN Gly
O
Gly Trppy Gly NH
OtBu
170a  
a) HOAc, 80 °C, 2 d 
b) 1) ZnBr2, CH2Cl2, 25 °C, 1 d; 2) H2O 
c) 1) ZnBr2, CHCl3, 60 °C, 2 d; 2) H2O 
d) CeCl3∙7 H2O, NaI, MeCN, 80 °C, 3 d 
e) 2 × repetition of d) 
 
a) traces 
b) traces 
c) traces 
d) 25:75 
e) 49:51 
 
2 Ac Gly N
H
Gly
O
Gly Gly Trppy Ala Val O
OtBu
170b  
a) HOAc, 80 °C, 2 d 
b) 1) ZnBr2, CH2Cl2, 25 °C, 1 d; 2) H2O 
c) 2 × repetition of b) 
d) 1) ZnBr2, CHCl3, 60 °C, 1 d; 2) H2O 
e) CeCl3∙7 H2O, NaI, MeCN, 80 °C, 1 d 
f) 4 × repetition of e) 
 
a) traces 
b) traces 
c) 38:62 
d) 67:33 
e) 79:21 
f) 100:0 
 
3 Ac Ala N
H
Ala Ala Gly Trppy Gly NH
O
STrt
170c  
a) 2 N HCl in HOAc, 25 °C, 1 d 
b) 2 N HBr in HOAc, 25 °C, 1 d 
c) LiCl in MeOH, 70 °C, 1 d 
d) HOAc, 80 °C, 1 d 
e) 2 N HBr in HOAc, 80 °C, 1 d 
a) 0:100 
b) 0:100 
c) 0:100 
d) 0:100 
e) 0:100 
 
 
The acrylated peptide 167b was reacted with 10 mol % [RuCl2(p-cymene)]2 in acetic acid at 80 °C. 
The reaction was performed on a 30 µmol scale, which corresponds to 26 mg of peptide 169b. After 
the cleavage and crystallization from cold diethylether, only a very small amount of peptide was 
obtained, which was not sufficient for an NMR analysis. The LC-MS analysis revealed acetylated 
peptide 173b. Either the acrylate was transesterificated with acetic acid or the double bond was 
hydrolyzed. The unexpectedly little amount of peptide might be obtained, because of a partial 
cleavage of the peptide from the resin during the deprotection procedures. Repeatedly exposing the 
peptide 170b to different Lewis acids might have partially cleaved the peptide from the resin. The 
acetic acid solution did not contain any peptide as confirmed by LC-MS analysis (Table 40, entry 1a). 
For the experiments with Lewis acids the reaction solutions were not tested. 
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Ac Gly N
H
Gly
O
Gly Gly Val O
O
167b
O
1) [RuCl2(p-cymene)]2 
    (10 mol %)
    HOAc, 80 °C, 15 h, air
2) TFA/TIS/CH2Cl2/H2O
    (95:2.5:1.25:1.25)
Ac Gly N
H
O
169b
O
HN
Ala
O
Val OH
N
2-py
O
Gly
Gly
Gly
N
H
Ala
O
N
2-py
H
Ac Gly N
H
Gly
O
Gly Gly Val OH
O
173b
MeO
N
H
Ala
O
N
2-py
H
 
Scheme 90: Ruthenium-catalyzed on-resin cyclization. 
 
 
3.5 Miscellaneous C–H Modification Reactions on Tryptophan 
3.5.1 Reactions with Miscellaneous Michael Acceptors 
Based on the ruthenium-catalyzed addition of acrylates and vinyl ketones to tryptophan, the scope of 
unsaturated substrates suitable for this kind of addition should be expanded to further Michael 
acceptors (Table 41). β-Substituted, α,β-unsaturated ketones 175 and 177, acrylonitrile 179, 
vinylpyridine 181 and vinyl sulfone 183 did not react with tryptophan under the previously developed 
reaction conditions for the coupling of acrylates and vinyl ketones (entries 1–5). 
Maleimide 185 afforded the desired hydroarylation product 186 in 76% yield at 100 °C for 15 h. A 
reaction temperature of 80 °C led to an incomplete conversion. Due to prochiral sites of the 
maleimide 185, a 1:1 mixture of two diastereomers 186 was obtained. This result could be a starting 
point for a new series of tryptophan modifications. An advantage is the facile accessibility of 
maleimides from primary amines and maleic anhydride. The question of the stereoselectivity might 
be solved by substrate-control via more bulky or chiral substituents on the nitrogen of the maleimide 
or by catalyst-control applying chiral ligands. 
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Table 41: Ruthenium-catalyzed C–H alkylation with miscellaneous Michael acceptors.a 
+
N
AcHN
CO2Me
2-py
H
N
AcHN
CO2Me
2-py
Alk
HOAc, 80 °C, 15 h, air
[RuCl2(p-cymene)]2 (10 mol %)
56h
Michael
acceptor
 
entry Michael acceptor product yield 
1 O
MeMe
Me
175  
N
AcHN
CO2Me
2-py
176
Me
O
Me
Me
 
0% 
2 O
177  
N
AcHN
CO2Me
2-py
178
O
 
0% 
3 
179
CN
 
N
AcHN
CO2Me
2-py
180
CN
 
0% 
4 
181
N
 
N
AcHN
CO2Me
2-py
182
N
 
0% 
5 
183
S
Ph
O
O
 
N
AcHN
CO2Me
2-py
184
S
Ph
O
O
 
0% 
6 N
O
O
Cy
185  
N
AcHN
CO2Me
2-py
186
N
O
O
Cy
 
76%b 
a: Reaction conditions: 56h (0.15 mmol), alkene (0.45 mmol), [RuCl2(p-cymene)]2 (10 mol %), HOAc (0.15 mL), 80 °C, 
15 h, air. b: The reaction was carried out at 100 °C. A 1:1 mixture of two diastereomers was isolated. 
 
 
3.5.2 Reactions with Various Unsaturated Compounds 
Ruthenium-catalyzed C–H activation with various unsaturated compounds were investigated 
(Table 42). The reaction conditions were similar to those of comparable reactions found in the 
literature.126 Electroneutral and oxidative attempts with terminal or internal alkynes 37a and 37b, as 
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well as with terminal allene 187 and bromostyrene 188 did not succeed (entries 1–5). Either no 
conversion was observed or complex mixtures of products were obtained. 
The coupling of acrylamide 131a under oxidative conditions afforded the alkenylated product 189ha 
in 9% yield (entry 6). The reaction conditions were adapted from a similar alkenylation with 
acrylates.127 The yield is rather low due to a low conversion of the substrate 56h, but no byproduct 
formation was observed. An optimization of these reaction conditions would enable a novel way for 
C–H alkenylations with acrylamides and/or acrylates. 
The last two examples demonstrate an SN2’-type substitution of allyl acetate 190a and vinyl 
dioxolanone 192a to tryptophan 56h (entries 7 and 8). The corresponding allyl products 191ha and 
193ha were isolated in 59 and 53% yield, respectively. Recently, a decarboxylative approach using 
dioxolanone 192a was also developed in our group using a manganese-catalyzed C–H activation 
reaction.128 In this case, the catalytic system consisted of 10 mol % MnBr(CO)5 and 20 mol % sodium 
acetate in trifluoroethanol at 100 °C. The two successive reactions with acetate 190a and 
dioxolanone 192a under simple reaction conditions using [RuCl2(p-cymene)]2 in acetic acid at 80 °C 
can be used as a base for further allylations of tryptophan peptides. 
 
 
Table 42: Ruthenium-catalyzed reactions with unsaturated compounds.a 
+
N
AcHN
CO2Me
2-py(m)
H
N
AcHN
CO2Me
2-py(m)
[RuCl2(p-cymene)]2 (10 mol %)
(2-pym)
(2-py)
unsaturated
compound
56g
56h
R
additives, solvent, T, t
 
entry Trp unsat. comp. reaction conditions result 
1 
 
56g 
 
37a
(2.0 equiv)
H nBu
 
HOAc (1.0 equiv), DMF, 120 °C, 2 d, N2 
 
complex mixture of 
productsb 
2 
 
56g 
 
37a
(2.0 equiv)
H nBu
 
Cu(OAc)2 (1.0 equiv), AgPF6 (10 mol %), 
HFIP, 120 °C, 1 d, N2 
no conversionc 
 
3 
 
56g 
 
37b
(2.0 equiv)
Ph Ph
 
AgSbF6 (40 mol %), HOPiv (5.0 equiv), 
iPrOH, 120 °C, 2 d, N2 
complex mixture of 
productsb 
4 
 
56g 
 
•
nPent
187
(3.0 equiv)  
MesCO2K (30 mol %), toluene, 120 °C, 1 d, 
N2 
no conversionc 
 
5 
 
56g 
 
Br
Ph
188
(1.2 equiv)  
1-AdCO2H (30 mol %), K2CO3 (3.0 equiv), 
m-xylene, 140 °C, 1 d, N2 
no conversionc 
 
6 
 
56h 
 
NHiPr
O
131a
(2.0 equiv)  
KPF6 (20 mol %), Cu(OAc)2 (2.0 equiv), 
H2O, 110 °C, 17 h, N2 N
AcHN
CO2Me
2-py
189ha: 9%
NHiPr
O
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entry Trp unsat. comp. reaction conditions result 
7 56h 
OAc
190a
(3.0 equiv)  
HOAc, 80 °C, 15 h, air 
N
AcHN
CO2Me
2-py
191ha: 59%  
8 56h 
O
O
O
192a
(3.0 equiv)  
HOAc, 80 °C, 15 h, air 
N
AcHN
CO2Me
2-py
193ha: 53%
OH
 
a: Reaction conditions: 56 (0.15 mmol), unsat. comp. (1.2–3.0 equiv), [RuCl2(p-cymene)]2 (10 mol %), additives, 
solvent. b: Determined by TLC analysis. c: Determined by NMR analysis. 
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4 Summary and Outlook 
The development of sustainable chemical syntheses for the production of highly functionalized 
organic molecules, such as drugs, agrochemicals and functional materials, is of great topical 
importance for academia and industries. C–H activation contributed to an improvement of the 
strategies used for chemical syntheses, because its step- and atom-economy and the catalytic use of 
transition metals facilitate short and simple preparations of complex structures. The aim of this work 
was the development of postsynthetic peptide modification reactions applying C–H activation 
strategies. 
The palladium-catalyzed C–H arylation method was successfully applied to the synthesis of arylated 
peptides (Scheme 91).89 Diaryliodonium salts were used as mild arylating agents and Pd(OAc)2 was 
employed as the catalyst. The use of a variety of solvents, such as DMF, toluene, DCE and acetic acid, 
was possible. The reaction was shown to be water-tolerant and proceeded selectively at the C2 
position of the natural tryptophan in a complex peptide. 
 
N
H
H
peptide
Pd
[Ar2I]OTs
N
H
Ar
peptide
     
 use of natural Trp
 C2 selectivity
 mild arylating agent
 ambient temperature
 no racemization
 use of different solvents incl. water possible
 medium functional group tolerance
 
Scheme 91: Palladium-catalyzed C–H arylation of peptides. 
 
Ruthenium as an inexpensive transition metal for C–H activation reactions was explored. The 
optimized reaction conditions for the C–H arylation of pyridylated tryptophans allowed the 
introduction of diversely decorated aryl moieties, affording C–H arylated peptides (Scheme 92).117 A 
large functional group tolerance was illustrated by the preparation of arylated tryptophans. Also, β3-
homo-tryptophans and tryptophan peptides delivered the C–H arylated products. A bioorthogonal 
test proved the reaction to be tolerant towards almost all natural amino acids. Furthermore, the 
reaction is water-tolerant and despite of the basic medium, no racemization of the stereocenters of 
the amino acids was detected. Arylated products with an extended π-system showed enhanced 
fluorescence properties as compared to the corresponding unarylated compounds. Different modes 
of ligation were demonstrated including a twofold C–H activation sequence applying palladium- and 
ruthenium-catalysis, delivering uniquely branched ligation products. 
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N
H
peptide1
Ru
N
peptide1
 C2 selectivity for Trppy
 commercially available/
    easily accessible arylating agents
 no racemization
 water-tolerance
 high functional group tolerance
 tolerance towards most natural amino acids
 β-amino acids
 fluoescence labeling
 ligation incl. twofold C−H activation
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Scheme 92: Ruthenium-catalyzed C–H arylation of peptides. 
 
 
A transition metal-catalyzed C–H alkylation of peptides was achieved through ruthenium-catalysis 
(Scheme 93). The hydroarylation of unactivated alkenes was shown to be feasible and also the 
coupling with vinyl ketones, acrylates and thioacrylates proceeded smoothly without noteworthy 
drawbacks. Furthermore, the acryloyl moiety was introduced into peptides which enabled the 
ligation of peptides. Another pursued strategy was the introduction of a phenyl bromide-containing 
acrylate as a linker for a subsequent C–H arylation. 
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 high functional group tolerance
 tolerance towards most natural amino acids
 ligation with peptides incl. twofold C−H activation
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Scheme 93: Ruthenium-catalyzed C–H alkylation of peptides. 
 
 
The ruthenium-catalyzed alkylation procedure was successfully extended to peptides on-resin 
(Scheme 94). This approach possesses all advantages that are generally associated with on-resin 
procedures. On-resin peptides derived from the SPPS were reacted with acrylates and vinyl ketones 
in the presence of a ruthenium-catalyst. A cleavage from the resin delivered C–H alkylated peptides 
and thus, alkylated peptides with up to ten amino acids were prepared this way. 
Future work could be the ligation with acryloyl peptides using this on-resin C–H modification 
method. Also, on-resin cyclizations of peptides should be feasible. Unfortunately, it was not possible 
to selectively deprotect serine or cysteine on-resin. However, serine with a more acid-labile 
protecting group, such as a silyl ether, or serine with a free hydroxy group could be incorporated into 
the peptide in order to enable an on-resin acryloylation. Also, the direct coupling of Fmoc-
Ser(acryloyl)-OH during the SPPS could be possible. 
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 first successful & applicable on-resin C−H modification of peptides
 common resins applicable, simple reaction set up
 most side chain protections are maintained during Ru-catalysis
 use of excess of reagents possible
 no solubility problems
 no jellification & aggregation
 simple purification of the resin, removal of catalyst traces
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Scheme 94: Ruthenium-catalyzed on-resin C–H alkylation of peptides. 
 
 
Other envisioned ruthenium-catalyzed C–H modification reactions are the hydroarylation with 
maleimides as well as allylations with allyl acetates and vinyl dioxolanones (Scheme 95). The 
preliminary individual examples present a starting point for additional research on other alkylation 
and allylation reactions. 
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Scheme 95: Further ruthenium-catalyzed C–H modifications of tryptophan. 
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5 Experimental Part 
5.1 General Remarks 
Unless otherwise noticed, all reacitons were carried out under an atmosphere of N2 using pre-dried 
glassware and standard Schlenk techniques. Yields refer to isolated compounds, estimated to be 
>95% pure as determined by 1H NMR. 
 
Vacuum 
The following pressure was measured using a rotary vane pump RZ6 from Vacuubrand®: 2 mbar 
(uncorrected value). 
 
Melting Points 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from Barloworld 
Scientific. Values are uncorrected. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on TLC plates Alugram® Xtra Sil G/UV254, 
detection was done under UV light at 254 nm. Manual flash column separations were carried out on 
Merck Geduran Silica 60 (0.063–0.200 mm, 70–230 mesh ASTM). Preparative TLC (PTLC) was carried 
out on TLC plates pre-coated with aluminium oxide F-254 (type E) or with silica. Recycling preparative 
HPLC (GPC) was carried out on a JAI® (LC-92XX II Series, injection- and control-valve, UV and RI 
detector) connected to JAIGEL HH series columns. Chloroform of HPLC grade stabilized with ethanol 
was employed. HPLC chromatograms were recorded on an Agilent 1290 Infinity using the column 
CHIRALPAK® IC-3 and hexanes/ethyl acetate (1:1, 1 mL/min, detection at 274 nm). LC-MS 
chromatograms were recorded on an Agilent 6100s Series Single Quad using the RP column ZORBAX 
SB-C18, 5 µm. The flow rate was set to 0.5 mL/min, detection at 270 and 290 nm. The methods used 
are as follows: 
  
Experimental Part 
111 
 
Table 43: LC-MS methods. 
method 
length t/min 
acetonitrile 
(0.1% TFA) 
water 
(0.1% TFA) 
15 min 0 60 40 
 5 100 0 
 13 100 0 
 15 60 40 
22 min 0 60 40 
 5 100 0 
 20 100 0 
 22 60 40 
 
 
Solvents 
Solvents for column chromatography were purified via distillation under reduced pressure prior to 
their use. Solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored 
under N2 according to following standard procedures.129 
Solvents purified by solvent purification system (SPS-800) from M. Braun: Dichloromethane, 
tetrahydrofurane, diethylether, dimethylformamide. 
Solvents dried and distilled from Na using benzophenone as indicator: Methanol, tert-amylalcohol, 
toluene, meta-xylene, hexanes, 1,4-dioxane, 1,2-dimethoxyethane. 
Solvents dried and distilled from CaH2: dichloroethane, dimethylacetamide, dimethylformamide, 
dimethylsulfoxide, N-methyl-2-pyrrolidone, γ-valerolactone. 
For synthesis grade solvents for reactions under air were used without further purification: 
trifluoroacetic acid, acetic acid, propionic acid, all buffer solutions, γ-valerolactone, tert-amylalcohol, 
toluene, meta-xylene, 1,2-dimethoxyethane, n-octane, hexanes, aq. HCl (12 M). 
For peptide synthesis grade solvent for the SPPS: DMF. 
 
Reagents 
Chemicals obtained from commercial sources (with a purity >95%) were used without further 
purification. The following compounds were synthesized according to previously described literature 
protocols: 
Protected amino acids and peptides,130 homologated tryptophans 120,131 N-pyridyl tryptophans 56h, 
56j and 120,44 N-pyrimidyl tryptophans 56e, 56f and 56g44 (from 2-Iodopyrimidine),132 iodonium 
tosylate 78a,133 allyloxyarenes 28x and 28y,134 pyrene 66u,135 bromopyrene 28t,136 acrylates 129,137 
thioacrylate 129q137 at –88 °C, vinyl ketones 130,138 allene 187,139 peptides from the SPPS 159.140 
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The following chemicals were kindly provided by the persons mentioned below: 
Karsten Rauch: [RuCl2(p-cymene)]2, [Ru(OAc)2(p-cymene)]. 
Prof. Dr. Lutz Ackermann: Grubbs II. 
Michaela Bauer: tosylate 78f, tryptophan 56e, iodoferrocene 66c. 
Prof. Dr. Hongjun Ren: bromophenyl pyrene 28q, peptides 101d and 108. 
Nikolaos Kaplaneris: tryptophan 142hk, acryloyl peptide 148b. 
Wei Wang: iodophenyl-BODIPY 66w. 
Dr. Mélanie Lorion: vinyl ketone 130d. 
Dr. Alexander Bechtoldt: acrylates 129b, 129f, 129g, 129j, 129k, 129o, 129p, 129r, 129u and 129v. 
Dr. Ruhuai Mei: Dehydroalanine 129δ. 
 
NMR 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400, 500 or 600 MHz 
(1H NMR), 75, 100 or 125 MHz (13C NMR) or 282 MHz, 376 MHz and 471 MHz (19F NMR) on a Varian 
Inova 600, Varian Inova 500, Bruker Avance III HD 500, Bruker Avance III HD 400, Bruker Avance III 
400, Varian VNMRS 300, Bruker Avance 300, Varian Mercury VX 300, Varian Mercury 300, or Bruker 
Avance III 300 in the solvent indicated. Chemical shifts are reported as δ values in ppm relative to the 
residual proton peak of the deuterated solvent or its carbon atom, respectively. 
   1H NMR 13C NMR 
 CDCl3  7.26 ppm 77.16 ppm 
 DMSO-d6 2.50 ppm 39.52 ppm 
 CD3OD  3.31 ppm 49.00 ppm 
For characterization of the observed resonance multiplicities the following abbrevations were 
applied: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt 
(doublet of triplet), or analogue representations. The coupling constants J are reported in Hertz (Hz). 
 
IR 
Infrared spectroscopy (IR) was carried out on a Bruker® Alpha-P ATR spectrometer. Liquid samples 
were measured as film and solid samples neat. Spectra were recorded in the range from 4000 to 
600 cm−1. Analysis of the spectral data were carried out using Opus 6. Absorption is given in wave 
numbers (cm−1). 
 
MS 
Mass spectrometry electron ionization (EI) spectra were measured on a time-of-flight mass 
spectrometer AccuTOF from JOEL. Electrospray ionization (ESI) mass spectra were recorded on an Io-
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Trap mass spectrometer LCQ from Finnigan, a quadropole time-of-flight maXis from Bruker Daltonic 
or on a time-of-flight mass spectrometer microTOF from Bruker Daltonic. ESI-HRMS spectra were 
recorded on a Bruker Apex IV or Bruker Daltonic 7T, fourier transform ion cyclotron resonance 
(FTICR) mass spectrometer. The ratios of mass to charge (m/z) are indicated, intensities relative to 
the base peak (I = 100) are provided in parentheses. 
 
Fluorescence Spectroscopy 
Fluorescence excitation and emission data in solution were recorded on a Jasco® FP-8500 
spectrofluorometer. The scan speed was adjusted to 200 nm/min. All compounds were measured at 
a concentration of 1 mg/L in DMSO. 
 
UV-VIS Spectroscopy 
UV-Visible Spectroscopy was performed on a Jasco® V-770 spectrophotometer. A baseline in the 
appropriate solvent was obtained prior to recording spectra. 
 
Peptide Synthesis and Purification 
Peptides for on-resin reactions were synthesized by microwave-assisted solid phase peptide 
synthesis (SPPS) using hydroxymethyl polystyrene resin (Novabiochem®, 1.2 mmol/g), or Rink-Amide-
ChemMatrix® resin (Biotage, 0.50 mmol/g) or Fmoc-Rink-Amide AM resin (Iris Biotech, 0.55 mmol/g). 
SPPS was carried out in a CEM Liberty Blue™. Amino acids were coupled using Oxyma and DIC in 
DMF. Deprotection was performed with 20% piperidine in DMF. Cleavage was carried out in BD 
Discardit™ II 10 mL syringes fitted with a frit. Precipitated peptides were centrifuged with a Heraeus 
Megafuge 16R from Thermo Scientific™ for 3 min at 9800 rounds/min. 
 
5.2 General Procedures 
General procedure A for palladium-catalyzed C–H arylations of peptides with diaryliodonium salts: 
A mixture of peptide 80 (0.20 mmol), diphenyliodonium tosylate 78 (0.30 mmol) and Pd(OAc)2 
(5.0 mol %) in HOAc (3.0 mL) or H2O (3.0 mL) was stirred at 25 °C for 17 h. Thereafter, H2O (5 mL) 
was added and the aqueous layer was extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, dried with Na2SO4 and the solvent was removed in vacuo. The crude product was purified 
by column chromatography or GPC to yield the desired product 81. 
 
General procedure B1 for ruthenium-catalyzed C–H arylations of tryptophans with aryl halides: 
An oven dried Schlenk flask was charged with tryptophan 56 (0.30 mmol), solid aryl halide 28 or 66 
(0.33 mmol, 1.1 equiv), [RuCl2(p-cymene)]2 (9.2 mg, 5.0 mol %), 1-adamantylcarboxylic acid (16.2 mg, 
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30 mol %) and K2CO3 (124 mg, 3.0 equiv) and the flask was evacuated and refilled with N2 three 
times. Dry meta-xylene (3.0 mL) was added via syringe and the mixture was stirred at 120 °C for 22 h. 
Liquid aryl halides 28 and 66 were added after the addition of the solvent. After cooling to ambient 
temperature, the reaction mixture was diluted with EtOAc (3.0 mL) and purified by column 
chromatography, PTLC or GPC to yield products 67. 
 
General procedure B2 for ruthenium-catalyzed C–H arylations of tryptophans with aryl halides: 
An oven dried Schlenk flask was charged with tryptophan 56 or 120 (0.30 mmol), solid aryl halide 28 
or 66 (0.33 mmol, 1.1 equiv), [RuCl2(p-cymene)]2 (9.2 mg, 5.0 mol %), pentafluorobenzoic acid 
(19.1 mg, 30 mol %) and K3PO4 (191 mg, 3.0 equiv) and the flask was evacuated and refilled with N2 
three times. Dry meta-xylene (3.0 mL) was added via syringe and the mixture was stirred at 120 °C 
for 22 h. Liquid aryl halides 28 and 66 were added after the addition of the solvent. After cooling to 
ambient temperature, the reaction mixture was diluted with EtOAc (3.0 mL) and purified by column 
chromatography, PTLC or GPC to yield products 67 and 121. 
 
General procedure B3 for ruthenium-catalyzed C–H arylations of peptides with aryl halides: 
An oven dried Schlenk flask was charged with peptide 101 (50‒100 mg), solid aryl halide 28 
(1.1 equiv), [RuCl2(p-cymene)]2 (10 mol %), pentafluorobenzoic acid (60 mol %) and K3PO4 
(3.0 equiv) and the flask was evacuated and refilled with N2 three times. Dry meta-xylene (3.0 mL) 
was added via syringe and the mixture was stirred at 120 °C for 22 h. Liquid aryl halides 28 were 
added after the addition of the solvent. After cooling to ambient temperature, the reaction mixture 
was diluted with EtOAc (3.0 mL) and purified by column chromatography or PTLC to yield products 
102. 
 
General procedure B4 for ruthenium-catalyzed C–H arylations of peptides with dibromobenzenes: 
An oven dried Schlenk flask was charged with a peptide 56 or 101 (50–100 mg), dibromobenzene 28 
(0.5 equiv), [RuCl2(p-cymene)]2 (5.0 or 10 mol %), pentafluorobenzoic acid (30 or 60 mol %) and 
K3PO4 (3.0 equiv) and the flask was evacuated and refilled with N2 three times. Dry meta-xylene 
(3.0 mL) was added via syringe and the mixture was stirred at 120 °C for 22 h. After cooling to 
ambient temperature, the reaction mixture was diluted with EtOAc (3.0 mL) and purified by column 
chromatography or PTLC to yield products 117. 
 
General procedure C for ruthenium-catalyzed C–H alkylations of tryptophans with unactivated 
alkenes: 
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An oven dried Schlenk flask was charged with tryptophan 56 (0.30 mmol), [RuCl2(p-cymene)]2 
(18.4 mg, 10 mol %) and KO2CMes (18.2 mg, 30 mol %) and the flask was evacuated and refilled with 
N2 three times. Dry toluene (1.0 mL) and alkene 44 (3.0 equiv) were added via syringe and the 
mixture was stirred at 140 °C for 24 h. After cooling to ambient temperature, the reaction mixture 
was diluted with EtOAc (3.0 mL) and purified by column chromatography to yield products 107. 
 
General procedure D1 for ruthenium-catalyzed C–H alkylations of tryptophans with alkenes: 
A conical-bottom test tube was charged with tryptophan 56 or 120 (0.15 mmol) and [RuCl2(p-
cymene)]2 (9.2 mg, 10 mol %). HOAc (0.15 mL) and acrylate 129 or vinyl ketone 130 (1.3–3.0 equiv) 
were added. The tube was fitted with a septum and the mixture was stirred at 80 °C for 15 h. After 
cooling to ambient temperature, the reaction mixture was diluted with toluene (5.0 mL) and purified 
by column chromatography, PTLC or GPC to yield products 142 and 141. 
 
General procedure D2 for ruthenium-catalyzed C–H alkylations of peptides with alkenes: 
A conical-bottom test tube was charged with peptide 101 (50–100 mg) and [RuCl2(p-cymene)]2 
(10 mol %). HOAc (0.1–0.3 mL) and acrylate 129 or vinyl ketone 130 (1.1–5 equiv) were added. The 
tube was fitted with a septum and the mixture was stirred at 80 °C for 15 h. After cooling to ambient 
temperature, the reaction mixture was diluted with toluene (5.0 mL) and purified by column 
chromatography or PTLC to yield products 147 and 156. 
 
General procedure E for ruthenium-catalyzed on-resin C–H alkylations of peptides: 
A 10 mL conical-bottom test tube without a stir bar was charged with a peptide loaded resin 159 
(30 µmol) and [RuCl2(p-cymene)]2 (10 mol %). HOAc (30–150 µL) and acrylate 129 or vinyl ketone 
130 (3.0–10.0 equiv) were added. The test tube was fitted with a septum and the mixture was heated 
to 80 °C for 15 h with slightly shaking of the reaction vial. After cooling to ambient temperature, the 
mixture was transferred with methanol to a 10 mL syringe equipped with a frit. The resin was 
washed with HOAc (5×5 mL), MeOH (3×5 mL), HOAc (3×5 mL), MeOH (3×5 mL), and CH2Cl2 
(5 × 5 mL). After drying overnight at 40 °C, the resin was treated with TFA (3 mL) or 
TFA/TIS/CH2Cl2/H2O (3 mL, 95:2.5:1.25:1.25) at ambient temperature for 4 h. The cleavage solution 
was collected and the resin was washed with TFA (3 mL) and HOAc (3×5 mL). The collected washing 
solution was concentrated under reduced pressure and the peptide was three times precipitated 
from cold Et2O (–20 °C, 5 mL), centrifuged and decanted. The obtained solid peptide 161 was dried in 
vacuum. 
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5.3 Analytical Data 
5.3.1 Analytical Data for Arylated Peptides 81 and 105 
Ethyl acetyl-L-alanyl-2-phenyl-L-tryptophylglycinate (81aa) 
The general procedure A was followed using peptide 80a (80.5 mg). Purification by 
column chromatography (hexanes/EtOAc/MeOH 1:5:0.2) yielded peptide 81aa as a 
white solid (95 mg, 99% for the reaction in HOAc and 65 mg, 68% for the reaction 
in H2O). 
m. p.: 183 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 10.8 (br s, 1H), 8.31 (dd, J = 5.8, 5.8 Hz, 1H), 7.93 (d, J = 7.3 Hz, 1H), 
7.84 (d, J = 8.1 Hz, 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.31 (ddd, J = 8.2, 0.9, 0.9 Hz, 1H), 7.14 (d, J = 2.4 Hz, 
1H), 7.05 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 6.97 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H), 4.54 (ddd, J = 8.2, 8.2, 
4.9 Hz, 1H), 4.25 (dq, J = 7.1, 7.1 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.91–3.69 (m, 2H), 3.22–3.09 (m, 
1H), 2.97 (dd, J = 14.8, 8.4 Hz, 1H), 1.80 (s, 3H), 1.19 (t, J = 7.1 Hz, 2H), 1.14 (d, J = 7.1 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.3 (Cq), 171.9 (Cq), 169.5 (Cq), 169.4 (Cq), 135.7 (Cq), 135.4 
(Cq), 133.0 (Cq), 129.2 (Cq), 128.4 (CH), 128.3 (CH), 127.6 (CH), 121.7 (CH), 119.6 (CH), 118.8 (CH), 
111.2 (CH), 107.8 (Cq), 60.7 (CH2), 54.1 (CH), 48.8 (CH), 41.3 (CH2), 28.4 (CH2), 22.8 (CH3), 18.2 (CH3), 
14.4 (CH3). 
IR (ATR): 3272, 2968, 1732, 1631, 1539, 1449, 1369, 1302, 1241, 1192, 1157, 1026, 736, 699 cm‒1. 
MS (ESI) m/z (relative intensity) 979 (13) [2M+Na]+, 903 (4) [2M+H]+, 501 (100) [M+Na]+, 479 (41) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C26H31N4O5+ 479.2289 [M+H]+, found 479.2900. 
The measured data is in accordance with the literature data.97 
 
Methyl acetyl-L-phenylalanylglycyl-2-phenyl-L-tryptophanate (81ka) 
The general procedure A was followed using peptide 80k (69.7 mg). Purification 
by column chromatography (hexanes/EtOAc/MeOH 1:5:0.2) yielded peptide 81ka 
as a white solid (42 mg, 52% for the reaction in HOAc and 20 mg, 25% for the 
reaction in H2O). 
m. p.: 85 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 11.3 (s, 1H), 8.37–8.30 (m, 1H), 8.26–8.17 (m, 2H), 8.10–8.04 (m, 
1H), 7.95–7.92 (m, 2H), 7.68–7.62 (m, 2H), 7.62–58 (m, 2H), 7.53–7.48 (m, 1H), 7.28–7.16 (m, 6H), 
4.56–4.46 (m, 1H), 4.45–4.36 (m, 1H), 3.78–3.72 (m, 1H), 3.70–3.62 (m, 1H), 3.16 (s, 3H), 3.04–2.93 
(m, 2H), 2.77–2.66 (m, 2H), 1.90 (s, 3H). 
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13C NMR (126 MHz, DMSO-d6): δ = 172.3 (Cq), 172.0 (Cq), 169.7 (Cq), 169.0 (Cq), 138.5 (Cq), 136.3 
(Cq), 135.9 (Cq), 133.1 (Cq), 129.5 (CH), 129.1 (CH), 129.1 (Cq), 128.4 (CH), 128.4 (CH), 127.9 (CH), 
126.6 (CH), 121.9 (CH), 119.3 (CH), 118.9 (CH), 111.6 (CH), 106.9 (Cq), 54.5 (CH), 53.6 (CH), 52.0 (CH3), 
42.1 (CH2), 37.8 (CH2), 27.7 (CH2), 22.9 (CH3). 
IR (ATR): 3279, 1737, 1644, 1521, 1454, 1436, 1372, 1305, 1279, 1216, 742, 697 cm‒1. 
MS (ESI) m/z (relative intensity) 563 (100) [M+Na]+, 541 (58) [M+H]+. 
HR-MS (ESI) m/z calcd for C31H33N4O5+ 541.2445 [M+H]+, found 541.2449. 
 
Methyl acetyl-L-alanyl-2-phenyl-L-tryptophylglycinate (81la) 
The general procedure A was followed using peptide 80l (74.9 mg). Purification by 
column chromatography (hexanes/EtOAc/MeOH 1:5:0.2) yielded peptide 81la as a 
colorless solid (85 mg, 96% for the reaction in HOAc and 60 mg, 67% for the 
reaction in H2O). 
m. p.: 177 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 11.12 (s, 1H), 8.10 (t, J = 5.8 Hz, 1H), 7.91 (d, J = 7.2 Hz, 1H), 7.85 
(d, J = 8.3 Hz, 1H), 7.73–7.64 (m, 3H), 7.53–7.44 (m, 2H), 7.42–7.30 (m, 2H), 7.09 (ddd, J = 8.1, 7.0, 
1.2 Hz, 1H), 6.99 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.66 (q, J = 7.2 Hz, 1H), 4.20 (p, J = 7.0 Hz, 1H), 3.71 
(dd, J = 17.3, 5.9 Hz, 1H), 3.65–3.57 (m, 1H), 3.56 (s, 3H), 3.38–3.29 (m, 1H), 3.28 (s, 2H), 3.11 (dd, J = 
14.4, 6.9 Hz, 1H), 1.79 (s, 3H), 1.08 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.4 (Cq), 171.9 (Cq), 170.2 (Cq), 169.7 (Cq), 136.3 (Cq), 135.8 
(Cq), 133.2 (Cq), 129.4 (Cq), 129.0 (CH), 128.6 (CH), 127.7 (CH), 121.8 (CH), 119.6 (CH), 119.0 (CH), 
111.4 (CH), 107.9 (Cq), 54.2 (CH), 52.0 (CH3), 48.8 (CH), 41.1 (CH2), 28.3 (CH2), 22.9 (CH3), 18.2 (CH3). 
IR (ATR): 3270, 2924, 1743, 1631, 1540, 1448, 1369, 1201, 1177, 1010, 744, 698 cm‒1. 
MS (ESI) m/z (relative intensity) 951 (12) [2M+Na]+, 929 (2) [2M+H]+, 487 (100) [M+Na]+, 465 (31) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C25H29N4O5+ 465.2132 [M+H]+, found 465.2137. 
 
Methyl acetyl-L-aspargylglycyl-2-phenyl-L-tryptophanate (81ma) 
The general procedure A was followed using peptide 80m (83.3 mg). Purification 
by column chromatography (hexanes/EtOAc/MeOH 1:5:1) yielded peptide 81ma 
as a colorless solid (86 mg, 85% for the reaction in HOAc and 64 mg, 63% for the 
reaction in H2O). 
m. p.: 124 °C. 
1H NMR (500 MHz, DMSO-d6): δ = 11.22 (s, 1H), 8.27 (d, J = 7.3 Hz, 1H), 8.08 (d, J = 7.6 Hz, 1H), 7.97 
(dd, J = 5.9, 5.9 Hz, 1H), 7.66–7.58 (m, 2H), 7.56–7.48 (m, 3H), 7.42–7.34 (m, 2H), 7.32 (s, 1H), 7.11 
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(ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.03 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.83 (s, 1H), 4.54–4.46 (m, 2H), 3.68 
(dd, J = 16.9, 5.7 Hz, 1H), 3.63–3.56 (m, 1H), 3.37 (dd, J = 14.5, 8.8 Hz, 1H), 3.29 (s, 3H), 3.22 (dd, J = 
14.5, 6.0 Hz, 1H), 2.56–2.51 (m, 1H), 2.41 (dd, J = 15.5, 7.6 Hz, 1H), 1.84 (s, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 171.8 (Cq), 171.4 (Cq), 171.3 (Cq), 169.4 (Cq), 168.6 (Cq), 135.8 
(Cq), 135.3 (Cq), 132.6 (Cq), 128.6 (CH), 128.6 (Cq), 127.9 (CH), 127.4 (CH), 121.4 (CH), 118.8 (CH), 
118.4 (CH), 111.1 (CH), 106.5 (Cq), 53.2 (CH), 51.5 (CH), 49.8 (CH3), 41.8 (CH2), 37.1 (CH2), 27.1 (CH2), 
22.5 (CH3). 
IR (ATR): 3297, 1734, 1651, 1531, 1435, 1412, 1372, 1312, 1217, 744, 698 cm‒1. 
MS (ESI) m/z (relative intensity) 530 (100) [M+Na]+, 508 (19) [M+H]+. 
HR-MS (ESI) m/z calcd for C26H30N5O6+ 508.2191 [M+H]+, found 508.2186. 
 
Acetyl-L-alanyl-2-phenyl-L-tryptophylglycine (81na) 
The general procedure A was followed using peptide 80n (75.9 mg). Purification by 
column chromatography (EtOAc/MeOH 3:11:1) yielded peptide 81na as a 
colorless solid (72 mg, 80% for the reaction in HOAc and 44 mg, 49% for the 
reaction in H2O). 
m. p.: 120 °C. 
1H NMR (500 MHz, DMSO-d6): δ = 11.14 (d, J = 2.1 Hz, 1H), 8.53–8.22 (m, 1H), 7.75–7.71 (m, 1H), 
771–7.67 (m, 1H), 7.50–7.44 (m, 2H), 7.43–7.38 (m, 1H), 7.38–7.33 (m, 1H), 7.33–7.30 (m, 1H), 7.09–
7.03 (m, 1H), 6.99–6.92 (m, 1H), 4.62–4.55 (m, 1H), 4.24 (dddd, J = 7.1, 7.1, 7.1, 7.1 Hz, 1H), 3.55–
3.43 (m, 1H), 3.40–3.29 (m, 1H), 3.25–3.17 (m, 1H), 3.16–3.06 (m, 1H), 1.80 (s, 3H), 1.11 (d, J = 7.1 Hz, 
3H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.4 (Cq), 172.3 (Cq), 170.2 (Cq), 169.2 (Cq), 136.0 (Cq), 135.2 
(Cq), 132.8 (Cq), 129.1 (Cq), 128.6 (CH), 128.1 (CH), 127.2 (CH), 121.4 (CH), 119.3 (CH), 118.6 (CH), 
111.0 (CH), 108.1 (Cq), 54.4 (CH), 48.4 (CH), 43.8 (CH2), 28.0 (CH2), 22.3 (CH3), 18.0 (CH3). 
IR (ATR): 3296, 1644, 1599, 1533, 1449, 1396, 1344, 1307, 1262, 1242, 743, 697 cm‒1. 
MS (ESI) m/z (relative intensity) 473 (100) [M+Na]+, 451 (6) [M+H]+, 375 (24). 
HR-MS (ESI) m/z calcd for C24H26N4NaO5+ 473.1795 [M+Na]+, found 473.1774. 
 
Actyl-L-glutamylglycyl-2-phenyl-L-tryptophylglycine (81oa) 
The general procedure A was followed using peptide 80o (50.0 mg) and HOAc. 
Purification by column chromatography (EtOAc/MeOH 1:1) yielded peptide 
81oa as a white solid (41 mg, 72%). 
m. p.: 145 °C. 
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1H NMR (600 MHz, DMSO-d6): δ = 11.20 (s, 1H), 8.42 (dd, J = 13.3, 8.6 Hz, 1H), 8.28 (dd, J = 7.8, 
2.5 Hz, 1H), 8.24–8.18 (m, 1H), 7.74–7.65 (m, 3H), 7.52–7.43 (m, 2H), 7.39–7.25 (m, 4H), 7.07 (dddd, 
J = 7.9, 7.9, 1.1, 1.1 Hz, 1H), 6.99 (dddd, J = 7.9, 6.9, 2.7, 1.0 Hz, 1H), 6.74–6.67 (m, 1H), 4.6–4.57 (m, 
1H), 4.24–4.17 (m, 1H), 3.88 (br s, 1H), 3.77–3.68 (m, 1H), 3.58–3.48 (m, 1H), 3.44–3.33 (m, 2H), 
3.25–3.17 (m, 1H), 3.12–3.05 (m, 1H), 2.15–2.05 (m, 2H), 1.90–1.81 (m, 2H), 1.74 (s, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 175.1 (Cq), 173.9 (Cq), 173.9 (Cq), 171.9 (Cq), 171.8 (Cq), 171.7 
(Cq), 170.0 (Cq), 169.6 (Cq), 169.5 (Cq), 168.5 (Cq), 168.4 (Cq), 135.9 (Cq), 135.1 (Cq), 135.1 (Cq), 132.8 
(Cq), 129.0 (Cq), 129.0 (Cq), 128.6 (CH), 128.0 (CH), 127.2 (CH), 121.3 (CH), 119.1 (CH), 118.6 (CH), 
111.0 (CH), 108.0 (Cq), 108.0 (Cq), 54.5 (CH), 52.4 (CH), 43.9 (CH2), 42.0 (CH2), 31.5 (CH2), 27.9 (CH2), 
27.7 (CH2), 22.5 (CH3). 
IR (ATR): 3269, 1644, 1600, 1539, 1449, 1393, 1343, 1308, 1256, 1241, 743, 698 cm‒1. 
MS (ESI) m/z (relative intensity) 1151 (8) [2M+Na]+, 609 (44) [M–H+2Na]+, 587 (100) [M+Na]+, 565 (7) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C28H32N6NaO7+ 587.2225 [M+Na]+, found 587.2218. 
 
Methyl (tert-butoxycarbonyl)-L-phenylalanylglycyl-2-phenyl-L-tryptophanate (81va) 
The general procedure A was followed using peptide 80v (104.5 mg) and H2O. 
Purification by column chromatography (MTBE/MeOH 100:1) yielded peptide 
81va as a white solid (28 mg, 23%). 
m. p.: 125 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 11.21 (s, 1H), 8.32 (d, J = 7.7 Hz, 1H), 8.01 (dd, J = 5.7, 5.7 Hz, 1H), 
7.65–7.59 (m, 2H), 7.56 (d, J = 7.9 Hz, 1H), 7.53–7.47 (m, 2H), 7.42–7.37 (m, 1H), 7.37–7.34 (m, 1H), 
7.27–7.22 (m, 5H), 7.20–7.15 (m, 1H), 7.11 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.05–6.99 (m, 1H), 6.88 (d, 
J = 8.5 Hz, 1H), 4.58 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 4.20–4.14 (m, 1H), 3.74 (dd, J = 16.8, 5.6 Hz, 1H), 
3.63 (dd, J = 16.8, 5.6 Hz, 1H), 3.36 (dd, J = 14.5, 8.4 Hz, 1H), 3.33 (s, 3H), 3.25–3.18 (m, 1H), 2.99 (dd, 
J = 13.8, 4.3 Hz, 1H), 2.76–2.68 (m, 1H), 1.28 (s, 9H). 
13C NMR (126 MHz, DMSO-d6): δ = 171.8 (Cq), 171.7 (Cq), 168.5 (Cq), 155.2 (Cq), 135.8 (Cq), 135.4 
(Cq), 132.6 (Cq), 129.1 (CH), 128.6 (CH), 128.6 (Cq), 127.9 (CH), 127.9 (CH), 127.4 (CH), 126.0 (CH), 
121.4 (CH), 118.8 (CH), 118.4 (CH), 111.1 (CH), 106.4 (Cq), 78.0 (Cq), 55.6 (CH), 53.1 (CH), 51.6 (CH3), 
41.6 (CH2), 37.3 (CH2), 28.1 (CH3), 27.3 (CH2). 
IR (ATR): 3306, 2900, 1739, 1651, 1518, 1455, 1437, 1366, 1248, 1214, 1163, 1019, 741, 699 cm‒1. 
MS (ESI) m/z (relative intensity) 621 (100) [M+Na]+, 599 (52) [M+H]+. 
HR-MS (ESI) m/z calcd for C34H38N4NaO6+ 621.2684 [M+Na]+, found 621.2661. 
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Ethyl acetyl-L-alanyl-2-(4-bromophenyl)-L-tryptophyl-glycinate (81af) 
The general procedure A was followed using peptide 80a (81.2 mg), iodonium 
tosylate 78f (185 mg) and HOAc. Purification by column chromatography (EtOAc/ 
THF 9:1) yielded peptide 81af as a white solid (74 mg, 67%). 
m. p.: 191 °C. 
1H NMR (600 MHz, CD3OD): δ = 7.68–7.57 (m, 5H), 7.36 (d, J = 8.1 Hz, 1H), 7.13 (dd, J = 7.6, 7.6 Hz, 
1H), 7.05 (dd, J = 7.5, 7.5 Hz, 1H), 4.71 (dd, J = 7.3, 7.3 Hz, 1H), 4.19–4.07 (m, 3H), 3.79 (d, J = 17.6 Hz, 
1H), 3.61 (d, J = 17.6 Hz, 1H), 3.51 (dd, J = 14.7, 7.3 Hz, 1H), 3.34–3.30 (m, 1H), 1.90 (s, 3H), 1.21 (t, J = 
7.1 Hz, 3H), 1.12 (d, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 174.5 (Cq), 173.6 (Cq), 173.5 (Cq), 170.8 (Cq), 137.7 (Cq), 135.9 (Cq), 
133.5 (Cq), 132.8 (CH), 131.0 (CH), 130.4 (Cq), 123.0 (CH), 122.3 (Cq), 120.2 (CH), 119.9 (CH), 112.0 
(CH), 108.5 (Cq), 62.3 (CH2), 55.3 (CH), 50.9 (CH), 42.1 (CH2), 28.4 (CH2), 22.4 (CH3), 17.4 (CH3), 14.5 
(CH3). 
IR (ATR): 3278, 1730, 1629, 1589, 1538, 1452, 1370, 1205, 1006, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 1139/1137 (13) [2M+Na]+, 581/579 (100) [M+Na]+, 559/557 (5) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C26H3079BrN4O5+ 557.1394 [M+H]+, found 557.1375. 
 
Ethyl acetyl-glycyl-2-(4-bromophenyl)-L-tryptophylglycinate (81wf) 
The general procedure A was followed using peptide 80w (100 mg), iodonium 
tosylate 78f (204 mg) and HOAc. Purification by column chromatography (EtOAc/ 
THF 5:2) yielded peptide 81wf as a white solid (80 mg, 57%). 
m. p.: 205 °C. 
1H NMR (500 MHz, DMSO-d6): δ = 11.23 (s, 1H), 8.36 (dd, J = 5.8, 5.8 Hz, 1H), 8.13–8.05 (m, 1H), 7.96 
(dd, J = 5.7, 5.7 Hz, 1H), 7.72–7.61 (m, 5H), 7.33 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 7.10 (ddd, J = 8.1, 7.0, 
1.2 Hz, 1H), 7.00 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.74–4.66 (m, 1H), 4.04 (q, J = 7.0 Hz, 2H), 3.75–3.68 
(m, 2H), 3.62 (dd, J = 16.9, 5.7 Hz, 1H), 3.46 (dd, J = 16.9, 5.4 Hz, 1H), 3.27 (dd, J = 14.4, 6.3 Hz, 1H), 
3.04 (dd, J = 14.4, 7.5 Hz, 1H), 1.80 (s, 3H), 1.15 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 171.5 (Cq), 169.5 (Cq), 169.4 (Cq), 168.6 (Cq), 136.0 (Cq), 134.1 
(Cq), 132.0 (Cq), 131.5 (CH), 130.2 (CH), 128.9 (Cq), 121.7 (CH), 120.6 (Cq), 119.2 (CH), 118.8 (CH), 
111.1 (CH), 108.1 (Cq), 60.4 (CH2), 53.5 (CH), 41.9 (CH2), 40.8 (CH2), 28.2 (CH2), 22.4 (CH3), 14.0 
(CH3). 
IR (ATR): 3294, 1740, 1684, 1624, 1526, 1434, 1202, 1008, 737, 706, 673 cm‒1. 
MS (ESI) m/z (relative intensity) 1111/1109 (54) [2M+Na]+, 1088/1086 (7) [2M+H]+, 567/565 (100) 
[M+Na]+, 545/543 (19) [M+H]+. 
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HR-MS (ESI) m/z calcd for C25H2879BrN4O5+ 543.1236 [M+H]+, found 543.1233. 
Ethyl acetyl-1-(2-pyridyl)-L-tryptophyl-2-(4-bromophenyl)-L-tryptophylglycinate (105bf) 
The general procedure A was followed using peptide 103b (30 mg), iodonium 
tosylate 78f (46 mg) and TFA at 60 °C. Purification by column chromatography 
(EtOAc/THF 9:1) yielded peptide 105bf as a white solid (13 mg, 35%). 
m. p.: 164 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 11.22 (s, 1H), 8.54 (ddd, J = 5.0, 2.9, 2.9 Hz, 1H), 8.35 (d, J = 8.4 Hz, 
1H), 8.17–8.10 (m, 1H), 8.03–7.90 (m, 2H), 7.76–7.54 (m, 5H), 7.35–7.32 (m, 1H), 7.28–7.21 (m, 2H), 
7.21–7.13 (m, 2H), 7.13–6.97 (m, 1H), 4.70 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 4.63 (ddd, J = 8.1, 8.1, 
5.3 Hz, 2H), 4.09–3.91 (m, 2H), 3.70–3.61 (m, 1H), 3.56–3.47 (m, 1H), 3.37–3.32 (m, 2H), 3.11–3.04 
(m, 1H), 2.92 (dd, J = 14.8, 8.5 Hz, 1H), 1.75 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 171.4 (Cq), 170.9 (Cq), 169.2 (Cq), 169.2 (Cq), 152.0 (Cq), 148.4 
(CH), 139.0 (CH), 135.9 (Cq), 134.7 (Cq), 134.2 (Cq), 131.9 (Cq), 131.4 (CH), 130.1 (CH), 129.9 (Cq), 
128.8 (Cq), 124.3 (CH), 122.9 (CH), 121.6 (CH), 120.7 (CH), 120.5 (Cq), 119.9 (CH), 119.0 (CH), 118.7 
(CH), 114.5 (Cq), 113.9 (CH), 113.7 (CH), 111.0 (CH), 108.0 (Cq), 60.3 (CH2), 53.7 (CH), 52.8 (CH), 40.7 
(CH2), 28.1 (CH2), 27.2 (CH2), 22.5 (CH3), 13.9 (CH3). 
IR (ATR): 3260, 1652, 1592, 1473, 1455, 1437, 1185, 1133, 1010, 800, 745, 720 cm‒1. 
MS (ESI) m/z (relative intensity) 773/771 (100) [M+Na]+, 751/749 (39) [M+H]+. 
HR-MS (ESI) m/z calcd for C39H3879BrN6O5+ 749.2082 [M+H]+, found 749.2070. 
 
5.3.2 Analytical Data for Arylated Tryptophans 67 
Methyl tert-butoxycarbonyl-1-(2-pyrimidyl)-2-(4-methoxyphenyl)-L-tryptophanate (67eb) 
The general procedure B1 was followed using tryptophan 56e (119 mg) and 4-
bromoanisole (28b, 62 mg). Purification by column chromatography (hexanes/ 
EtOAc 1:1) yielded tryptophan 67eb as a white solid (49 mg, 33%) and 
diarylated tryptophan 67ebb as a white solid (18 mg, 12%). 
m. p.: 154 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 8.73 (d, J = 4.9 Hz, 2H), 7.96–7.91 (m, 1H), 7.67 (d, J = 7.6 Hz, 1H), 
7.32 (dd, J = 4.8, 4.8 Hz, 1H), 7.26–7.18 (m, 2H), 7.16 (d, J = 7.7 Hz, 1H), 7.13–7.09 (dm, J = 8.4 Hz, 
2H), 6.93–6.88 (dm, J = 8.4 Hz, 2H), 4.19 (ddd, J = 7.6, 7.6, 7.6 Hz, 1H), 3.77 (s, 3H), 3.42 (s, 3H), 3.17 
(dd, J = 14.4, 7.2 Hz, 1H), 3.08 (dd, J = 14.4, 7.8 Hz, 1H), 1.30 (s, 9H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.2 (Cq), 158.6 (CH), 158.4 (Cq), 157.0 (Cq), 155.0 (Cq), 137.2 
(Cq), 136.0 (Cq), 130.7 (CH), 128.8 (Cq), 124.5 (Cq), 123.0 (CH), 121.3 (CH), 118.9 (CH), 118.3 (CH), 
113.5 (CH), 112.9 (Cq), 112.3 (CH), 78.2 (Cq), 55.0 (CH3), 54.3 (CH), 51.6 (CH3), 28.0 (CH3). 
IR (ATR): 1974, 1741, 1708, 1561, 1507, 1456, 1421, 1365, 1345, 1244, 1160, 1026, 832, 745 cm‒1. 
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MS (ESI) m/z (relative intensity) 1027 (43) [2M+Na]+, 1005 (4) [2M+H]+, 525 (100) [M+Na]+, 503 (14) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C28H30N4NaO5+ 525.2108 [M+H]+, found 525.2092. 
 
Methyl tert-butoxycarbonyl-1-(2-pyrimidyl)-2,7-di(4-methoxyphenyl)-L-tryptophanate (67ebb) 
The general procedure B1 was followed using tryptophan 56e (119 mg) and 4-
bromoanisole (28b, 62 mg). Purification by column chromatography (hexanes/ 
EtOAc 1:1) yielded tryptophan 67eb as a white solid (49 mg, 33%) and 
diarylated tryptophan 67ebb as a white solid (18 mg, 12%). 
m. p.: 161 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 8.25 (d, J = 4.8 Hz, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.26–7.20 (m, 1H), 
7.14–7.08 (m, 1H), 7.07–7.00 (m, 4H), 6.85–6.79 (m, 4H), 6.58–6.52 (m, 2H), 4.21 (ddd, J = 7.6, 7.6, 
7.6 Hz, 1H), 3.71 (s, 3H), 3.66 (s, 3H), 3.46 (s, 3H), 3.15 (dd, J = 14.5, 7.1 Hz, 1H), 3.09 (dd, J = 14.4, 
8.0 Hz, 1H), 1.31 (s, 9H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.2 (Cq), 170.2 (Cq), 158.7 (Cq), 157.4 (CH), 157.0 (Cq), 155.1 
(Cq), 138.8 (Cq), 133.5 (Cq), 131.8 (Cq), 131.7 (CH), 129.2 (Cq), 128.7 (CH), 126.5 (Cq), 124.6 (CH), 
123.1 (Cq), 120.4 (CH), 118.9 (CH), 117.7 (CH), 113.3 (CH), 113.2 (CH), 110.6 (Cq), 78.2 (Cq), 55.0 
(CH3), 54.9 (CH3), 54.4 (CH), 51.6 (CH3), 28.0 (CH3), 26.4 (CH2). 
IR (ATR): 2974, 1741, 1708, 1562, 1506, 1417, 1364, 1242, 1161, 1053, 1026, 832, 791, 745 cm‒1. 
MS (ESI) m/z (relative intensity) 631 (100) [M+Na]+, 609 (1) [M+H]+. 
HR-MS (ESI) m/z calcd for C35H36N4NaO6+ 631.2527 [M+Na]+, found 631.2510. 
 
Methyl acetyl-1-(2-pyrimidyl)-2-(4-methoxyphenyl)-L-tryptophanate (67gb) 
The general procedure B1 was followed using tryptophan 56g (101 mg) and 4-
bromoanisole (28b, 62 mg). Purification by GPC yielded tryptophan 67gb as a 
white solid (44 mg, 33%) and diarylated tryptphan 67gbb as a white solid 
(11 mg, 7%). 
m. p.: 131 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 8.73 (dd, J = 4.9, 0.6 Hz, 2H), 8.31–8.22 (m, 1H), 7.97–7.89 (m, 1H), 
7.69–7.62 (m, 1H), 7.33 (ddd, J = 4.8, 4.8, 0.6 Hz, 1H), 7.28–7.17 (m, 2H), 7.15–7.06 (dm, J = 8.4 Hz, 
2H), 6.95–6.84 (dm, J = 8.4 Hz, 2H), 4.50 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 3.77 (s, 3H), 3.40 (s, 3H), 3.17 
(dd, J = 14.2, 7.7 Hz, 1H), 3.08 (dd, J = 14.2, 7.1 Hz, 1H), 1.75 (s, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 171.9 (Cq), 169.0 (Cq), 158.6 (CH), 158.4 (Cq), 157.0 (Cq), 137.3 
(Cq), 136.0 (Cq), 130.8 (CH), 128.7 (Cq), 124.4 (Cq), 123.1 (CH), 121.4 (CH), 118.8 (CH), 118.3 (CH), 
113.5 (CH), 112.6 (Cq), 112.4 (CH), 55.0 (CH3), 52.6 (CH), 51.6 (CH3), 26.7 (CH2), 22.2 (CH3). 
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IR (ATR): 3262, 1739, 1653, 1560, 1507, 1455, 1419, 1371, 1344, 1244, 1175, 1026, 833, 745 cm‒1. 
MS (ESI) m/z (relative intensity) 911 (31) [2M+Na]+, 889 (5) [2M+H]+, 467 (100) [M+Na]+, 445 (80) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C25H25N4O4+ 445.1870 [M+H]+, found 445.1870. 
 
Methyl acetyl-1-(2-pyrimidyl)-2,7-di(4-methoxyphenyl)-L-tryptophanate (67gbb) 
The general procedure B1 was followed using tryptophan 56g (101 mg) and 4-
bromoanisole (28b, 62 mg). Purification by GPC yielded tryptophan 67gb as a 
white solid (44 mg, 33%) and diarylated tryptphan 67gbb as a white solid 
(11 mg, 7%). 
m. p.: 172 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 8.25 (d, J = 4.8 Hz, 2H), 7.67 (dd, J = 7.9, 1.2 Hz, 1H), 7.25 (dd, J = 
7.9, 7.3 Hz, 1H), 7.09–6.96 (m, 4H), 6.85–6.77 (m, 4H), 6.60–6.52 (m, 2H), 4.51 (ddd, J = 7.3, 7.3, 
7.3 Hz, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 3.44 (s, 3H), 3.21–3.04 (m, 2H), 1.77 (s, 3H). 
13C NMR (75 MHz, DMSO-d6): δ = 171.9 (Cq), 169.1 (Cq), 158.7 (Cq), 157.4 (CH), 156.9 (Cq), 139.0 (Cq), 
133.6 (Cq), 131.8 (Cq), 131.5 (CH), 129.0 (Cq), 128.7 (CH), 126.6 (Cq), 124.7 (CH), 123.0 (Cq), 120.5 
(CH), 118.9 (CH), 117.6 (CH), 113.2 (CH), 113.1 (CH), 110.3 (Cq), 79.13 (Cq), 55.1 (CH3), 55.0 (CH3), 
52.8 (CH), 51.6 (CH3), 26.7 (CH2), 22.4 (CH3). 
IR (ATR): 3255, 1741, 1661, 1515, 1423, 1372, 1345, 1248, 1177, 1023, 830, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 1101 (6) [2M+H]+, 573 (31) [M+Na]+, 551 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C32H31N4O5+ 551.2289 [M+H]+, found 551.2284. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-methoxyphenyl)-L-tryptophanate (67hb) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 4-
bromoanisole (28b, 62 mg). Purification by GPC yielded tryptophan 67hb as a 
white solid (98 mg, 74% and 93 mg, 70% when procedure B2 was followed). 
m. p.: 90 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.55 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.64‒7.61 (m, 2H), 7.51 (ddd, J = 
8.1, 7.4, 2.0 Hz, 1H), 7.22‒7.17 (m, 2H), 7.16 (dm, J = 8.6 Hz, 2H), 7.14‒7.12 (m, 1H), 6.84 (dm, J = 
8.6 Hz, 2H), 6.66 (ddd, J = 7.8, 0.9, 0.9 Hz, 1H), 5.79 (d, J = 7.8 Hz, 1H), 4.76 (dt, J = 7.9, 5.8 Hz, 1H), 
3.78 (s, 3H), 3.45 (dd, J = 14.7, 5.9 Hz, 1H), 3.40 (dd, J = 14.7, 5.9 Hz, 1H), 3.38 (s, 3H), 1.69 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 169.4 (Cq), 159.1 (Cq), 151.6 (Cq), 148.8 (CH), 137.4 (CH), 
137.2 (Cq), 136.8 (Cq), 131.6 (CH), 128.7 (Cq), 123.9 (Cq), 123.2 (CH), 121.7 (CH), 121.3 (CH), 121.1 
(CH), 118.6 (CH), 114.1 (CH), 111.5 (CH), 110.1 (Cq), 55.3 (CH), 52.7 (CH3), 52.1 (CH3), 26.7 (CH2), 23.0 
(CH3). 
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IR (ATR): 3053, 2950, 2834, 1739, 1656, 1506, 1455, 1435, 1245, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 466 (100) [M+Na]+, 444 (48) [M+H]+, 313 (6), 250 (5). 
HR-MS (ESI) m/z calcd for C26H26N3O4+ 444.1918 [M+H]+, found 444.1913. 
 
Methyl acetyl-1-(2-pyridyl)-2-(benzoic acid methyl ester-4-yl)-L-tryptophanate (67hd) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 
methyl 4-bromobenzoate (28d, 71 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 67hd as a white solid (99 mg, 70% and 
117 mg, 83% when procedure B2 was followed). 
m. p.: 100 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.52 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.99 (dm, J = 8.5 Hz, 2H), 7.67‒7.56 
(m, 2H), 7.53 (ddd, J = 7.8, 1.8, 1.8 Hz, 1H), 7.34 (dm, J = 8.5 Hz, 2H), 7.27‒7.17 (m, 2H), 7.14 (ddd, J = 
7.5, 4.9, 1.0 Hz, 1H), 6.71 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 5.76 (d, J = 7.9 Hz, 1H), 4.79 (dt, J = 8.1, 
5.7 Hz, 1H), 3.88 (s, 3H), 3.54‒3.39 (m, 2H), 3.30 (s, 3H), 1.68 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 171.8 (Cq), 169.3 (Cq), 166.3 (Cq), 151.2 (Cq), 149.0 (CH), 137.7 (CH), 
137.2 (Cq), 136.5 (Cq), 136.2 (Cq), 130.2 (CH), 129.6 (CH), 129.2 (Cq), 128.7 (Cq), 123.8 (CH), 121.6 
(CH), 121.6 (CH), 121.3 (CH), 119.1 (CH), 111.6 (Cq), 111.4 (CH), 52.6 (CH), 52.2 (CH3), 52.1 (CH3), 26.8 
(CH2), 23.0 (CH3). 
IR (ATR): 3068, 2939, 1740, 1656, 1468, 1455, 1436, 1246, 1176, 744 cm‒1. 
MS (ESI) m/z (relative intensity) 494 (100) [M+Na]+, 472 (26) [M+H]+, 341 (3). 
HR-MS (ESI) m/z calcd for C27H26N3O5+ 472.1867 [M+H]+, found 472.1867. 
 
Methyl acetyl-1-(2-pyridyl)-2-(3-methoxyphenyl)-L-tryptophanate (67he) 
The general procedure B2 was followed using tryptophan 56h (101 mg) and 3-
bromoanisole (28e, 62 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67he as a white solid (71 mg, 53%) and diarylated tryptophan 
67hee as a white solid (13 mg, 10%). 
m. p.: 88 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.70‒7.65 (m, 2H), 7.56 (ddd, J = 
8.1, 7.4, 1.9 Hz, 1H), 7.30‒7.22 (m, 3H), 7.18 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.89‒6.83 (m, 2H), 
6.81‒6.78 (m, 1H), 6.76‒6.71 (m, 1H), 5.68 (d, J = 7.9 Hz, 1H), 4.85‒4.77 (m, 1H), 3.71 (s, 3H), 
3.58‒3.44 (m, 2H), 3.42 (s, 3H), 1.72 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 169.4 (Cq), 159.5 (Cq), 151.6 (Cq), 148.8 (CH), 137.5 (CH), 
137.1 (Cq), 137.0 (Cq), 133.0 (Cq), 129.6 (CH), 128.7 (Cq), 123.5 (CH), 122.8 (CH), 121.6 (CH), 121.4 
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(CH), 121.2 (CH), 118.9 (CH), 115.7 (CH), 113.9 (CH), 111.5 (CH), 110.6 (Cq), 55.3 (CH3), 52.7 (CH), 52.2 
(CH3), 26.7 (CH2), 23.0 (CH3). 
IR (ATR): 3053, 2951, 1740, 1658, 1588, 1455, 1434, 1366, 1035, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 443 (6) [M]+, 313 (100), 298 (10), 269 (11), 234 (8), 204 (5). 
HR-MS (ESI) m/z calcd for C26H26N3O4+ 443.1845 [M]+, found 443.1853. 
 
Methyl acetyl-1-(2-pyridyl)-2,7-di(3-methoxyphenyl)-L-tryptophanate (67hee) 
The general procedure B2 was followed using tryptophan 56h (101 mg) and 3-
bromoanisole (28e, 62 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67he as a white solid (71 mg, 53%) and diarylated tryptophan 
67hee as a white solid (13 mg, 10%). 
m. p.: 110 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.91 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.66 (dd, J = 7.9, 1.2 Hz, 1H), 7.29–
7.09 (m, 5H), 6.88 (dd, J = 7.9, 7.9 Hz, 1H), 6.82 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 6.78–6.70 (m, 2H), 
6.70–6.62 (m, 2H), 6.53 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.45 (s, br., 1H), 5.82 (d, J = 7.9 Hz, 1H), 4.79 
(ddd, J = 7.9, 5.7, 5.7 Hz, 1H), 3.60 (s, 3H), 3.59 (s, 3H), 3.52–3.44 (m, 1H), 3.46 (s, 3H), 3.39 (dd, J = 
14.7, 6.0 Hz, 1H), 1.73 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.2 (Cq), 169.8 (Cq), 159.2 (Cq), 158.5 (Cq), 151.5 (Cq), 147.9 (CH), 
141.2 (Cq), 139.3 (Cq), 136.4 (CH), 133.9 (Cq), 132.9 (Cq), 129.6 (Cq), 129.3 (CH), 128.4 (CH), 127.1 
(Cq), 125.8 (CH), 123.6 (CH), 123.3 (CH), 121.7 (CH), 121.5 (CH), 120.7 (CH), 118.3 (CH), 116.3 (CH), 
114.1 (CH), 113.9 (CH), 112.4 (CH), 109.7 (Cq), 55.3 (CH3), 55.1 (CH3), 52.8 (CH), 52.3 (CH3), 26.7 
(CH2), 23.2 (CH3). 
IR (ATR): 2921, 2852, 1741, 1655, 1584, 1469, 1436, 1410, 1216, 1175, 1036, 782, 743, 700 cm‒1. 
HR-MS (EI) m/z calcd for C33H31N3O5+ 549.2264 [M]+, found 549.2279. 
 
Methyl acetyl-1-(2-pyridyl)-2-(benzoic acid ethyl ester-3-yl)-L-tryptophanate (67hf) 
The general procedure B2 was followed using tryptophan 56h (101 mg) and ethyl 
3-bromobenzoate (28f, 76 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67hf as a white solid (96 mg, 66%). 
m. p.: 83 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.53 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.96 (ddd, J = 7.2, 1.8, 1.8 Hz, 1H), 
7.94‒7.92 (m, 1H), 7.67‒7.65 (m, 1H), 7.61‒7.59 (m, 1H), 7.53 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.41‒7.36 (m, 2H), 7.23 (dddd, J = 15.0, 7.2, 7.2, 1.2 Hz 2H), 7.14 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 6.74 
(ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 5.72 (d, J = 8.0 Hz, 1H), 4.80 (dt, J = 8.0, 5.8 Hz, 1H), 4.32 (q, J = 7.2 Hz, 
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2H), 3.47 (dd, J = 14.4, 6.0 Hz, 1H), 3.42 (dd, J = 14.4, 6.0 Hz, 1H), 3.34 (s, 3H), 1.71 (s, 3H), 1.33 (t, J = 
7.2 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 171.9 (Cq), 169.4 (Cq), 165.7 (Cq), 151.2 (Cq), 149.0 (CH), 137.6 (CH), 
137.1 (Cq), 136.3 (Cq), 134.6 (CH), 132.1 (Cq), 131.3 (CH), 130.8 (Cq), 128.8 (CH), 128.6 (Cq), 128.5 
(CH), 123.7 (CH), 121.7 (CH), 121.6 (CH), 121.3 (CH), 119.0 (CH), 111.4 (CH), 111.1 (Cq), 61.2 (CH2), 
52.5 (CH), 52.2 (CH3), 26.8 (CH2), 23.0 (CH3), 14.3 (CH3). 
IR (ATR): 3294, 3068, 1715, 1660, 1468, 1455, 1435, 1278, 1244, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 508 (100) [M+Na]+, 486 (34) [M+H]+. 
HR-MS (ESI) m/z calcd for C28H28N3O5+ 486.2023 [M+H]+, found 486.2019. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-anilino)-L-tryptophanate (67hg) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 4-
bromoaniline (28g, 57 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67hg as a white solid (99 mg, 77% and 98 mg, 76% when 
procedure B2 was followed). 
m. p.: 189 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.59 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.68‒7.59 (m, 2H), 7.53 (ddd, J = 
8.0, 7.4, 2.0 Hz, 1H), 7.24‒7.17 (m, 2H), 7.15 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.02 (dm, J = 8.6 Hz, 2H), 
6.69 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 6.62 (dm, J = 8.6 Hz, 2H), 5.67 (d, J = 7.7 Hz, 1H), 4.76 (dt, J = 7.7, 
5.8 Hz, 1H), 3.78 (br s, 2H), 3.49‒3.38 (m, 2H), 3.43 (s, 3H), 1.71 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.1 (Cq), 169.5 (Cq), 151.7 (Cq), 148.7 (CH), 146.2 (Cq), 137.8 (Cq), 
137.4 (CH), 136.7 (Cq), 131.5 (CH), 128.8 (Cq), 123.0 (CH), 121.8 (CH), 121.2 (Cq), 121.2 (CH), 121.0 
(CH), 118.5 (CH), 115.0 (CH), 111.5 (CH), 109.6 (Cq), 52.8 (CH), 52.1 (CH3), 26.6 (CH2), 23.0 (CH3). 
IR (ATR): 3449, 3356, 2922, 1734, 1630, 1466, 1456, 1434, 1367, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 451 (69) [M+Na]+, 429 (100) [M+H]+, 298 (6). 
HR-MS (ESI) m/z calcd for C25H25N4O3+ 429.1921 [M+H]+, found 429.1926. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-nitrophenyl)-L-tryptophanate (67hi) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 1-
bromo-4-nitrobenzene (28i, 67 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 67hi as a yellow solid (14 mg, 10% and 25 mg, 18% 
when procedure B2 was followed). 
m. p.: 91 °C. 
1H NMR (500 MHz, CDCl3): δ = 8.54 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 8.20‒8.16 (dm, J = 8.5 Hz, 2H), 7.69 
(ddd, J = 7.6, 1.4, 0.7 Hz, 1H), 7.65 (ddd, J = 8.0, 7.5, 1.9 Hz, 1H), 7.61‒7.58 (m, 1H), 7.46‒7.42 (dm, J = 
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8.5 Hz, 2H), 7.32‒7.26 (m, 2H), 7.25‒7.20 (m, 1H), 6.88 (dt, J = 8.0, 1.0 Hz, 1H), 5.83 (d, J = 7.9 Hz, 1H), 
4.84 (ddd, J = 8.0, 6.6, 5.5 Hz, 1H), 3.54‒3.42 (m, 2H), 3.36 (s, 3H), 1.76 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.2 (Cq), 169.6 (Cq), 151.2 (Cq), 149.6 (CH), 147.0 (Cq), 139.0 (Cq), 
138.3 (CH), 137.7 (Cq), 135.2 (Cq), 131.2 (CH), 128.9 (Cq), 124.6 (CH), 123.8 (CH), 122.2 (CH), 121.9 
(CH), 121.7 (CH), 119.6 (CH), 112.9 (Cq), 111.6 (CH), 52.8 (CH), 52.4 (CH3), 27.2 (CH2), 23.2 (CH3). 
IR (ATR): 2923, 1739, 1657, 1589, 1513, 1468, 1454, 1435, 1340, 1212, 1106, 854, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 939 (10) [2M+Na]+, 917 (1) [2M+H]+, 481 (97) [M+Na]+, 459 (100) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C25H23N4O5+ 459.1663 [M+H]+, found 459.1662. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-fluorophenyl)-L-tryptophanate (67hk) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 1-
bromo-4-fluorobenzene (28k, 58 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 67hk as a white solid (106 mg, 82% and 123 mg, 95% 
when procedure B2 was followed). 
m. p.: 102 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.59‒8.56 (m, 1H), 7.67‒7.56 (m, 3H), 7.28‒7.22 (m, 4H), 7.21‒7.17 
(m, 1H), 7.07‒7.01 (m, 2H), 6.75‒6.71 (m, 1H), 5.74 (d, J = 8.0 Hz, 1H), 4.81 (dt, J = 8.0, 5.8 Hz, 1H), 
3.51‒3.39 (m, 2H), 3.38 (s, 3H), 1.74 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 172.1 (Cq), 169.5 (Cq), 162.3 (d, 1JCF = 248.9 Hz, Cq), 151.4 (Cq), 149.0 
(CH), 137.9 (CH), 137.0 (Cq), 136.4 (Cq), 132.3 (d, 3JCF = 8.1 Hz, CH), 128.8 (Cq), 127.9 (d, 4JCF = 3.6 Hz, 
Cq), 123.6 (CH), 121.8 (CH), 121.7 (CH), 121.4 (CH), 119.0 (CH), 115.7 (d, 2JCF = 21.6 Hz, CH), 111.5 
(CH), 110.7 (Cq), 52.6 (CH), 52.2 (CH3), 26.7 (CH2), 23.0 (CH3). 
19F NMR (376 MHz, CDCl3): δ = ‒112.9 (m). 
IR (ATR): 3053, 2951, 1740, 1655, 1504, 1468, 1455, 1435, 1156, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 454 (100) [M+Na]+, 432 (24) [M+H]+, 301 (3). 
HR-MS (ESI) m/z calcd for C25H23FN3O3+ 432.1718 [M+H]+, found 432.1711. 
 
Methyl acetyl-1,2-di(2-pyridyl)-L-tryptophanate (67hm) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 2-
bromopyridine (28m, 52 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67hm as a white solid (118 mg, 95% and 20 mg, 16% when 
procedure B2 was followed). 
m. p.: 111 °C. 
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1H NMR (300 MHz, CDCl3): δ = 9.88 (d, J = 4.7 Hz, 1H), 8.72 (ddd, J = 5.0, 1.8, 1.0 Hz, 1H), 8.58 (ddd, 
J = 4.9, 2.0, 0.9 Hz, 1H), 7.76‒7.66 (m, 2H), 7.61 (ddd, J = 8.0, 7.4, 1.9 Hz, 1H), 7.51 (ddd, J = 7.8, 7.8, 
1.8 Hz, 1H), 7.33‒7.22 (m, 3H), 7.20 (ddd, J = 7.2, 4.8, 0.9 Hz, 1H), 6.89 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 
6.81 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 4.65 (ddd, J = 11.0, 4.8, 3.3 Hz, 1H), 3.76 (s, 3H), 3.36 (dd, J = 14.1, 
3.4 Hz, 1H), 3.17 (dd, J = 14.1, 11.0 Hz, 1H), 2.02 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.9 (Cq), 170.4 (Cq), 151.7 (Cq), 150.2 (Cq), 149.2 (CH), 148.6 (CH), 
137.8 (CH), 137.7 (Cq), 136.3 (CH), 135.4 (Cq), 128.2 (Cq), 125.9 (CH), 124.6 (CH), 122.3 (CH), 121.7 
(CH), 121.6 (CH), 121.4 (CH), 119.4 (CH), 115.0 (Cq), 111.7 (CH), 54.0 (CH), 52.3 (CH3), 26.1 (CH2), 22.9 
(CH3). 
IR (ATR): 3022, 1746, 1671, 1588, 1551, 1468, 1455, 1434, 1365, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 437 (100) [M+Na]+, 415 (38) [M+H]+, 284 (2), 236 (3). 
HR-MS (ESI) m/z calcd for C24H23N4O3+ 415.1765 [M+H]+, found 415.1763. 
 
Methyl acetyl-1-(2-pyridyl)-2-ferrocenyl-L-tryptophanate (67hc) 
The general procedure B2 was followed using tryptophan 56h (101 mg) and 
iodoferrocene (66c, 140 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67hc as a yellow solid (26 mg, 17% and 81 mg, 52% when 
procedure B2 was followed and 20 mol % [Ru]2 and 120 mol % F5C6CO2H were 
used). 
m. p.: 128 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.68 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 
7.59‒7.52 (m, 1H), 7.42‒7.36 (m, 1H), 7.27 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.19‒7.11 (m, 2H), 6.90 
(ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 6.19 (d, J = 7.6 Hz, 1H), 4.95 (q, J = 7.3 Hz, 1H), 4.29‒4.23 (m, 2H), 
4.23‒4.18 (m, 2H), 3.98 (s, 5H), 3.73 (d, J = 7.2 Hz, 2H), 3.59 (s, 3H), 1.95 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.9 (Cq), 169.6 (Cq), 152.4 (Cq), 149.0 (CH), 137.8 (Cq), 137.6 (CH), 
135.1 (Cq), 129.2 (Cq), 122.9 (CH), 122.7 (CH), 122.0 (CH), 121.0 (CH), 117.9 (CH), 110.8 (CH), 110.8 
(Cq), 69.7 (CH), 69.6 (CH), 69.5 (CH), 68.4 (CH), 68.3 (CH), 53.3 (CH), 52.4 (CH3), 29.0 (CH2), 23.3 
(CH3).  
IR (ATR): 3284, 3054, 2952, 1738, 1651, 1468, 1435, 1367, 1208, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 544 (93) [M+Na]+, 522 (100) [M+H]+, 434 (9), 391 (9). 
HR-MS (ESI) m/z calcd for C29H28FeN3O3+ 522.1475 [M+H]+, found 522.1473. 
 
Methyl acetyl-1-(2-pyridyl)-2-(2-naphthyl)-L-tryptophanate (67ho) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 2-
bromonaphthalene (28o, 68 mg). Purification by column chromatography (EtOAc) 
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yielded tryptophan 67ho as a white solid (78 mg, 56% and 121 mg, 87% when procedure B2 was 
followed) and diarylated tryptophan 67hoo was isolated as a white solid (20 mg, 11% when 
procedure B1 was followed). 
m. p.: 113 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.58 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.86‒7.66 (m, 5H), 7.52 (ddd, J = 
6.2, 3.4, 3.4 Hz, 1H), 7.45 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 7.33‒7.21 (m, 5H), 7.13 (ddd, J = 7.5, 4.9, 
1.0 Hz, 1H), 6.73 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 5.68 (d, J = 8.0 Hz, 1H), 4.82 (dt, J = 8.0, 5.7 Hz, 1H), 
3.55 (ddd, J = 18.6, 14.7, 5.7 Hz, 2H), 3.21 (s, 3H), 1.59 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 171.9 (Cq), 169.4 (Cq), 151.5 (Cq), 148.9 (CH), 137.6 (CH), 137.2 (Cq), 
137.1 (Cq), 133.1 (Cq), 132.4 (Cq), 129.5 (CH), 129.2 (Cq), 128.8 (Cq), 128.1 (CH), 128.0 (CH), 127.8 
(CH), 127.6 (CH), 126.6 (CH), 126.5 (CH), 123.5 (CH), 121.6 (CH), 121.4 (CH), 121.2 (CH), 118.9 (CH), 
111.5 (CH), 111.1 (Cq), 52.7 (CH), 52.0 (CH3), 26.8 (CH2), 22.9 (CH3). 
IR (ATR): 3285, 3035, 2939, 1737, 1652, 1468, 1453, 1434, 1367, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 486 (100) [M+Na]+, 464 (49) [M+H]+, 333 (3). 
HR-MS (ESI) m/z calcd for C29H26N3O3+ 464.1969 [M+H]+, found 464.1968. 
 
Methyl acetyl-1-(2-pyridyl)-2,7-di(2-naphthyl)-L-tryptophanate (67hoo) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 2-
bromonaphthalene (28o, 68 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67ho as a white solid (78 mg, 56% and 121 mg, 87% when 
procedure B2 was followed) and diarylated tryptophan 67hoo was isolated as a 
white solid (20 mg, 11% when procedure B1 was followed). 
m. p.: 133 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.79–7.68 (m, 5H), 7.67–7.59 (m, 2H), 7.59–7.51 (m, 1H), 7.51–7.42 
(m, 3H), 7.42–7.27 (m, 5H), 7.19–7.10 (m, 2H), 6.85 (ddd, J = 7.6, 7.6, 1.9 Hz, 1H), 6.65 (d, J = 7.9 Hz, 
1H), 6.41–6.33 (m, 1H), 5.72 (d, J = 7.9 Hz, 1H), 4.84 (ddd, J = 8.0, 5.7, 5.7 Hz, 1H), 3.58 (dd, J = 14.7, 
5.6 Hz, 1H), 3.48 (dd, J = 14.7, 5.9 Hz, 1H), 3.29 (s, 3H), 1.67 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.3 (Cq), 169.8 (Cq), 151.5 (Cq), 148.0 (CH), 139.5 (Cq), 137.4 (Cq), 
136.4 (CH), 134.5 (Cq), 133.1 (Cq), 132.8 (Cq), 132.6 (Cq), 131.7 (Cq), 130.4 (CH), 129.9 (Cq), 129.2 (Cq), 
128.2 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH), 127.8 (CH), 127.7 (CH), 127.5 (CH), 127.2 (Cq), 127.2 
(CH), 126.8 (CH), 126.8 (CH), 126.7 (CH), 126.3 (CH), 125.9 (CH), 125.7 (CH), 123.8 (CH), 121.6 (CH), 
120.9 (CH), 118.5 (CH), 110.2 (Cq), 52.9 (CH), 52.2 (CH3), 26.8 (CH2), 23.1 (CH3). 
IR (ATR): 2921, 2852, 1737, 1655, 1467, 1436, 1415, 1220, 1196, 1176, 1130, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 1201 (2) [2M+Na]+, 1179 (2) [2M+H]+, 612 (31) [M+Na]+, 590 (100) 
[M+H]+. 
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HR-MS (ESI) m/z calcd for C39H32N3O3+ 590.2438 [M+H]+, found 590.2434. 
Methyl acetyl-1-(2-pyridyl)-2-(1-pyrenyl)-L-tryptophanate (67hp) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 1-
bromopyrene (28p, 93 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67hp as a white solid (52 mg, 32% and 21 mg, 13% when 
procedure B2 was followed). 
Due to formation of rotamers, the NMR spectra show a double set of signals. 
m. p.: 156 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.46 (dd, J = 4.9, 1.8 Hz, 1H), 8.43 (dd, J = 4.9, 1.8 Hz, 1H), 8.25‒8.12 
(m, 3H), 8.11‒8.00 (m, 10H), 7.97‒7.89 (m, 4H), 7.85‒7.79 (m, 4H), 7.77‒7.74 (m, 1H), 7.38‒7.28 (m, 
6H), 7.12 (ddd, J = 7.7, 7.7, 1.9 Hz, 2H), 6.91 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.88 (ddd, J = 7.7, 4.9, 
1.0 Hz, 1H), 6.54 (d, J = 8.2 Hz, 1H), 6.48 (d, J = 8.1 Hz, 1H), 5.47 (d, J = 7.8 Hz, 1H), 5.42 (d, J = 7.6 Hz, 
1H), 4.75‒4.67 (m, 2H), 3.55 (dd, J = 14.9, 5.2 Hz, 1H), 3.40 (dd, J = 14.8, 6.9 Hz, 1H), 3.33 (dd, J = 
14.8, 5.5 Hz, 1H), 3.25 (dd, J = 14.8, 5.5 Hz, 1H), 3.21 (d, J = 6.9 Hz, 7H), 1.19 (s, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.1 (Cq), 172.0 (Cq), 169.7 (Cq), 169.5 (Cq), 151.5 (Cq), 151.5 (Cq), 
148.9 (CH), 148.9 (CH), 137.6 (CH), 137.3 (CH), 136.2 (Cq), 136.0 (Cq), 131.7 (Cq), 131.6 (Cq), 131.3 
(Cq), 131.3 (Cq), 130.9 (Cq), 130.8 (Cq), 130.4 (Cq), 130.4 (Cq), 129.5 (CH), 129.5 (CH), 129.0 (CH), 
129.0 (CH), 128.9 (CH), 128.8 (Cq), 128.7 (Cq), 128.7 (CH), 128.5 (CH), 128.4 (CH), 127.5 (CH), 127.5 
(CH), 126.6 (CH), 126.5 (CH), 126.4 (Cq), 126.2 (Cq), 125.9 (CH), 125.8 (CH), 125.7 (CH), 125.7 (CH), 
124.9 (CH), 124.8 (CH), 124.8 (CH), 124.7 (CH), 124.5 (Cq), 124.4 (Cq), 123.9 (CH), 123.9 (CH), 121.6 
(CH), 121.5 (CH), 121.4 (CH), 121.3 (CH), 120.8 (CH), 120.6 (CH), 119.2 (CH), 119.1 (CH), 112.8 (Cq), 
112.6 (Cq), 112.1 (CH), 112.0 (CH), 52.7 (CH), 52.6 (CH), 52.2 (CH3), 52.1 (CH3), 27.3 (CH2), 27.0 (CH2), 
22.9 (CH3), 22.5 (CH3). 
IR (ATR): 2921, 1736, 1654, 1569, 1467, 1455, 1434, 1368, 1212, 849, 723 cm‒1. 
MS (ESI) m/z (relative intensity) 1097 (3) [2M+Na]+, 1075 (3) [2M+H]+, 560 (63) [M+Na]+, 538 (100) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C35H28N3O3+ 538.2125 [M+H]+, found 538.2128. 
 
Methyl acetyl-1-(2-pyridyl)-2-[4-(1-pyrenyl)phenyl]-L-tryptophanate (67hq) 
The general procedure B1 was followed using tryptophan 56h (101 mg) and 
1-(4-iodophenyl)pyrene (66q, 133 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 67hq as a white solid (94 mg, 51% and 
136 mg, 74% when procedure B2 was followed). 
m. p.: 123 °C. 
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1H NMR (600 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.24‒8.18 (m, 3H), 8.16‒8.06 (m, 
4H), 8.03 (ddd, J = 7.6, 0.8, 0.8 Hz, 1H), 7.96 (dd, J = 7.8, 0.8 Hz, 1H), 7.72 (dddd, J = 8.3, 2.0, 2.0, 
0.9 Hz, 2H), 7.65 (ddd, J = 8.1, 7.5, 2.0 Hz, 1H), 7.63 (dm, J = 7.8 Hz, 2H), 7.46 (dm, J = 7.8 Hz, 2H), 
7.32‒7.24 (m, 3H), 6.87 (dddd, J = 8.1, 0.9, 0.9, 0.9 Hz, 1H), 5.86 (d, J = 7.9 Hz, 1H), 4.90 (dt, J = 7.9, 
5.4 Hz, 1H), 3.66 (dd, J = 15.0, 5.4 Hz, 1H), 3.61 (dd, J = 15.0, 5.4 Hz, 1H), 3.48 (s, 3H), 1.79 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ = 172.2 (Cq), 169.6 (Cq), 151.7 (Cq), 149.1 (CH), 140.8 (Cq), 137.6 (CH), 
137.3 (Cq), 137.2 (Cq), 136.6 (Cq), 131.5 (Cq), 130.9 (Cq), 130.8 (CH), 130.8 (Cq), 130.5 (CH), 129.0 (Cq), 
128.4 (Cq), 127.8 (CH), 127.6 (CH), 127.4 (CH), 127.4 (CH), 126.1 (CH), 125.3 (CH), 125.0 (Cq), 125.0 
(CH), 124.9 (Cq), 124.7 (CH), 124.7 (CH), 123.6 (CH), 121.9 (CH), 121.6 (CH), 121.4 (CH), 119.0 (CH), 
111.6 (CH), 110.8 (Cq), 52.7 (CH), 52.2 (CH3), 26.7 (CH2), 23.1 (CH3). 
IR (ATR): 3043, 1737, 1660, 1587, 1467, 1454, 1434, 1367, 1210, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 636 (26) [M+Na]+, 614 (33) [M+H]+, 533 (30), 437 (85), 415 (100). 
HR-MS (ESI) m/z calcd for C41H32N3O3+ 614.2438 [M+H]+, found 614.2427. 
 
Methyl acetyl-1-(2-pyridyl)-2-[2-(6-allyloxy)naphthalyl]-L-tryptophanate (67hu) 
The general procedure B2 was followed using tryptophan 56h (101 mg) and 
2-(allyloxy)-6-bromonaphthalene (28u, 87 mg). Purification by column chro-
matography (EtOAc) yielded tryptophan 67hu as a white solid (39 mg, 25% 
and 56 mg, 36% when procedure B2 was followed and 10 mol % [Ru]2 was used). 
m. p.: 98 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.57 (dd, J = 5.0, 1.8 Hz, 1H), 7.78–7.60 (m, 5H), 7.44 (ddd, J = 7.8, 7.8, 
1.9 Hz, 1H), 7.29–7.16 (m, 4H), 7.12 (ddd, J = 5.2, 5.2, 1.9 Hz, 2H), 6.71 (dd, J = 8.1, 1.1 Hz, 1H), 6.12 
(dddd, J = 17.4, 10.5, 5.3, 5.3 Hz, 1H), 5.71 (d, J = 7.7 Hz, 1H), 5.53–5.42 (m, 1H), 5.37–5.30 (m, 1H), 
4.81 (ddd, J = 7.9, 5.6, 5.6 Hz, 1H), 4.65 (ddd, J = 5.3, 1.5, 1.5 Hz, 2H), 3.62–3.44 (m, 2H), 3.23 (s, 3H), 
1.59 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.0 (Cq), 169.5 (Cq), 157.2 (Cq), 151.7 (Cq), 149.0 (CH), 137.7 (CH), 
137.5 (Cq), 137.2 (Cq), 133.8 (Cq), 133.0 (CH), 133.0 (CH), 129.6 (CH), 129.5 (CH), 129.0 (Cq), 128.7 
(Cq), 128.4 (CH), 127.1 (CH), 127.0 (Cq), 123.5 (CH), 121.8 (CH), 121.4 (CH), 121.3 (CH), 119.8 (CH), 
118.9 (CH), 118.0 (CH2), 111.7 (CH), 110.9 (Cq), 106.9 (CH), 69.0 (CH2), 52.8 (CH), 52.1 (CH3), 26.9 
(CH2), 23.0 (CH3). 
IR (ATR): 3296, 3039, 1735, 1647, 1627, 1606, 1589, 1468, 1455, 1435, 1367, 1204, 993, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 1061 (24) [2M+Na]+, 542 (100) [M+Na]+, 520 (59) [M+H]+. 
HR-MS (ESI) m/z calcd for C32H30N3O4+ 520.2231 [M+H]+, found 520.2228. 
  
N
AcHN
CO2Me
2-py
O
Experimental Part 
132 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-styryl)-L-tryptophanate (67hv) 
The general procedure B2 was followed using tryptophan 56h (101 mg) and 4-
bromostyrene (28v, 93 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 67hv as a white solid (96 mg, 74%). 
m. p.: 161 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.55 (dd, J = 5.0, 1.9 Hz, 1H), 7.66–7.58 (m, 2H), 7.51 (ddd, J = 7.8, 7.8, 
1.9 Hz, 1H), 7.38–7.30 (m, 2H), 7.26–7.09 (m, 6H), 6.72–6.58 (m, 2H), 5.73 (dd, J = 17.6, 0.8 Hz, 1H), 
5.26 (dd, J = 10.9, 0.7 Hz, 1H), 4.78 (ddd, J = 8.0, 5.7, 5.7 Hz, 1H), 3.55–3.39 (m, 2H), 3.33 (s, 3H), 1.66 
(s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.0 (Cq), 169.6 (Cq), 151.6 (Cq), 149.0 (CH), 137.7 (CH), 137.2 (Cq), 
137.1 (Cq), 137.1 (Cq), 136.1 (CH), 131.2 (Cq), 130.6 (CH), 128.9 (Cq), 126.4 (CH), 123.6 (CH), 121.8 
(CH), 121.6 (CH), 121.3 (CH), 119.0 (CH), 114.8 (CH2), 111.6 (CH), 110.8 (Cq), 52.8 (CH), 52.2 (CH3), 
26.8 (CH2), 23.1 (CH3). 
IR (ATR): 1734, 1654, 1469, 1456, 1435, 1367, 1212, 728 cm‒1. 
MS (ESI) m/z (relative intensity) 901 (22) [2M+Na]+, 879 (2) [2M+H]+, 462 (100) [M+Na]+, 440 (83) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C27H26N3O3+ 440.1969 [M+H]+, found 440.1959. 
 
Acetyl-1-(2-pyridyl)-2-(4-acetylphenyl)-L-tryptophan (67jl) 
The general procedure B1 was followed using tryptophan 56j (48 mg) and 4-
bromoacetophenone (28l, 32 mg). H2O/MeCN (1:1, 1.5 mL) was used instead of 
m-xylene. After cooling to ambient temperature, HCl (12 M, 1 mL) was added to 
the reaction mixture and the water phase was extracted with EtOAc (3×10 mL). The organic layers 
were combined and the solvent was removed in vacuum. Purification by column chromatography 
(CH2Cl2/HOAc 5:1) yielded tryptophan 67jl as a white solid (41 mg, 63%). 
m. p.: 167 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 8.52 (d, J = 4.6 Hz, 1H), 8.01 (d, J = 7.1 Hz, 1H), 7.88 (d, J = 7.5 Hz, 
2H), 7.76 (dd, J = 7.4, 7.4 Hz, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.44 (d, J = 7.7 Hz, 2H), 7.29 (dd, J = 7.3, 
4.8 Hz, 1H), 7.24–7.09 (m, 2H), 6.93 (d, J = 8.0 Hz, 1H), 4.53–4.33 (m, 1H), 3.27–3.11 (m, 1H), 3.02–
2.87 (m, 1H), 2.55 (s, 3H), 1.67 (s, 1H). 
13C NMR (126 MHz, DMSO-d6): δ = 197.7 (Cq), 168.3 (Cq), 151.6 (Cq), 149.3 (CH), 138.6 (CH), 137.5 
(Cq), 137.0 (Cq), 135.7 (Cq), 135.4 (Cq), 130.6 (CH), 129.4 (Cq), 128.2 (CH), 123.3 (CH), 122.1 (CH), 
121.7 (CH), 120.9 (CH), 120.8 (CH), 116.6 (Cq), 111.2 (CH), 55.2 (CH), 29.5 (CH2), 27.1 (CH3), 23.4 
(CH3). 
IR (ATR): 2954, 2924, 2853, 1706, 1469, 1455, 1435, 1365, 1162, 742 cm‒1. 
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MS (ESI) m/z (relative intensity) 905 (15) [2M+Na]+, 464 (100) [M+Na]+, 442 (22) [M+H]+. 
HR-MS (ESI) m/z calcd for C26H24N3O4+ 442.1767 [M+H]+, found 442.1770. 
 
Acetyl-1-(2-pyridyl)-2-(3-methyl-benzoic acid-4-yl)-L-tryptophan (67jβ) 
The general procedure B1 was followed using tryptophan 56j (48 mg) and 4-
bromo-2-methylbenzoic acid (28β, 35 mg). After cooling to ambient tempera-
ture, HCl (12 M, 1 mL) was added and the solvent was removed in vacuum. 
Purification by column chromatography (first column EtOAc/THF/HOAc 12:2:1, followed by second 
column CH2Cl2/HOAc 6:1) yielded tryptophan 67jβ as a white solid (42 mg, 61%). 
m. p.: 210 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 8.55 (dd, J = 5.0, 1.8 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.73 (td, J = 
7.7, 1.9 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.27 (dd, J = 
7.5, 4.9 Hz, 1H), 7.18–7.09 (m, 4H), 7.01 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 4.51 (ddd, J = 7.1, 
7.1, 7.1 Hz, 1H), 3.20 (dd, J = 14.2, 5.8 Hz, 1H), 2.96 (dd, J = 14.1, 7.7 Hz, 1H), 2.41 (s, 3H), 1.69 (s, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.6 (Cq), 168.0 (Cq), 151.3 (Cq), 148.6 (CH), 137.9 (CH), 136.7 
(Cq), 136.5 (Cq), 136.3 (Cq), 132.1 (CH), 131.8 (Cq), 128.8 (Cq), 126.8 (CH), 122.4 (CH), 121.4 (CH), 
121.3 (CH), 120.2 (CH), 119.9 (CH), 114.2 (Cq), 110.9 (CH), 54.7 (CH), 28.6 (CH2), 22.7 (CH3), 21.9 
(CH3). 
IR (ATR): 3390, 2918, 2850, 1576, 1469, 1455, 1436, 1394, 1365, 1285, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 937 (13) [2M+Na]+, 480 (100) [M+Na]+, 458 (40) [M+H]+. 
HR-MS (ESI) m/z calcd for C26H24N3O5+ 458.1710 [M+H]+, found 458.1708. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-bromophenyl)-L-tryptophanate (67hγ) 
The general procedure B1 was followed using tryptophan 56h (200 mg) and 1,4-
dibromobenzene (28γ, 154 mg) in 4 mL m-xylene. Purification by column chroma-
tography yielded tryptophan 67hγ as a white solid (51 mg, 17%). 
m. p.: 103 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.57–8.53 (m, 1H), 7.63 (ddd, J = 6.9, 1.3, 1.3 Hz, 1H), 7.60–7.55 (m, 
2H), 7.44 (dd, J = 8.3, 1.2 Hz, 2H), 7.25–7.20 (m, 2H), 7.20–7.16 (m, 1H), 7.13–7.09 (m, 2H), 6.73 (dd, 
J = 8.0, 1.0 Hz, 1H), 5.72 (d, J = 8.0 Hz, 1H), 4.83–4.75 (m, 1H), 3.46 (ddd, J = 14.7, 6.1, 1.1 Hz, 1H), 
3.41 (ddd, J = 14.7, 5.3, 1.1 Hz, 1H), 3.34 (d, J = 1.1 Hz, 3H), 1.71 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.2 (Cq), 169.7 (Cq), 151.4 (Cq), 149.3 (CH), 138.1 (CH), 137.3 (Cq), 
136.3 (Cq), 132.1 (CH), 132.0 (CH), 131.0 (Cq), 129.0 (Cq), 123.9 (CH), 122.4 (Cq), 121.9 (CH), 121.9 
(CH), 121.6 (CH), 119.2 (CH), 111.6 (CH), 111.2 (Cq), 52.7 (CH), 52.3 (CH3), 26.8 (CH2), 23.2 (CH3). 
IR (ATR): 2952, 2922, 1740, 1653, 1468, 1454, 1435, 1368, 1212, 1009, 742, 729 cm‒1. 
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MS (ESI) m/z (relative intensity) 1009/1007 (36) [2M+Na]+, 987/985 (2) [2M+H]+, 516/514 (81) 
[M+Na]+, 494/492 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C25H2379BrN3O3+ 492.0917 [M+H]+, found 492.0912. 
 
5.3.3 Analytical Data for Arylated β3-homo-Tryptophans 121 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(benzoic acid methyl ester-4-yl)-β3-homo-L-
tryptophanate (121ad) 
The general procedure B2 was followed using tryptophan 120a (100 mg) and 
methyl 4-bromobenzoate (28d, 58 mg). Purification by column chromato-
graphy (hexanes/EtOAc 1:1) yielded tryptophan 121ad as a white solid 
(72 mg, 54%). 
m. p.: 96 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.56‒8.47 (m, 1H), 7.95 (dm, J = 8.3 Hz, 2H), 7.83 (d, J = 6.5 Hz, 1H), 
7.63 (ddd, J = 6.9, 2.3, 2.3 Hz, 1H), 7.53 (ddd, J = 7.8, 7.8, 1.9 Hz, 1H), 7.31 (dm, J = 8.3 Hz, 2H), 
7.27‒7.19 (m, 2H), 7.13 (dd, J = 7.4, 4.9 Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 5.13‒5.02 (m, 1H), 4.36‒4.22 
(m, 1H), 3.89 (s, 3H), 3.37 (s, 3H), 3.28‒3.17 (m, 1H), 3.12 (dd, J = 13.9, 8.3 Hz, 1H), 2.37‒2.19 (m, 2H), 
1.34 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ = 166.5 (Cq), 155.0 (Cq), 151.4 (Cq), 149.0 (CH), 137.6 (CH), 137.4 (Cq), 
136.6 (Cq), 135.9 (Cq), 135.2 (Cq), 130.3 (CH), 129.7 (CH), 129.5 (CH), 129.0 (Cq), 128.5 (Cq), 123.8 
(CH), 121.4 (CH), 121.4 (CH), 119.8 (CH), 113.8 (Cq), 111.3 (CH), 79.1 (Cq), 52.2 (CH3), 51.4 (CH3), 48.0 
(CH), 37.0 (CH2), 29.4 (CH2), 28.3 (CH3). 
IR (ATR): 2954, 2924, 2853, 1706, 1469, 1455, 1435, 1365, 1162, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 566 (100) [M+Na]+, 544 (62) [M+H]+, 488 (57), 432 (33). 
HR-MS (ESI) m/z calcd for C31H34N3O6+ 544.2442 [M+H]+, found 544.2448. 
 
Benzyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(benzoic acid methyl ester-4-yl)-β3-homo-L-
tryptophanate (121bd) 
The general procedure B2 was followed using tryptophan 120b (100 mg) and 
methyl 4-bromobenzoate (28d, 58 mg). Purification by column chromato-
graphy (hexanes/EtOAc 1:1) yielded tryptophan 121bd as a white solid 
(52 mg, 32% and 21 mg, 13% when procedure B2 was followed). 
m. p.: 92 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.54 (dd, J = 4.8, 1.9 Hz, 1H), 7.98–7.92 (m, 2H), 7.80 (d, J = 7.8 Hz, 
1H), 7.66 (d, J = 8.2 Hz, 1H), 7.54 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.35–7.29 (m, 4H), 7.29–7.20 (m, 3H), 
7.17–7.13 (m, 1H), 6.76 (d, J = 8.1 Hz, 1H), 5.01 (d, J = 9.2 Hz, 1H), 4.93 (d, J = 12.3 Hz, 1H), 4.80 (d, J = 
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12.4 Hz, 1H), 4.33 (ddd, J = 8.2, 8.2, 3.7 Hz, 1H), 3.90 (s, 3H), 3.26–3.10 (m, 2H), 2.45–2.31 (m, 2H), 
1.35 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 171.6 (Cq), 166.8 (Cq), 155.2 (Cq), 151.6 (Cq), 149.3 (CH), 137.9 (CH), 
137.6 (Cq), 136.9 (Cq), 136.1 (Cq), 135.7 (Cq), 130.5 (CH), 129.8 (CH), 129.3 (Cq), 128.8 (Cq), 128.7 
(CH), 128.3 (CH), 128.2 (CH), 124.0 (CH), 121.7 (CH), 121.6 (CH), 120.0 (CH), 114.1 (Cq), 111.5 (CH), 
79.3 (Cq), 66.3 (CH2), 52.4 (CH3), 48.2 (CH), 37.5 (CH2), 29.4 (CH2), 28.4 (CH3). 
IR (ATR): 2979, 1716, 1469, 1455, 1436, 1364, 1275, 1163, 1103, 770, 742, 697 cm‒1. 
MS (ESI) m/z (relative intensity) 1261 (2) [2M+Na]+, 1239 (2) [2M+H]+, 642 (100) [M+Na]+, 620 (51) 
[M+H]+, 564 (45) [M–Hpy+Na]+, 520 (16) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C37H38N3O6+ 620.2755 [M+H]+, found 620.2752. 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(3,4,5-trimethoxyphenyl)-β3-homo-L-tryptophanate 
(121ax) 
The general procedure B2 was followed using tryptophan 120a (100 mg) and 5-
bromo-1,2,3-trimethoxybenzene (28x, 67 mg). Purification by column chroma-
tography (hexanes/EtOAc 1:1) yielded tryptophan 121ax as a white solid 
(67 mg, 48%). 
m. p.: 87 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.59 (dd, J = 4.8, 1.8 Hz, 1H), 7.81 (d, J = 6.7 Hz, 1H), 7.69–7.61 (m, 
1H), 7.56 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.30–7.20 (m, 2H), 7.17 (dd, J = 7.4, 5.0 Hz, 1H), 6.74 (d, J = 
8.0 Hz, 1H), 6.46 (s, 2H), 5.18–5.08 (m, 1H), 4.31 (dddd, J = 8.8, 7.0, 7.0, 3.8 Hz, 1H), 3.86 (s, 3H), 3.69 
(s, 6H), 3.45 (s, 3H), 3.25–3.18 (m, 2H), 2.38–2.33 (m, 2H), 1.38 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 155.2 (Cq), 153.1 (Cq), 152.1 (Cq), 148.9 (CH), 137.7 (CH), 137.6 (Cq), 
137.1 (Cq), 128.7 (Cq), 127.1 (Cq), 123.5 (CH), 121.7 (CH), 121.4 (CH), 119.6 (CH), 112.6 (Cq), 111.5 
(CH), 107.9 (CH), 61.1 (CH3), 56.3 (CH3), 51.5 (CH), 48.2 (CH2), 37.2 (CH2), 28.5 (CH3). 
IR (ATR): 2938, 1704, 1585, 1502, 1457, 1436, 1237, 1163, 1123, 1004, 744 cm‒1. 
MS (ESI) m/z (relative intensity) 1173 (32) [2M+Na]+, 1151 (15) [2M+H]+, 598 (100) [M+Na]+, 576 (89) 
[M+H]+, 520 (84), 476 (31) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C32H38N3O7+ 576.2704 [M+H]+, found 576.2699. 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(4-fluorophenyl)-β3-homo-L-tryptophanate (121ak) 
The general procedure B2 was followed using tryptophan 120a (100 mg) and 1-
bromo-4-fluorobenzene (28k, 47 mg). Purification by column chromatography 
(hexanes/EtOAc 1:1) yielded tryptophan 121ak as a white solid (109 mg, 89%). 
m. p.: 75 °C. 
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1H NMR (300 MHz, CDCl3): δ = 8.59‒8.54 (m, 1H), 7.86‒7.78 (m, 1H), 7.69‒7.61 (m, 1H), 7.56 (ddd, J = 
7.8, 7.8, 1.9 Hz, 1H), 7.30‒7.20 (m, 4H), 7.16 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.06‒6.97 (m, 2H), 6.75 
(dd, J = 8.0, 1.0 Hz, 1H), 5.10 (d, J = 9.3 Hz, 1H), 4.31 (td, J = 9.0, 8.3, 4.2 Hz, 1H), 3.45 (s, 3H), 
3.23‒3.05 (m, 2H), 2.33 (dd, J = 5.4, 3.0 Hz, 2H), 1.38 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ = 162.2 (d, 1JCF = 248.1 Hz, Cq), 155.1 (Cq), 151.6 (Cq), 149.0 (CH), 137.6 
(CH), 137.1 (Cq), 136.0 (Cq), 132.3 (d, 3JCF = 8.1 Hz, CH), 128.5 (Cq), 128.0 (Cq), 127.9 (d, 4JCF = 3.1 Hz, 
Cq), 123.5 (CH), 121.5 (CH), 121.4 (CH), 119.6 (CH), 115.5 (d, 2JCF = 21.5 Hz, CH), 112.9 (Cq), 111.3 
(CH), 79.1 (Cq), 51.4 (CH), 47.9 (CH3), 36.9 (CH2), 29.6 (CH2), 28.3 (CH3). 
19F NMR (376 MHz, CDCl3): δ = ‒113.5 (m). 
IR (ATR): 2954, 2854, 1706, 1588, 1468, 1455, 1436, 1365, 1158, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 526 (100) [M+Na]+, 504 (28) [M+H]+, 448 (41), 404 (20) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C29H31FN3O4+ 504.2293 [M+H]+, found 504.2289. 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(4-anilino)-β3-homo-L-tryptophanate (121ag) 
The general procedure B2 was followed using tryptophan 120a (100 mg) and 4-
bromoaniline (28g, 46 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 121ag as a white solid (117 mg, 96%). 
m. p.: 95 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.57 (dd, J = 5.0, 1.9 Hz, 1H), 7.81‒7.67 (m, 1H), 7.68 (dd, J = 6.3, 
3.1 Hz, 1H), 7.53‒7.49 (m, 1H), 7.21 (dm, J = 8.4 Hz, 2H), 7.12 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.01 (dm, 
J = 8.4 Hz, 2H), 6.70 (d, J = 8.1 Hz, 1H), 6.61 (d, J = 7.9 Hz, 2H), 5.06 (d, J = 8.5 Hz, 1H), 4.29 (dd, J = 8.8, 
5.8 Hz, 1H), 3.59 (br s, 2H), 3.46 (s, 3H), 3.19‒3.07 (m, 2H), 2.32 (d, J = 5.6 Hz, 2H), 1.38 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 155.0 (Cq), 151.9 (Cq), 148.6 (CH), 145.6 (Cq), 137.5 (Cq), 
137.3 (CH), 136.8 (Cq), 131.5 (CH), 128.7 (Cq), 122.8 (CH), 121.7 (Cq), 121.6 (CH), 121.0 (CH), 120.9 
(CH), 119.2 (CH), 115.0 (CH), 111.8 (Cq), 111.4 (CH), 79.0 (Cq), 51.4 (CH), 48.1 (CH2), 37.3 (CH2), 29.4 
(CH3), 28.4 (CH3). 
IR (ATR): 3437, 2976, 1698, 1509, 1468, 1455, 1435, 1365, 1047, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 523 (100) [M+Na]+, 501 (41) [M+H]+, 445 (38), 401 (20) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C29H33N4O4+ 501.2496 [M+H]+, found 501.2495. 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-[4-(1-pyrenyl)phenyl]-β3-homo-L-tryptophanate (121aq) 
The general procedure B2 was followed using tryptophan 120a (95 mg) 
and 1-(4-bromophenyl)pyrene (28q, 96 mg). Purification by column 
chromatography (hexanes/EtOAc 1:1) yielded tryptophan 121aq as a white 
solid (45 mg, 28%). 
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m. p.: 84 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.65 (dd, J = 4.9, 1.8 Hz, 1H), 8.22 (dd, J = 10.0, 7.6 Hz, 2H), 8.20‒8.17 
(m, 2H), 8.11‒8.10 (m, 2H), 8.07 (d, J = 9.3 Hz, 1H), 8.03 (dd, J = 7.6, 7.6 Hz, 1H), 7.99 (d, J = 7.8 Hz, 
1H), 7.93‒7.88 (m, 1H), 7.78‒7.73 (m, 1H), 7.65 (ddd, J = 7.8, 7.8, 2.1 Hz, 1H), 7.61 (d, J = 7.9 Hz, 2H), 
7.46 (d, J = 7.9 Hz, 2H), 7.30 (ddd, J = 7.2, 6.5, 3.8 Hz, 2H), 7.22 (dd, J = 7.5, 4.9 Hz, 1H), 6.91 (d, J = 8.0 
Hz, 1H), 5.23 (d, J = 9.1 Hz, 1H), 4.49‒4.40 (m, 1H), 3.47 (s, 3H), 3.39‒3.28 (m, 2H), 2.47‒2.44 (m, 2H), 
1.42 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 172.2 (Cq), 155.3 (Cq), 151.9 (Cq), 149.1 (CH), 140.5 (Cq), 137.6 (CH), 
137.4 (Cq), 136.9 (Cq), 131.5 (Cq), 131.0 (Cq), 130.9 (Cq), 130.8 (Cq), 130.7 (CH), 130.6 (CH), 128.8 (Cq), 
128.5 (Cq), 127.7 (CH), 127.7 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 126.1 (CH), 125.3 (CH), 125.1 
(Cq), 125.0 (CH), 125.0 (CH), 124.9 (Cq), 124.7 (CH), 123.6 (CH), 121.8 (CH), 121.5 (CH), 119.7 (CH), 
113.2 (Cq), 111.6 (CH), 79.3 (Cq), 53.6 (CH), 51.6 (CH3), 37.3 (CH2), 29.9 (CH2), 28.6 (CH3). 
IR (ATR): 2963, 1705, 1468, 1455, 1435, 1364, 1164, 1047, 1019, 844, 780, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 1394 (32) [2M+Na]+, 1372 (47) [2M+H]+, 708 (74) [M+Na]+, 686 (100) 
[M+H]+, 630 (62), 586 (13) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C45H40N3O4+ 686.3013 [M+H]+, found 686.3017. 
 
5.3.4 Analytical Data for Arylated Peptides 102 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(benzoic acid methyl ester-4-yl)-L-tryptophylglycyl-L-
tryptophanate (102bd) 
The general procedure B3 was followed using peptide 101b (100 mg) and 
methyl 4-bromobenzoate (28d, 37 mg). Purification by column chromato-
graphy (EtOAc) yielded peptide 102bd as a white solid (78 mg, 64%). 
m. p.: 121 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.55‒8.47 (m, 1H), 7.94 (dm, J = 8.4 Hz, 2H), 7.77‒7.69 (m, 1H), 
7.65‒7.51 (m, 2H), 7.51‒7.41 (m, 1H), 7.41‒7.35 (m, 1H), 7.29 (dm, J = 8.4 Hz, 2H), 7.27‒7.20 (m, 4H), 
7.19‒7.08 (m, 2H), 7.03 (ddd, J = 9.1, 5.4, 2.6 Hz, 1H), 6.86‒6.79 (m, 1H), 6.64‒6.56 (m, 1H), 
6.50‒6.40 (m, 1H), 4.96‒4.80 (m, 1H), 4.78‒4.68 (m, 1H), 4.44‒4.27 (m, 1H), 3.88 (s, 3H), 3.60 (s, 3H), 
3.51‒3.39 (m, 1H), 3.39‒3.27 (m, 2H), 3.27‒3.15 (m, 2H), 1.24 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 171.8 (Cq), 166.6 (Cq), 166.1 (Cq), 151.3 (Cq), 149.1 (CH), 
138.0 (CH), 137.4 (Cq), 136.2 (Cq), 136.1 (Cq), 134.3 (CH), 131.4 (Cq), 130.3 (CH), 129.8 (CH), 129.4 
(Cq), 128.3 (Cq), 128.2 (Cq), 128.2 (Cq), 127.3 (Cq), 124.1 (CH), 123.6 (CH), 123.3 (CH), 122.1 (CH), 
121.8 (CH), 121.6 (CH), 119.5 (CH), 118.3 (CH), 114.1 (CH), 111.4 (CH), 109.2 (Cq), 80.4 (Cq), 55.7 (CH), 
55.1 (CH), 52.4 (CH3), 52.2 (CH3), 43.2 (CH2), 34.0 (CH2), 28.2 (CH3), 27.2 (CH2). 
IR (ATR): 3327, 1714, 1661, 1611, 1513, 1469, 1455, 1436, 1276, 741 cm‒1. 
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MS (ESI) m/z (relative intensity) 795 (81) [M+Na]+, 773 (27) [M+H]+, 721 (100). 
HR-MS (ESI) m/z calcd for C43H45N6O8+ 773.3293 [M+H]+, found 773.3281. 
 
Benzyl tert-butoxycarbonyl-L-leucyl-L-alanyl-1-(2-pyridyl)-2-(benzoic acid methyl ester-4-yl)-β3-
homo-L-tryptophanate (102cd) 
The general procedure B3 was followed using peptide 101c (50 mg) and 
methyl 4-bromobenzoate (28d, 17 mg). Purification by column chromato-
graphy (EtOAc) yielded peptide 102cd as a white solid (39 mg, 65%). 
m. p.: 88 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.56 (dd, J = 5.0, 1.9 Hz, 1H), 7.97 (dm, J = 8.5 Hz, 2H), 7.86‒7.84 (m, 
1H), 7.67‒7.64 (m, 1H), 7.55 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.36 (dm, J = 8.5 Hz, 2H), 7.35‒7.28 (m, 
5H), 7.28‒7.22 (m, 4H), 7.16 (dd, J = 7.4, 4.9 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.54 (d, J = 7.3 Hz, 1H), 
5.03 (d, J = 7.9 Hz, 1H), 4.94 (d, J = 12.4 Hz, 1H), 4.77 (d, J = 12.3 Hz, 1H), 4.61 (tt, J = 11.5, 4.6 Hz, 1H), 
4.26 (tt, J = 7.1, 7.1 Hz, 1H), 4.12‒4.06 (m, 1H), 3.90 (s, 3H), 3.24 (dd, J = 14.2, 5.8 Hz, 1H), 3.15 (dd, 
J = 14.2, 9.0 Hz, 1H), 2.41 (dd, J = 16.8, 5.4 Hz, 1H), 2.37 (dd, J = 16.8, 5.4 Hz, 1H), 1.27 (s, 9H), 1.17 (d, 
J = 7.0 Hz, 3H), 0.95 (d, J = 2.2 Hz, 3H), 0.94 (d, J = 2.3 Hz, 3H), 0.89 (t, J = 7.0 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 172.1 (Cq), 171.1 (Cq), 171.1 (Cq), 166.5 (Cq), 156.8 (Cq), 151.3 (Cq), 
149.0 (CH), 137.7 (CH), 137.4 (Cq), 136.5 (Cq), 136.0 (Cq), 135.3 (Cq), 130.3 (CH), 129.6 (CH), 129.5 
(Cq), 129.1 (Cq), 128.5 (Cq), 128.4 (CH), 128.1 (CH), 128.0 (CH), 128.0 (CH), 123.9 (CH), 121.7 (CH), 
121.5 (CH), 119.6 (CH), 113.4 (Cq), 111.5 (CH), 66.2 (CH2), 52.2 (CH), 48.9 (CH), 47.0 (CH3), 41.2 (CH2), 
36.6 (CH2), 29.0 (CH2), 28.4 (CH3), 24.8 (CH3), 23.1 (CH3), 21.9 (CH), 18.1 (CH). 
IR (ATR): 3315, 2954, 2923, 2853, 1720, 1646, 1468, 1455, 1436, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 826 (100) [M+Na]+, 804 (20) [M+H]+, 752 (20). 
HR-MS (ESI) m/z calcd for C46H53N5O8Na+ 826.3786 [M+Na]+, found 826.3781. 
 
Ethyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(4-fluorophenyl)-L-tryptophyl-L-leucyl-L-tryptophanate 
(102dk) 
The general procedure B3 was followed using peptide 101d (100 mg) and 1-
bromo-4-fluorobenzene (28k, 27 mg). Purification by column chromatography 
(EtOAc) yielded peptide 102dk as a white solid (58 mg, 51%). 
m. p.: 117 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.64‒8.59 (m, 1H), 8.58‒8.55 (m, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.63 (d, 
J = 7.8 Hz, 1H), 7.59 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.52‒7.46 (m, 1H), 7.31‒7.20 (m, 6H), 7.19 (dd, J = 
7.4, 4.8 Hz, 1H), 7.13 (dd, J = 7.5, 7.5 Hz, 1H), 7.07 (dd, J = 7.4, 7.4 Hz, 1H), 7.02 (ddd, J = 8.6, 8.6, 
2.9 Hz, 2H), 6.87‒6.83 (m, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.68‒6.61 (m, 1H), 6.37 (d, J = 8.0 Hz, 1H), 
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4.82‒4.75 (m, 1H), 4.58 (d, J = 7.7 Hz, 1H), 4.33 (q, J = 7.7 Hz, 2H), 4.10 (ddddd, J = 18.0, 14.0, 11.1, 
7.0, 3.7 Hz, 1H), 3.38 (ddd, J = 14.9, 5.9, 2.1 Hz, 1H), 3.31 (dd, J = 14.9, 5.3 Hz, 1H), 3.27‒3.19 (m, 2H), 
1.88 (br s, 1H), 1.55 (dt, J = 13.9, 7.2 Hz, 1H), 1.47‒1.40 (m, 1H), 1.30 (s, 9H), 1.21 (t, J = 7.1 Hz, 2H), 
0.81 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 171.5 (Cq), 170.7 (Cq), 162.4 (d, 1JCF = 249.0 Hz, Cq), 151.4 
(Cq), 149.0 (CH), 137.9 (CH), 137.1 (Cq), 136.7 (Cq), 136.03 (Cq), 136.01 (Cq), 132.4 (d, 3JCF = 8.1 Hz, 
CH), 128.2 (Cq), 127.6 (d, 4JCF = 3.4 Hz, Cq), 127.4 (Cq), 123.4 (CH), 123.3 (CH), 121.9 (CH), 121.73 (CH), 
121.66 (CH), 121.55 (CH), 119.4 (CH), 118.4 (CH), 118.3 (CH), 115.9 (d, 2JCF = 21.6 Hz, CH), 115.7 (CH), 
111.30 (CH), 109.4 (Cq), 109.3 (Cq), 80.6 (Cq), 61.5 (CH2), 52.6 (CH), 52.4 (CH), 51.5 (CH), 40.3 (CH2), 
28.1 (CH3), 27.4 (CH2), 26.6 (CH2), 24.6 (CH), 22.6 (CH3), 22.3 (CH3), 14.0 (CH3). 
19F NMR (376 MHz, CDCl3): δ = ‒112.6 (m). 
IR (ATR): 3325, 1645, 1505, 1469, 1455, 1436, 1221, 1157, 839, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 825 (100) [M+Na]+, 803 (29) [M+H]+, 789 (20). 
HR-MS (ESI) m/z calcd for C46H52N6O6F+ 803.3927 [M+H]+, found 803.3920. 
 
Ethyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(benzoic acid methyl ester-4-yl)-L-tryptophyl-L-
tryptophylglycinate (102ed) 
The general procedure B3 was followed using peptide 101e (100 mg) and 
methyl 4-bromobenzoate (28d, 36 mg). Purification by column chromato-
graphy (EtOAc) yielded peptide 102ed as a white solid (84 mg, 70%). 
m. p.: 137 °C. 
1H NMR (500 MHz, CDCl3): δ = 9.13 (s, 1H), 8.71‒8.64 (m, 1H), 7.93 (dm, J = 7.8 Hz, 2H), 7.79 (d, J = 
7.9 Hz, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.57 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.37‒7.19 (m, 6H),  7.17 (dm, 
J = 7.8 Hz, 2H), 7.11 (dd, J = 7.6, 7.6 Hz, 1H), 7.00 (dd, J = 7.6, 7.6 Hz, 1H), 6.85‒6.78 (m, 1H), 6.71 (d, 
J = 8.0 Hz, 1H), 6.36‒6.30 (m, 1H), 6.17 (d, J = 7.2 Hz, 1H), 4.45 (q, J = 6.6 Hz, 1H), 4.26‒4.16 (m, 1H), 
4.11 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 3.89‒3.85 (m, 1H), 3.77 (dd, J = 17.9, 5.8 Hz, 1H), 3.47 (dd, J = 
15.0, 6.0 Hz, 1H), 3.28‒3.16 (m, 2H), 2.87 (dd, J = 15.0, 6.0 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H), 1.09 (s, 
9H). 
13C NMR (125 MHz, CDCl3): δ = 171.5 (Cq), 169.3 (Cq), 166.4 (Cq), 155.4 (Cq), 151.2 (Cq), 148.9 (CH), 
138.1 (CH), 137.3 (Cq), 136.1 (Cq), 136.0 (Cq), 135.9 (Cq), 130.4 (CH), 130.0 (CH), 129.6 (Cq), 128.4 
(Cq), 128.3 (Cq), 127.5 (Cq), 124.3 (CH), 123.4 (CH), 122.0 (CH), 121.8 (CH), 121.8 (CH), 121.7 (CH), 
120.1 (CH), 119.5 (CH), 118.1 (CH), 111.9 (Cq), 111.5 (CH), 111.1 (CH), 108.9 (Cq), 80.1 (Cq), 61.1 
(CH2), 55.3 (CH), 53.6 (CH), 52.3 (CH3), 41.2 (CH2), 28.3 (CH3), 27.8 (CH), 26.1 (CH2), 26.0 (CH2), 14.1 
(CH3). 
IR (ATR): 3341, 1720, 1660, 1469, 1455, 1435, 1366, 1276, 1163, 741 cm‒1. 
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MS (ESI) m/z (relative intensity) 809 (100) [M+H]+, 787 (5). 
HR-MS (ESI) m/z calcd for C44H47N6O8+ 809.3269 [M+H]+, found 809.3270. 
Benzyl tert-butoxycarbonyl-L-leucyl-L-alanyl-1-(2-pyridyl)-2-(6-indolyl)-β3-homo-L-tryptophanate 
(102cz) 
The general procedure B3 was followed using peptide 101c (50 mg) and 6-
bromoindole (28z, 16 mg). Purification by column chromatography (1% Et3N 
in EtOAc) yielded peptide 102cz as a white solid (41 mg, 70%). 
m. p.: 122 °C. 
1H NMR (600 MHz, CDCl3): δ = 9.21 (s, 1H), 8.51 (dd, J = 4.9, 1.9 Hz, 1H), 7.70 (dd, J = 15.2, 7.9 Hz, 
2H), 7.52 (d, J = 8.1 Hz, 1H), 7.39‒7.32 (m, 2H), 7.32‒7.25 (m, 3H), 7.24‒7.19 (m, 3H), 7.17 (ddd, J = 
7.4, 7.4, 1.2 Hz, 1H), 7.04 (ddd, J = 7.4, 4.8, 1.0 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 6.72‒6.65 (m, 2H), 
6.48 (dd, J = 2.5, 2.5 Hz, 1H), 6.21 (s, 1H), 4.98 (d, J = 8.4 Hz, 1H), 4.89 (d, J = 12.3 Hz, 1H), 4.80 (d, J = 
12.3 Hz, 1H), 4.59‒4.51 (m, 1H), 4.10 (tt, J = 7.0, 7.0 Hz, 1H), 4.05‒3.96 (m, 1H), 3.17 (dd, J = 14.4, 
6.9 Hz, 1H), 3.06 (dd, J = 14.4, 7.3 Hz, 1H), 2.50 (dd, J = 16.2, 5.4 Hz, 1H), 2.42 (dd, J = 16.3, 6.0 Hz, 
1H), 2.09 (br s, 1H), 1.62 (dp, J = 19.7, 6.5 Hz, 1H), 1.53 (td, J = 11.3, 9.3, 5.0 Hz, 1H), 1.46‒1.41 (m, 
1H), 1.38 (s, 9H), 0.96 (d, J = 7.1 Hz, 3H), 0.87 (d, J = 6.5 Hz, 6H). 
13C NMR (125 MHz, CDCl3): δ = 172.3 (Cq), 171.2 (Cq), 171.2 (Cq), 155.7 (Cq), 151.9 (Cq), 148.6 (CH), 
138.5 (Cq), 137.5 (CH), 136.9 (Cq), 135.8 (Cq), 135.6 (Cq), 128.7 (Cq), 128.5 (CH), 128.3 (CH), 128.1 
(CH), 127.5 (Cq), 125.8 (CH), 124.7 (Cq), 123.1 (CH), 122.1 (CH), 121.5 (CH), 121.2 (CH), 121.0 (CH), 
120.7 (CH), 118.8 (CH), 113.7 (CH), 112.1 (Cq), 111.7 (CH), 102.1 (CH), 80.1 (Cq), 66.2 (CH2), 53.1 (CH), 
48.8 (CH), 47.6 (CH), 40.9 (CH2), 37.7 (CH2), 29.0 (CH2), 28.2 (CH3), 24.6 (CH), 23.0 (CH3), 21.7 (CH3), 
18.5 (CH3). 
IR (ATR): 3294, 2955, 1645, 1513, 1468, 1453, 1436, 1366, 1248, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 807 (100) [M+Na]+, 785 (24) [M+H]+, 717 (6). 
HR-MS (ESI) m/z calcd for C46H53N6O6+ 785.4021 [M+H]+, found 785.4021. 
 
Methyl tert-butoxycarbonyl-glycyl-1-(2-pyridyl)-2-(6-indolyl)-L-tryptophylglycinate (102fz) 
The general procedure B3 was followed using peptide 101f (50 mg) and 6-
bromoindole (28z, 21 mg). Purification by column chromatography (1% Et3N in 
EtOAc) yielded peptide 102fz as a white solid (38 mg, 62%). 
m. p.: 126 °C. 
1H NMR (600 MHz, CDCl3): δ = 9.35 (s, 1H), 8.49 (dd, J = 5.2, 1.9 Hz, 1H), 7.68 (ddd, J = 15.4, 7.3, 
1.8 Hz, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.42 (s, 1H), 7.41‒7.35 (m, 1H), 7.20 (ddddd, J = 7.1, 7.1, 7.1, 7.1, 
1.4 Hz, 2H), 7.14 (dd, J = 2.8, 2.8 Hz, 1H), 7.08 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.96 (s, 1H), 6.80 (dd, J = 
8.1, 1.5 Hz, 1H), 6.66 (dd, J = 17.2, 8.0 Hz, 2H), 6.46‒6.42 (m, 1H), 5.19‒5.12 (m, 1H), 4.77 (q, J = 
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7.2 Hz, 1H), 3.83 (dd, J = 18.0, 5.7 Hz, 1H), 3.65‒3.58 (m, 1H), 3.57 (s, 3H), 3.44‒3.36 (m, 3H), 3.30 
(dd, J = 14.7, 7.2 Hz, 1H), 1.38 (s, 9H). 
13C NMR (75 MHz, CDCl3): δ = 171.4 (Cq), 169.8 (Cq), 169.4 (Cq), 156.1 (Cq), 151.9 (Cq), 148.6 (CH), 
138.9 (Cq), 137.7 (CH), 137.0 (Cq), 135.8 (Cq), 128.7 (Cq), 127.4 (Cq), 125.8 (CH), 124.5 (Cq), 123.1 
(CH), 121.9 (CH), 121.7 (CH), 121.2 (CH), 121.2 (CH), 120.6 (CH), 118.8 (CH), 113.4 (CH), 111.6 (CH), 
111.0 (Cq), 102.0 (CH), 80.1 (Cq), 54.1 (CH), 52.2 (CH3), 43.8 (CH2), 41.2 (CH2), 28.2 (CH3), 27.8 (CH2). 
IR (ATR): 3300, 1747, 1652, 1506, 1469, 1454, 1436, 1365, 1162, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 647 (100) [M+Na]+, 625 (75) [M+H]+, 304 (22). 
HR-MS (ESI) m/z calcd for C34H37N6O6+ 625.2769 [M+H]+, found 625.2766. 
 
Ethyl tert-butoxycarbonyl-1-(2-pyridyl)-2-[4-(1-pyrenyl)phenyl]-L-tryptophyl-L-leucyl-L-
tryptophanate (102dq) 
The general procedure B3 was followed using peptide 101d (100 mg) and 1-
(4-bromophenyl)pyrene (28q, 55 mg). Purification by column chromato-
graphy (EtOAc) yielded peptide 102dq as a white solid (80 mg, 58%). 
m. p.: 120 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.66 (dd, J = 5.0, 1.9 Hz, 1H), 8.53 (s, 1H), 8.22 (dd, J = 7.6, 1.4 Hz, 2H), 
8.17 (d, J = 7.5 Hz, 1H), 8.13 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 1.4 Hz, 2H), 8.05‒8.01 (m, 2H), 7.96 (d, 
J = 7.8 Hz, 1H), 7.78 (dd, J = 7.7, 1.3 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.68 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 
7.63‒7.60 (m, 2H), 7.51‒7.47 (m, 3H), 7.30 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 7.28‒7.23 (m, 4H), 
7.13‒7.10 (m, 1H), 7.08‒7.05 (m, 1H), 6.96 (d, J = 8.0 Hz, 1H), 6.90‒6.86 (m, 1H), 6.69 (d, J = 6.0 Hz, 
1H), 6.47 (d, J = 8.2 Hz, 1H), 4.81 (dt, J = 7.8, 5.7 Hz, 1H), 4.75 (d, J = 7.6 Hz, 1H), 4.49 (d, J = 7.5 Hz, 
1H), 4.39 (q, J = 7.7 Hz, 1H), 4.10 (qq, J = 10.8, 7.1 Hz, 2H), 3.56 (dd, J = 14.9, 6.0 Hz, 1H), 3.52‒3.45 
(m, 1H), 3.32 (dd, J = 15.0, 5.1 Hz, 1H), 3.21 (dd, J = 14.8, 6.6 Hz, 1H), 1.60 (dt, J = 13.9, 7.2 Hz, 1H), 
1.50 (dt, J = 13.4, 6.6 Hz, 1H), 1.31 (s, 9H), 1.19 (t, J = 7.1 Hz, 3H), 0.83 (d, J = 6.2 Hz, 3H), 0.82 (d, J = 
6.2 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 171.6 (Cq), 171.4 (Cq), 170.7 (Cq), 155.5 (Cq), 151.6 (Cq), 148.9 (CH), 
140.8 (Cq), 137.6 (CH), 137.5 (Cq), 137.3 (Cq), 136.6 (Cq), 136.0 (Cq), 131.4 (Cq), 130.8 (Cq), 130.8 (CH), 
130.7 (Cq), 130.5 (CH), 130.4 (Cq), 128.3 (Cq), 128.3 (Cq), 127.6 (CH), 127.5 (CH), 127.4 (CH), 127.4 
(Cq), 127.3 (CH), 126.0 (CH), 125.2 (CH), 124.9 (Cq), 124.9 (CH), 124.8 (CH), 124.8 (Cq), 124.6 (CH), 
123.6 (CH), 123.2 (CH), 121.8 (CH), 121.8 (CH), 121.6 (CH), 121.5 (CH), 119.3 (CH), 119.2 (CH), 118.3 
(CH), 111.6 (CH), 111.3 (Cq), 111.2 (CH), 109.4 (Cq), 80.5 (Cq), 61.5 (CH2), 52.7 (CH), 51.7 (CH), 40.5 
(CH2), 28.2 (CH3), 27.5 (CH2), 27.0 (CH2), 27.0 (CH), 24.7 (CH), 22.6 (CH3), 22.4 (CH3), 14.1 (CH3). 
IR (ATR): 3412, 3050, 2958, 1651, 1469, 1455, 1436, 1366, 1021, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 1007 (100) [M+Na]+, 985 (26) [M+H]+, 885 (4) [M–Boc+H]+. 
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HR-MS (ESI) m/z calcd for C62H61N6O6+ 985.4647 [M+H]+, found 985.4625. 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-[4-(1-pyrenyl)phenyl]-L-tryptophylglycyl-L-
tryptophanate (102bq) 
The general procedure B3 was followed using peptide 101b (65 mg) and 1-
(4-bromophenyl)pyrene (28q, 40 mg). Purification by column chromato-
graphy (EtOAc) yielded peptide 102bq as a white solid (10 mg, 10%). 
m. p.: 132 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.66‒8.60 (m, 1H), 8.26‒8.19 (m, 2H), 8.19‒8.13 (m, 1H), 8.13‒8.07 
(m, 2H), 8.07‒8.00 (m, 2H), 8.00‒7.92 (m, 2H), 7.80‒7.75 (m, 1H), 7.72‒7.65 (m, 2H), 7.62‒7.56 (m, 
2H), 7.47‒7.43 (m, 2H), 7.43‒7.39 (m, 1H), 7.31‒7.23 (m, 4H), 7.13‒7.08 (m, 1H), 7.06‒7.02 (m, 1H), 
6.98‒6.93 (m, 1H), 6.90‒6.86 (m, 1H),  4.82‒4.73 (m, 1H), 4.56‒4.48 (m, 1H), 3.90‒3.83 (m, 1H), 3.62 
(s, 3H), 3.61‒3.57 (m, 1H), 3.50‒3.44 (m, 2H), 3.29 (dd, J = 15.0, 5.6 Hz, 1H), 3.22 (dd, J = 15.0, 5.4 Hz, 
1H), 1.36 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ = 172.2 (Cq), 172.0 (Cq), 168.2 (Cq), 161.1 (Cq), 155.7 (Cq), 149.2 (CH), 
141.0 (Cq), 138.0 (CH), 137.4 (Cq), 136.8 (Cq), 136.8 (Cq), 136.2 (Cq), 131.6 (Cq), 131.1 (Cq), 131.0 (CH), 
130.9 (Cq), 130.6 (CH), 130.4 (Cq), 130.4 (CH), 128.5 (Cq), 127.9 (CH), 127.7 (CH), 127.7 (CH), 127.7 
(CH), 127.5 (CH), 127.4 (Cq), 126.2 (CH), 125.4 (CH), 125.1 (CH), 124.8 (CH), 125.0 (Cq), 123.9 (CH), 
123.6 (CH), 122.2 (CH), 122.1 (CH), 121.9 (CH), 121.8 (CH), 121.7 (CH), 119.6 (CH), 119.4 (CH), 118.5 
(CH), 109.2 (Cq), 80.6 (Cq), 54.5 (CH), 52.6 (CH3), 51.5 (CH), 43.5 (CH2), 28.4 (CH3), 27.4 (CH2). 27.2 
(CH2). 
IR (ATR): 2958, 2922, 2853, 1713, 1455, 1437, 1259, 1160, 1090, 1013, 846, 794 cm‒1. 
MS (ESI) m/z (relative intensity) 937 (94) [M+Na]+, 915 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C57H51N6O6+ 915.3865 [M+H]+, found 915.3858. 
 
Benzyl tert-butoxycarbonyl-L-leucyl-L-alanyl-1-(2-pyridyl)-2-(4-bromophenyl)-β3-homo-L-
tryptophanate (102cγ) 
The general procedure B3 was followed using peptide 101c (100 mg) and 1,4-
dibromobenzene (28γ, 39 mg). Purification by column chromatography (EtOAc) 
yielded peptide 102cγ as a white solid (38 mg, 31%). 
m. p.: 131 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.61–8.56 (m, 1H), 7.89–7.82 (m, 1H), 7.80–7.73 (m, 1H), 7.60 (ddd, J = 
7.7, 7.7, 2.0 Hz, 1H), 7.37–7.28 (m, 7H), 7.25–7.17 (m, 3H), 7.17–7.09 (m, 2H), 6.91 (d, J = 8.3, 1H), 
5.43 (d, J = 8.3 Hz, 1H), 4.98 (d, J = 12.2 Hz, 1H), 4.92 (d, J = 12.2 Hz, 1H), 4.57–4.45 (m, 1H), 4.44–4.32 
(m, 1H), 4.32–4.18 (m, 1H), 3.43–3.29 (m, 1H), 3.16 (dd, J = 14.1, 9.9 Hz, 1H), 2.38 (dd, J = 16.1, 
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4.6 Hz, 1H), 2.28–2.12 (m, 1H), 1.84–1.54 (m, 2H), 1.51 (s, 9H), 1.49–1.46 (m, 1H), 1.23 (d, J = 7.0 Hz, 
3H), 1.00 (d, J = 6.3 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.7 (Cq), 171.5 (Cq), 171.5 (Cq), 155.8 (Cq), 151.7 (Cq), 149.1 (CH), 
137.4 (CH), 137.1 (Cq), 136.3 (Cq), 135.6 (Cq), 131.7 (Cq), 130.4 (CH), 128.9 (Cq), 128.6 (CH), 128.6 
(CH), 128.4 (CH), 128.3 (CH), 123.8 (CH), 121.6 (CH), 121.5 (CH), 121.2 (CH), 119.5 (CH), 113.2 (Cq), 
111.6 (CH), 79.9 (Cq), 66.4 (CH2), 53.1 (CH), 49.2 (CH), 46.6 (CH), 41.5 (CH2), 37.3 (CH2), 29.8 (CH2), 
28.5 (CH3), 24.9 (CH), 18.8 (CH3), 14.2 (CH3). 
IR (ATR): 3288, 2957, 2927, 1647, 1518, 1467, 1454, 1436, 1365, 1163, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 826/824 (1) [M+H]+, 731/729 (92), 726/724 (50) [M–Boc+H]+, 
720/718 (100). 
HR-MS (ESI) m/z calcd for C44H5179BrN5O6+ 824.3017 [M+H]+, found 824.3004. 
 
Benzyl tert-butoxycarbonyl-L-leucyl-L-alanyl-1-(2-pyridyl)-2-(4-hydroxyphenyl)-β3-homo-L-
tryptophanate (102cδ) 
The general procedure D2 was followed using tryptophan 101c (10.0 mg) and 
tryptophan 142hk (10.8 mg). Purification by column chromatography (EtOAc) 
yielded peptide 102cδ as a colorless oil (7.5 mg, 61%). 
1H NMR (500 MHz, CDCl3): δ = 8.59–8.54 (m, 1H), 7.65 (ddd, J = 6.8, 5.2, 1.3 Hz, 2H), 7.53 (ddd, J = 
7.6, 7.6, 1.9 Hz, 1H), 7.36–7.29 (m, 3H), 7.28–7.26 (m, 1H), 7.25–7.16 (m, 2H), 7.14 (ddd, J = 5.5, 5.5, 
2.8 Hz, 1H), 7.08 (dm, J = 8.5 Hz, 2H), 6.78 (dm, J = 8.5 Hz, 2H), 6.74 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 
7.1 Hz, 1H), 6.12 (d, J = 6.5 Hz, 1H), 4.99 (d, J = 12.1 Hz, 2H), 4.91 (d, J = 12.3 Hz, 1H), 4.55 (ddd, J = 
8.4, 6.0, 6.0 Hz, 1H), 4.13–4.04 (m, 1H), 3.94–3.86 (m, 1H), 3.30–3.23 (m, 1H), 3.15 (dd, J = 14.5, 
6.0 Hz, 1H), 2.50 (dd, J = 16.2, 5.6 Hz, 1H), 2.41 (dd, J = 16.2, 6.3 Hz, 1H), 1.69–1.60 (m, 2H), 1.28–1.23 
(m, 1H), 1.05 (d, J = 7.0 Hz, 3H), 0.92 (d, J = 6.2 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.2 (Cq), 171.4 (Cq), 171.4 (Cq), 156.6 (Cq), 156.3 (Cq), 151.7 (Cq), 
148.8 (CH), 138.1 (CH), 137.4 (Cq), 137.0 (Cq), 135.7 (Cq), 131.7 (CH), 129.2 (Cq), 128.7 (CH), 128.5 
(CH), 128.4 (CH), 123.6 (Cq), 123.4 (CH), 122.1 (CH), 121.6 (CH), 121.4 (CH), 119.0 (CH), 116.5 (CH), 
111.7 (CH), 111.5 (Cq), 80.9 (Cq), 66.5 (CH2), 53.5 (CH), 48.9 (CH), 47.5 (CH), 41.4 (CH2), 37.6 (CH2), 
29.8 (CH2), 28.5 (CH3), 25.0 (CH), 23.2 (CH3), 21.8 (CH3), 18.9 (CH3). 
IR (ATR): 3285, 2960, 1715, 1683, 1651, 1510, 1468, 1456, 1436, 1366, 1259, 1163, 1019, 745 cm‒1. 
MS (ESI) m/z (relative intensity) 784 (100) [M+Na]+, 762 (41) [M+H]+, 674 (10), 381 (29). 
HR-MS (ESI) m/z calcd for C44H52N5O7+ 762.3861 [M+H]+, found 762.3839. 
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5.3.5 Analytical Data for Ligated Peptides 123, 117, and 126 
(E)-1,2-Bis{4-[methyl acetyl-1-(2-pyridyl)-L-tryptophanate]-2-yl}phenylethene (123) 
Tryptophan 67hz (30.0 mg, 68 µmol) and Grubbs II catalyst 
(2.9 mg, 10 mol %) were stirred in CH2Cl2 (0.3 mL) at 40 °C for 6 h 
under N2. Purification by column chromatography (EtOAc) 
yielded peptide 123 as a white solid (26 mg, 90%). 
m. p.: 179 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 8.56 (ddd, J = 4.9, 1.9, 0.8 Hz, 2H), 8.30 (d, J = 7.8 Hz, 2H), 7.77 
(ddd, J = 7.8, 7.8, 2.0 Hz, 2H), 7.73–7.66 (m, 2H), 7.57 (d, J = 8.4 Hz, 4H), 7.56–7.50 (m, 2H), 7.32 (ddd, 
J = 7.5, 4.9, 1.0 Hz, 2H), 7.25 (d, J = 8.8 Hz, 4H), 7.23–7.16 (m, 6H), 6.97 (ddd, J = 8.1, 0.9, 0.9 Hz, 2H), 
4.55 (ddd, J = 7.3, 7.3, 7.3 Hz, 2H), 3.41 (s, 6H), 3.36–3.12 (m, 4H), 1.75 (s, 6H). 
13C NMR (126 MHz, DMSO-d6): δ = 171.7 (Cq), 168.9 (Cq), 150.8 (Cq), 148.8 (CH), 138.2 (CH), 136.9 
(Cq), 136.6 (Cq), 136.1 (Cq), 130.4 (Cq), 130.2 (CH), 128.3 (CH), 128.0 (Cq), 126.2 (CH), 122.8 (CH), 
121.9 (CH), 121.5 (CH), 120.6 (CH), 118.8 (CH), 111.4 (Cq), 111.1 (CH), 52.7 (CH), 51.6 (CH3), 26.8 
(CH2), 22.2 (CH3). 
IR (ATR): 3322, 2924, 1740, 1649, 1532, 1469, 1455, 1435, 1367, 1248, 1223, 781, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 1723 (3) [2M+Na]+, 1701 (1) [2M+H]+, 873 (100) [M+Na]+, 851 (73) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C52H47N6O6+ 851.3552 [M+H]+, found 851.3551. 
 
1,4-Bis{2-[methyl acetyl-1-(2-pyridyl)]-L-tryptophanate}benzene (117a) 
The general procedure B4 was followed using tryptophan 56h (100 mg), 
1,4-dibromobenzene (28ν, 35 mg) and 5 mol % [Ru]2. Purification by 
column chromatography (1% Et3N in EtOAc) yielded peptide 117a as a 
white solid (101 mg, 91%). 
m. p.: 118 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 8.53 (ddd, J = 5.0, 1.9, 0.8 Hz, 2H), 8.28 (d, J = 7.8 Hz, 2H), 7.78 
(ddd, J = 7.7, 7.7, 2.0 Hz, 2H), 7.72‒7.69 (m, 2H), 7.59‒7.56 (m, 2H), 7.33 (ddd, J = 7.5, 4.9, 1.0 Hz, 
2H), 7.23‒7.18 (m, 8H), 6.88 (ddd, J = 8.1, 1.0, 1.0 Hz, 2H), 4.50 (q, J = 7.4 Hz, 2H), 3.41 (s, 6H), 3.26 
(dd, J = 14.4, 7.4 Hz, 2H), 3.19 (dd, J = 14.4, 7.2 Hz, 2H), 1.76 (s, 6H). 
13C NMR (125 MHz, DMSO-d6): δ = 172.2 (Cq), 169.4 (Cq), 151.1 (Cq), 149.2 (CH), 138.5 (CH), 137.1 
(Cq), 137.0 (Cq), 131.1 (Cq), 130.3 (CH), 128.4 (Cq), 123.3 (CH), 122.2 (CH), 121.7 (CH), 121.1 (CH), 
119.3 (CH), 112.0 (Cq), 111.7 (CH), 53.1 (CH), 52.1 (CH3), 27.1 (CH2), 22.7 (CH3). 
IR (ATR): 3276, 1738, 1651, 1587, 1468, 1454, 1435, 1346, 1035, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 771 (100) [M+Na]+, 749 (13) [M+H]+. 
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HR-MS (ESI) m/z calcd for C44H41N6O6+ 749.3082 [M+H]+, found 749.3076. 
 
1,3-Bis{2-[methyl acetyl-1-(2-pyridyl)]-L-tryptophanate}benzene (117b) 
The general procedure B4 was followed using tryptophan 56h (100 mg), 
1,3-dibromobenzene (28, 35 mg) and 5 mol % [Ru]2. Purification by 
column chromatography (1% Et3N in EtOAc) yielded peptide 117b as a 
white solid (91 mg, 82%). 
m. p.: 147 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.59 (ddd, J = 4.9, 2.0, 0.9 Hz, 2H), 7.76‒7.73 (m, 2H), 7.69‒7.63 (m, 
5H), 7.30‒7.24 (m, 4H), 7.21 (ddd, J = 7.4, 4.8, 1.1 Hz, 2H), 7.14‒7.10 (m, 1H), 6.96 (dd, J = 7.7, 1.7 Hz, 
2H), 6.89‒6.86 (m, 2H), 6.50 (d, J = 8.1 Hz, 2H), 4.89‒4.81 (m, 2H), 3.54 (s, 6H), 3.44 (dd, J = 14.4, 
6.1 Hz, 2H), 3.30 (dd, J = 14.4, 7.3 Hz, 2H), 1.74 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ = 173.0 (Cq), 170.0 (Cq), 151.5 (Cq), 149.1 (CH), 137.7 (CH), 137.2 (Cq), 
136.7 (Cq), 132.6 (Cq), 132.2 (CH), 129.9 (CH), 128.4 (Cq), 128.3 (CH), 123.8 (CH), 121.7 (CH), 121.5 
(CH), 119.0 (CH), 111.6 (Cq), 111.4 (CH), 52.6 (CH), 52.4 (CH3), 27.4 (CH2), 22.8 (CH3). 
IR (ATR): 3278, 1736, 1654, 1588, 1468, 1454, 1434, 1367, 1345, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 771 (100) [M+Na]+, 749 (15) [M+H]+. 
HR-MS (ESI) m/z calcd for C44H41N6O6+ 749.3082 [M+H]+, found 749.3076. 
 
1,4-Bis({2-[benzyl tert-butoxycarbonyl-1-(2-pyridyl)]-L-tryptophyl}-L-alaninate)benzene (117c) 
The general procedure B4 was followed using Boc-Trppy-Ala-OBn (101, 
80 mg), 1,4-dibromobenzene (28ν, 17 mg) and 10 mol % [Ru]2. Purification 
by column chromatography (1% Et3N in EtOAc) yielded peptide 117c as a 
white solid (67 mg, 79%). 
m. p.: 105 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.52 (dd, J = 5.1, 2.7 Hz, 2H), 7.76‒7.68 (m, 2H), 7.55 (dd, J = 7.9, 
7.9 Hz, 2H), 7.34‒7.20 (m, 16H), 7.20‒7.06 (m, 6H), 6.77 (d, 8.2 Hz, 2H), 6.70 (d, 8.2 Hz, 2H), 
5.13‒5.01 (m, 4H), 5.01‒4.94 (m, 2H), 4.44‒4.26 (m, 4H), 3.39‒3.22 (m, 4H), 1.37‒1.17 (m, 24H). 
13C NMR (100 MHz, CDCl3): δ = 172.1 (Cq), 171.3 (Cq), 155.0 (Cq), 151.5 (Cq), 148.9 (CH), 137.4 (CH), 
137.0 (Cq), 136.7 (Cq), 135.4 (Cq), 131.4 (Cq), 130.4 (CH), 128.6 (Cq), 128.5 (CH), 128.1 (CH), 128.0 
(CH), 123.6 (CH), 121.4 (CH), 121.4 (CH), 121.1 (CH), 119.1 (CH), 111.6 (CH), 79.7 (Cq), 66.9 (CH2), 54.3 
(CH), 48.2 (CH), 28.2 (CH3), 18.0 (CH3). 
IR (ATR): 3323, 2923, 1662, 1469, 1454, 1436, 1365, 1153, 742, 697 cm‒1. 
MS (ESI) m/z (relative intensity) 1181 (17) [M+Na]+, 1159 (15) [M+H]+, 599 (100). 
HR-MS (ESI) m/z calcd for C68H71N8O10+ 1159.5288 [M+H]+, found 1159.5292. 
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1,4-Bis{[methyl tert-butoxycarbonyl-glycyl-1-(2-pyridyl)-L-tryptophan-2-yl]glycinate}benzene 
(117d) 
The general procedure B4 was followed using peptide 101f (50.0 mg), 1,4-
dibromobenzene (28ν, 11.6 mg) and 10 mol% [Ru]2. Purification by 
column chromatography (1% Et3N in EtOAc) yielded peptide 117d as a 
white solid (19 mg, 35%). 
m. p.: 133 °C. 
1H NMR (600 MHz, CD3OD): δ = 8.49 (ddd, J = 5.0, 1.9, 0.8 Hz, 2H), 7.80 (ddd, J = 7.8, 7.8, 1.9 Hz, 4H), 
7.51–7.46 (m, 2H), 7.35 (ddd, J = 7.6, 5.0, 1.1 Hz, 2H), 7.28–7.27 (m, 4H), 7.25–7.17 (m, 4H), 7.02 (d, 
J = 8.1 Hz, 2H), 4.72–4.66 (m, 2H), 3.81 (d, J = 17.5 Hz, 2H), 3.73 (d, J = 17.3 Hz, 2H), 3.69–3.66 (m, 
2H), 3.65 (s, 6H), 3.59 (d, J = 16.8 Hz, 2H), 3.52–3.43 (m, 4H), 1.39 (s, 18H). 
13C NMR (126 MHz, CDCl3): δ = 173.4 (Cq), 171.7 (Cq), 171.3 (Cq), 171.3 (Cq), 152.6 (Cq), 149.7 (CH), 
139.9 (CH), 138.7 (Cq), 138.5 (Cq), 132.5 (Cq), 131.6 (CH), 129.9 (Cq), 124.3 (CH), 123.6 (CH), 123.3 
(CH), 122.2 (CH), 120.2 (CH), 112.1 (Cq), 80.8 (Cq), 55.1 (CH), 52.6 (CH3), 44.8 (CH2), 44.8 (CH2), 42.0 
(CH2), 28.7 (CH3). 
IR (ATR): 3311, 2928, 1748, 1652, 1515, 1470, 1454, 1436, 1365, 1207, 1162, 780 cm‒1. 
MS (ESI) m/z (relative intensity) 1115 (100) [M+Na]+, 1093 (12) [M+H]+. 
HR-MS (ESI) m/z calcd for C58H65N10O12+ 1093.4778 [M+H]+, found 1093.4772. 
 
1-{2-[Ethyl (acetyl-L-alanyl)-L-tryptophylglycinate]}-4-{2-[methyl acetyl-1-(2-pyridyl)-L-
tryptophanate]}benzene (126a) 
The general procedure B3 was followed using peptide 99af (40 mg) and 
tryptophan 56h (36 mg). Purification by column chromatography (1% Et3N in 
EtOAc/THF 1:1) yielded peptide 126a as a white solid (31 mg, 53%). 
m. p.: 147 °C. 
1H NMR (600 MHz, DMSO-d6): δ = 11.21 (s, 1H), 8.58 (ddd, J = 4.9, 2.0, 
0.9 Hz, 1H), 8.35 (d, J = 7.7 Hz, 1H), 8.13 (dd, J = 5.8, 5.8 Hz, 1H), 7.96 (dd, J = 7.6, 7.6 Hz, 2H), 7.80 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.75‒7.72 (m, 3H), 7.70 (d, J = 8.0 Hz, 1H), 7.58‒7.55 (m, 1H), 7.34 
(dddd, J = 8.6, 7.5, 3.9, 1.5 Hz, 4H), 7.26‒7.20 (m, 2H), 7.10 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.03‒6.98 
(m, 2H), 4.69 (ddd, J = 8.4, 7.1, 7.1 Hz, 1H), 4.59 (q, J = 7.4 Hz, 1H), 4.25 (dt, J = 9.4, 7.1 Hz, 1H), 
4.07‒3.99 (m, 2H), 3.71 (dd, J = 17.3, 5.9 Hz, 1H), 3.58 (dd, J = 17.3, 5.6 Hz, 1H), 3.43 (s, 3H), 3.34 
(ddd, J = 14.4, 11.3, 7.5 Hz, 2H), 3.25 (dd, J = 14.4, 6.8 Hz, 1H), 3.12 (dd, J = 14.5, 6.8 Hz, 1H), 1.80 (s, 
3H), 1.78 (s, 3H), 1.14 (t, J = 7.1 Hz, 3H), 1.10 (d, J = 7.0 Hz, 3H). 
13C NMR (125 MHz, DMSO-d6): δ = 172.3 (Cq), 172.1 (Cq), 171.7 (Cq), 169.6 (Cq), 169.6 (Cq), 169.5 
(Cq), 151.4 (Cq), 149.4 (CH), 138.7 (CH), 137.4 (Cq), 137.2 (Cq), 136.4 (Cq), 134.7 (Cq), 132.3 (Cq), 130.6 
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(CH), 130.4 (Cq), 129.4 (Cq), 128.6 (Cq), 128.0 (CH), 123.3 (CH), 122.4 (CH), 122.0 (CH), 121.2 (CH), 
119.6 (CH), 119.4 (CH), 119.0 (CH), 112.0 (Cq), 111.7 (CH), 111.4 (CH), 108.5 (Cq), 97.6 (CH), 60.8 
(CH2), 54.2 (CH), 53.4 (CH), 52.2 (CH3), 48.9 (CH), 41.4 (CH2), 27.9 (CH2), 27.3 (CH2), 22.9 (CH3), 22.8 
(CH3), 18.7 (CH3), 14.5 (CH3). 
IR (ATR): 3360, 2927, 2855, 1733, 1645, 1537, 1514, 1455, 1371, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 836 (24) [M+Na]+, 814 (8) [M+H]+, 405 (100). 
HR-MS (ESI) m/z calcd for C45H48N7O7+ 814.3559 [M+H]+, found 814.3547. 
 
1-{2-[Ethyl (acetyl-L-alanyl)-L-tryptophyl-glycinate]}-4-(2-{benzyl [(tert-butoxycarbonyl)-L-leucyl-L-
alanyl-1-(2-pyridyl)]}-β3-homo-L-tryptophanate)benzene (126b) 
The general procedure B3 was followed using peptide 99af (20 mg) and 
peptide 101c (24 mg). Purification by column chromatography (1% Et3N in 
EtOAc) yielded peptide 126b as a white solid (23 mg, 56%). 
m. p.: 145 °C. 
1H NMR (600 MHz, CDCl3): δ = 10.19 (s, 1H), 8.57 (dd, J = 4.9, 1.9 Hz, 1H), 
7.64‒7.56 (m, 5H), 7.53 (dd, J = 8.2, 8.2 Hz, 1H), 7.35‒7.30 (m, 3H), 7.30‒7.24 (m, 4H), 7.24‒7.18 (m, 
5H), 7.18‒7.13 (m, 2H), 7.11 (dd, J = 7.5, 7.5 Hz, 1H), 7.04 (dd, J = 7.5, 7.5 Hz, 1H), 6.85‒6.78 (m, 2H), 
6.77‒6.72 (m, 1H), 6.66 (d, J = 8.1 Hz, 1H), 5.05 (d, J = 7.1 Hz, 1H), 4.97 (s, 2H), 4.65‒4.59 (m, 1H), 
4.30 (ddd, J = 12.9, 6.6, 6.6 Hz, 2H), 4.04 (dddd, J = 18.0, 10.9, 7.1, 3.7 Hz, 3H), 3.92‒3.84 (m, 1H), 
3.77‒3.70 (m, 1H), 3.57 (dd, J = 15.2, 4.8 Hz, 1H), 3.52‒3.42 (m, 2H), 3.42‒3.35 (m, 1H), 3.23 (dd, J = 
14.8, 5.2 Hz, 1H), 2.54 (dd, J = 16.3, 5.7 Hz, 1H), 2.32 (dd, J = 16.2, 8.1 Hz, 1H), 1.66 (s, 3H), 1.54 (s, 
9H), 1.44‒1.34 (m, 2H), 1.19 (d, J = 7.0 Hz, 3H), 1.16 (t, J = 7.2 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.77 (d, 
J = 6.7 Hz, 3H), 0.64 (d, J = 6.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.4 (Cq), 171.7 (Cq), 171.5 (Cq), 171.1 (Cq), 170.7 (Cq), 169.9 (Cq), 
169.2 (Cq), 161.3 (Cq), 156.0 (Cq), 151.8 (Cq), 149.2 (CH), 137.9 (CH), 137.4 (Cq), 136.3 (Cq), 136.1 (Cq), 
135.6 (Cq), 134.4 (Cq), 131.7 (Cq), 131.4 (Cq), 130.3 (CH), 129.7 (Cq), 128.5 (CH), 128.3 (CH), 128.2 
(CH), 126.5 (CH), 123.6 (CH), 122.8 (CH), 122.1 (CH), 121.8 (CH), 121.4 (CH), 119.7 (CH), 119.5 (CH), 
118.9 (CH), 111.6 (CH), 111.6 (Cq), 111.2 (CH), 107.3 (Cq), 81.3 (Cq), 66.4 (CH2), 61.1 (CH2), 53.5 (CH), 
53.4 (CH), 49.3 (CH), 48.0 (CH), 47.5 (CH), 41.4 (CH2), 40.9 (CH2), 37.4 (CH2), 29.7 (CH2), 28.3 (CH3), 
27.2 (CH2), 24.7 (CH), 23.1 (CH3), 22.8 (CH3), 21.1 (CH3), 19.6 (CH3), 19.0 (CH3), 14.0 (CH3). 
IR (ATR): 3284, 2925, 1722, 1644, 1515, 1469, 1454, 1367, 1162, 1021, 742, 697 cm‒1. 
MS (ESI) m/z (relative intensity) 1168 (100) [M+Na]+, 1146 (24) [M+H]+, 542 (21). 
HR-MS (ESI) m/z calcd for C64H76N9O11+ 1146.5659 [M+H]+, found 1146.5657. 
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5.3.6 Analytical Data for Alkylated Tryptophans 107, 133, and 137 
Methyl acetyl-1-(2-pyrimidyl)-2-decyl-L-tryptophanate (107gb) 
The general procedure C was followed using tryptophan 56g (101 mg) and 1-decene 
(44b, 126 mg). Purification by column chromatography (hexanes/EtOAc 1:2) yielded 
tryptophan 107gb as a colorless oil (55 mg, 38% at 120 °C and 86 mg, 60% when the 
reaction was carried out at 140 °C). 
1H NMR (600 MHz, DMSO-d6): δ = 8.93 (d, J = 4.9 Hz, 2H), 8.43 (d, J = 8.0 Hz, 1H), 8.02–7.97 (m, 1H), 
7.57–7.52 (m, 1H), 7.44 (dd, J = 4.8, 4.8 Hz, 1H), 7.17–7.12 (m, 2H), 4.54 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 
3.56 (s, 3H), 3.19 (dd, J = 14.5, 6.9 Hz, 1H), 3.14 (dd, J = 7.4, 7.4 Hz, 1H), 3.12–3.05 (m, 2H), 1.82 (s, 
3H), 1.29–1.09 (m, 16H), 0.83 (t, J = 7.1 Hz, 3H). 
13C NMR (76 MHz, DMSO-d6): δ = 172.2 (Cq), 169.2 (Cq), 158.8 (CH), 157.2 (Cq), 138.6 (Cq), 135.7 (Cq), 
128.7 (Cq), 127.9 (CH), 121.1 (CH), 118.2 (CH), 117.8 (CH), 113.0 (CH), 111.5 (Cq), 52.8 (CH), 51.7 
(CH3), 31.2 (CH2), 29.4 (CH2), 28.8 (CH2), 28.7 (CH2), 28.7 (CH2), 28.6 (CH2), 28.5 (CH2), 26.5 (CH2), 
24.8 (CH2), 22.3 (CH3), 22.0 (CH2), 13.8 (CH3). 
IR (ATR): 2923, 2853, 1743, 1654, 1560, 1458, 1420, 1372, 1342, 1209, 1175, 744 cm‒1. 
MS (ESI) m/z (relative intensity) 979 (13) [2M+Na]+, 957 (16) [2M+H]+, 501 (33) [M+Na]+, 479 (100) 
[M+H]+, 343 (17). 
HR-MS (ESI) m/z calcd for C28H39N4O3+ 479.3017 [M+H]+, found 479.3006. 
 
Methyl tert-butoxycarbonyl-1-(2-pyrimidyl)-2-decyl-L-tryptophanate (107eb) 
The general procedure C was followed using tryptophan 56e (60 mg) and 1-decene 
(44b, 63 mg). Purification by column chromatography (hexanes/EtOAc 6:1) yielded 
tryptophan 107eb as a colorless oil (25 mg, 31%). 
1H NMR (600 MHz, DMSO-d6): δ = 8.93 (d, J = 4.8 Hz, 2H), 7.99 (ddd, J = 7.1, 3.6, 3.6 Hz, 1H), 7.53 
(ddd, J = 7.2, 3.6, 3.6 Hz, 1H), 7.44 (dd, J = 4.8, 4.8 Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.19–7.09 (m, 2H), 
4.22 (ddd, J = 7.7, 7.7, 7.7 Hz, 1H), 3.59 (s, 3H), 3.23–3.01 (m, 4H), 1.42–1.07 (m, 16H), 0.84 (t, J = 
6.6 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.2 (Cq), 158.6 (CH), 157.0 (Cq), 155.0 (Cq), 138.5 (Cq), 135.5 
(Cq), 128.6 (Cq), 122.1 (CH), 121.0 (CH), 118.0 (CH), 117.7 (CH), 112.8v, 111.7 (Cq), 78.1 (Cq), 54.3 
(CH), 51.6 (CH3), 31.1 (CH2), 29.4 (CH2), 28.8 (CH2), 28.7 (CH2), 28.7 (CH2), 28.5 (CH2), 28.5 (CH2), 
28.0 (CH3), 26.0 (CH2), 24.8 (CH2), 22.0 (CH2), 13.8 (CH3). 
MS (ESI) m/z (relative intensity) 1095 (100) [2M+Na]+, 1072 (65) [2M+H]+, 559 (92) [M+Na]+, 537 (77) 
[M+H]+, 437 (62) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C31H45N4O4+ 537.3435 [M+H]+, found 537.3436. 
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Methyl phthaloyl-1-(2-pyrimidyl)-2-decyl-L-tryptophanate (107fb) 
The general procedure C was followed using tryptophan 56f (107 mg) and 1-decene 
(44b, 105 mg). Purification by column chromatography (hexanes/EtOAc 2:1) 
yielded tryptophan 107fb as a colorless oil (19 mg, 13%). 
1H NMR (301 MHz, DMSO-d6): δ = 8.88 (d, J = 4.8 Hz, 2H), 7.95–7.88 (m, 1H), 7.83 (s, 3H), 7.54 (dd, J = 
6.6, 2.0 Hz, 1H), 7.42 (dd, J = 4.8, 4.8 Hz, 1H), 7.30–7.23 (m, 1H), 7.15–7.01 (m, 2H), 5.26 (dd, J = 10.4, 
4.8 Hz, 1H), 3.73 (s, 3H), 3.67–3.48 (m, 4H), 1.21–1.10 (m, 16H), 0.85 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 169.0 (Cq), 167.0 (Cq), 158.8 (CH), 157.0 (Cq), 138.8 (Cq), 135.7 
(Cq), 135.0 (CH), 130.7 (Cq), 128.3 (Cq), 123.4 (CH), 122.4 (CH), 121.2 (CH), 118.3 (CH), 117.7 (CH), 
112.8 (CH), 110.8 (Cq), 52.7 (CH), 51.6 (CH3), 31.2 (CH2), 29.4 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 
(CH2), 28.5 (CH2), 28.3 (CH2), 24.8 (CH2), 23.5 (CH2), 22.0 (CH2), 13.9 (CH3). 
MS (ESI) m/z (relative intensity) 1155 (10) [2M+Na]+, 589 (100) [M+Na]+, 567 (60) [M+H]+. 
HR-MS (ESI) m/z calcd for C34H39N4O4+ 567.2966 [M+H]+, found 567.2939. 
 
Methyl acetyl-1-(2-pyridyl)-2-decyl-L-tryptophanate (107hb) 
The general procedure C was followed using tryptophan 56h (107 mg) and 1-
decene (44b, 105 mg). Purification by column chromatography (hexanes/EtOAc 2:1) 
yielded tryptophan 107hb as a colorless oil (19 mg, 13%). 
1H NMR (301 MHz, DMSO-d6): δ = 8.88 (d, J = 4.8 Hz, 2H), 7.95–7.88 (m, 1H), 7.85–7.80 (m, 3H), 7.54 
(dd, J = 6.6, 2.0 Hz, 1H), 7.42 (dd, J = 4.8, 4.8 Hz, 1H), 7.30–7.23 (m, 1H), 7.15–7.01 (m, 2H), 5.26 (dd, 
J = 10.4, 4.8 Hz, 1H), 3.73 (s, 3H), 3.67–3.48 (m, 4H), 1.21–1.10 (m, 16H), 0.85 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 169.0 (Cq), 167.0 (Cq), 158.8 (CH), 157.0 (Cq), 138.8 (Cq), 135.7 
(Cq), 135.0 (CH), 130.7 (Cq), 128.3 (Cq), 123.4 (CH), 122.4 (CH), 121.2 (CH), 118.3 (CH), 117.7 (CH), 
112.8 (CH), 110.8 (Cq), 52.7 (CH), 51.6 (CH3), 31.2 (CH2), 29.4 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 
(CH2), 28.5 (CH2), 28.3 (CH2), 24.8 (CH2), 23.5 (CH2), 22.0 (CH2), 13.9 (CH3). 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-decyl-L-tryptophanate (107kb) 
The general procedure C was followed using tryptophan 56k (40 mg) and 1-decene 
(44b, 43 mg). Purification by column chromatography (hexanes/EtOAc 1:1) yielded 
tryptophan 107kb as a colorless oil (13 mg, 24%). 
1H NMR (300 MHz, CDCl3): δ = 8.65 (dd, J = 5.0, 1.8 Hz, 1H), 7.89 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.57–
7.46 (m, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.33 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.29–7.21 (m, 1H), 7.18–7.05 
(m, 2H), 5.13 (d, J = 8.2 Hz, 1H), 4.64 (ddd, J = 6.5, 6.5, 6.5 Hz, 1H), 3.67 (s, 3H), 3.32–3.26 (m, 2H), 
2.92–2.84 (m, 2H), 1.34–1.04 (m, 16H), 0.88 (t, J = 6.8 Hz, 3H). 
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13C NMR (126 MHz, CDCl3): δ = 172.9 (Cq), 155.2 (Cq), 151.7 (Cq), 149.6 (CH), 139.5 (Cq), 138.3 (CH), 
136.8 (Cq), 128.8 (Cq), 122.2 (CH), 122.0 (CH), 121.3 (CH), 120.5 (CH), 118.4 (CH), 109.9 (CH), 108.3 
(Cq), 79.9 (Cq), 54.3 (CH), 52.4 (CH3), 32.1 (CH2), 29.9 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 
(CH2), 29.3 (CH2), 28.5 (CH3), 27.8 (CH2), 24.9 (CH2), 22.9 (CH2), 14.3 (CH3). 
MS (ESI) m/z (relative intensity) 1093 (50) [2M+Na]+, 1071 (24) [2M+H]+, 558 (100) [M+Na]+, 536 (92) 
[M+H]+, 436 (36) [M–Boc+H]+. 
HR-MS (ESI) m/z calcd for C32H46N3O4+ 536.483 [M+H]+, found 536.3471. 
 
Methyl acetyl-1-(2-pyrimidyl)-2-(1-phenylethane-2-yl)-L-tryptophanate (133ga) 
The general procedure C was followed using tryptophan 56g (101 mg) and styrene 
(132a, 47 mg). Purification by column chromatography (EtOAc) yielded tryptophan 
133ga as a colorless oil (5 mg, 4%). 
1H NMR (300 MHz, DMSO-d6): δ = 9.00 (d, J = 4.8 Hz, 2H), 8.45 (d, J = 8.0 Hz, 1H), 
8.13–8.05 (m, 1H), 7.59–7.52 (m, 1H), 7.49 (dd, J = 4.8, 4.8 Hz, 1H), 7.29–7.21 (m, 2H), 7.21–7.09 (m, 
5H), 4.58 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 3.55 (s, 3H), 3.47–3.32 (m, 2H), 3.14 (dd, J = 14.5, 6.7 Hz, 1H), 
3.03 (dd, J = 14.5, 7.7 Hz, 1H), 2.66 (dd, J = 8.1, 8.1 Hz, 2H), 1.81 (s, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.2 (Cq), 169.3 (Cq), 159.0 (CH), 157.2 (Cq), 141.1 (Cq), 137.5 
(Cq), 135.6 (Cq), 128.7 (Cq), 128.2 (CH), 128.1 (CH), 125.9 (CH), 122.5 (CH), 121.3 (CH), 118.3 (CH), 
117.9 (CH), 113.4 (CH), 112.2 (Cq), 52.7 (CH), 51.8 (CH3), 35.8 (CH2), 27.7 (CH2), 26.4 (CH2), 22.3 
(CH3). 
IR (ATR): 2945, 1738, 1680, 1655, 1576, 1543, 1446, 1374, 1355, 1339, 1276, 1177, 801, 749 cm‒1. 
MS (ESI) m/z (relative intensity) 907 (30) [2M+Na]+, 465 (100) [M+Na]+, 443 (38) [M+H]+. 
HR-MS (ESI) m/z calcd for C26H27N4O3+ 433.2078 [M+H]+, found 443.2066. 
 
Methyl acetyl-1-(2-pyrimidyl)-2-(2-norbornyl)-L-tryptophanate (137ga) 
The general procedure C was followed using tryptophan 56g (40 mg) 
and norbornene (136a, 43 mg). Purification by column chromato-
graphy (hexanes/EtOAc 1:1) yielded tryptophan 137ga as a colorless 
oil (13 mg, 24%). 
The NMR spectra show a quadruple set of signals. 
1H NMR (300 MHz, DMSO-d6): δ = 9.00 (d, J = 1.4 Hz, 4H), 8.98 (d, J = 1.4 Hz, 4H), 8.55–8.46 (m, 4H), 
8.25–8.20 (m, 2H), 7.98–7.90 (m, 4H), 7.88–7.82 (m, 2H), 7.61–7.29 (m, 24H), 7.14–7.04 (m, 8H), 
4.64–4.48 (m, 4H), 3.92 (s, 3H), 3.85 (s, 3H), 3.69–3.57 (m, 4H), 3.52 (s, 3H), 3.47–3.30 (m, 4H), 3.42 
(s, 3H), 3.28–3.16 (m, 4H), 2.74–2.69 (m, 2H), 2.60–2.56 (m, 2H), 2.22–2.14 (m, 4H), 1.85 (s, 6H), 1.83 
(s, 6H), 1.64–1.31 (m, 16H), 1.31–1.01 (m, 16H). 
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13C NMR (126 MHz,DMSO-d6): δ = 172.0 (Cq), 171.9 (Cq), 167.0 (Cq), 167.0 (Cq), 165.9 (Cq), 158.9 
(CH), 158.9 (CH), 157.3 (Cq), 157.2 (Cq), 155.8 (Cq), 154.6 (Cq), 154.5 (Cq), 140.4 (Cq), 140.4 (Cq), 137.0 
(Cq), 136.0 (Cq), 136.0 (Cq), 135.3 (Cq), 135.1 (Cq), 132.2 (CH), 131.0 (CH), 130.6 (CH), 129.1 (Cq), 
129.0 (Cq), 128.7 (CH), 128.6 (CH), 128.2 (CH), 128.1 (CH), 128.1 (CH), 127.9 (CH), 127.8 (CH), 127.7 
(CH), 127.0 (Cq), 126.8 (Cq), 126.4 (Cq), 126.3 (CH), 126.2 (CH), 125.7 (CH), 124.2 (CH), 124.0 (CH), 
123.5 (CH), 123.4 (Cq), 122.1 (Cq), 122.0 (CH), 120.4 (CH), 120.3 (CH), 119.0 (CH), 118.9 (CH), 117.8 
(CH), 117.7 (CH), 111.0 (CH), 110.6 (CH), 108.9 (Cq), 108.7 (Cq), 106.8 (CH), 106.6 (CH), 53.7 (CH), 53.5 
(CH), 52.0 (CH3), 51.6 (CH3), 51.5 (CH3), 40.9 (CH), 40.8 (CH), 40.3 (CH), 38.6 (CH2), 38.0 (CH2), 36.9 
(CH2), 36.8 (CH), 35.9 (CH), 30.1 (CH2), 30.1 (CH2), 28.3 (CH2), 28.2 (CH2), 27.2 (CH2), 27.0 (CH2), 22.3 
(CH3), 22.3 (CH3). 
IR (ATR): 3344, 3244, 2917, 1738, 1632, 1510, 1467, 1457, 1435, 1367, 1210, 1179, 837, 746 cm‒1. 
MS (ESI) m/z (relative intensity) 887 (75) [2M+Na]+, 455 (100) [M+Na]+, 433 (13) [M+H]+. 
HR-MS (ESI) m/z calcd for C25H28N4NaO3+ 455.2054 [M+Na]+, found 455.2055. 
 
5.3.7 Analytical Data for Alkylated Tryptophans 141 
Methyl acetyl-1-(2-pyrimidyl)-2-(butane-3-one-1-yl)-L-tryptophanate (141ga) 
The general procedure D1 was followed using tryptophan 56g (50.8 mg) and but-3-
en-2-one (130a, 32 mg). Purification by column chromatography (EtOAc) yielded 
tryptophan 141ga as a colorless oil (56 mg, 91%). 
1H NMR (400 MHz, CDCl3): δ = 8.75 (d, J = 4.8 Hz, 2H), 8.24–8.19 (m, 1H), 7.51–7.46 (m, 1H), 7.24–
7.17 (m, 2H), 7.15 (dd, J = 4.8, 4.8 Hz, 1H), 6.40 (d, J = 8.0 Hz, 1H), 4.92 (ddd, J = 7.9, 6.3, 6.3 Hz, 1H), 
3.65 (s, 3H), 3.41–3.31 (m, 2H), 3.31–3.21 (m, 2H), 2.76–2.61 (m, 2H), 2.07 (s, 3H), 1.92 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ = 207.9 (Cq), 172.6 (Cq), 170.2 (Cq), 158.3 (CH), 158.0 (Cq), 137.7 (Cq), 
136.4 (Cq), 129.6 (Cq), 123.3 (CH), 122.0 (CH), 118.1 (CH), 117.3 (CH), 115.0 (CH), 112.2 (Cq), 52.7 
(CH), 52.5 (CH3), 43.7 (CH2), 30.0 (CH3), 27.1 (CH2), 23.0 (CH3), 20.4 (CH2). 
IR (ATR): 3302, 1740, 1709, 1677, 1581, 1561, 1536, 1456, 1423, 1374, 1355, 1339, 1276, 1178, 1125, 
801, 749 cm‒1. 
MS (ESI) m/z (relative intensity) 431 (100) [M+Na]+, 409 (27) [M+H]+, 224 (10). 
HR-MS (ESI) m/z calcd for C22H25N4O4+ 409.1870 [M+H]+, found 409.1870. 
 
Methyl acetyl-1-(2-pyridyl)-2-(butane-3-one-1-yl)-L-tryptophanate (141ha) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and but-3-
en-2-one (130a, 32 mg). Purification by column chromatography (EtOAc) yielded 
tryptophan 141ha as a colorless oil (61 mg, 99%). 
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1H NMR (301 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.88 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 
7.54–7.48 (m, 1H), 7.41 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.31 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.27–7.20 
(m, 1H), 7.13–7.07 (m, 2H), 6.33 (d, J = 7.8 Hz, 1H), 4.91 (ddd, J = 7.8, 6.1, 6.1 Hz, 1H), 3.66 (s, 3H), 
3.38–3.20 (m, 2H), 3.07 (ddd, J = 7.8, 7.8, 2.0 Hz, 2H), 2.54–2.43 (m, 2H), 1.97 (s, 3H), 1.91 (s, 3H). 
13C NMR (76 MHz, CDCl3): δ = 207.3 (Cq), 172.6 (Cq), 169.9 (Cq), 151.2 (Cq), 149.7 (CH), 138.5 (CH), 
137.3 (Cq), 136.7 (Cq), 128.6 (Cq), 122.3 (CH), 122.3 (CH), 120.9 (CH), 120.7 (CH), 118.3 (CH), 109.9 
(CH), 109.0 (Cq), 52.8 (CH), 52.3 (CH3), 42.9 (CH2), 29.8 (CH3), 27.0 (CH2), 23.0 (CH3), 18.9 (CH2). 
IR (ATR): 3277, 2952, 2926, 1740, 1713, 1655, 1585, 1470, 1459, 1436, 1367, 1218, 1165, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 837 (38) [2M+Na]+, 430 (90) [M+Na]+, 408 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H26N3O4+ 408.1918 [M+H]+, found 408.1916. 
 
Methyl acetyl-1-(2-pyridyl)-2-(octane-3-one-1-yl)-L-tryptophanate (141hb) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and oct-
1-en-3-one (130b, 37 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 141hb as a colorless oil (67 mg, 97%). 
1H NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.92 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 
7.56–7.51 (m, 1H), 7.45 (ddd, J = 7.9, 0.9, 0.9 Hz, 1H), 7.35 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.29–7.26 
(m, 1H), 7.18–7.11 (m, 2H), 6.32 (d, J = 7.8 Hz, 1H), 4.95 (ddd, J = 7.7, 6.0, 6.0 Hz, 1H), 3.71 (s, 3H), 
3.36 (dd, J = 14.8, 6.0 Hz, 1H), 3.30 (dd, J = 14.8, 6.0 Hz, 1H), 3.16–3.03 (m, 2H), 2.46 (dd, J = 7.6, 
7.6 Hz, 2H), 2.21 (ddd, J = 7.2, 7.2, 1.2 Hz, 2H), 1.95 (s, 3H), 1.48–1.40 (m, 2H), 1.28–1.19 (m, 2H), 
1.19–1.10 (m, 2H), 0.84 (dd, J = 7.2, 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 209.9 (Cq), 172.6 (Cq), 169.9 (Cq), 151.2 (Cq), 149.6 (CH), 138.7 (CH), 
137.5 (Cq), 136.7 (Cq), 128.7 (Cq), 122.4 (CH), 122.3 (CH), 121.0 (CH), 120.8 (CH), 118.4 (CH), 110.0 
(CH), 109.1 (Cq), 52.8 (CH), 52.4 (CH3), 42.7 (CH2), 41.9 (CH2), 31.2 (CH2), 27.0 (CH2), 23.4 (CH2), 23.1 
(CH3), 22.4 (CH2), 19.0 (CH2), 13.9 (CH3). 
IR (ATR): 3290, 2953, 2928, 1742, 1711, 1654, 1585, 1470, 1458, 1436, 1369, 1216, 1130, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 949 (92) [2M+Na]+, 486 (100) [M+Na]+, 464 (26) [M+H]+. 
HR-MS (ESI) m/z calcd for C27H34N3O4+ 464.2544 [M+H]+, found 464.2541. 
 
Methyl acetyl-1-(2-pyridyl)-2-(2-benzoylethane-1-yl)-L-tryptophanate (141hc) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 1-
phenylprop-2-en-1-one (130c, 59 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 141hc as a white solid (48 mg, 68%). 
m. p.: 150 °C. 
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1H NMR (500 MHz, CDCl3): δ = 8.60 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.90 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.81–7.76 (m, 2H), 7.58–7.55 (m, 1H), 7.53 (dddd, J = 8.6, 7.1, 1.3, 1.3 Hz, 1H), 7.46 (ddd, J = 8.0, 1.0, 
1.0 Hz, 1H), 7.40 (dd, J = 8.2, 7.3 Hz, 2H), 7.32 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30–7.27 (m, 1H), 7.18–
7.14 (m, 2H), 6.31 (d, J = 7.8 Hz, 1H), 4.99 (ddd, J = 7.9, 5.9, 5.9 Hz, 1H), 3.71 (s, 3H), 3.40 (dd, J = 14.8, 
6.1 Hz, 1H), 3.33 (dd, J = 14.8, 5.8 Hz, 1H), 3.30–3.20 (m, 2H), 3.16–3.02 (m, 2H), 1.95 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 198.8 (Cq), 172.7 (Cq), 169.9 (Cq), 151.3 (Cq), 149.8 (CH), 138.6 (CH), 
137.6 (Cq), 136.8 (Cq), 136.4 (Cq), 133.2 (CH), 128.8 (Cq), 128.6 (CH), 127.9 (CH), 122.4 (CH), 122.4 
(CH), 121.1 (CH), 120.8 (CH), 118.4 (CH), 110.0 (CH), 109.1 (Cq), 52.8 (CH), 52.4 (CH3), 38.3 (CH2), 27.1 
(CH2), 23.2 (CH3), 19.5 (CH2). 
IR (ATR): 3334, 3060, 1740, 1674, 1580, 1470, 1458, 1435, 1368, 1206, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 961 (21) [2M+Na]+, 939 (1) [2M+H]+, 492 (100) [M+Na]+, 470 (44) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C28H28N3O4+ 470.2074 [M+H]+, found 470.2074. 
 
Methyl tert-butoxycarbonyl-1-(2-pyridyl)-2-(butane-3-one-1-yl)-L-tryptophanate (141ka) 
The general procedure D1 was followed using tryptophan 56k (59.3 mg) and but-3-
en-2-one (130a, 32 mg) in H2O/HOAc (9:1, 150 µL). Purification by column chroma-
tography (hexanes/EtOAc 1:2) yielded trytophan 141ka as a white solid (62 mg, 
89%). 
m. p.: 87 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.90 (ddd, J = 7.4, 2.0 Hz, 1H), 7.57–
7.50 (m, 1H), 7.43 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.33 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30–7.26 (m, 1H), 
7.20–7.09 (m, 2H), 5.13 (d, J = 8.5 Hz, 1H), 4.64 (ddd, J = 6.7, 6.7, 6.7 Hz, 1H), 3.69 (s, 3H), 3.37–3.20 
(m, 2H), 3.09 (dd, J = 7.6, 7.6 Hz, 2H), 2.62–2.52 (m, 2H), 2.03 (s, 3H), 1.40 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 207.0 (Cq), 172.7 (Cq), 155.0 (Cq), 151.3 (Cq), 149.6 (CH), 138.4 (CH), 
137.4 (Cq), 136.7 (Cq), 128.7 (Cq), 122.2 (CH), 122.2 (CH), 121.0 (CH), 120.7 (CH), 118.5 (CH), 109.9 
(CH), 109.1 (Cq), 79.8 (Cq), 54.1 (CH), 52.3 (CH3), 43.4 (CH2), 29.9 (CH3), 28.4 (CH3), 27.7 (CH2), 19.2 
(CH2). 
IR (ATR): 3302, 2928, 1725, 1652, 1586, 1471, 1458, 1436, 1367, 1167, 1020, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 953 (21) [2M+Na]+, 488 (100) [M+Na]+, 466 (24) [M+H]+. 
HR-MS (ESI) m/z calcd for C26H32N3O5+ 466.2336 [M+H]+, found 466.2334. 
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Methyl acetyl-1-(2-pyridyl)-2-(N-tert-butoxycarbonyl-2-oxo-1-aminobutan-4-yl)-L-tryptophanate 
(141hd) 
The general pyrocedure D1 was followed using tryptophan 56h (50.6 mg) and 
tert-butyl (2-oxobut-3-en-1-yl)carbamate (129d, 30 mg) in H2O/HOAc (9:1, 
150 µL). Purification by column chromatography (EtOAc) yielded trytophan 
141hd as a white solid (68 mg, 88%). 
m. p.: 96 °C. 
1H NMR (500 MHz, CDCl3): δ = 8.65–8.60 (m, 1H), 7.92 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.54–7.49 (m, 
1H), 7.46 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.35 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30–7.27 (m, 1H), 7.17–
7.12 (m, 2H), 6.23 (d, J = 8.0 Hz, 1H), 5.19–5.14 (m, 1H), 4.93 (ddd, J = 8.1, 6.1, 6.1 Hz, 1H), 3.84 (d, J = 
5.0 Hz, 2H), 3.68 (s, 3H), 3.34 (dd, J = 14.8, 6.5 Hz, 1H), 3.29 (dd, J = 14.8, 5.7 Hz, 1H), 3.20–2.08 (m, 
2H), 2.54 (dd, J = 7.2, 7.2 Hz, 2H), 1.96 (s, 3H), 1.42 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 204.7 (Cq), 172.6 (Cq), 169.9 (Cq), 155.6 (Cq), 151.1 (Cq), 149.8 (CH), 
138.7 (CH), 136.8 (Cq), 136.7 (Cq), 128.7 (Cq), 122.5 (CH), 122.4 (CH), 120.9 (CH), 120.9 (CH), 118.4 
(CH), 110.1 (CH), 109.3 (Cq), 79.9 (Cq), 52.9 (CH), 52.5 (CH3), 50.2 (CH2), 39.4 (CH2), 28.3 (CH3), 27.2 
(CH2), 23.2 (CH3), 19.0 (CH2). 
IR (ATR): 3303, 2929, 1732, 1708, 1658, 1524, 1471, 1456, 1436, 1367, 1249, 1218, 1162, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 1067 (17) [2M+Na]+, 545 (100) [M+Na]+, 523 (7) [M+H]+. 
HR-MS (ESI) m/z calcd for C28H35N4O6+ 523.2551 [M+H]+, found 523.2545. 
 
5.3.8 Analytical Data for Alkylated Tryptophans 142 
Methyl acetyl-1-(2-pyridyl)-2-(ethyl propionate-3-yl)-L-tryptophanate (142ha) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and ethyl 
acrylate (129a, 45 mg). Purification by column chromatography (EtOAc) yielded 
tryptophan 142ha as a colorless oil (59 mg, 90%). 
1H NMR (300 MHz, CDCl3): δ = 8.63 (dd, J = 4.9, 1.8 Hz, 1H), 7.91 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.59–
7.51 (m, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.34 (dd, J = 7.2, 5.1 Hz, 1H), 7.30–7.24 (m, 1H), 7.18–7.09 (m, 
2H), 6.36 (d, J = 7.6 Hz, 1H), 4.96 (ddd, J = 7.7, 6.0, 6.0 Hz, 1H), 4.02 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 
3.38 (dd, J = 14.7, 6.0 Hz, 1H), 3.31 (dd, J = 14.7, 6.0 Hz, 1H), 3.27–3.13 (m, 2H), 2.29 (ddd, J = 9.0, 7.1, 
2.5 Hz, 2H), 1.95 (s, 3H), 1.16 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 172.2 (Cq), 169.7 (Cq), 150.9 (Cq), 149.4 (CH), 138.7 (CH), 
136.8 (Cq), 136.6 (Cq), 128.5 (Cq), 122.4 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 118.5 (CH), 109.8 
(CH), 109.4 (Cq), 60.5 (CH2), 52.8 (CH), 52.3 (CH3), 33.7 (CH2), 27.1 8 (CH2), 23.1 (CH3), 20.3 (CH2), 
14.1 (CH3). 
IR (ATR): 2954, 2927, 1731, 1655, 1470, 1459, 1436, 1369, 1176, 742 cm‒1. 
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MS (ESI) m/z (relative intensity) 897 (24) [2M+Na]+, 460 (79) [M+Na]+, 438 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C24H28N3O5+ 438.2023 [M+H]+, found 438.2026. 
 
Methyl acetyl-1-(2-pyridyl)-2-(benzyl propionate-3-yl)-L-tryptophanate (142hb) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and benzyl 
acrylate (129b, 36 mg). Purification by column chromatography (EtOAc) yielded 
tryptophan 142hb as a colorless oil (66 mg, 89%). 
1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.90 (ddd, J = 8.0, 7.4, 1.9 Hz, 1H), 
7.57–7.51 (m, 1H), 7.41 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.33 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30–7.23 
(m, 3H), 7.21–7.12 (m, 4H), 6.27 (d, J = 7.8 Hz, 1H), 5.01 (s, 2H), 4.96 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 
3.67 (s, 3H), 3.35 (dd, J = 14.7, 6.0 Hz, 1H), 3.32‒3.29 (m, 1H), 3.29–3.21 (m, 2H), 2.36 (ddd, J = 8.8, 
7.0, 2.0 Hz, 2H), 1.94 (s, 3H). 
13C NMR (76 MHz, CDCl3): δ = 172.5 (Cq), 172.2 (Cq), 169.9 (Cq), 150.9 (Cq), 149.5 (CH), 138.7 (CH), 
136.7 (Cq), 136.6 (Cq), 135.6 (Cq), 128.5 (Cq), 128.4 (CH), 128.1 (CH), 128.0 (CH), 122.5 (CH), 122.3 
(CH), 120.9 (CH), 120.8 (CH), 118.5 (CH), 109.9 (CH), 109.5 (Cq), 66.3 (CH2), 52.7 (CH), 52.3 (CH3), 33.6 
(CH2), 26.9 (CH2), 23.0 (CH3), 20.2 (CH2). 
IR (ATR): 3060, 2951, 1732, 1655, 1470, 1458, 1436, 1212, 1161, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 1021 (27) [2M+Na]+, 522 (71) [M+Na]+, 500 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C29H30N3O5+ 500.2180 [M+H]+, found 500.2178. 
 
Methyl acetyl-1-(2-pyridyl)-2-(n-butyl propionate-3-yl)-L-tryptophanate (142hc) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and n-
butyl acrylate (129c, 57 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 142hc as a colorless oil (62 mg, 90%). 
1H NMR (600 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.94 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 
7.59–7.52 (m, 1H), 7.48 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.36 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.30–7.26 
(m, 1H), 7.18–7.10 (m, 2H), 6.32 (d, J = 7.8 Hz, 1H), 4.98 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 3.97 (t, J = 
6.7 Hz, 2H), 3.72 (s, 3H), 3.44–3.27 (m, 2H), 3.21 (td, J = 7.3, 4.5 Hz, 2H), 2.29 (ddd, J = 8.9, 7.0, 2.1 Hz, 
2H), 1.96 (s, 3H), 1.58–1.43 (m, 2H), 1.35–1.19 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.5 (Cq), 172.4 (Cq), 169.8 (Cq), 151.0 (Cq), 149.5 (CH), 138.6 (CH), 
136.9 (Cq), 136.7 (Cq), 128.6 (Cq), 122.5 (CH), 122.3 (CH), 121.0 (CH), 120.8 (CH), 118.5 (CH), 109.9 
(CH), 109.4 (Cq), 64.5 (CH2), 52.8 (CH), 52.4 (CH3), 33.8 (CH2), 30.6 (CH2), 27.1 (CH2), 23.2 (CH3), 20.4 
(CH2), 19.1 (CH2), 13.7 (CH3). 
IR (ATR): 2957, 2935, 1731, 1655, 1585, 1470, 1459, 1436, 1369, 1174, 1148, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 953 (24) [2M+Na]+, 488 (45) [M+Na]+, 466 (100) [M+H]+. 
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HR-MS (ESI) m/z calcd for C26H32N3O5+ 466.2336 [M+H]+, found 466.2338. 
 
Methyl acetyl-1-(2-pyridyl)-2-[(2-ethyl)n-hexyl propionate-3-yl]-L-tryptophanate (142hd) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) 
and 2-ethylhexyl acrylate (129d, 55 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 142hd as a colorless oil (58 mg, 74%, 
dr = 1:1). 
1H NMR (600 MHz, CDCl3): δ = 8.65–8.61 (m, 1H), 7.93 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.57–7.52 (m, 
1H), 7.47 (dd, J = 7.9, 1.1 Hz, 1H), 7.37–7.33 (m, 1H), 7.29–7.25 (m, 1H), 7.18–7.11 (m, 2H), 6.34 (d, 
J = 7.8 Hz, 1H), 4.97 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 3.93–3.84 (m, 2H), 3.71 (s, 3H), 3.37 (dd, J = 14.8, 
6.0 Hz, 1H), 3.32 (dd, J = 14.8, 6.0 Hz, 1H), 3.27–3.15 (m, 2H), 2.35–2.25 (m, 2H), 1.96 (s, 3H), 1.50–
1.43 (m, 1H), 1.29‒1.21 (m, 4H), 1.21‒1.17 (m, 4H), 0.86 (t, J = 7.0 Hz, 3H), 0.81 (t, J = 7.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.5 (Cq), 172.4 (Cq), 169.8 (Cq), 151.0 (Cq), 149.5 (CH), 138.5 (CH), 
136.8 (Cq), 136.7 (Cq), 128.6 (Cq), 122.4 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 118.5 (CH), 109.9 
(CH), 109.3 (Cq), 67.0 (CH2), 52.8 (CH), 52.4 (CH3), 38.6 (CH), 33.7 (CH2), 30.3 (CH2), 28.9 (CH2), 27.1 
(CH2), 23.7 (CH2), 23.1 (CH3), 23.0 (CH2), 20.4 (CH2), 14.1 (CH3), 11.0 (CH3). 
IR (ATR): 2957, 2929, 2859, 1732, 1657, 1471, 1459, 1437, 1370, 1173, 1148, 732 cm‒1. 
MS (ESI) m/z (relative intensity) 1065 (53) [2M+Na]+, 544 (62) [M+Na]+, 522 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C30H40N3O5+ 522.2962 [M+H]+, found 522.2960. 
 
Methyl acetyl-1-(2-pyridyl)-2-(2,2,2-trifluoroethyl propionate-3-yl)-L-tryptophanate (142he) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
2,2,2-trifluoroethyl acrylate (129e, 46 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 142he as a colorless oil (52 mg, 71%). 
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.92 (ddd, J = 7.8, 7.4, 1.9 Hz, 1H), 
7.59–7.50 (m, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.35 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30 (ddd, J = 6.0, 3.2, 
0.7 Hz, 1H), 7.19–7.12 (m, 2H), 6.19 (d, J = 7.8 Hz, 1H), 4.97 (ddd, J = 8.0, 5.9, 5.9 Hz, 1H), 4.38 (q, J = 
8.4 Hz, 2H), 3.69 (s, 3H), 3.38 (dd, J = 14.7, 6.3 Hz, 1H), 3.32 (dd, J = 14.7. 6.3 Hz, 1H), 3.28–3.11 (m, 
2H), 2.55–2.45 (m, 2H), 1.96 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 170.7 (Cq), 169.6 (Cq), 151.0 (Cq), 149.6 (CH), 138.5 (CH), 
136.6 (Cq), 136.2 (Cq), 128.6 (Cq), 122.7 (q, 1JC-F =277.5 Hz, CF3), 122.6 (CH), 122.3 (CH), 120.8 (CH), 
120.7 (CH), 118.5 (CH), 110.0 (CH), 109.5 (Cq), 60.3 (q, 2JC-F = 36.6 Hz, CH2), 52.9 (CH), 52.4 (CH3), 33.3 
(CH2), 27.2 (CH2), 23.2 (CH3), 20.2 (CH2). 
19F NMR (282 MHz, CDCl3): δ = –73.84 (m). 
IR (ATR): 3292, 1749, 1652, 1541, 1472, 1459, 1437, 1368, 1267, 1139, 729 cm‒1. 
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MS (ESI) m/z (relative intensity) 1005 (18) [2M+Na]+, 514 (100) [M+Na]+, 492 (33) [M+H]+. 
HR-MS (ESI) m/z calcd for C24H25F3N3O5+ 492.1741 [M+H]+, found 492.1734. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-methoxyphenyl propionate-3-yl)-L-tryptophanate (142hf) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) 
and 4-methoxyphenyl acrylate (129f, 40 mg). Purification by column 
chromatography (EtOAc) yielded tryptophan 142hf as a colorless oil 
(56 mg, 73%). 
1H NMR (600 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.94 (ddd, J = 7.2, 7.2, 1.8 Hz, 1H), 
7.60–7.54 (m, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.37 (dd, J = 7.5, 4.9 Hz, 1H), 7.33–7.29 (m, 1H), 7.19–7.15 
(m, 2H), 6.87–6.78 (m, 4H), 6.28 (d, J = 7.8 Hz, 1H), 4.98 (ddd, J = 8.0, 5.9, 5.9 Hz, 1H), 3.76 (s, 3H), 
3.70 (s, 3H), 3.40 (dd, J = 15.1, 6.2 Hz, 1H), 3.37–3.31 (m, 2H), 3.31–3.26 (m, 1H), 2.62–2.51 (m, 2H), 
1.90 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 171.3 (Cq), 169.8 (Cq), 157.1 (Cq), 151.0 (Cq), 149.6 (CH), 
143.8 (Cq), 138.6 (CH), 136.7 (Cq), 136.4 (Cq), 128.6 (Cq), 122.5 (CH), 122.3 (CH), 122.1 (CH), 120.9 
(CH), 120.8 (CH), 118.5 (CH), 114.3 (CH), 109.9 (CH), 109.6 (Cq), 55.6 (CH3), 52.8 (CH), 52.4 (CH3), 33.8 
(CH2), 27.2 (CH2), 23.1 (CH3), 20.4 (CH2). 
IR (ATR): 2952, 2927, 1742, 1654, 1505, 1470, 1459, 1436, 1369, 1190, 1135, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 1053 (42) [2M+Na]+, 538 (100) [M+Na]+, 516 (71) [M+H]+. 
HR-MS (ESI) m/z calcd for C29H30N3O6+ 516.2129 [M+H]+, found 516.2126. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-acetylphenyl propionate-3-yl)-L-tryptophanate (142hg) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) 
and 4-acetylphenyl acrylate (129g, 42 mg). Purification by column chroma-
tography (EtOAc) yielded tryptophan 142hg as a colorless oil (55 mg, 70%). 
1H NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.93 (dm, J = 8.7 Hz, 3H), 7.59–7.53 
(m, 1H), 7.50 (dd, J = 8.0, 1.0 Hz, 1H), 7.40–7.28 (m, 2H), 7.21–7.13 (m, 2H), 7.05 (dm, J = 8.7 Hz, 2H), 
6.25 (d, J = 7.8 Hz, 1H), 4.97 (ddd, J = 7.9, 6.0, 6.0 Hz, 1H), 3.68 (s, 3H), 3.48–3.21 (m, 4H), 2.75–2.61 
(m, 2H), 2.57 (s, 3H), 1.92 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 196.6 (Cq), 172.4 (Cq), 170.3 (Cq), 169.7 (Cq), 154.0 (Cq), 151.0 (Cq), 
149.7 (CH), 138.5 (CH), 136.6 (Cq), 136.2 (Cq), 134.6 (Cq), 129.8 (CH), 128.5 (Cq), 122.6 (CH), 122.3 
(CH), 121.5 (CH), 120.8 (CH), 120.8 (CH), 118.5 (CH), 110.0 (CH), 109.6 (Cq), 52.9 (CH), 52.4 (CH3), 34.0 
(CH2), 27.2 (CH2), 26.6 (CH3), 23.1 (CH3), 20.3 (CH2). 
IR (ATR): 2952, 2927, 1745, 1680, 1585, 1471, 1459, 1436, 1265, 1201, 1119, 739 cm‒1. 
MS (ESI) m/z (relative intensity) 550 (100) [M+Na]+, 528 (72) [M+H]+. 
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HR-MS (ESI) m/z calcd for C30H30N3O6+ 528.2129 [M+H]+, found 528.2136. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-chlorophenyl propionate-3-yl)-L-tryptophanate (142hj) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
4-chlorophenyl acrylate (129j, 41 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 142hj as a white solid (50 mg, 64%). 
m. p.: 84 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.94 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.58–7.55 (m, 1H), 7.51 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.36 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.33–7.31 
(m, 1H), 7.28 (dm, J = 8.8 Hz, 2H), 7.19–7.15 (m, 2H), 6.89 (dm, J = 8.8 Hz, 2H), 6.21 (d, J = 7.8 Hz, 1H), 
4.97 (ddd, J = 7.9, 6.0, 6.0 Hz, 1H), 3.69 (s, 3H), 3.39 (dd, J = 14.8, 6.4 Hz, 1H), 3.37–3.31 (m, 2H), 
3.31–3.26 (m, 1H), 2.67–2.55 (m, 2H), 1.92 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 170.7 (Cq), 169.7 (Cq), 151.1 (Cq), 149.7 (CH), 148.8 (Cq), 
138.5 (CH), 136.6 (Cq), 136.3 (Cq), 131.1 (Cq), 129.3 (CH), 128.6 (Cq), 122.7 (CH), 122.6 (CH), 122.3 
(CH), 120.8 (CH), 120.8 (CH), 118.5 (CH), 110.0 (CH), 109.6 (Cq), 52.9 (CH), 52.4 (CH3), 33.9 (CH2), 27.2 
(CH2), 23.2 (CH3), 20.4 (CH2). 
IR (ATR): 2953, 2925, 1741, 1654, 1468, 1471, 1459, 1436, 1197, 1133, 1086, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 1061 (5) [2M+Na]+, 542 (100) [M+Na]+, 520 (69) [M+H]+. 
HR-MS (ESI) m/z calcd for C28H27ClN3O5+ 520.1634 [M+H]+, found 520.1639. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-styryl propionate-3-yl)-L-tryptophanate (142ho) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) 
and 4-styryl acrylate (129o, 34 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 142ho as a white solid (42 mg, 55%). 
m. p.: 108 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.67 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.94 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.60–7.54 (m, 1H), 7.51 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.37 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.35 (dm, J = 
8.6 Hz, 2H), 7.32–7.29 (m, 1H), 7.19–7.15 (m, 2H), 6.89 (dm, J = 8.6 Hz, 2H), 6.66 (dd, J = 17.6, 
10.9 Hz, 1H), 6.29 (d, J = 7.8 Hz, 1H), 5.67 (dd, J = 17.6, 0.8 Hz, 1H), 5.22 (dd, J = 10.8, 0.8 Hz, 1H), 4.99 
(ddd, J = 7.8, 5.9, 5.9 Hz, 1H), 3.70 (s, 3H), 3.43–3.26 (m, 4H), 2.64–2.53 (m, 2H), 1.90 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 170.9 (Cq), 169.9 (Cq), 151.1 (Cq), 149.9 (Cq), 149.7 (CH), 
138.6 (CH), 136.7 (Cq), 136.4 (Cq), 135.7 (CH), 135.3 (Cq), 128.6 (Cq), 127.0 (CH), 122.6 (CH), 122.3 
(CH), 121.4 (CH), 120.9 (CH), 120.8 (CH), 118.5 (CH), 114.0 (CH2), 110.0 (CH), 109.6 (Cq), 52.9 (CH), 
52.5 (CH3), 33.9 (CH2), 27.2 (CH2), 23.1 (CH3), 20.4 (CH2). 
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IR (ATR): 3265, 2934, 1743, 1655, 1586, 1505, 1470, 1459, 1436, 1368, 1197, 1166, 1135, 782, 
742 cm‒1. 
MS (ESI) m/z (relative intensity) 1045 (100) [2M+Na]+, 534 (99) [M+Na]+, 512 (15) [M+H]+. 
HR-MS (ESI) m/z calcd for C30H30N3O5+ 512.2180 [M+H]+, found 512.2172. 
 
Methyl acetyl-1-(2-pyridyl)-2-(5-pent-1-ene propionate-3-yl)-L-tryptophanate (142hp) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
pent-4-en-1-yl acrylate (129p, 42 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 142hp as a colorless oil (54 mg, 75%). 
1H NMR (600 MHz, CDCl3): δ = 8.62–8.66 (m, 1H), 7.92 (ddd, J = 8.0, 7.4, 
2.0 Hz, 1H), 7.58–7.52 (m, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.35 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.31–7.27 
(m, 1H), 7.19–7.11 (m, 2H), 6.27 (d, J = 7.9 Hz, 1H), 5.74 (dddd, J = 16.9, 10.2, 6.6, 6.6 Hz, 1H), 5.00–
4.91 (m, 3H), 4.02–3.95 (m, 2H), 3.71 (s, 3H), 3.37 (dd, J = 14.9, 6.2 Hz, 1H), 3.32 (dd, J = 14.9, 6.2 Hz, 
1H), 3.26–3.15 (m, 2H), 2.36–2.26 (m, 2H), 2.05–2.00 (m, 2H), 1.96 (s, 3H), 1.66–1.60 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 172.3 (Cq), 169.7 (Cq), 151.0 (Cq), 149.5 (CH), 138.5 (CH), 
137.2 (CH), 136.8 (Cq), 136.6 (Cq), 128.5 (Cq), 122.4 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 118.5 
(CH), 115.2 (CH2), 109.9 (CH), 109.4 (Cq), 64.0 (CH2), 52.8 (CH), 52.4 (CH3), 33.7 (CH2), 29.9 (CH2), 
27.7 (CH2), 27.1 (CH2), 23.1 (CH3), 20.3 (CH2). 
IR (ATR): 3274, 2952, 1732, 1655, 1470, 1459, 1436, 1368, 1167, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 977 (6) [2M+Na]+, 500 (91) [M+Na]+, 478 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C27H32N3O5+ 478.2336 [M+H]+, found 478.2342. 
 
Methyl acetyl-1-(2-pyridyl)-2-(S-cyclohexyl propanethioate-3-yl)-L-tryptophanate (142hq) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and S-
cyclohexyl prop-2-enethioate (129q, 77 mg). Purification by column chromato-
graphy (EtOAc) yielded tryptophan 142hq as a white solid (57 mg, 75%). 
m. p.: 185 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.94 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.57–7.52 (m, 1H), 7.49 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.36 (ddd, J = 7.5, 4.8, 1.0 Hz, 1H), 7.31–7.27 
(m, 1H), 7.17–7.12 (m, 2H), 6.24 (d, J = 7.8 Hz, 1H), 4.97 (ddd, J = 7.8, 5.9, 5.9 Hz, 1H), 3.71 (s, 3H), 
3.45–3.37 (m, 1H), 3.35 (dd, J = 14.8, 5.9 Hz, 1H), 3.30 (dd, J = 14.8, 5.9 Hz, 1H), 3.27–3.15 (m, 2H), 
2.51 (ddd, J = 8.6, 6.8, 2.7 Hz, 2H), 1.97 (s, 3H), 1.84–1.78 (m, 2H), 1.67–1.61 (m, 2H), 1.58–1.51 (m, 
1H), 1.41–1.18 (m, 5H). 
13C NMR (126 MHz, CDCl3): δ = 197.8 (Cq), 172.4 (Cq), 169.7 (Cq), 150.9 (Cq), 149.5 (CH), 138.7 (CH), 
136.7 (Cq), 136.5 (Cq), 128.6 (Cq), 122.5 (CH), 122.3 (CH), 120.9 (CH), 120.8 (CH), 118.5 (CH), 109.9 
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(CH), 109.5 (Cq), 52.8 (CH), 52.5 (CH3), 43.3 (CH2), 42.4 (CH), 33.0 (CH2), 27.1 (CH2), 25.9 (CH2), 25.6 
(CH2), 23.2 (CH3), 21.0 (CH2). 
IR (ATR): 2927, 2852, 1742, 1675, 1470, 1459, 1436, 1369, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 1037 (36) [2M+Na]+, 530 (100) [M+Na]+, 508 (11) [M+H]+. 
HR-MS (ESI) m/z calcd for C28H34N3O4S+ 508.2265 [M+H]+, found 508.2252. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-fluorobenzyl propionate-3-yl)-L-tryptophanate (142hr) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
4-fluorobenzyl acrylate (129r, 37 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 142hr as a colorless oil (51 mg, 66%). 
1H NMR (500 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.90 (ddd, J = 
7.7, 7.7, 2.0 Hz, 1H), 7.56–7.52 (m, 1H), 7.40 (ddd, J = 7.9, 1.0, 1.0 Hz, 1H), 7.33 (ddd, J = 7.5, 4.9, 
1.0 Hz, 1H), 7.29–7.26 (m, 1H), 7.20–7.13 (m, 4H), 6.98–6.90 (m, 2H), 6.25 (d, J = 7.8 Hz, 1H), 4.99–
4.92 (m, 3H), 3.67 (s, 3H), 3.38–3.28 (m, 2H), 3.28–3.17 (m, 2H), 2.41–2.28 (m, 2H), 1.95 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.6 (Cq), 172.2 (Cq), 169.9 (Cq), 162.6 (d, 1JCF = 247.2 Hz, CF), 151.0 
(Cq), 149.6 (CH), 138.7 (CH), 136.7 (Cq), 136.6 (Cq), 131.5 (d, 4JCF = 3.2 Hz, Cq), 130.1 (d, 3JCF = 8.3 Hz, 
CH), 128.6 (Cq), 122.6 (CH), 122.3 (CH), 121.0 (CH), 120.9 (CH), 118.6 (CH), 115.4 (d, 
2JCF = 21.6 Hz, 
CH), 110.0 (CH), 109.6 (Cq), 65.6 (CH2), 52.8 (CH), 52.4 (CH3), 33.6 (CH2), 27.0 (CH2), 23.1 (CH3), 20.3 
(CH2). 
19F NMR (471 MHz, CDCl3): δ = –113.5 (m). 
IR (ATR): 2953, 1732, 1656, 1586, 1511, 1471, 1459, 1436, 1370, 1221, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 1057 (52) [2M+Na]+, 540 (100) [M+Na]+, 518 (17) [M+H]+. 
HR-MS (ESI) m/z calcd for C29H29FN3O5+ 518.2086 [M+H]+, found 518.2081. 
 
Methyl acetyl-1-(2-pyridyl)-2-(2-hydroxyethyl propionate-3-yl)-L-tryptophanate (142hs) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
2-hydroxyethyl acrylate (129s, 34 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 142hs as a colorless oil (34 mg, 51%). 
1H NMR (300 MHz, CDCl3): δ = 7.88 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.47–7.37 (m, 2H), 7.31 (ddd, J = 
7.5, 4.9, 1.0 Hz, 1H), 7.26–7.18 (m, 1H), 7.13–7.05 (m, 2H), 6.67 (d, J = 6.9 Hz, 1H), 4.84 (ddd, J = 7.7, 
6.2, 6.2 Hz, 1H), 4.03 (ddd, J = 5.8, 2.6, 1.5 Hz, 2H), 3.66‒3.53 (m, 2H), 3.59 (s, 3H), 3.34‒3.25 (m, 2H), 
3.25–3.15 (m, 2H), 2.31 (dd, J = 7.8, 1.9 Hz, 2H), 1.93 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 172.2 (Cq), 170.3 (Cq), 150.8 (Cq), 149.5 (CH), 138.6 (CH), 
136.5 (Cq), 136.5 (Cq), 128.2 (Cq), 122.3 (CH), 122.3 (CH), 120.9 (CH), 120.6 (CH), 118.1 (CH), 109.9 
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(CH), 109.4 (Cq), 66.3 (CH2), 60.4 (CH2), 53.1 (CH), 52.4 (CH3), 33.9 (CH2), 27.2 (CH2), 22.9 (CH3), 20.5 
(CH2). 
IR (ATR): 3292, 2953, 1733, 1654, 1586, 1471, 1458, 1436, 1370, 1223, 1167, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 929 (12) [2M+Na]+, 476 (100) [M+Na]+, 454 (75) [M+H]+. 
HR-MS (ESI) m/z calcd for C24H28N3O6+ 454.1973 [M+H]+, found 454.1971. 
 
Methyl acetyl-1-(2-pyridyl)-2-{2-[2-(2-methoxyethoxy)ethoxy]ethyl propionate-3-yl}-L-
tryptophanate (142ht) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
2-[2-(2-methoxyethoxy)ethoxy]ethyl acrylate (129t, 49 mg). Purification by 
column chromatography (EtOAc) yielded tryptophan 142ht as a colorless oil 
(62 mg, 74%). 
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.92 (ddd, J = 7.5, 7.5, 2.1 Hz 1H), 
7.58–7.49 (m, 1H), 7.47 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.34 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30–7.23 
(m, 1H), 7.18–7.09 (m, 2H), 6.35 (d, J = 7.7 Hz, 1H), 4.96 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 4.16–4.10 (m, 
2H), 3.70 (s, 3H), 3.63–3.56 (m, 8H), 3.56–3.50 (m, 2H), 3.36 (s, 3H), 3.35–3.31 (m, 2H), 3.28–3.13 (m, 
2H), 2.34 (ddd, J = 8.7, 6.9, 1.9 Hz, 2H), 1.95 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.5 (Cq), 172.3 (Cq), 169.8 (Cq), 151.1 (Cq), 149.7 (CH), 138.5 (CH), 
136.7 (Cq), 136.7 (Cq), 128.5 (Cq), 122.4 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 118.5 (CH), 109.9 
(CH), 109.3 (Cq), 71.9 (CH2), 70.5 (CH2), 70.5 (CH2), 70.5 (CH2), 69.0 (CH2), 63.7 (CH2), 59.0 (CH3), 
52.8 (CH), 52.4 (CH3), 33.6 (CH2), 27.1 (CH2), 23.1 (CH3), 20.3 (CH2). 
IR (ATR): 3289, 2947, 2876, 1733, 1658, 1584, 1568, 1532, 1474, 1459, 1437, 1369, 1177, 1104, 
744 cm‒1. 
MS (ESI) m/z (relative intensity) 1133 (3) [2M+Na]+, 578 (100) [M+Na]+, 556 (55) [M+H]+. 
HR-MS (ESI) m/z calcd for C29H38N3O8+ 556.2653 [M+H]+, found 556.2646. 
 
Methyl acetyl-1-(2-pyridyl)-2-((–)-menthyl propionate-3-yl)-L-tryptophanate (142hu) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and 
(‒)-menthyl acrylate (129u, 47 mg). Purification by column chromatography 
(EtOAc) yielded tryptophan 142hu as a white solid (51 mg, 62%). 
m. p.: 84 °C. 
1H NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.93 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 
7.57–7.52 (m, 1H), 7.46 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.35 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.30–7.27 
(m, 1H), 7.17–7.11 (m, 2H), 6.30 (d, J = 7.7 Hz, 1H), 4.97 (ddd, J = 7.8, 5.9, 5.9 Hz, 1H), 4.56 (ddd, J = 
10.9, 10.9, 4.4 Hz, 1H), 3.72 (s, 3H), 3.37 (dd, J = 14.8, 6.0 Hz, 1H), 3.32 (dd, J = 14.8, 6.0 Hz, 1H), 3.28–
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3.15 (m, 2H), 2.24 (dd, J = 7.6, 7.6 Hz, 2H), 1.96 (s, 3H), 1.79 (dddd, J = 12.0, 3.9, 3.9, 1.9 Hz, 1H), 
1.67–1.52 (m, 3H), 1.39 (ddddd, J = 15.2, 8.5, 3.2, 3.2, 3.2 Hz, 1H), 1.29–1.17 (m, 1H), 1.04–0.92 (m, 
1H), 0.83 (d, J = 6.5 Hz, 3H), 0.82–0.79 (m, 1H), 0.79–0.77 (m, 1H), 0.77 (d, J = 7.0 Hz, 3H), 0.62 (d, J = 
6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 171.9 (Cq), 151.1 (Cq), 149.5 (CH), 138.4 (CH), 136.8 (Cq), 
136.7 (Cq), 130.0 (Cq), 128.6 (Cq), 122.4 (CH), 122.1 (CH), 120.8 (CH), 120.7 (CH), 118.5 (CH), 109.8 
(CH), 109.4 (Cq), 74.3 (CH), 52.8 (CH), 52.4 (CH3), 47.0 (CH), 40.9 (CH2), 34.2 (CH2), 33.9 (CH2), 31.4 
(CH), 27.1 (CH2), 26.4 (CH), 23.7 (CH2), 23.1 (CH3), 22.1 (CH3), 20.8 (CH3), 20.5 (CH2), 16.5 (CH3). 
IR (ATR): 2953, 2927, 2868, 1729, 1656, 1471, 1459, 1436, 1369, 1176, 1148, 739 cm‒1. 
MS (ESI) m/z (relative intensity) 1117 (49) [2M+Na]+, 570 (69) [M+Na]+, 548 (100) [M+H]+, 410 (11) 
[M–menthol+H]+. 
HR-MS (ESI) m/z calcd for C32H42N3O5+ 548.3119 [M+H]+, found 548.3109. 
 
Methyl acetyl-1-(2-pyridyl)-2-(cholesteryl propionate-3-yl)-L-tryptophanate (142hv) 
The general procedure D1 was followed using tryptophan 
56h (50.6 mg), cholesteryl acrylate (129v, 98 mg) and a 
mixture of HOAc (150 µL) and toluene (150 µL) as the 
solvent. The reaction was carried out at 100 °C. Purification 
by column chromatography (EtOAc) yielded tryptophan 142hv as a white solid (100 mg, 86%). 
m. p.: 92 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.64 (dd, J = 4.8, 2.0 Hz, 1H), 7.92 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.55–
7.49 (m, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.34 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.27–7.24 (m, 1H), 7.15–7.10 
(m, 2H), 6.34 (d, J = 7.8 Hz, 1H), 5.31–5.26 (m, 1H), 4.95 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 4.46 (dddd, J = 
10.9, 10.9, 6.5, 4.4 Hz, 1H), 3.70 (s, 3H), 3.36 (dd, J = 14.8, 6.0 Hz, 1H), 3.30 (dd, J = 14.8, 6.0 Hz, 1H), 
3.23–3.12 (m, 2H), 2.29–2.17 (m, 2H), 2.17–2.12 (m, 2H), 2.00–1.95 (m, 1H), 1.95–1.89 (m, 1H), 1.93 
(s, 3H), 1.84–1.76 (m, 2H), 1.75–1.69 (m, 1H), 1.58–0.95 (m, 21H), 0.94 (s, 3H), 0.89 (d, J = 6.6 Hz, 3H), 
0.85 (d, J = 6.6 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H), 0.64 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 171.7 (Cq), 170.0 (Cq), 151.1 (Cq), 149.7 (CH), 139.4 (Cq), 
138.6 (CH), 137.0 (Cq), 136.7 (Cq), 128.6 (Cq), 122.6 (CH), 122.4 (CH), 122.4 (CH), 121.1 (CH), 120.7 
(CH), 118.4 (CH), 109.9 (CH), 109.3 (Cq), 74.2 (CH), 56.7 (CH), 56.2 (CH), 52.9 (CH), 52.5 (CH3), 50.0 
(CH), 42.4 (Cq), 39.8 (CH2), 39.6 (CH2), 38.0 (CH2), 37.0 (CH2), 36.6 (Cq), 36.2 (CH2), 35.8 (CH), 34.0 
(CH2), 31.9 (CH2), 31.9 (CH), 28.3 (CH2), 28.1 (CH), 27.7 (CH2), 27.1 (CH2), 24.3 (CH2), 23.9 (CH2), 23.2 
(CH3), 22.9 (CH3), 22.6 (CH3), 21.1 (CH2), 20.4 (CH2), 19.3 (CH3), 18.8 (CH3), 11.9 (CH3). 
IR (ATR): 3294, 2952, 1733, 1647, 1557, 1471, 1458, 1436, 1369, 1202, 1169, 1141, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 800 (100) [M+Na]+, 778 (26) [M+H]+. 
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HR-MS (ESI) m/z calcd for C49H68N3O5+ 778.5153 [M+H]+, found 778.5133. 
 
Methyl acetyl-1-(2-pyridyl)-2-(tert-butyl propionate-3-yl)-L-tryptophanate (142hx) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and tert-
butyl acrylate (129x, 57 mg). Purification by column chromatography (EtOAc) 
yielded tryptophan 142hx as a colorless oil (28 mg, 40%). 
1H NMR (600 MHz, CDCl3): δ = 8.65‒8.63 (m, 1H), 7.93 (dd, J = 7.2, 7.2 Hz, 1H), 7.56‒7.52 (m, 1H), 
7.47 (d, J = 8.0 Hz, 1H), 7.35 (dd, J = 7.2, 4.8 Hz, 1H), 7.31‒7.27 (m, 1H), 7.18‒7.11 (m, 3H), 6.27 (d, J = 
7.8 Hz, 1H), 4.97 (ddd, J = 7.9, 6.0. 6.0 Hz, 1H), 3.71 (s, 3H), 3.37 (dd, J = 14.8, 6.1 Hz, 1H), 3.33 (dd, J = 
14.8, 6.1 Hz, 1H), 3.22‒3.11 (m, 2H), 2.22‒2.12 (m, 2H), 1.96 (s, 3H), 1.33 (s, 9H). 
13C NMR (76 MHz, CDCl3): δ = 172.5 (Cq), 171.7 (Cq), 170.0 (Cq), 150.9 (Cq), 149.3 (CH), 139.0 (CH), 
137.2 (Cq), 136.7 (Cq), 128.7 (Cq), 122.5 (CH), 122.4 (CH), 121.2 (CH), 120.9 (CH), 118.5 (CH), 109.8 
(CH), 109.5 (Cq), 80.5 (Cq), 52.8 (CH), 52.4 (CH3), 34.9 (CH2), 27.9 (CH3), 27.0 (CH2), 23.1 (CH3), 20.5 
(CH2). 
IR (ATR): 3291, 1733, 1646, 1557, 1471, 1458, 1435, 1369, 1203, 1141, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 953 (41) [2M+Na]+, 488 (100) [M+Na]+, 466 (80) [M+H]+, 410 (88) 
[M–tBu+H]+. 
HR-MS (ESI) m/z calcd for C26H32N3O5+ 466.2336 [M+H]+, found 466.2326. 
 
5.3.9 Analytical Data for Alkylated Tryptophans 158 and 186 
Methyl Nα-acetyl-Nα-[3-(isopropylamino)-3-oxopropyl]-1-(2-pyridyl)-L-tryptophanate (158ha) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg) and N-
isopropylacrylamide (131a, 30 mg) in H2O/HOAc (9:1, 150 µL). Purification by 
column chromatography (EtOAc) yielded trytophan 158ha as a white solid (68 mg, 
88%). 
m. p.: 85 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.53–8.48 (m, 1H), 8.13 (d, J = 8.3 Hz, 1H), 7.82–7.77 (m, 1H), 7.53 (d, 
J = 7.6 Hz, 2H), 7.43 (d, J = 8.3 Hz, 1H), 7.28–7.23 (m, 1H), 7.18 (dd, J = 8.0, 7.0 Hz, 1H), 7.14 (dd, J = 
7.4, 4.8 Hz, 1H), 6.31 (d, J = 7.9 Hz, 1H), 4.95 (ddd, J = 7.9, 5.5, 5.5 Hz, 1H), 4.31 (t, J = 6.3 Hz, 2H), 
4.08–4.00 (m, 1H), 3.67 (s, 3H), 3.34 (dd, J = 14.9, 5.5 Hz, 1H), 3.29 (dd, J = 14.9, 5.6 Hz, 1H), 2.42 (t, 
J = 6.3 Hz, 2H), 2.00 (s, 3H), 1.11 (d, J = 6.6 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.3 (Cq), 170.8 (Cq), 169.8 (Cq), 152.0 (Cq), 148.6 (CH), 138.9 (CH), 
135.3 (Cq), 130.4 (Cq), 124.5 (CH), 123.7 (CH), 121.5 (CH), 120.2 (CH), 119.0 (CH), 114.7 (CH), 113.4 
(Cq), 113.1 (CH), 60.9 (CH2), 52.9 (CH), 52.6 (CH3), 41.7 (CH), 36.3 (CH2), 27.7 (CH2), 23.0 (CH3), 21.1 
(CH3). 
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IR (ATR): 3288, 2971, 1737, 1644, 1591, 1542, 1472, 1455, 1437, 1368, 1230, 1037, 742 cm‒1. 
 
Methyl acetyl-1-(2-pyridyl)-2-(1-cyclohexylpyrrolidine-2,5-dione-3-yl)-L-tryptophanate (186) 
The general procedure D1 was followed using tryptophan 56h (25.0 mg, 74 µmol) 
and 1-cyclohexyl-1H-pyrrole-2,5-dione (185, 20 mg, 0.11 mmol, 1.5 equiv) in 74 µL 
HOAc at 100 °C. Purification by column chromatography (EtOAc) yielded trytophan 
186 as a colorless oil (29 mg, 56 µmol, 76%, dr = 1:1). 
Due to formation of two diastereomers, the NMR spectra show a double set of signals. 
1H NMR (500 MHz, CDCl3): δ = 8.45 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 8.42 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 
7.91 (ddd, J = 7.2, 7.2, 2.0 Hz, 1H), 7.89 (ddd, J = 7.2, 7.2, 2.0 Hz, 1H), 7.69–7.65 (m, 1H), 7.56–7.51 
(m, 3H), 7.41–7.38 (m, 1H), 7.34–7.31 (m, 1H), 7.31–7.27 (m, 2H), 7.25–7.22 (m, 2H), 7.22–7.15 (m, 
3H), 6.87 (d, J = 8.4 Hz, 1H), 5.02 (ddd, J = 8.5, 6.0, 4.4 Hz, 1H), 4.76 (ddd, J = 9.8, 4.8, 4.8 Hz, 1H), 
4.46–4.38 (m, 2H), 3.99 (dddd, J = 12.3, 12.3, 3.9, 3.9 Hz, 1H), 3.90 (dddd, J = 12.3, 12.3, 3.9, 3.9 Hz, 
1H), 3.79 (s, 3H), 3.62 (s, 3H), 3.57–3.50 (m, 1H), 3.46 (dd, J = 14.8, 4.8 Hz, 1H), 3.20 (dd, J = 15.0, 
6.0 Hz, 1H), 3.11 (dd, J = 14.8, 9.9 Hz, 1H), 3.03 (dd, J = 18.0, 6.7 Hz, 1H), 2.95 (dd, J = 18.0, 9.7 Hz, 
1H), 2.83 (dd, J = 18.2, 10.0 Hz, 1H), 2.54 (dd, J = 18.2, 6.3 Hz, 1H), 2.20–2.09 (m, 2H), 2.09–1.95 (m, 
2H), 2.01 (s, 3H), 1.98 (s, 3H), 1.89–1.77 (m, 4H), 1.68–1.60 (m, 4H), 1.52–1.42 (m, 2H), 1.39–1.23 (m, 
4H), 1.23–1.14 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ = 177.9 (Cq), 177.9 (Cq), 175.7 (Cq), 175.7 (Cq), 173.0 (Cq), 172.1 (Cq), 
171.1 (Cq), 170.6 (Cq), 151.0 (Cq), 150.9 (Cq), 149.5 (CH), 149.4 (CH), 139.0 (CH), 138.9 (CH), 136.6 
(Cq), 136.5 (Cq), 131.6 (Cq), 130.2 (Cq), 128.0 (Cq), 127.6 (Cq), 123.9 (CH), 123.7 (CH), 122.3 (CH), 
122.3 (CH), 121.5 (CH), 121.2 (CH), 120.6 (CH), 119.9 (CH), 119.1 (CH), 119.1 (CH), 114.4 (Cq), 114.4 
(Cq) 110.4 (CH), 110.3 (CH), 53.0 (CH), 52.5 (CH3), 52.5 (CH3), 52.2 (CH), 52.1 (CH), 52.0 (CH), 38.3 
(CH), 37.8 (CH), 35.8 (CH2), 34.3 (CH2), 28.9 (CH2), 28.7 (CH2), 28.6 (CH2), 28.6 (CH2), 27.0 (CH2), 26.9 
(CH2), 25.9 (CH2), 25.8 (CH2), 25.8 (CH2), 25.8 (CH2), 25.0 (CH2), 25.0 (CH2), 23.0 (CH3), 22.6 (CH3). 
IR (ATR): 3282, 2935, 2856, 1740, 1693, 1583, 1472, 1436, 1397, 1370, 1186, 1141, 735 cm‒1. 
MS (ESI) m/z (relative intensity) 1055 (64) [2M+Na]+, 539 (100) [M+Na]+, 517 (7) [M+H]+. 
HR-MS (ESI) m/z calcd for C29H33N4O5+ 517.2445 [M+H]+, found 517.2440. 
 
5.3.10 Analytical Data for Olefinated and Allylated Tryptophans 143, 189, 191, and 193 
(E)-Methyl acetyl-1-(2-pyridyl)-2-(ethyl propenoate-3-yl)-L-tryptophanate (143ha) 
The general procedure D1 was followed using tryptophan 56h (50.6 mg), ethyl 
acrylate (129a, 45 mg), [Ru(OAc)2(p-cymene)]2 (42 mg) and NaCl (175 mg). 
Purification by column chromatography (EtOAc) yielded tryptophan 143ha as a 
colorless oil (10 mg, 15%). 
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1H NMR (600 MHz, CDCl3): δ = 8.71 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.91 (ddd, J = 7.8, 7.8, 1.8 Hz, 1H), 
7.68 (d, J = 16.2 Hz, 1H), 7.62 (d,  J = 8.4 Hz, 1H), 7.41 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.31 (ddd, J = 8.9, 
8.1, 0.9 Hz, 2H), 7.27–7.24 (m, 1H), 7.19 (ddd, J = 7.9, 6.9, 1.0 Hz, 1H), 6.06 (d, J = 7.9 Hz, 1H), 5.49 (d, 
J = 16.2 Hz, 1H), 5.02 (ddd, J = 7.9, 5.5, 5.5 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 3.66 (s, 3H), 3.56 (d, J = 
5.5 Hz, 2H), 1.94 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 171.7 (Cq), 169.6 (Cq), 166.5 (Cq), 151.2 (Cq), 149.8 (CH), 139.4 (Cq), 
138.7 (CH), 132.0 (Cq), 131.5 (CH), 128.5 (Cq), 125.5 (CH), 123.0 (CH), 122.3 (CH), 121.5 (CH), 119.7 
(CH), 119.0 (CH), 118.2 (Cq), 111.0 (CH), 60.6 (CH2), 52.7 (CH), 52.6 (CH3), 27.5 (CH2), 23.2 (CH3), 14.4 
(CH3). 
IR (ATR): 3276, 2956, 2923, 2853, 1737, 1663, 1527, 1469, 1454, 1438, 1369, 1178, 1030, 746 cm‒1. 
MS (ESI) m/z (relative intensity) 893 (34) [2M+Na]+, 458 (53) [M+Na]+, 436 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C24H26N3O5+ 436.1867 [M+H]+, found 436.1857. 
 
(E)-Methyl acetyl-1-(2-pyridyl)-2-(isopropylacrylamide-3-yl)-L-tryptophanate (189ha) 
A Schlenk flask was charged with tryptophan 56h (50.0 mg, 148 µmol), 
isopropylacrylamide (131a, 33.5 mg, 296 µmol, 2.0 equiv), [RuCl2(p-cymene)]2 
(4.5 mg, 7.4 µmol, 5.0 mol %), KPF6 (5.4 mg, 30 µmol, 20 mol%) and 
Cu(OAc)2∙H2O (53.8 mg, 296 µmol, 2.0 equiv) and the flask was evacuated and refilled with N2 three 
times. H2O (0.5 mL) was added via syringe and the mixture was stirred at 110 °C for 17 h. After 
cooling to ambient temperature, the reaction mixture was diluted with EtOAc (3.0 mL) and purified 
by column chromatography. The product 189ha was obtained as a white solid (6.0 mg, 13 µmol, 9%). 
m. p.: 93 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.74–8.63 (m, 1H), 7.90 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.50 (d, J = 
16.1 Hz, 1H), 7.44 (ddd, J = 7.8, 1.4 Hz, 2H), 7.35 (ddd, J = 7.7, 3.7, 1.3 Hz, 2H), 7.24–7.12 (m, 2H), 6.67 
(d, J = 16.1 Hz, 1H), 6.66–6.61 (m, 1H), 6.44 (d, J = 7.9 Hz, 1H), 4.87 (ddd, J = 9.5, 7.9, 4.7 Hz, 1H), 
4.21–4.05 (m, 1H), 3.52–3.30 (m, 2H), 3.41 (s, 3H), 2.05 (s, 3H), 1.21 (d, J = 6.5 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 172.8 (Cq), 169.7 (Cq), 165.0 (Cq), 151.0 (Cq), 149.8 (CH), 138.6 (CH), 
137.5 (Cq), 133.1 (Cq), 129.0 (Cq), 127.7 (CH), 124.8 (CH), 124.4 (CH), 122.5 (CH), 121.9 (CH), 121.3 
(CH), 118.7 (CH), 114.1 (Cq), 111.3 (CH), 53.2 (CH3), 52.8 (CH), 41.6 (CH), 30.2 (CH2), 23.6 (CH3), 23.0 
(CH3), 22.9 (CH3). 
IR (ATR): 3278, 2954, 2924, 1733, 1646, 1556, 1471, 1457, 1436, 1371, 1204, 1170, 1141, 743 cm‒1. 
MS (ESI) m/z (relative intensity) 897 (5) [2M+Na]+, 471 (100) [M+Na]+, 449 (53) [M+H]+, 362 (35). 
HR-MS (ESI) m/z calcd for C25H29N4O4+ 449.2183 [M+H]+, found 449.2188. 
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Methyl acetyl-1-(2-pyridyl)-2-allyl-L-tryptophanate (191ha) 
The general procedure D1 was followed using tryptophan 56h (25.0 mg, 74 µmol) and 
allylacetate (190a, 22 mg, 0.22 mmol, 3.0 equiv) in 74 µL HOAc. Purification by column 
chromatography (EtOAc) yielded trytophan 191ha as a colorless oil (16.4 mg, 59%). 
1H NMR (600 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.2, 1.2 Hz, 1H), 7.87 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 
7.55–7.51 (m, 1H), 7.42 (dd, J = 8.1, 1.0 Hz, 1H), 7.33–7.28 (m, 2H), 7.17–7.12 (m, 2H), 6.12 (d, J = 
7.8 Hz, 1H), 5.68 (dddd, J = 17.3, 10.1, 5.8, 5.8 Hz, 1H), 4.92 (ddd, J = 7.9, 5.9, 5.9 Hz, 1H), 4.83 (dddd, 
J = 10.0, 1.6, 1.6, 1.6 Hz, 1H), 4.72 (dddd, J = 17.1, 1.6, 1.6, 1.6 Hz, 1H), 3.70–3.68 (m, 2H), 3.68 (s, 
3H), 3.33 (d, J = 6.0 Hz, 2H), 1.94 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.6 (Cq), 169.8 (Cq), 151.4 (Cq), 149.5 (CH), 138.3 (CH), 136.9 (Cq), 
135.9 (Cq), 135.2 (CH), 128.7 (Cq), 122.5 (CH), 122.3 (CH), 121.4 (CH), 120.8 (CH), 118.4 (CH), 116.1 
(CH2), 110.2 (CH), 109.3 (Cq), 53.0 (CH), 52.6 (CH3), 29.2 (CH2), 27.3 (CH2), 23.4 (CH3). 
IR (ATR): 3276, 2952, 1740, 1655, 1586, 1470, 1458, 1436, 1369, 1222, 1202, 732 cm‒1. 
MS (ESI) m/z (relative intensity) 777 (15) [2M+Na]+, 400 (50) [M+Na]+, 378 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C22H24N3O3+ 378.1812 [M+H]+, found 378.1806. 
 
Methyl acetyl-1-(2-pyridyl)-2-((E)-but-2-en-1-ol-4-yl)-L-tryptophanate (193ha) 
The general procedure D1 was followed using tryptophan 56h (25.0 mg, 74 µmol) 
and 4-vinyl-1,3-dioxolan-2-one (192a, 25 mg, 0.22 mmol, 3.0 equiv) in 74 µL 
HOAc. Purification by column chromatography (EtOAc) yielded trytophan 193ha 
as a colorless oil (16 mg, 39 µmol, 53%). 
1H NMR (600 MHz, CDCl3): δ = 8.67–8.61 (m, 1H), 7.89–7.84 (m, 1H), 7.54–7.47 (m, 1H), 7.44–7.38 
(m, 1H), 7.35–7.30 (m, 1H), 7.29–7.27 (m, 1H), 7.16–7.11 (m, 2H), 6.08 (d, J = 7.9 Hz, 1H), 5.23 (dddd, 
J = 15.3, 6.1, 6.1, 1.8 Hz, 1H), 5.13–5.04 (m, 1H), 4.91 (ddd, J = 8.0, 5.8, 5.8 Hz, 1H), 3.68 (s, 3H), 3.57 
(ddd, J = 6.1, 1.6, 1.6 Hz, 2H), 3.33 (d, J = 5.9 Hz, 2H), 1.94 (s, 3H), 1.42 (dddd, J = 6.4, 1.6, 1.6, 1.6 Hz, 
2H). 
13C NMR (126 MHz, CDCl3): δ = 172.6 (Cq), 169.7 (Cq), 151.5 (Cq), 149.5 (CH), 138.2 (CH), 136.9 (CH), 
136.9 (CH), 128.7 (Cq), 127.5 (Cq), 126.8 (Cq), 122.4 (CH), 122.3 (CH), 121.5 (CH), 120.7 (CH), 118.3 
(CH), 110.2 (CH), 108.7 (Cq), 53.0 (CH), 52.6 (CH3), 28.2 (CH2), 27.2 (CH2), 23.4 (CH3), 17.9 (CH2). 
MS (ESI) m/z (relative intensity) 430 (27) [M+Na]+, 408 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H25N3O4+ 408.1918 [M+H]+, found 408.1912. 
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5.3.11 Analytical Data for Alkylated Peptides 147 
Ethyl acetyl-1-(2-pyridyl)-2-[(2-ethyl)n-hexyl propionate-3-yl]-L-tryptophyl-L-tryptophyl-glycinate 
(147jd) 
The general procedure D2 was followed using peptide 101j (10.0 mg) and 
2-ethylhexyl acrylate (129d, 16 mg) in 100 µL HOAc. Purification by PTLC 
(EtOAc) yielded peptide 147jd as a colorless oil (7.9 mg, 60%). 
1H NMR (500 MHz, CD3OD): δ = 8.61 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 8.06 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.60–7.57 (m, 1H), 7.55 (ddd, J = 7.9, 1.0, 1.0 Hz, 1H), 7.51–7.47 (m, 
2H), 7.29 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 7.18–7.15 (m, 1H), 7.10–7.07 (m, 2H), 7.06 (s, 1H), 7.04 (ddd, 
J = 8.1, 7.0, 1.2 Hz, 1H), 6.94 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 4.73–4.66 (m, 1H), 4.63–4.59 (m, 1H), 4.11 
(ddd, J = 7.1. 7.1, 7.1 Hz, 2H), 3.89–3.79 (m, 2H), 3.78–3.67 (m, 2H), 3.26–3.19 (m, 2H), 3.17 (dd, J = 
7.6, 7.6 Hz, 2H), 3.08 (ddd, J = 14.7, 7.1, 3.9 Hz, 2H), 2.34–2.27 (m, 1H), 2.22 (ddd, J = 15.9, 7.8, 
7.8 Hz, 1H), 1.82 (s, 3H), 1.38 (p, J = 6.0 Hz, 1H), 1.22 (dd, J = 7.2, 7.2 Hz, 3H), 1.20–1.15 (m, 8H), 0.85 
(dd, J = 7.1, 7.1 Hz, 3H), 0.77 (dd, J = 7.4, 7.4 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 174.1 (Cq), 173.5 (Cq), 173.2 (Cq), 173.0 (Cq), 170.7 (Cq), 152.4 (Cq), 
150.5 (CH), 140.5 (CH), 138.4 (Cq), 137.8 (Cq), 137.7 (Cq), 129.6 (Cq), 128.8 (Cq), 124.8 (CH), 124.1 
(CH), 123.4 (CH), 123.1 (CH), 122.2 (CH), 121.7 (CH), 119.7 (CH), 119.7 (CH), 119.2 (CH), 112.2 (CH), 
111.2 (Cq), 110.7 (CH), 110.5 (Cq), 67.9 (CH2), 62.2 (CH2), 55.6 (CH), 55.4 (CH), 42.2 (CH2), 40.1 (CH), 
34.5 (CH2), 31.4 (CH2), 30.0 (CH2), 28.7 (CH2), 27.9 (CH2), 24.8 (CH2), 24.0 (CH2), 22.6 (CH3), 21.5 
(CH2), 14.5 (CH3), 14.4 (CH3), 11.3 (CH3). 
IR (ATR): 2958, 2927, 2858, 1732, 1634, 1583, 1470, 1456, 1436, 1193, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 1579 (4) [2M+Na]+, 801 (100) [M+Na]+, 779 (20) [M+H]+. 
HR-MS (ESI) m/z calcd for C44H55N6O7+ 779.4127 [M+H]+, found 779.4122. 
 
Ethyl N-acetyl-1-(2-pyridyl)-2-(2,2,2-trifluoroethyl propionate-3-yl)-L-tryptophyl-L-leucyl-L-
tryptophanate (147ke) 
The general procedure D2 was followed using peptide 101k (20.0 mg) and 
2,2,2-trifluoroethyl acrylate (129e, 24 mg) in 120 µL HOAc. Purification by 
column chromatography (EtOAc) yielded peptide 147ke as a white solid 
(14.1 mg, 57%). 
m. p.: 104 °C. 
1H NMR (600 MHz, CD3OD): δ = 8.60 (dd, J = 5.1, 1.9 Hz, 1H), 8.00 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.65–
7.61 (m, 2H), 7.48–7.43 (m, 2H), 7.29 (d, J = 8.3 Hz, 1H), 7.15–7.11 (m, 1H), 7.09–7.03 (m, 4H), 6.97 
(ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 4.73 (dd, J = 7.2, 7.2 Hz, 1H), 4.52 (dd, J = 7.0, 7.0 Hz, 1H), 4.44 (ddd, J = 
8.8, 8.8, 8.8 Hz, 2H), 4.40 (dd, J = 9.5, 5.5 Hz, 1H), 4.00 (ddd, J = 7.1, 7.1, 7.1 Hz, 2H), 3.25 (dd, J = 
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14.4, 7.6 Hz, 1H), 3.22–3.15 (m, 2H), 3.15–3.07 (m, 3H), 2.48–2.33 (m, 2H), 1.91 (s, 3H), 1.61–1.54 (m, 
1H), 1.50–1.38 (m, 2H), 1.06 (dd, J = 7.2, 7.2 Hz, 3H), 0.87 (d, J = 7.8 Hz, 3H), 0.86 (d, J = 7.8 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 173.9 (Cq), 173.3 (Cq), 173.2 (Cq), 172.9 (Cq), 172.1 (Cq), 152.3 (Cq), 
150.4 (CH), 140.6 (CH), 138.4 (Cq), 137.9 (Cq), 137.2 (Cq), 129.7 (Cq), 128.6 (Cq), 125.6 (Cq), 124.5 
(CH), 124.1 (CH), 123.4 (CH), 123.3 (CH), 122.3 (CH), 121.6 (CH), 119.7 (CH), 119.7 (CH), 119.1 (CH), 
112.2 (CH), 111.3 (Cq), 110.7 (CH), 110.4 (Cq), 62.2 (CH2), 61.0 (CH2), 55.4 (CH), 55.1 (CH), 52.9 (CH), 
42.4 (CH2), 33.9 (CH2), 28.4 (CH2), 28.1 (CH2), 25.7 (CH), 23.4 (CH3), 22.6 (CH3), 22.3 (CH3), 21.2 
(CH2), 14.3 (CH3). 
19F NMR (376 MHz, CD3OD): δ = –75.43 (m). 
IR (ATR): 3281, 2930, 1739, 1634, 1458, 1435, 1378, 1281, 1146, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 827 (100) [M+Na]+, 805 (30) [M+H]+. 
HR-MS (ESI) m/z calcd for C42H47F3N6O7+ 805.3531 [M+H]+, found 805.3550. 
 
Ethyl N-acetyl-1-(2-pyridyl)-2-(4-bromophenyl propionate-3-yl)-L-tryptophyl-L-tryptophyl-glycinate 
(147jk) 
The general procedure D2 was followed using peptide 101j (20.0 mg) and 4-
bromophenyl acrylate (129k, 11 mg) in 100 µL HOAc. Purification by PTLC 
(EtOAc) yielded peptide 147jk as a white solid (16.4 mg, 58%). 
m. p.: 144 °C. 
1H NMR (400 MHz, DMSO-d6): δ = 9.01 (d, J = 6.7 Hz, 1H), 8.73 (ddd, J = 4.7, 2.0, 0.8 Hz, 1H), 8.71 (s, 
1H), 8.44 (dd, J = 5.9, 5.9 Hz, 1H), 8.27–8.21 (m, 1H), 8.21–8.13 (m, 1H), 7.75 (ddd, J = 8.0, 1.0, 1.0 Hz, 
1H), 7.65–7.53 (m, 4H), 7.38–7.30 (m, 3H), 7.28 (dm, J = 8.8 Hz, 2H), 7.21–7.12 (m, 2H), 6.73 (dm, J = 
8.8 Hz, 2H), 4.89 (ddd, J = 12.0, 9.3, 2.3 Hz, 1H), 4.66 (ddd, J = 10.5, 6.8, 3.7 Hz, 1H), 4.11 (q, J = 
7.1 Hz, 2H), 3.95–3.81 (m, 2H), 3.51–3.40 (m, 1H), 2.21–3.23 (m, 1H), 3.12–2.80 (m, 5H), 2.15–2.03 
(m, 1H), 1.99 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6): δ = 175.2 (Cq), 172.5 (Cq), 172.0 (Cq), 171.3 (Cq), 170.8 (Cq), 170.0 
(Cq), 157.7 (Cq), 151.1 (Cq), 150.3 (CH), 140.1 (CH), 137.0 (Cq), 135.6 (Cq), 135.4 (Cq), 132.4 (CH), 
130.9 (Cq), 128.0 (CH), 125.6 (CH), 124.1 (CH), 123.5 (CH), 123.0 (CH), 121.3 (CH), 121.1 (CH), 119.8 
(CH), 119.3 (Cq), 119.1 (CH), 118.2 (CH), 116.3 (CH), 111.4 (Cq), 110.5 (CH), 110.0 (Cq), 61.0 (CH2), 
54.9 (CH), 50.8 (CH), 41.4 (CH2), 37.0 (CH2), 29.0 (CH2), 27.7 (CH2), 23.3 (CH3), 23.1 (CH2), 14.6 (CH3). 
IR (ATR): 3288, 1739, 1641, 1531, 1471, 1458, 1436, 1196, 1123, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 1665 (14) [2M+Na]+, 845/843 (100) [M+Na]+, 823/821 (5) [M+H]+. 
HR-MS (ESI) m/z calcd for C42H4279BrN6O7+ 821.2293 [M+H]+, found 821.2283. 
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5.3.12 Analytical Data for Alkylated Peptides 156 
Ethyl acetyl-1-(2-pyridyl)-2-(butane-3-one-1-yl)-L-tryptophyl-L-tryptophyl-glycinate (156ja) 
The general procedure D2 was followed using peptide 101j (40.0 mg) and but-3-
en-2-one (130a, 14 mg) in 200 µL HOAc. Purification by PTLC (first PTLC with 
EtOAc/THF 3:2, followed by a second PTLC with MeCN) yielded peptide 156ja as 
a white solid (37 mg, 83%). 
m. p.: 105 °C. 
1H NMR (300 MHz, CD3OD): δ = 8.60 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 8.03 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.57 (ddd, J = 5.7, 3.2, 0.8 Hz, 1H), 7.54–7.44 (m, 3H), 7.29 (ddd, J = 8.1, 0.9. 0.9 Hz, 1H), 7.16–6.99 
(m, 5H), 6.99–6.89 (m, 1H), 4.67 (ddd, J = 11.5, 5.4, 2.0 Hz, 2H), 4.16–4.04 (m, 2H), 3.77–3.70 (m, 2H), 
3.27–3.14 (m, 2H), 3.15–2.99 (m, 4H), 2.58–2.38 (m, 2H), 1.94 (s, 3H), 1.82 (s, 3H), 1.25–1.17 (dd, J = 
7.2, 7.2 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 210.0 (Cq), 173.6 (Cq), 173.2 (Cq), 173.1 (Cq), 170.8 (Cq), 152.3 (Cq), 
150.4 (CH), 140.6 (CH), 138.4 (Cq), 138.3 (Cq), 137.8 (Cq), 129.6 (Cq), 128.7 (Cq), 124.8 (CH), 124.1 
(CH), 123.3 (CH), 123.2 (CH), 122.2 (CH), 121.6 (CH), 119.7 (CH), 119.5 (CH), 119.2 (CH), 112.2 (CH), 
110.8 (CH), 110.7 (Cq), 110.4 (Cq), 62.3 (CH2), 55.6 (CH), 55.4 (CH), 43.5 (CH2), 42.1 (CH2), 29.8 (CH3), 
28.8 (CH2), 28.0 (CH2), 22.6 (CH3), 20.0 (CH2), 14.5 (CH3). 
IR (ATR): 3300, 2912, 1740, 1703, 1628, 1539, 1471, 1458, 1437, 1368, 1206, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 687 (100) [M+Na]+, 665 (26) [M+H]+. 
HR-MS (ESI) m/z calcd for C37H41N6O6+ 665.3082 [M+H]+, found 665.3067. 
 
Ethyl acetyl-1-(2-pyridyl)-2-(octane-3-one-1-yl)-L-tryptophyl-L-leucyl-L-tryptophanate (156kb) 
The general procedure D2 was followed using peptide 101k (15.0 mg) and oct-1-
en-3-one (130b, 14 mg) in 150 µL HOAc. Purification by PTLC (hexanes/EtOAc 
1:4) yielded peptide 156kb as a colorless oil (9.2 mg, 51%). 
1H NMR (500 MHz, CD3OD): δ = 8.60 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.01 (ddd, J = 
7.7, 7.7, 1.9 Hz, 1H), 7.63 (ddd, J = 8.9, 8.0, 0.9 Hz, 2H), 7.49–7.43 (m, 2H), 7.29 (ddd, J = 8.2, 0.9, 
0.9 Hz, 1H), 7.14–7.09 (m, 1H), 7.09–7.01 (m, 4H), 6.97 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 4.71 (dd, J = 7.2, 
7.2 Hz, 1H), 4.55 (dd, J = 6.9, 6.9 Hz, 1H), 4.42 (dd, J = 9.5, 5.6 Hz, 1H), 4.05–3.98 (m, 2H), 3.27–3.21 
(m, 2H), 3.22–3.03 (m, 2H), 3.03–2.97 (m, 2H), 2.51–2.36 (m, 3H), 2.20 (ddd, J = 7.3, 7.3, 2.1 Hz, 1H), 
1.91 (s, 3H), 1.62–1.15 (m, 9H), 1.08 (dd, J = 7.1, 7.1 Hz, 3H), 0.92–0.84 (m, 6H), 0.81 (dd, J = 7.3, 
7.3 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 212.5 (Cq), 174.2 (Cq), 173.5 (Cq), 173.5 (Cq), 173.1 (Cq), 152.6 (Cq), 
150.5 (CH), 140.8 (CH), 138.5 (Cq), 138.4 (Cq), 138.0 (Cq), 129.8 (Cq), 128.7 (Cq), 124.6 (CH), 124.2 
(CH), 123.6 (CH), 123.3 (CH), 122.4 (CH), 121.6 (CH), 119.8 (CH), 119.7 (CH), 119.2 (CH), 112.3 (CH), 
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110.9 (Cq), 110.8 (CH), 110.5 (Cq), 62.2 (CH2), 55.4 (CH), 55.2 (CH), 52.9 (CH), 43.5 (CH2), 42.5 (CH2), 
42.3 (CH2), 32.6, (CH2) 28.3 (CH2), 28.2 (CH2), 25.6 (CH), 24.5 (CH2), 23.5 (CH2), 23.4 (CH3), 22.6 
(CH3), 22.2 (CH3), 20.0 (CH2), 14.3 (CH3), 14.3 (CH3). 
IR (ATR): 2955, 2926, 1736, 1711, 1636, 1583, 1566, 1458, 1436, 1369, 1206, 741 cm‒1. 
MS (ESI) m/z (relative intensity) 799 (100) [M+Na]+, 777 (28) [M+H]+. 
HR-MS (ESI) m/z calcd for C45H56N6O6+ 777.4334 [M+H]+, found 777.4303. 
 
Ethyl (tert-butoxycarbonyl)-1-(2-pyridyl)-2-(butane-3-one-1-yl)-L-tryptophyl-L-tryptophyl-glycinate 
(156ea) 
The general procedure D2 was followed using peptide 101e (50.0 mg) and but-3-
en-2-one (130a, 16 mg) in 150 µL H2O/HOAc 9:1. Purification by GPC yielded 
peptide 156ea as a colorless oil (31 mg, 56%). 
1H NMR (600 MHz, CDCl3): δ = 8.72 (s, 1H), 8.65 (dd, J = 4.9, 2.0 Hz, 1H), 7.90 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.61 (dd, J = 7.3, 3.4 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.36 (ddd, J = 7.8, 
4.8, 1.0 Hz, 1H), 7.30–7.27 (m, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.19–7.13 (m, 2H), 7.12–7.05 (m, 2H), 
6.91–6.85 (m, 1H), 6.82 (s, 1H), 6.70 (d, J = 6.4 Hz, 1H), 6.60–6.52 (m, 1H), 5.03 (d, J = 6.3 Hz, 1H), 
4.71 (ddd, J = 8.1, 5.8, 5.8 Hz, 1H), 4.39 (ddd, J = 6.4, 6.4, 6.4 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.85 (dd, 
J = 17.6, 5.7 Hz, 1H), 3.73 (dd, J = 17.6, 5.7 Hz, 1H), 3.34–3.26 (m, 2H), 3.17 (dd, J = 14.7, 6.7 Hz, 1H), 
3.14–3.05 (m, 2H), 2.96 (dd, J = 15.2, 6.1 Hz, 1H), 2.48 (dd, J = 7.6, 7.6 Hz, 2H), 1.96 (s, 3H), 1.22 (t, J = 
7.2 Hz, 2H), 1.21 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ = 207.1 (Cq), 171.6 (Cq), 171.2 (Cq), 169.0 (Cq), 155.5 (Cq), 151.0 (Cq), 
149.5 (CH), 138.6 (CH), 137.5 (Cq), 136.7 (Cq), 135.9 (Cq), 128.3 (Cq), 127.3 (Cq), 123.7 (CH), 122.5 
(CH), 122.4 (CH), 121.8 (CH), 121.2 (CH), 120.9 (CH), 119.4 (CH), 118.7 (CH), 118.0 (CH), 111.2 (CH), 
109.9 (CH), 109.2 (Cq), 109.0 (Cq), 80.2 (Cq), 61.1 (CH2), 55.4 (CH), 53.7 (CH), 42.9 (CH2), 41.3 (CH2), 
29.8 (CH3), 28.0 (CH3), 27.1 (CH2), 26.7 (CH2), 19.0 (CH2), 14.1 (CH3). 
IR (ATR): 3323, 2978, 2919, 1660, 1488, 1471, 1458, 1436, 1365, 1194, 1162, 1019, 739 cm‒1. 
MS (ESI) m/z (relative intensity) 1467 (10) [2M+Na]+, 745 (100) [M+Na]+, 723 (39) [M+H]+. 
HR-MS (ESI) m/z calcd for C40H47N6O7+ 723.3501 [M+H]+, found 723.3493. 
 
5.3.13 Analytical Data for Ligated Peptides 149 
Methyl acetyl-1-(2-pyridyl)-2-[O-(ethyl acetyl L-phenylalaninate-4-yl) propionate-3-yl]-L-
tryptophanate (149a) 
The general procedure D2 was followed using tryptophan 56h (30.0 mg) and tyrosine 
148a (29.9 mg) in 270 µL HOAc. Purification by column chromatography (EtOAc/ 
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MeOH 25:1) yielded peptide 149a as a white solid (34 mg, 59%). 
m. p.: 111 °C. 
1H NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 5.0, 1.9, 0.8 Hz, 1H), 7.94 (td, J = 7.7, 2.0 Hz, 1H), 7.60–
7.53 (m, 1H), 7.51 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.37 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.34–7.27 (m, 1H), 
7.21–7.13 (m, 2H), 7.06 (dm, J = 8.4 Hz, 2H), 6.86 (dm, J = 8.4 Hz, 2H), 6.22 (d, J = 7.8 Hz, 1H), 5.94 (d, 
J = 7.7 Hz, 1H), 4.97 (ddd, J = 7.9, 5.9, 5.9 Hz, 1H), 4.83 (ddd, J = 7.8, 5.8, 5.8 Hz, 1H), 4.16 (q, J = 
7.2 Hz, 2H), 3.70 (s, 3H), 3.45–3.21 (m, 4H), 3.16–3.02 (m, 2H), 2.64–2.54 (m, 2H), 1.99 (s, 3H), 1.91 
(s, 3H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.6 (Cq), 171.5 (Cq), 171.0 (Cq), 169.9 (Cq), 169.6 (Cq), 151.3 (Cq), 
149.8 (CH), 149.6 (Cq), 138.7 (CH), 136.8 (Cq), 136.5 (Cq), 133.7 (Cq), 130.3 (CH), 128.8 (Cq), 122.7 
(CH), 122.5 (CH), 121.5 (CH), 121.0 (CH), 121.0 (CH), 118.7 (CH), 110.2 (CH), 109.8 (Cq), 61.8 (CH2), 
53.3 (CH), 53.0 (CH), 52.6 (CH3), 37.5 (CH2), 34.1 (CH2), 27.4 (CH2), 23.4 (CH3), 23.3 (CH3), 20.6 (CH2), 
14.4 (CH3). 
IR (ATR): 3315, 2927, 1750, 1726, 1652, 1544, 1441, 1369, 1202, 1138, 1138, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 665 (100) [M+Na]+, 643 (4) [M+H]+, 528 (47). 
HR-MS (ESI) m/z calcd for C35H39N4O8+ 643.2762 [M+H]+, found 643.2766. 
 
{N-acetyl [ethyl-1-(2-pyridyl)-2-{[N-acetyl (L-phenylalanineamide-4-yl) propionate-3-yl]}-L-
tryptophyl-L-tryptophyl-glycinate]}[Nω-(O-ethyl)acetate-2-yl] (149d) 
The general procedure D2 was followed using peptide 101j (10.0 mg) and peptide 
148c (6.7 mg). Purification by PTLC (EtOAc/MeOH 7:1) yielded peptide 149d as a 
white solid (9.2 mg, 57%). 
m. p.: 93 °C. 
1H NMR (500 MHz, CD3OD): δ = 8.65 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.08 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.67–7.58 (m, 2H), 7.52–7.46 (m, 2H), 7.28 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 7.20 (dm, J = 8.6 Hz, 3H), 
7.14–7.07 (m, 2H), 7.08–7.01 (m, 2H), 6.94 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.82 (dm, J = 8.6 Hz, 2H), 
4.69 (dd, J = 7.2, 7.2 Hz, 1H), 4.65–4.58 (m, 2H), 4.15 (ddd, J = 7.1, 7.1, 7.1 Hz, 2H), 4.10 (ddd, J = 7.1, 
7.1, 7.1 Hz, 2H), 3.90–3.87 (m, 3H), 3.76–3.66 (m, 2H), 3.28–3.21 (m, 4H), 3.17–3.08 (m, 2H), 3.08–
3.01 (m, 2H), 2.84 (dd, J = 14.1, 9.2 Hz, 1H), 2.61–2.53 (m, 1H), 2.53–2.44 (m, 1H), 1.87 (s, 3H), 1.78 
(s, 3H), 1.24 (dd, J = 7.1, 7.1 Hz, 3H), 1.20 (dd, J = 7.1, 7.1 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 175.1 (Cq), 174.8 (Cq), 174.4 (Cq), 174.3 (Cq), 174.2 (Cq), 173.8 (Cq), 
172.0 (Cq), 171.9 (Cq), 153.5 (Cq), 151.8 (Cq), 151.7 (CH), 141.8 (CH), 139.5 (Cq), 138.9 (Cq), 138.6 (Cq), 
137.3 (Cq), 132.2 (CH), 130.7 (Cq), 129.9 (Cq), 125.9 (CH), 125.3 (CH), 124.6 (CH), 124.3 (CH), 123.5 
(CH), 123.3 (CH), 122.8 (CH), 120.8 (CH), 120.3 (CH), 117.2 (CH), 113.3 (CH), 112.5 (Cq), 111.9 (CH), 
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111.6 (Cq), 63.3 (CH2), 63.3 (CH2), 56.8 (CH), 56.6 (CH), 56.4 (CH), 43.1 (CH2), 43.1 (CH2), 39.1 (CH2), 
35.5 (CH2), 29.7 (CH2), 29.0 (CH2), 23.5 (CH3), 23.4 (CH3), 22.3 (CH2), 15.5 (CH3), 15.5 (CH3). 
IR (ATR): 3292, 1730, 1669, 1653, 1568, 1472, 1465, 1437, 1372, 1197, 744 cm‒1. 
MS (ESI) m/z (relative intensity) 979 (100) [M+Na]+, 957 (2) [M+H]+, 703 (14). 
HR-MS (ESI) m/z calcd for C51H56N8NaO11+ 979.3961 [M+Na]+, found 979.3960. 
 
Benzyl (acetyl-L-serinyl)-L-leucyl-L-alanyl-1-(2-pyridyl)-2-[(methyl (acetyl-L-phenylalanyl)-L-
alaninate-3-yl) propionate-3-yl]-β3-homo-L-tryptophanate (149e) 
The general procedure D2 was followed using peptide Ac-Ser-Leu-Ala-
β3hTrppy-OBn (101, 10.8 mg) and peptide 148b (11.2 mg) in 50 µL HOAc. 
Purification by PTLC (first PTLC with EtOAc/MeOH 8:1, followed by a 
second PTLC with EtOAc/MeOH 10:1) yielded peptide 149e as a white solid (6.9 mg, 42%). 
m. p.: 142 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.91 (ddd, 
J = 7.7, 7.7, 2.0 Hz, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 7.2, 1.6 Hz, 1H), 7.46–7.40 (m, 2H), 7.34 
(ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.31 (d, J = 3.0 Hz, 5H), 7.28–7.21 (m, 2H), 7.21–7.14 (m, 4H), 7.14–7.07 
(m, 2H), 6.90 (s, 1H), 6.81 (d, J = 7.7 Hz, 1H), 6.49 (d, J = 8.6 Hz, 1H), 5.12–5.06 (m, 2H), 5.04 (ddd, J = 
8.3, 8.3, 6.0 Hz, 1H), 4.84 (ddd, J = 8.7, 4.7, 4.7 Hz, 1H), 4.71–4.65 (m, 1H), 4.56 (dd, J = 7.3, 7.3 Hz, 
2H), 4.47 (dd, J = 11.5, 3.8 Hz, 1H), 4.40–4.34 (m, 1H), 4.26 (dd, J = 11.4, 5.4 Hz, 1H), 3.71–3.68 (m, 
1H), 3.69 (s, 3H), 3.27–3.22 (m, 1H), 3.22–3.15 (m, 2H), 3.15–3.07 (m, 2H), 3.07–2.98 (m, 2H), 2.93 
(dd, J = 14.0, 7.8 Hz, 1H), 2.66 (dd, J = 16.2, 5.8 Hz, 1H), 2.62–2.57 (dd, J = 16.2, 5.8 Hz, 1H), 2.35–2.24 
(m, 2H), 1.98 (s, 3H), 1.83 (s, 3H), 1.69–1.64 (m, 1H), 1.22 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 5.7 Hz, 3H), 
0.88 (d, J = 5.7 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 172.6 (Cq), 172.2 (Cq), 172.2 (Cq), 171.6 (Cq), 171.2 (Cq), 170.6 (Cq), 
170.3 (Cq), 170.2 (Cq), 169.4 (Cq), 151.2 (Cq), 149.6 (CH), 138.7 (CH), 136.6 (Cq), 136.4 (Cq), 136.4 (Cq), 
136.3 (Cq), 135.5 (Cq), 129.2 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 126.7 (CH), 122.4 
(CH), 122.3 (CH), 121.0 (CH), 120.8 (CH), 118.7 (CH), 110.7 (Cq), 109.9 (CH), 68.7 (CH2), 66.6 (CH2), 
63.8 (CH2), 54.9 (CH), 54.8 (CH), 53.9 (CH), 53.7 (CH), 52.7 (CH), 51.5 (CH3), 49.0 (CH), 40.4 (CH2), 38.9 
(CH2), 38.3 (CH2), 34.0 (CH2), 29.2 (CH2), 25.0 (CH), 23.2 (CH3), 23.2 (CH3), 23.1 (CH3), 21.4 (CH3), 
20.7 (CH2), 18.9 (CH3). 
IR (ATR): 3290, 2938, 1733, 1645, 1531, 1471, 1457, 1437, 1124, 742 cm‒1. 
MS (ESI) m/z (relative intensity) 1083 (100) [M+Na]+, 1061 (26) [M+H]+, 550 (60). 
HR-MS (ESI) m/z calcd for C56H69N8O13+ 1061.4979 [M+H]+, found 1061.4963. 
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Butane-1,4-diyl bis[methyl acetyl-1-(2-pyridyl)-2-(propionate-3-yl)-L-tryptophanate] (149j) 
The general procedure D2 was followed using tryptophan 56h (50.6 mg) 
and butane-1,4-diyl diacrylate (129ζ, 15 mg). Purification by column 
chromatography (EtOAc) yielded peptide 149j as a white solid (35 mg, 
54%). 
m. p.: 86 °C. 
1H NMR (500 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 2.0, 0.8 Hz, 2H), 7.91 (ddd, J = 8.0, 7.5, 2.0 Hz, 2H), 
7.56–7.53 (m, 2H), 7.45 (ddd, J = 8.0, 1.0, 1.0 Hz, 2H), 7.33 (ddd, J = 7.4, 4.9, 1.0 Hz, 2H), 7.29–7.27 
(m, 2H), 7.16–7.13 (m, 4H), 6.31 (d, J = 7.8 Hz, 2H), 4.95 (ddd, J = 7.8, 6.0, 6.0 Hz, 2H), 3.96–3.89 (m, 
4H), 3.69 (s, 6H), 3.40–3.27 (m, 4H), 3.25–3.12 (m, 4H), 2.31 (ddd, J = 8.5, 7.0, 3.1 Hz, 4H), 1.94 (s, 
6H), 1.61–1.66 (m, 4H), 1.46–1.51 (m, 4H). 
13C NMR (126 MHz, CDCl3): δ = 172.5 (Cq), 172.3 (Cq), 169.8 (Cq), 162.5 (Cq), 151.1 (Cq), 149.6 (CH), 
138.5 (CH), 136.7 (Cq), 136.7 (Cq), 128.5 (Cq), 122.4 (CH), 122.3 (CH), 120.9 (CH), 120.7 (CH), 118.4 
(CH), 109.9 (CH), 109.3 (Cq), 63.9 (CH2), 52.8 (CH), 52.4 (CH3), 33.7 (CH2), 27.1 (CH2), 25.1 (CH2), 23.1 
(CH3), 20.4 (CH2). 
IR (ATR): 2953, 2924, 1731, 1653, 1470, 1459, 1436, 1369, 1167, 740 cm‒1. 
MS (ESI) m/z (relative intensity) 895 (100) [M+Na]+, 873 (71) [M+H]+, 456 (80). 
HR-MS (ESI) m/z calcd for C48H53N6O10+ 873.3818 [M+H]+, found 873.3799. 
 
5.3.14 Analytical Data for Tryptophan 166a 
Nα-(9-Fluorenylmethoxycarbonyl)-1-(2-pyridyl)-L-tryptophan (166a) 
A solution of FmocOSu (9-Fluorenylmethyl N-succinimidyl carbonate, 1.89 g, 5.6 mmol) 
in dioxane (20 mL) was added dropwise to a solution of H-Trppy-OH∙2HCl (1.98 g, 
5.6 mmol) and DIEA (9.7 mL, 56 mmol) in dioxane/DMF (1:1, 500 mL). The mixture was 
stirred at ambient temperature for 10 h. Then, the solvent was removed in vacuum and the product 
was purified by column chromatography (2% HOAc in hexanes/EtOAc 1:1). The product 166a was 
obtained as a white solid (1.78 g, 63%). 
m. p.: 93 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 12.79 (br s, 1H), 8.54 (dd, J = 5.0, 1.8 Hz, 1H), 8.35 (d, J = 8.2 Hz, 
1H), 7.94 (ddd, J = 9.0, 7.5, 1.9 Hz, 1H), 7.88 (s, 1H), 7.84 (d, J = 7.6 Hz, 2H), 7.77 (d, J = 8.3 Hz, 1H), 
7.72–7.58 (m, 4H), 7.40–7.30 (m, 2H), 7.31–7.12 (m, 5H), 4.37 (ddd, J = 8.9, 8.9, 4.6 Hz, 1H), 4.25–
4.11 (m, 3H), 3.30 (dd, J = 14.7, 4.7 Hz, 1H), 3.14 (dd, J = 14.7, 9.6 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6): δ = 173.1 (Cq), 155.7 (Cq), 151.7 (Cq), 148.3 (CH), 143.5 (Cq), 140.4 
(Cq), 138.8 (CH), 134.6 (Cq), 129.5 (Cq), 128.6 (CH), 127.9 (CH), 127.3 (CH), 126.7 (CH), 125.1 (CH), 
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122.8 (CH), 120.8 (CH), 119.8 (CH), 118.6 (CH), 114.4 (Cq), 113.7 (CH), 113.6 (CH), 65.6 (CH2), 54.3 
(CH), 46.5 (CH), 26.6 (CH2). 
IR (ATR): 1713, 1592, 1472, 1453, 1437, 1318, 1219, 1050, 758, 736 cm‒1. 
MS (ESI) m/z (relative intensity) 1029 (30) [2M+Na]+, 1007 (24) [2M+H]+, 526 (100) [M+Na]+, 504 (79) 
[M+H]+. 
HR-MS (ESI) m/z calcd for C31H26N3O4+ 504.1918 [M+H]+, found 504.1906. 
 
5.3.15 Analytical Data for Alkylated Peptides 161 
(Acetyl glycyl)-L-alanyl-L-alanyl-1-(2-pyridyl)-2-(octane-3-one-1-yl)-L-tryptophyl-glycyl-L-phenyl-
alanyl-L-valin (161a) 
The general procedure E was followed using resin 159a (60.0 mg, 
0.63 mmol/g, 37.8 µmol) and oct-1-en-3-one (130b, 24 mg, 190 mol) 
in 300 µL HOAc. Purification yielded peptide 161a as a white solid (28.2 mg, 29.6 µmol, 78%). 
1H NMR (500 MHz, CD3OD): δ = 8.62 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.08 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 
7.89 (s, 1H, NH or OH), 7.62–7.59 (m, 1H), 7.55 (ddd, J = 7.9, 1.0, 1.0 Hz, 1H), 7.49 (ddd, J = 7.6, 5.0, 
1.1 Hz, 1H), 7.28–7.20 (m, 4H), 7.20–7.14 (m, 2H), 7.13–7.06 (m, 2H), 5.18 (s, 2H, NH), 4.64–4.59 (m, 
1H), 4.55–4.50 (m, 1H), 4.32–4.23 (m, 2H), 4.19–4.15 (m, 1H), 3.97–3.82 (m, 3H), 3.45–3.36 (m, 1H), 
3.26–3.21 (m, 1H), 3.23–3.16 (m, 1H), 3.15–3.06 (m, 1H), 3.01–2.93 (m, 1H), 2.54–2.41 (m, 2H), 2.24 
(dd, J = 7.3, 7.3 Hz, 2H), 2.16–2.10 (m, 1H), 1.98 (s, 3H), 1.43–1.34 (m, 4H), 1.33 (d, J = 7.0 Hz, 3H), 
1.24 (d, J = 7.0 Hz, 3H), 1.23–1.18 (m, 2H), 1.15–1.08 (m, 2H), 0.92 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 
7.0 Hz, 3H), 0.82 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CD3OD): δ = 212.2 (Cq), 175.6 (Cq), 175.0 (Cq), 174.1 (Cq), 174.0 (Cq), 172.7 (Cq), 
172.4 (Cq), 171.4 (Cq), 152.6 (Cq), 150.6 (CH), 140.8 (CH), 138.9 (Cq), 138.5 (Cq), 138.4 (Cq), 131.0 
(CH), 130.4 (Cq), 129.8 (CH), 127.6 (CH), 124.2 (CH), 123.4 (CH), 123.3 (CH), 121.8 (CH), 119.6 (CH), 
111.1 (Cq), 110.9 (CH), 61.4 (CH), 56.6 (CH), 56.3 (CH), 51.4 (CH), 51.0 (CH), 44.0 (CH2), 43.6 (CH2), 
43.5 (CH2), 42.8 (CH2), 38.5 (CH2), 32.7 (CH), 32.4 (CH2), 27.5 (CH2), 24.6 (CH2), 23.5 (CH2), 22.6 
(CH3), 20.2 (CH2), 20.2 (CH3), 18.6 (CH3), 17.6 (CH3), 17.3 (CH3), 14.8 (CH3). 
IR (ATR): 3272, 2954, 2926, 1627, 1532, 1451, 1436, 1387, 1370, 1261, 1174, 873, 710 cm‒1. 
MS (ESI) m/z (relative intensity) 974 (100) [M+Na]+, 952 (9) [M+H]+. 
HR-MS (ESI) m/z calcd for C50H65N9NaO10+ 974.4747 [M+Na]+, found 974.4730. 
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(Acetyl L-alanyl)-glycyl-glycyl-L-valinyl-L-alanyl-glycyl-1-(2-pyridyl)-2-(benzyl propionate-3-yl)-L-
tryptophyl-glycyl-glycinamide (161d) 
The general procedure E was followed using resin 159b 
(85.9 mg, 0.35 mmol/g, 30.0 µmol) and benzyl acrylate (129b, 
15 mg, 90 µmol) in 300 µL HOAc. Purification yielded peptide 161d as a white solid (21.0 mg, 
20.8 µmol, 69%). 
1H NMR (500 MHz, DMSO-d6, 70 °C): δ = 8.64–8.61 (m, 1H), 8.13–8.08 (m, 1H), 8.08–8.03 (m, 1H), 
8.02–7.72 (m, 8H), 7.66–7.63 (m, 1H), 7.62–7.58 (d, J = 9 Hz, 1H), 7.55–7.52 (m, 1H), 7.49–7.46 (m, 
1H), 7.19–7.16 (m, 1H), 7.12–7.06 (m, 4H), 6.95–6.80 (br s, 2H), 4.31–4.21 (m, 2H), 4.20–4.14 (m, 1H), 
3.81–3.69 (m, 10H), 3.68–3.62 (m, 2H), 3.53 (s, 2H), 3.10–2.97 (m, 2H), 2.45–2.39 (m, 1H), 2.22–2.18 
(m, 1H), 2.05–1.97 (m, 1H), 1.86 (s, 3H), 1.25 (d, J = 7.0 Hz, 3H), 1.22 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 
7.0 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6, 70 °C): δ = 173.2 (Cq), 172.9 (Cq), 171.2 (Cq), 171.2 (Cq), 171.1 (Cq), 
169.8 (Cq), 169.6 (Cq), 169.5 (Cq), 169.3 (Cq), 169.0 (Cq), 161.4 (CH), 149.3 (CH), 139.0 (CH), 128.7 
(CH), 125.9 (CH), 122.6 (CH), 121.6 (CH), 121.2 (CH), 120.0 (CH), 118.5 (CH), 190.7 (CH), 70.2 (CH2), 
58.0 (CH), 48.9 (CH), 48.9 (CH), 42.7 (CH2), 42.6 (CH2), 42.4 (CH2), 42.3 (CH2), 42.3 (CH2), 41.5 (CH2), 
40.8 (CH2), 31.0 (CH), 30.6 (CH2), 23.0 (CH3), 19.0 (CH3), 18.7 (CH2), 17.9 (CH3), 17.6 (CH3), 17.6 
(CH3). 
IR (ATR): 3279, 2926, 1648, 1628, 1535, 1422, 1372, 1236, 1024, 672 cm‒1. 
MS (ESI) m/z (relative intensity) 1301 (9) [M+Na]+, 1279 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C61H95N15NaO15+ 1301.6501 [M+Na]+, found 1301.6487. 
 
(Acetyl L-isoleucyl)-L-alanyl-L-glutaminyl-glycyl-L-leucyl-glycyl-L-alanyl-(1-(2-pyridyl)-2-({2-[2-(2-
methoxyethoxy)ethoxy]ethyl} propionate-3-yl)-L-tryptophyl)-glycyl-L-alaninamide (161f) 
The general procedure E was followed using resin 159c 
(81.0 mg, 0.37 mmol/g, 30.0 µmol) and 2-[2-(2-methoxy-
ethoxy)ethoxy]ethyl acrylate (129t, 65 mg, 300 µmol) in 300 µL HOAc. Purification yielded peptide 
161f as a white solid (16.5 mg, 12.9 µmol, 43%). 
1H NMR (600 MHz, DMSO-d6): δ = 8.64–8.62 (m, 1H, CH), 8.21 (dd, J = 5.7, 5.7 Hz, 1H, NH), 8.18 (dd, 
J = 5.7, 5.7 Hz, 1H, NH), 8.10–8.05 (m, 3H, 2NH, CH), 8.02 (d, J = 7.0 Hz, 1H, NH), 7.96 (d, J = 7.9 Hz, 
1H, NH), 7.94–7.89 (m, 2H, NH), 7.81 (d, J = 7.5 Hz, 1H, NH), 7.66–7.64 (m, 1H, CH), 7.55–7.52 (m, 1H, 
CH), 7.49–7.45 (m, 1H, CH), 7.26–7.23 (m, 1H, NH), 7.22–7.19 (m, 1H, NH), 7.19–7.17 (m, 1H, CH), 
7.10–7.07 (m, 2H, CH), 7.01 (br s, 1H, NH), 6.74 (br s, 1H, NH), 4.34–4.09 (m, 7H), 3.80–3.64 (m, 6H), 
3.55–3.11 (m, 15H), 2.15–2.05 (m, 2H), 1.92–1.82 (m, 1H), 1.85 (s, 3H), 1.77–1.64 (m, 2H), 1.62–1.53 
(m, 1H), 1.52–1.36 (m, 3H), 1.29–1.12 (m, 10H), 1.12–1.03 (m, 1H), 0.92–0.76 (m, 12H). 
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13C NMR (76 MHz, DMSO-d6): δ = 174.4 (Cq), 174.4 (Cq), 174.0 (Cq), 172.9 (Cq), 172.6 (Cq), 172.3 (Cq), 
171.7 (Cq), 171.3 (Cq), 169.7 (Cq), 169.0 (Cq), 169.0 (Cq), 168.5 (Cq), 161.8 (CH), 155.0 (Cq), 152.7 (Cq), 
148.9 (CH), 139.7 (CH), 136.0 (Cq), 135.2 (Cq), 130.4 (Cq), 129.3 (CH), 126.6 (CH), 121.4 (CH), 120.4 
(CH), 119.4 (CH), 114.8 (Cq), 114.3 (CH), 71.7 (CH2), 71.6 (CH2), 70.2 (CH2), 70.1 (CH2), 70.0 (CH2), 
69.9 (CH2), 58.5 (CH3), 57.4 (CH), 52.8 (CH), 51.6 (CH), 49.0 (CH), 48.7 (CH), 48.5 (CH), 48.4 (CH), 42.6 
(CH2), 42.4 (CH2), 42.4 (CH2), 41.2 (CH2), 41.1 (CH2), 36.9 (CH), 31.8 (CH2), 28.4 (CH2), 24.9 (CH2), 
24.6 (CH), 23.5 (CH3), 23.0 (CH3), 22.1 (CH3), 18.7 (CH3), 18.3 (CH3), 18.2 (CH3), 15.8 (CH3), 11.5 
(CH3). 
IR (ATR): 3290, 2960, 2935, 1652, 1539, 1454, 1412, 1242, 1202, 1132, 1025, 751 cm‒1. 
MS (ESI) m/z (relative intensity) 1301 (1) [M+Na]+, 820 (100). 
HR-MS (ESI) m/z calcd for for C60H90N14NaO17+ 1301.6501 [M+Na]+, found 1301.6477. 
 
(Acetyl L-alanyl)-L-argininyl-glycyl-L-alanyl-L-alanyl-L-leucyl-1-(2-pyridyl)-2-(butane-3-one-1-yl)-L-
tryptophyl-L-valinyl-L-valinamide (161g) 
The general procedure E was followed using resin 159d 
(81.0 mg, 0.37 mmol/g, 30.0 µmol) and but-3-en-2-one (130a, 
21 mg, 300 µmol) in 300 µL HOAc. Purification yielded peptide 161g as a white solid (24.0 mg, 
21.2 µmol, 71%). 
1H NMR (500 MHz, DMSO-d6): δ = 8.66–8.60 (m, 1H, CH), 8.25–7.82 (m, 11H, 10NH, CH), 7.81–7.60 
(m, 4H, 3NH, CH), 7.56 (d, J = 7.5 Hz, 1H, CH), 7.52–7.43 (m, 2H, NH, CH), 7.37–7.21 (m, 2H, 2NH), 
7.21–7.11 (m, 2H, NH, CH), 7.11–7.04 (m, 2H, 2CH), 7.04–6.98 (m, 2H, 2NH), 4.70– 4.60 (m, 1H), 
4.40–4.13 (m, 8H), 4.13–4.02 (m, 1H), 3.77–3.64 (m, 2H), 3.23–3.12 (m, 1H), 3.12–3.03 (m, 2H), 3.03–
2.91 (m, 3H), 2.48–2.35 (m, 2H), 1.95 (s, 3H), 1.83 (s, 3H), 1.75–1.64 (m, 1H), 1.64–1.41 (m, 5H), 1.41–
1.31 (m, 1H), 1.30–1.08 (m, 7H), 1.02–0.94 (m, 3H), 0.92–0.73 (m, 18H). 
13C NMR (126 MHz, DMSO-d6): δ = 207.7 (Cq), 173.2 (Cq), 172.4 (Cq), 172.3 (Cq), 172.2 (Cq), 172.1 
(Cq), 171.6 (Cq), 171.1 (Cq), 170.9 (Cq), 169.8 (Cq), 168.7 (Cq), 157.1 (Cq), 151.1 (Cq), 150.0 (CH), 139.7 
(CH), 137.7 (Cq), 136.7 (Cq), 135.2 (Cq), 128.7 (Cq), 123.2 (CH), 122.3 (CH), 121.8 (CH), 120.5 (CH), 
119.3 (CH), 110.3 (CH), 58.1 (CH), 58.0 (CH), 57.9 (CH), 51.8 (CH), 49.0 (CH), 48.8 (CH), 48.7 (CH), 48.5 
(CH), 43.2 (CH2), 42.3 (CH2), 41.2 (CH2), 40.9 (CH2), 31.0 (CH3), 29.5 (CH2), 27.6 (CH2), 25.4 (CH2), 
24.7 (CH), 24.6 (CH), 23.6 (CH3), 23.5 (CH3), 23.0 (CH3), 22.8 (CH3), 22.2 (CH3), 22.1 (CH3), 19.8 (CH3), 
19.2 (CH2), 18.6 (CH3), 18.4 (CH3), 18.3 (CH3), 13.0 (CH). 
IR (ATR): 3277, 2960, 1622, 1519, 1470, 1165, 697 cm‒1. 
MS (ESI) m/z (relative intensity) 1152 (2) [M+Na]+, 1130 (85) [M+H]+, 1060 (35), 797 (85), 663 (100). 
HR-MS (ESI) m/z calcd for C55H84N15O11+ 1130.6469 [M+H]+, found 1130.6461. 
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(Acetyl L-alanyl)-L-arginyl-glycyl-L-alanyl-L-alanyl-L-leucyl-1-(2-pyridyl)-2-({2-[2-(2-methoxyethoxy)-
ethoxy]ethyl} propionate-3-yl)-L-tryptophyl-L-valinyl-L-valinamide (161h) 
The general procedure E was followed using resin 159d 
(81.0 mg, 0.37 mmol/g, 30.0 µmol) and 2-[2-(2-methoxy-
ethoxy)ethoxy]ethyl acrylate (129t, 65 mg, 300 µmol) in 300 µL HOAc. Purification yielded peptide 
161h as a white solid (17.2 mg, 13.6 µmol, 45%). 
1H NMR (500 MHz, DMSO-d6): δ = 8.6–8.54 (m, 1H, CH), 8.10–7.91 (m, 3H, 2NH, CH), 7.91–7-78 (m, 
3H, 3NH), 7.78–7.60 (m, 2H, NH, CH), 7.60–7.52 (m, 1H, NH), 7.52–7.42 (m, 3H, 2NH, CH), 7.42–7.34 
(m, 3H, NH, 2CH), 7.20–7.05 (m, 2H, NH, CH), 7.05–6.88 (br s, 3H, 3NH), 6.88–6.68 (br s, 1H, NH), 
4.35–4.15 (m, 7H), 4.15–4.08 (m, 1H), 3.76–3.68 (m, 2H), 3.58–3.32 (m, 12H), 3.24 (s, 3H), 3.16–3.07 
(m, 4H), 2.54–2.48 (m, 2H), 2.38–2.32 (m, 2H), 2.08–1.92 (m, 2H), 1.86 (s, 3H), 1.81–1.69 (m, 1H), 
1.68–1.56 (m, 2H), 1.56–1.45 (m, 3H), 1.45–1.32 (m, 1H), 1.32–1.16 (m, 9H), 0.92–0.77 (m, 18H). 
13C NMR (126 MHz, DMSO-d6): δ = 172.6 (Cq), 172.3 (Cq), 172.3 (Cq), 171.6 (Cq), 171.6 (Cq), 171.5 
(Cq), 171.5 (Cq), 171.4 (Cq), 171.3 (Cq), 170.3 (Cq), 169.2 (Cq), 164.6 (Cq), 156.7 (Cq), 150.5 (Cq), 149.2 
(CH), 138.5 (CH), 136.2 (Cq), 128.5 (Cq), 125.7 (CH), 122.3 (CH), 121.0 (CH), 119.7 (CH), 113.6 (CH), 
111.7 (Cq), 110.5 (CH), 71.1 (CH2), 71.0 (CH2), 69.6 (CH2), 69.5 (CH2), 69.5 (CH2), 69.4 (CH2), 57.7 
(CH3), 57.7 (CH), 57.3 (CH), 57.3 (CH), 52.1 (CH), 51.2 (CH), 48.4 (CH), 48.2 (CH), 48.1 (CH), 42.1 (CH2), 
41.9 (CH2), 41.9 (CH2), 30.9 (CH2), 30.8 (CH2), 30.0 (CH), 29.9 (CH), 28.6 (CH2), 24.6 (CH2), 24.6 (CH2), 
24.0 (CH), 22.6 (CH3), 22.2 (CH3), 22.1 (CH3), 21.5 (CH3), 21.5 (CH3), 18.9 (CH3), 17.7 (CH3), 17.7 
(CH3), 17.6 (CH3), 17.5 (CH3). 
IR (ATR): 3278, 2954, 1618, 1509, 1472, 1094 cm‒1. 
MS (ESI) m/z (relative intensity) 1278 (5) [M+H]+, 1066 (15), 746 (100) 641 (18). 
HR-MS (ESI) m/z calcd for C61H96N15O15+ 1278.7205 [M+H]+, found 1278.7169. 
 
Ac Ala Arg Gly Ala Ala Leu Trppy Val Val NH2
OO
O
O
MeO
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